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Abstract 
 
Life  science  firms  compete  in  rapidly  changing  environments  that  demand  substantial 
resources and capabilities. Nevertheless, there are a growing number of small life science 
firms,  and  these  firms  are  having  a  profound  impact  on  innovation  in  the  industry. 
However, little is known on how these firms overcome resource constraints to finance and 
develop R&D resources and capabilities. Consequently, the purpose of this thesis is to 
empirically explore how small life science firms develop R&D and financial resources and 
capabilities. A closely related area that this research is also fundamentally concerned with 
is how R&D and financial resources and capabilities affect firms‟ early growth.      
 
The  central  aim  of  this  research  is  to  unearth  insights  on  the  motivations,  assets  and 
processes that lead to the development of R&D and financial resources and capabilities. To 
accomplish this, the research draws on the resource-based view and dynamic capabilities. 
The  resources-based  view  is  interested  in  the  resources  from  which  firms  derive 
competitive  advantages.  Whilst  dynamic  capabilities  focus  on  how  firms  in  rapidly 
changing  environments  –  especially  high  technology  environments  –  configure  and 
reconfigure their assets and capabilities to develop competitive advantages. Because this 
research is concerned with the development of key resources and capabilities of firms in 
rapidly  changing  environments,  a  resource-based  view  influenced  dynamic  capabilities 
framework  is  used  to  isolate  the  development  of  R&D  and  financial  resources  and 
capabilities of life science firms. 
 
An in depth case study approach is used to examine the research questions. It draws on 
longitudinal data collected from six life science firms. Data has been collected from twenty 
interviews and over 3000 pages of secondary data. The interview data is abstracted using 
four  techniques:  1)  identifying  repetitions,  2)  looking  for  transitions,  3)  identifying 
similarities and differences and 4) cutting and sorting notable quotes. Following Miles and 
Huberman  (1994),  the  data  is  then  analysed  using  a  multiple  step  abstraction  and 
condensing process. A unique triangulation technique is used at the end of the study where 
the key informants are surveyed on the results of the qualitative analysis.    
 
Results from the study indicate that a unique set of past decisions, future opportunities, 
assets, capabilities and routines leads to the development of R&D and financial resources 
and  capabilities.  It  is  evident  in  all  of  the  case  firms  in  this  study  that  scientific 
breakthroughs, partnership opportunities, the founders‟ experience and the firm‟s ability to 
integrate resources and learn from earlier paths are vital to the development of R&D and 
financial resources and capabilities.  
 
The study makes several contributions to the practice and scholarship of management. It 
provides insights on how small life science firms develop the R&D and financial resources 
to compete in  a highly  dynamic industry. From a scholarly perspective, it extends the 
dynamic  capabilities  framework  and  offers  empirical  support  to  several  categories  of 
dynamic capabilities. It also offers support to R&D and financial capabilities as categories 
of  complementary  assets.  This  thesis  identifies  details  of  the  aforementioned  aspects, 
discusses  the  importance  of  the  findings  in  relation  to  the  literature,  and  offers  future 
research directions. 
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Definitions and acronyms  
 
CAs  Complementary assets. Auxiliary assets and capabilities needed in the 
commercialisation of an innovation. 
 
Endowments  For the purposes of this study endowments are the cumulative resources, 
assets and capabilities that a firm possesses. 
 
GCAs  Generic complementary assets. CAs that are easily developed or bought on 
the free market. 
 
IO  Industrial Organisational economics 
 
NTBFs  New Technology Based Firms 
 
Particalise  This refers to a process of breaking up matter into very fine particles. 
 
Paths  Opportunities that are available to firms or past decisions that affect a firm‟s 
strategy.   
 
Positions  Resources, assets or capabilities that a firm possesses. 
 
RBV  Resource-Based View  
 
ROI  Return On Investment 
 
SCAs  Specialised Complementary Assets. Auxiliary assets and capabilities 
that are not easily obtained or contracted.   
 
SEC  Securities Exchange Commission. US regulatory body that all firms traded 
on a US stock exchange must report to. 
 
SBIR Grant  Small Business Innovation Research grant; US government grant given to 
small innovative firms that have a technology that can help fill a government 
need.  
 
TMT  Top Management Team. These are executive-level managers that are in 
charge of the firm. 
 
VC  Venture Capital. High risk capital invested in promising ventures. 
 
VCs  Venture Capitalists. The study refers to this as the firm(s) that invests in 
high-risk ventures. 
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Chapter 1 – Introduction   
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
  To provide an overview of the life science industry in the USA and globally in the 
contextual setting for the research. 
  To discuss the fundamental issues in the resource-based view of the firm and how 
this interacts with the dynamic capabilities framework that this study draws on. 
  To delineate the broad aims and objectives relating to the development of financial 
assets and capabilities in life science ventures. 
  To provide an overview of the structure of the research and a brief description of 
each chapter.   12 
 
1.1 Background of the research 
This thesis examines the resource and capability development of small life science firms. 
Its focus is on R&D and financial resources and capabilities, what they are, how they are 
determined and deployed by small life science firms towards competitive advantage. This 
study is specifically interested in small life science firms that are less than 250 employees 
and in the early stages of development; which the study refers to as life science ventures. A 
growing number of these ventures are springing up around the world, and these small 
ventures are having a profound effect on the industry (Van Beuzekom & Arundel, 2009). 
Evidence suggests that these ventures require a unique set of R&D and financial resources 
and capabilities to grow (Baum & Silverman, 2004; Murray & Wolfson, 2010; Zheng, Liu, 
& George, 2009). 
 
Although there is a growing recognition of the importance of R&D and financial resources 
and capabilities on the growth of young life science ventures, research on the development 
of these resources is still scarce. Studies on these topics tend to focus on larger firms 
(Mittra, 2007; Rothaermel & Hess, 2007). This is largely attributed to the public nature of 
large life science firms and the fact that data is more readily available. Moreover, Murray 
and Wolfson (2010) suggest that the nature of life science start-ups has changed drastically 
in the last five years. This has made studying these firms difficult, and this coupled with 
the  fact  that  these  firms  often  fail,  make  studying  small  life  science  firms  difficult. 
However, it is estimated that over forty per cent of biotech innovations stem from firms of 
under 250 employees, and there are over 300 life science start-ups formulated in the United 
States (US) each year (Van Beuzekom & Arundel, 2009). Thus investigating how these 
firms  develop  R&D and financial  resources  and capabilities is  an important topic that 
needs  to  be  addressed.  This  thesis  aims  to  help  fill  this  gap  by  examining  the  paths, 
positions and processes that lead to the development of life science ventures‟ R&D and 
financial resources and capabilities.   
 
The  literature  on  life  science  firms  reveals  that  they  are  highly  innovative  and  that 
innovation  is  often  the  motivation  for  their  start-up  (Audretsch,  2001).  Furthermore, 
innovation drives the strategic path of these firms. Often life science ventures are focused 
on the development of innovation at the onset and do not have revenues to support the 
firm‟s  operations  (Baum  &  Silverman,  2004;  Powell,  Koput,  Bowie,  &  Smith-Doerr, 
2002). In consequence, life science ventures face large resource constraints. Despite this, 13 
 
few studies examine how life science firms overcome these restraints to develop R&D and 
financial resources and capabilities. 
 
Resources and capabilities are germane to the development of life science firms, and for 
this  reason,  both  the resource based  view (RBV) and dynamic  capabilities  models  are 
particularly good lenses for looking at life science firms (Coombs & Deeds, 2000; Madhok 
& Osegowitsch, 2000; Rothaermel & Hess, 2007). The RBV concentrates on the valuable, 
rare,  imperfectly  imitable  and  non-substitutable  resources  that  lead  to  long-term 
competitive advantages (Barney, 1991).  
 
Dynamic  capabilities  is  fundamentally  concerned  with  how  firms  reconfigure  their 
resources  and  capabilities  in  response  to  rapidly  changing  environments  (Teece,  1986; 
Teece,  Pisano,  &  Shuen,  1997).  Accordingly,  firms  use  dynamic  capabilities,  such  as 
higher  level  learning  abilities,  to  create  competitive  advantages  (Winter,  2000).  Firms 
develop dynamic capabilities from their paths, positions and processes (Teece et al., 1997).  
Past paths represent the events that shaped the firm‟s present state, such as large scale 
investments  in  technology.  Future  paths  are  the  strategic  options  available  to  the  firm 
(Winter, 2003). The past decisions (past paths) and opportunities (future paths) are often 
the main motivators in a firm‟s strategic decisions; i.e. firms strategize according to the 
opportunities  available  and  restraints  caused  by  previous  decisions  (Eisenhardt,  2000). 
Positions represent the resources and capabilities of the firm (Madhok & Osegowitsch, 
2000).  Processes  represent  a  firm‟s  systems  and  routines  of  utilising    resources  and 
capabilities (Teece et al., 1997). Two important by-products that stems from a firm‟s paths, 
positions and processes are key resources and capabilities. Firms with high-level dynamic 
capabilities are capable of developing complementary assets (Rothaermel and Hess, 2007; 
Teece, 2007).  
 
Complementary assets  (CAs) are the auxiliary  assets  that are needed in  the growth  of 
technology firms (Rothaermel, 2001a; Tripsas, 1997); e.g. R&D, manufacturing, logistics, 
distribution and service assets. For instance, many firms have a core technology that they 
are  aiming  to  pursue,  but  in  order  to  bring  the  technology  to  market;  the  firms  need 
auxiliary  R&D  assets  to  refine  the  technology.  In  this  instance  R&D  assets  could  be 
viewed through a CAs lens (Teece, 1986).   
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Research is especially interested in the specialised complementary assets (SCAs) that are 
needed in firm growth. These are the CAs that are not easily developed or contracted for 
and  are  a  major  source  of  competitive  advantage.  An  example  of  an  SCA  is  service 
capabilities of a medical device firm. In many cases medical devices require specialised 
service capabilities to maintain the product, and if a firm is unable to service the device, 
then the device cannot be commercialised. These capabilities are such that they require 
sophisticated and often tacit knowledge that cannot easily be replicated. Whilst generic 
complementary assets (GCAs) are needed, they are not a source of competitive advantage 
(Teece, 1986; Teece, 2007; Trispas, 1997). For this reason, most studies focus on SCAs.  
 
The present research takes an integrative approach to looking at the R&D and financial 
resources and capabilities needed in life science firm growth by integrating a framework 
based on the resource-based view (RBV) and dynamic capabilities. At the heart of this 
thesis is dynamic capabilities, and according to this theory, firms continually respond to 
changing environmental conditions by reconfiguring assets and capabilities (Teece et al., 
1997; Winter, 2003). This study also integrates the RBV by incorporating the importance 
of  resource  picking  abilities  with  dynamic  capabilities.  Accordingly,  a  firm‟s  resource 
picking abilities and dynamic capabilities is what leads the development of competitive 
advantages ( Eckhardt & Shane, 2010; Makadok, 2001; Teece, 1986; Tripsas, 1997); i.e. 
the firm chooses the best resources available to it and then dynamically works with these 
resources to maximise their resources‟ value.  
 
A review of the literature reveals that a number of resources and capabilities are required 
for  the  commercialisation  of  a  life  science  innovation:  R&D  (Deeds,  DeCarolis,  & 
Coombs,  2000;  Lowe  &  Taylor,  1998),  finance  (Powell  et  al.,  2002),  specialised 
production  (Motohashi,  2008;  Rothaermel,  2001b),  distribution  (Arora  &  Gambardella, 
1990;  Rothaermel,  2001b)  and  service  (Tripsas,  1997).  Teece  (1986)  suggests  that  the 
resources needed for growth depends on the unique strategic circumstances of the firm. 
Most  studies  assume  that  key  resources  and  capabilities  come  entirely  from  internal 
sources or partners. This is contrary to the R&D literature which clearly indicates that 
innovation is often the result of the combined effort of many entities, such as universities, 
industry consortiums and governments (Miotti & Sachwald, 2003). Another shortcoming 
of studies investigating resources and capabilities is that they ignore the element of time. 
To date, few studies have looked at the development of key resources and capabilities 
throughout the growth of a firm; nor have studies properly examined the effect of R&D 15 
 
and  financial  resources  and  capabilities  throughout  the  early  growth  of  life  science 
ventures.   
 
Teece (1986) suggests that the resources and capabilities needed for a firm to grow depend 
on the strategic circumstances of the firms – which are largely influenced by industrial 
forces. The present research is fundamentally concerned with the life  science industry, 
which has rapidly-changing technological and regulatory environments, making a firm‟s 
ability to reconfigure its resources and capabilities to respond to these changes paramount 
(Rothaermel  &  Hess,  2007).  Furthermore,  previous  research  indicates  that  life  science 
firms have specific resources and capabilities that are essential to the commercialisation of 
innovations  –  including  R&D  and  financial  resources  and  capabilities  (Arora  & 
Gambardella,  1990;  Rothaermel,  2001b).  Moreover,  life  science  firms  in  the  US  are 
heavily reliant on equity investors (Gompers & Lerner, 2004; Lerner & Merges, 1998) and 
the ability to attract capital and manage the finances of a firm –  which is critical to growth. 
Because of this, it is important for this thesis to integrate the influence of VC on the 
development of R&D and financial resources and capabilities.   
 
This thesis examines the resource and capability development of life science ventures. Its 
focus is on strategic R&D and financial resources and capabilities, what they are and how 
they are determined and deployed by firms towards competitive advantage. Life science 
firms  have  been  examined  extensively  in  management  studies.  However,  little  work 
examines how new life science ventures develop key R&D and financial resources and 
capabilities.  The  extant  research  does  not  offer  sound  insight  specific  to  life  science 
ventures, nor does it address how these firms develop R&D and financial resources and 
capabilities. Moreover, the existing theory does not provide strong constructs on this topic. 
The objective of this study is to help close these gaps. Thus the research objectives and 
questions are as follows:  
 
Objective 1 
To  explore  and  examine  how  key  R&D  and  financial  resources  and  capabilities  are 
developed. 
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Q1) How does an innovation affect the development of firms? 
1a) Does the source of an innovation affect the development of R&D and 
financial resources and capabilities? 
2a)  Does  the  type  of  innovation  affect  the  development  of  R&D  and 
financial resources and capabilities? 
 
Q2)  Do  partnerships  have  a  major  bearing  on  the  development  of  R&D  and 
financial resources and capabilities? 
2a)  How  do  life  science  ventures  know  what  inputs  they  have  to  offer 
potential partners? 
2b) How do life science ventures identify what partners have to offer? 
 
Q3)  How  does  the  p ursuit  of  financing  impact  the  development  of  life  science 
ventures? 
3a) How do different financial strategies impact the financial trajectories of 
firms?  
 
Q4)  Are  highly  trained,  skilled  and  experienced  individuals  driving  the 
development of R&D and financial resources and capabilities? 
 4a)  Are  star  scientist s playing  an  important  role  in  the  development  of  a 
firm‟s R&D? 
 
Q5)  What  processes  are  important  to  the  development  of  life  science  ventures ‟ 
R&D and financial resources and capabilities?   
 
Objective 2 
To explore and examine the effect of R&D and financial resources and capabilities on the 
growth of life science ventures. 
 
Q6) How are R&D and financial resources integral to life science ventures? 
6a) How closely linked are R&D and financial resources and capabilities? 
6b) Do R&D and financial resources co-evolve? 
 
Q7) Can R&D and financial resources and capabilities serve as a CA? 
 
Q8) Can R&D and financial resources and capabilities act as an SCA?  
 
The first objective stems from the fact that little research investigates the development of 
R&D  and  financial resources  and  capabilities  in  life  science  ventures.  Despite  the 
importance of R&D and financial resources and capabilities, research has not paid much 
attention  to  these  in  the  context  of  life  science  ventures.  The  literature  underscores  the 
importance of R&D (Kenney, 1986) and financial (Baum & Silverman, 2004; Powell et al., 
2002) resources  and  capabilities  of  larger  life  science firms – but little work examines 17 
 
these from a small life science firm‟s perspective.  There is a real gap in understanding 
how life science ventures develop R&D and financial resources and capabilities.  
 
The second object stems from the fact that little research examines the effect of R&D and 
financial resources and capabilities on the early growth of life science ventures. It is clear 
from the entrepreneurship literature that new firms are often at a disadvantage because of 
resource constraints and liability of newness  (Singh, Tucker, & House, 1986). Life science 
new  ventures  face  particularly  large  constraints,  as  the  industry  requires  substantial 
allotments of financial and human capital (Baum & Silverman, 2004). Despite this fact, 
scores of life science ventures have successfully sprung up all around the globe. However, 
scholarly research fails  to properly examine how new life science ventures‟ R&D and 
financial  resources  and  capabilities  help  them  overcome  large  resource  restraints  to 
successfully grow and prosper. 
 
This research aims to – at least partially – fill the gaps identified above. In order to do so, 
this research uses a RBV influenced dynamic capabilities framework to examine the paths, 
positions and processes that lead to the development of R&D and financial resources and 
capabilities. This framework provides an ideal  lens to isolate the underpinnings of the 
development of R&D and financial resources and capabilities in life science ventures. The 
paths aspect allows questions to be developed that focus on the motivation for developing 
R&D and financial resources; i.e. what opportunities and past decisions influenced these? 
The positions aspect allows for questions to focus on the resources that are leveraged to 
create these resources and capabilities. The processes aspect allows for questions to isolate 
the important routines firms use to develop R&D and financial resources and capabilities. 
 
1.2 Research approach 
This research adopts a qualitative approach in looking at the research objectives. The lack 
of  defined  constructs  on  the  development  of  life  science  firms‟  R&D  and  financial 
resources and capabilities makes a qualitative approach appropriate. Moreover, this was 
also influenced by the fact that the main theory – dynamic capabilities – pertinent to this 
study is not well- developed. The consequence is a need to uncover meaning in the original 
context and to allow for a theory-building rather than theory-testing approach. The best 
way to accomplish this is through qualitative methods (Edmondson & McManus, 2007; 
Eisenhardt & Graebner, 2007).  18 
 
 
One  method  that  is  often  used  in  a  qualitative  manner  is  the  case  study.  This  is  a 
particularly good method for providing deep insights and for building theory (Eisenhardt, 
1989). Therefore, the case study method was chosen as the research vehicle for this study. 
An abductive process that recognised that research does not have to be purely inductive or 
deductive was used to both extend and build new theory. This study takes a longitudinal 
approach to investigating the development of resources and capabilities over time.  
 
Life  science  firms  were  chosen  for  this  research  because  the  researcher  has  practical 
management  experience  in  a  firm  in  the  industry,  and  this  study  was  spurred  by  the 
researcher‟s quest to unearth insights on how life science ventures can more effectively 
develop key resources and capabilities. Thus, six small life science firms served as the 
sample for the study. Moreover, the industry and the characteristics of life science firms 
are ideal for the examination of R&D and financial resources. This thesis is also part of 
wider, on-going research at the University of Glasgow‟s Centre for Internationalisation and 
Enterprise  Research  (CIER),  which  is  looking  at  the  growth  of  life  science  firms. 
Following Eisenhardt (1991), this research adopts a funnelling process  that consists of 
multiple rounds of interviews where each round builds on the previous round; the first 
round  of  interviews  was  conducted,  and,  subsequently,  a  more-concentrated  interview 
schedule was created with the intent of honing down the results from the first round of 
interviews. A third round of interviews was then conducted with the firms. The interview 
schedule for this round of interviews was created based on the analysis of the first two 
rounds of interviews and triangulated the key findings from the study.  
 
Each round of interviews‟ schedules contained both open and closed-ended questions. The 
open-ended  questions  allowed  the  respondents  to  offer  undirected  insights,  whilst  the 
closed-ended  questions  captured  specific  points  (Kvale  &  Brinkmann,  2008).  These 
questions  aimed to  unearth insights  on the important  assets  and capabilities needed in 
growth. The second round of interviews probed the paths, positions and processes leading 
to the development of R&D and financial resources and capabilities inherent to the early 
growth of life science firms.  
 
Over 3000 pages of secondary data supplemented the twenty plus hours of interview data. 
The data was analysed using Miles and Huberman‟s (1994) three-level abstraction process. 
The  analysis  uses  several  of  Russell  and  Bernard‟s  (2003)  qualitative  data  analysis 19 
 
techniques  for  each  level  of  abstraction;  i.e.  1)  identifying  repetitions,  2)  looking  for 
transitions, 3) identifying similarities and differences and 4) cutting and sorting notable 
quotes. A case log and a qualitative software program were used to track and query the 
data. A within-case, within-group and cross-case analysis then further refines the data. 
Tables, graphs and charts are used as the basis for the analysis and presentation of the 
findings. 
 
1.3 Structure of the thesis 
This research focuses on the R&D and financial resources and capabilities needed in the 
early growth of life science firms. The fact that this is an industry-based study made it 
important to begin the research with an overview of the life science industry. This review 
reveals  that  this  is  a  highly  innovative  industry  with  rapidly  changing  environments 
(Cooke, 2002; Madhok & Osegowitsch, 2000). A firm‟s resources and capabilities are vital 
to its competitive position in the industry. Because of the importance of resources and 
capabilities to this study, the resource-based view and dynamic capabilities are appropriate 
models to examine this research through; therefore, the second part of the literature review 
overviews the resource-based literatures. This reveals that the resource based paradigm has 
evolved from Penrose‟s seminal ideas on productive inputs into the RBV, and recently it 
has evolved into the modern-day theory of dynamic capabilities, which is concerned with 
how firms  reconfigure their  resources  and  capabilities in  response to  rapidly  changing 
environments  (Teece  et  al.,  1997).  For  this  reason  it  is  an  ideal  lens  to  look  at  the 
development  of  resources  and  capabilities  in  life  science  ventures  (Madhok  & 
Osegowitsch, 2000) and consequently is the main theory that the present study draws on.  
 
The third part of the thesis presents the qualitative methods chosen to examine the research 
questions.  It  starts  with  an  overview  of  the  philosophical  influences  that  affected  the 
research  methods  chosen,  and  it  then  goes  on  to  detail  the  data  collection  process. 
Subsequently the chapter details the rigorous abstraction techniques that were formulated 
on the basis of Miles and Huberman (1994), Bernard and Ryan (2003) and Eisenhardt 
(1989).  This  abstraction  involves  a  systematic  process  of  identifying  themes,  trends, 
missing information and patterns in the data. A within-case, cross-group and cross-case 
analysis  serves  to  further  refine  the  data  and  present  the  findings  in  a  parsimonious 
manner. The chapter then discusses the measures taken to ensure validity and reliability. A 20 
 
number of techniques – including multiple means of triangulation – assure reliability and 
validity, or trustworthiness, as it is often referred to in the qualitative literature. 
 
The  results  are  presented  in  a  within-group,  cross-group  and  cross-case  analysis. 
Subsequently  the  findings  in  relation  to  the  literature  are  put  forth.  The  structure  and 
relation of each part of this thesis is depicted in Figure 1-1, and it is then sequentially 
detailed chapter-by-chapter below.  21 
 
Figure 1-1: Thesis structure 
 
   22 
 
Chapter One introduces the background of the study, the main bodies of literature that the 
study draws on, the research methods, the research framework, objectives and structure of 
the study. The aim of this chapter is to overview and lay out the thesis.  
 
Chapter Two presents a review of the literature related to the characteristics of life science 
firms.  It  begins  with  a  brief  taxonomy  of  the  industry  and  a  discussion  of  the  main 
characteristics of life science firms. A section on growth is included because this research 
is concerned with how R&D and financial resources and capabilities affect growth. This 
section establishes the appropriate ways to measure and view the growth of life science 
ventures.  
 
Chapter Three presents the second part of the literature review on the core theories upon 
which this thesis draws. The chapter starts with a discussion of Penrose‟s growth of the 
firm, and then moves on to overview the development of the RBV, dynamic capabilities 
and CAs. A section on CAs is included because CAs are auxiliary assets and capabilities 
needed in the commercialisation of innovations, and are especially important to life science 
innovations  (Rothaermel,  2001a).  Moreover,  R&D  has  been  viewed  through  a  CAs 
perspective, which also makes it important to this research. 
 
Chapter Four presents the research‟s framework, objectives and questions. It first lays out 
the dynamic capabilities framework that the study draws on. Subsequently it lays out the 
objectives of the study, and then it details the research questions.  
 
Chapter Five discusses the research methods selected for this study. A qualitative approach 
is  taken  based  on  the  philosophical  influences  of  the  study.  The  chapter  justifies  the 
rationale  for  this  approach  and  further  discusses  the  exact  case  method  used.  It  then 
justifies the rationale for the choice of case firms.  
 
Chapter Six presents the findings from the analysis. Following Senker and Sharp (1997), 
the six case firms are divided into three groups based on industry subsector. For each 
group a within-case analysis is presented followed by an in depth cross-group analysis. 
Then the triangulation questionnaire that was completed by each firm is presented. This 
provides a framework for a cross-case analysis and serves to validate the findings.  The 
analysis uses the following framework to present the findings: 
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1.  Introduction of the firms. 
2.  A comparison of the paths, positions and processes that led to the development of 
R&D and financial resources and capabilities.  
3.  A comparison on the effect of the R&D and financial resources and capabilities on 
early growth. 
4.  Conclusion. 
 
Chapter Seven discusses the findings of the study. It first uses the framework developed in 
chapter six to delineate the findings in relation to the objectives of the research and the 
literature. Next the chapter underscores the significance of the findings to practitioners and 
policy makers. The chapter then moves on to discuss the shortcomings of the study. Finally 
comes an overview of the impact of the research and suggestions for future research.  
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Chapter 2 – Life Science Industry Context     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
 
  To give a background of the life science industry. 
 
   To discuss the general characteristics of life science firms. 
 
  To discuss the importance of specialised financing to life science firms.   25 
 
2.1 Introduction 
Life  science  ventures  compete  in  a  high  velocity  industry  where  innovation  takes 
substantial  capital  and  time  to  develop.  Despite  this,  the  number  of  small  life  science 
ventures is growing at an astonishing rate (Giovannetti, 2010). These firms have unique 
characteristics that influence their ability to compete. Therefore, it is important for this 
study to  establish  the context  of the industry.  In order  to  accomplish  this,  the chapter 
overviews the life science industry and the important factors that influence the industry. 
The second section presents an overview of the life science industry. This section provides 
important  statistics  and  taxonomy  of  the  firms  that  constitute  the  industry.  The  third 
section discusses the literature on firm growth. This section is included because this thesis 
is concerned with how resources and capabilities are developed in the early stages of life 
science firms‟ growth, and technology firms‟ growth patterns are markedly different than 
non-technology firms (Kazanjian & Drazin, 1990). Therefore, it is imperative to identify 
the appropriate lens to view the early growth  of life science firms. The fourth section 
overviews the financing sources and capabilities that young life science firms draw on. 
This section is important because life science ventures usually engage in costly research 
and do not have revenues in their first few years (Murray and Wolfson, 2010).  
 
This chapter establishes the context of the firms and the industry and gives an overview of 
the challenges these firms face and gives a broad understanding of what influences life 
science ventures and what resources they use to compete. 
 
2.2 Life science firms 
Life science firms are broadly defined as all firms involved in the commercialisation of 
products related to the scientific application of living organisms (Owen-Smith, Riccaboni, 
Pammolli,  &  Powell,  2002b;  Powell  &  Owen-Smith,  1998).  This  includes  the  fields 
presented in Table 2-1 below. Although there are thirty fields in this table, there is one 
predominant one – biotechnology. Most of the literature and statistics on life science focus 
on biotechnology. In many cases in the US, the term biotechnology is synonymous with 
the term life science; it could be argued that biotechnology encompasses all of the fields of 
life  science  in  some  way,  and  some  scholars  accept  the  use  of  the  two  terms 
interchangeably  (Powell  &  Owen-Smith,  1998).  The  United  Nations  Convention  on 
Biological  Diversity  (2009,  p.  216)  defines  biotechnology  as  ‘Any  technological 26 
 
application that uses biological systems, living organisms, or derivatives thereof, to make 
or modify products or processes for specific use‟. Van Beuzekom and Arundel (2006, p. 
14) define biotechnology as ‘the application of scientific and engineering principles to the 
processing of materials by biological agents to provide goods and services’. It is evident 
that biotechnology and life science are closely related, and the distinction, if any, is not 
important for the purposes of the present research. It is important to note that the firms this 
study  is  interested  in  are  ones  that  could  be  classified  as  either  life  science  or 
biotechnology. 
 
Table 2-1: Life science fields 
Agrotechnology  Biomedical Engineering  Food Science 
Animal Science  Biomedical Imaging  Genetics and Genomics 
Biochemistry  Biomedical Systems  Medical Imaging 
Techniques 
Biocontrol  Biomolecular 
Engineering 
Molecular Biology 
Biodynamics  Biomonitoring  Nanotechnology 
Bio-engineering  Biophysics  Neuroscience 
Bioinformatics and 
Biocomputing 
Biotechnology  Plant Science 
Biology  Cell Biology  Proteome and 
Proteomics 
Biomaterials  Ecology  Smart Biopolymers 
Biotechnology  Environmental Science  Tissue Engineering 
Source: Van Beuzekom and Arundel (2006, p. 65) 
 
2.2.1 Life science firms’ characteristics 
Life  science firms have unique characteristics  that allow them to  compete in  the high 
velocity environments that they face. In order to better understand the forces that influence 
the resources and capabilities needed in early growth, it is important to understand the 
main characteristics of firms in the industry. The four most relevant to this study are: 1) 
their  highly  innovative  nature,  2)  their  tendency  to  form  alliances,  3)  their  capitally 
intensive nature and 4) their reliance on scientific human capital. 
 
The defining trait of life science firms is innovativeness. From 1980 to 2008 the industry 
had more patents than any other; from 2004-2008 almost eight percent of the total patents 
filed in the US were life science patents – over 11,000 (Van Beuzekom & Arundel, 2009). 
A survey of life science executives found the number one goal of R&D is to discover 
breakthrough products (Deloitte & Touche, 2009). Decarolis and Deeds (1999) suggest 27 
 
that  innovation  in  the  life  sciences  is  measured  and  stored  in  the  forms  of  academic 
citations  and  patents.  They  also  note  that  greater  stocks  of  patents  and  citations  are 
correlated  with  superior  performance.  The  high  patenting  and  publishing  propensity 
demonstrates the creative destruction, which is so widespread in the industry, with new and 
better innovations constantly replacing the old (Kenney, 1986; Powell, Koput, & Smith-
Doerr, 1996; Roijakkers & Hagedoorn, 2006).  
 
A body of literature is developing on the influence of innovation on internationalisation 
(Burgel et al., 1998; Chetty & Stangl, 2010; Knight & Cavusgil, 2004). However, few 
researchers  have  looked  at  the  influence  of  innovation  on  the  internationalisation  of 
biotechnology firms. Madhok and Osegowitsch (2000) is one of the few papers that has 
examined  this  when  they  analysed  the  influence  of  innovation  through  a  dynamic 
capabilities lens. They found that being able to realign capabilities with other firms is 
important to growth in international markets. Although an interesting paper, especially in 
the dynamic capabilities perspective they take, but there is a lack of development in the 
process of changing capabilities. Moreover, it is based on static and out-dated secondary 
data on US and European biotech alliances. Nevertheless, this paper provides much-needed 
insights on the influence of international activity on the industry and on how life science 
firms‟ resources and capabilities allow them to compete in global markets. More research 
needs to follow Madhok and Osegowitsch (2000) in looking at biotechnology through a 
dynamic  capabilities  lens;  the  rapidly  changing  nature  of  the  industry  makes  dynamic 
capabilities an ideal lens through which to view it (Deeds et al., 2000). 
 
The  second  defining  trait  of  life  science  firms  is  their  reliance  on  alliances 
(Carayannopoulos & Auster, 2010; Powell et al., 1996) Often life science firms are lacking 
the scientific or commercialisation knowledge to  develop  their product(s), and for this 
reason  they  turn  to  other  firms  to  fill  in  their  knowledge  gaps.  The  Calabrese  and 
Silverman (2000) study found that establishing strong alliances is especially important to 
start-up life science firms. They suggest small biotech firms align themselves with partners 
that  have  complementing  capabilities.  One  important  source  of  these  alliances  is 
universities. Zucker et. al (1998) looked at the importance that top university researchers 
play in new biotechnology companies.  They found that standout university researchers are 
often  the  driving  force  behind  new  biotechnology  firm  formation.  Furthermore,  Rahm 
(1994)  study  of  over  1000  academic  researchers  found  that  over  seventy-five  percent 
engage regularly in consulting, and over eighy percent have former students in industry 28 
 
that  they  are  in  regular  contact  with.  This  is  further  evidenced  by  the  fact  that 
biotechnology firms tend to cluster spatially near top research universities (Owen-Smith, 
Riccaboni, Pammolli, & Powell, 2002; Zeller, 2001). In many cases innovation is birthed 
in  university  labs;  Rothaermel  (2007)  suggests  that  innovation  birthed  at  universities 
disseminate to industry in three main ways: (1) to work with the university scientists and 
VCs on forming a new company; (2) find established firms to partner with in an equity 
sharing agreement; and (3) license the rights to the technology to established firms.  Even 
if a firm‟s innovation was not birthed at a university, universities are still often important 
partners.  They  often  provide  testing  and  research  services,  and  university  professors 
regularly consult with firms in the industry (Perkmann & Walsh, 2008; Powell & Owen-
Smith, 1998). 
 
Alliances are central to a cooperative strategy. Gans et al. (2002) examine the alliance 
(cooperative strategy) versus competition strategy for commercialising innovations. Based 
on  a  study  of  118  new  innovative  firms,  this  study  suggests  that  firms  with  strong 
intellectual protection (i.e. patents) have a higher propensity to enter into a cooperative 
strategy; whereas firms with weaker intellectual property protection tend to enter into a 
competitive  strategy.  In  some  cases  firms  earn  higher  rents  from  innovations  from 
controlling the commercialisation process, which is a competitive strategy. They also find 
that  certain  industries  with  a  high  degree  of  technology  appropriability,  such  as 
biotechnology, tend to have a higher percentage of firms entering a cooperative strategy 
because  of  the  intensity  of  CAs  needed  for  commercialisation.  This  is  supportive  of 
Rothaermel (2001a) finding that incumbents in certain industries (e.g. biotechnology) have 
an advantage because of their established base of CAs. 
 
The  literature  on  alliances  is  well  developed  and  provides  interesting  insights  on  the 
influence of partnerships within the industry. However, research fails to properly examine 
the importance of alliances in formulating key assets, such as R&D and financial resources 
and capabilities. Rothaermel (2001a, 2001b and 2005) are a few of the only papers to 
investigate  this.  These  studies  confirm  that  alliances  provide  key  inputs,  and  that  the 
partnerships  between  small  and  large  firms  are  particularly  important  to  the 
commercialisation of innovations. Future work needs to build on these studies and offer 
more depth on the process of forming alliances amongst life science ventures that lead to 
important  assets.  Specifically,  work  is  needed  to  examine  how  alliances  impact  the 
development of R&D and financial resources and capabilities. 29 
 
The third defining trait of the life science industry is its capitally intensive nature. It can 
take years from the start of innovation until the time it is commercialised (Hall, 2002; 
Murray & Wolfson, 2010). This lag time from innovation to commercialisation requires 
great upfront investment with no revenue, especially challenging for new firms. To finance 
this incubation and growth many firms turn to VC (Gompers & Lerner, 2004; Lerner & 
Merges, 1998). VC is a form of financing that takes an equity stake in risky projects that 
offer the potential for great returns. In 2008 VCs provided over $4.4 billion in funding to 
biotechnology firms; with the average investment in each firm of $10.24 million dollars 
(Van Beuzekom & Arundel, 2009). Sorenson and Staurt (2001) examined the location of 
biotechnology firms and found that there is a correlation between the location of them and 
VCs; i.e. they are spatially located in the same areas. Furthermore, a statistically significant 
number  of  biotechnology  patents  comes  from  a  small  number  of  areas  (Zucker  et  al., 
1998). Powell et al. (2002) find that new biotechnology firms tend to locate in areas near 
sources of VC and of scientific innovation – mainly top tier research universities.  
 
The importance of human capital is the fourth defining trait of the industry. Zucker et al. 
(1998)  note  the  importance  of  star  researchers  to  the  growth  and  development  of 
biotechnology firms. This notion is further supported by Boxeman et al.‟s (2001) findings 
that  human  and  social  capital  are  two  of  the  most  important  building  blocks  of  new 
technology-based  companies.  The  clustering  of  biotechnology  companies  near  top 
universities  also  supports  this  idea  (Blumenthal,  Causino,  Campbell,  &  Louis,  1996; 
Zucker et al., 1998). Furthermore, an industry survey of biotechnology executives placed 
attracting scientific talent  as  one of the biggest  challenges  in  the industry  (Deloitte  & 
Touche, 2009). One way this challenge is addressed is through the recruitment of foreign 
scientists (Stephan & Levin, 2001); the National Science Foundation estimates that 15% of 
US biotechnology workers are foreign-born (Tsapogas J, 2007). Foreign-trained scientists 
are  not  only  significant  as  an  input  to  innovation,  but  also  as  a  possible  driver  to 
internationalisation.  Burgel  and  Murray  (1998)  present  evidence  that  foreign-educated 
managers  have  a  higher  propensity  to  globalise  their  firms  than  domestically-educated 
managers. Often new life science firms are founded by scientists, so it logically follows 
that foreign-educated scientists could be a driver to internationalisation in the industry. 
Given the international flows of scientific staff, it is perhaps no surprise that they then look 
to make international links when a new life science firm is founded. 30 
 
2.2.2 History and state of the industry during this research 
The application of scientific principles to biological agents started hundreds of years ago. 
However, this was not called biotechnology until the 1970s, when recombinant DNA was 
discovered (Yoxen, 1983). Another major milestone of the modern biotechnology industry 
is when the US Supreme Court ruled in Diamond vs. Chakrabarty (1980) that modified 
organisms  could  be  patented  (Argyres  &  Liebeskind,  1998).  This  sparked  massive 
investment in the industry and launched hundreds of new biotechnology ventures. These 
initial firms were primarily either large pharmaceutical companies or small firms started by 
science professors who kept their full-time faculty positions and started firms on the side 
(Zucker et al., 1998).  
 
The present study focuses on US life science firms, so it is important to understand the size 
and scope of the US life science industry. This paragraph summarizes Van Beuzekom and 
Arundel‟s (2009)  OECD statistics  of the US  life  science industry.  In  2009 the United 
States had the most life science firms of any country in the world with 3,301. Of these 
firms over seventy-five per cent employed fewer than fifty employees. The industry has 
seen substantial  growth in  the past  few  years.  Spending in  the industry  was  over $25 
billion in 2009, which is up from an estimated $15 billion in 2000. One clear issue is that 
whilst seventy-five percent of firms in the industry are less than fifty employees, over 
seventy per cent of the industries R&D spending is by firms over 250 employees. The total 
revenue for the industry was $554 billion in 2009, which is up from $318 billion in 2004. 
The average life science firm generated $168 million in revenue. From 2004-2008 11,474 
life  science  patents  were  filed  in  the  US,  which  constituted  forty-two  per  cent  of  the 
world‟s life science patents. These statistics help put the industry in perspective and clearly 
show that it is an important industry.  
 
The  global recession that  started in  the fall of 2008 greatly slowed the growth of the 
industry. Revenues fell by ten per cent in 2008. Funds raised from initial public offerings 
fell sixty percent from the 2007 levels. Venture capital funding dropped from $5.5 billion 
in 2007 to $4.4 billion in 2008 (Giovannetti, 2010). Only ten per cent of the 370 publicly- 
traded US life science firms had positive cash flow in 2008. Furthermore, in 2008 US 
biotech  stocks  were  down  by  a  mean  average  of  forty-nine  per  cent,  and  87%  of  the 
publicly-traded firms lost value. There were over eighty companies that laid off 5,000 or 
more employees (BIO, 2009). By the end of the present study (winter 2010), the industry 31 
 
was  on  the  way  up.  By  2010  early  informal  indicators  were  that  the  industry  was 
recovering, but the recession has led to some major changes. Academic research has yet to 
analyse  the  long-term  effect  of  the  recession.  The  overall  consensus  of  the  major 
consulting firms in the industry is that the industry will recover, but this recession will 
fundamentally change the industry. Ernst and Young (2010) and Aon Analytics (2009) 
suggest that firms will become leaner and develop proofs of concepts in a more cost-
effective manner. Several consultant reports also indicate that firms will need to make 
better  use  of  their  resources,  increase  organisational  efficiencies  and  develop  strategic 
partnerships in order to stay competitive. Interestingly, many of these reports emphasise 
the challenges to small firms, but do not offer depth into what these challenges are. It 
would be interesting to see how small life science ventures develop the R&D and financial 
resources to compete in such a dynamic and capitally intensive industry.  
 
The global recession is significant to this research because it was conducted in the midst of 
it. This may have impacted the data collected for this project. Lack of VC funding could 
particularly impact the results because VC was extremely difficult to obtain during the 
time of this study, which is significant because VC is germane to the growth of firms in 
industry (Baum & Silverman, 2004).  
 
2.2.3 Government policy  
A  number  of  variables  influence  the  development  of  scientific  knowledge  (Gibbons, 
Limoges, & Nowotny, 1994). For life science firms these variables are both internal and 
external. One of the main external variables is government. There are several ways that 
governments influence life science ventures. 
 
One of the biggest  influences  that  government  has  on life science ventures  is  through 
government approvals. In the US the FDA is the most influential approval process that 
firms must contend with. Any life science innovation that is used on humans must gain 
FDA approval (Giovannetti, 2010; Olson, 1997).  The FDA approval process is long and 
arduous and typically it takes three to twelve years to get a product through this process. 
Furthermore,  it  usually  costs between $250,000 to  $5 million to  obtain FDA approval 
(Giovannetti, 2010). These are the direct and indirect costs of testing products and getting 
them ready for the FDA process. Vernon et al. (2009) found that the FDA is one of the 
biggest factors in a life science firm‟s strategy. Firms plan around costs and resources for 32 
 
gaining FDA approval for their innovations. Surprisingly few studies examine the FDA‟s 
impact in regards to small firms. It would seem that the great costs involved with the FDA 
would make planning for their approval even more important for small firms. However, 
there is not a lot of depth in the literature offered on this topic. Furthermore, the FDA is 
more influential on some life science firms than others. For example, drug development 
firms have the most arduous FDA standards to contend with. It typically takes over eight 
rounds  of  FDA  tests  and  over  ten  years  to  get  a  new  drug  application  approved.  In 
comparison, many medical devices that focus on topical applications reach FDA approval 
with two tests and in less than four years (O‟Connor, 2010).  
 
Another policy area that influences the formation of firms are  the regulations involved 
with their start-up. Countries with easier rules and procedures for starting new firms have 
more than countries that have more cumbersome procedures for starting a new business 
(Audretsch, 2001; Gnyawali & Fogel, 1994; Wagner & Sternberg, 2004). Along the same 
lines, a country's legal system, which is important to patent protection, is critical to a 
thriving  life  science  industry.  Without  this  protection  many  firms  would  not  have  the 
incentive to innovate (Jaffe, 2000; Jaffe, Trajtenberg, & Romer, 2005; Trajtenberg, 1990). 
Furthermore, regulations that prohibit certain research or testing influence firms to look 
overseas to get around those in their home countries (Greis, Dibner, & Bean, 1995). 
 
Many  governments  have  used  policy  to  try  to  develop  and  grow  life  science-related 
industries; most often through tax breaks, government grants, and access to government 
property (Chen & McDermott, 1998; Cooke, 2002). Recently governments have become 
increasingly competitive with their incentives, so incentives are not as effective as they 
once  were  (Blomstrom  &  Kokko,  2003;  Nov,  2009).    Another  way  governments  can 
influence  life  science  firms  is  through  assisting  them  in  internationalisation.  Many 
countries create agencies dedicated to helping firms sell their goods abroad. America‟s 
main entity is  the Export Agency  which provides  low cost  or free assistance  to  firms 
wishing to  enter international  markets.  The effectiveness  of this  entity  has  is  not  well 
documented, and the few studies examining this topic are conflicting and inconclusive.  
 
Another important government influence on life science firms is educational policy, and in 
particular the government‟s support for research institutions. These institutions help create 
the places where many life science innovations are born (Blumenthal, Gluck, Louis, Stoto, 
& Wise, 1986; Shane, 2004; Zucker, Darby, & Armstrong, 2002). The US has excelled at 33 
 
transferring  academic  knowledge  to  industry.  This  is  largely  credited  to  the  fact  that 
government supported academic institutions do not take full control of the innovations that 
are created there (Giesecke, 2000). Instead the universities and the researchers that created 
them share the ownership rights, which incentivise researchers to create innovations that 
are marketable. Many universities have streamlined collaborating with industry through 
technology offices (Cardozo, Ardichvili, & Strauss, 2011; Friedman & Silberman, 2003). 
These offices market and license university created innovations and make the transfer of 
innovation more efficient.  
 
2.3 Firm growth  
This  study  is  interested  in  the  development  of  resources  and  capabilities  in  the  early 
growth of life science firms. Consequently, it is important to review the different growth 
lenses. Growth is the end goal in entrepreneurship, and at some point every firm has to 
grow or it will go out of business (Churchill & Lewis, 2000). Although easy to grasp in 
theory,  in  practice  it  is  an  elusive  concept  to  define  clearly  and  measure.  There  are 
numerous  ways  to  look  at  growth,  and  there  is  no  commonly  agreed  upon  growth 
definition within the literature (Renko, Carsrud, & Brännback, 2009) .  
 
Some of the most common measures of growth are based on financial indicators. Revenue 
growth is one measure that is particularly prevalent (Delmar, Davidsson, & Gartner, 2003; 
Evans, 1987; Reuber & Fischer, 2002).  Some other measures include employee growth 
(Del Monte & Papagni, 2003; Hart & Oulton, 1996), asset growth (Ijiri & Simon, 1964; 
Lang, Ofek, & Stulz, 1996) and profits (Chittenden, Hall, & Hutchinson, 1996; Jordan, 
Lowe, & Taylor, 1998).  Whilst all of these measures provide an indication of growth, 
Davidson et al. (2010) suggest that in a significant number of cases these numbers are 
contradicting. For example, a firm could have substantial revenue growth; whilst at the 
same time have substantial profit decline. Thus objective financial measures often provide 
insight on growth, but they do not always accurately portray the whole growth picture. 
Financial indicators are particularly deceptive for start-up firms, which often do not have 
revenues or many employees. This is especially true of life science firms, which often go 
years before they generate revenues or profits (Morecroft, Lane, & Viita, 1991; Tapon, 
Thong, & Bartell, 2001). 
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For start-up technology firms a better lens to gauge growth is through how firms develop 
from a start-up into an established firm. The literature offers a number of stages models to 
describe this type of growth. Most suggest firms start-up, develop, grow and then mature 
(Davidsson et al.; Kazanjian & Drazin, 1990; Scott & Bruce, 1987). Stages models are 
fundamentally concerned with change, how firms change from one type of operation into 
another. For example, at the inception, firms are usually informal and do not have an 
advanced  infrastructure,  and  then  at  some  point  a  firm  develops  a  more  advanced 
infrastructure and larger scale distribution; this is a point of growth according to stage 
models.  Davidson,  Achtenhagen  and  Naldi  (2009)  suggest  that  analysing  firm  growth 
through stages is often preferred because it captures growth over time. They also contend 
that studies on growth that do not capture this aspect of growth are invalid because they are 
prone to selection bias; i.e. studies select samples and measures of growth conducive to 
their studies. 
 
Whilst stages‟ lens of growth has some positive attributes, these models have also been 
widely criticised – the largest criticism being the lack of clear inflection points between 
stages (Dobbs & Hamilton, 2007; Garnsey, Stam, & Heffernan, 2006; Macpherson & Holt, 
2007). These critics contend that there is no clear and objective way to determine when 
one phase ends and another begins. Certainly this criticism should not be dismissed, but 
several of the proposed models have established inflection points that show where a firm 
goes from one phase and to another (Bleaney & Nishiyama, 2002; Kazanjian & Drazin, 
1989). Another common criticism of stages models is that different business environments 
have  different  influences  on  growth;  therefore,  it  is  difficult  for  ceteris  paribus 
comparisons (Kazanjian, 1988; Kazanjian & Drazin, 1990). For instance, a life science 
start-up  is  going  have  a  much  different  growth  path  than  a  start-up  bank  has;  mainly 
because there are drastically different environmental factors that influence the respective 
industries. For this reason, Kazanjiaan (1988) suggests that growth stages models should 
be industry specific.  
 
Kazanjiaan and Drazin (1990) then go on to offer a stages model of growth for technology 
firms. Based on this model several other researchers developed similar ones. For example, 
Autio et al. (2007) offers a four stage model that emphasises the importance of resource 
acquisition and use at each stage. The four stages that most of these models encompass are 
(1) conception and development, (2) commercialisation, (3) growth and (4) stability. All of 
the models emphasise transformation; i.e. firms transforming their organisational structure; 35 
 
and these models recognise that each stage brings a new set of variables and challenges 
and that organisations must react to these challenges to maintain growth.  
 
One challenge in industry studies is to find a suitable metric by which success can be 
measured. As above, growth as a concept is often used, but this can be expressed in various 
ways. Different industries and circumstances dictate which measures of growth are proper 
to use (Kazanjian, 1988). This thesis is concerned with the development of resources and 
capabilities in life science ventures. The life science firm overview has established that 
often these firms do not have revenues for many years. This makes traditional financial 
measures of growth invalid. A better way to look at growth for life science firms is through 
the phases of development. There are a number of models offered, each of which has 
different  points  of emphasis, but  all of them indicate that there  are trigger points  that 
determine  when  a  firm  moves  into  another  stage  of  growth.  Furthermore,  each  of  the 
models encompasses a conceptualisation, commercialisation, growth and maturity phases. 
Kazanjian and Drazin (1990) has  emerged as one of the more accepted growth stages 
models  of  technology-based  firms.  Based  on  the  review  of  the  growth  literature,  the 
present study takes the stance that this is the most relevant and accurate model for looking 
at the growth of life science ventures for this thesis. This study is specifically interested in 
the development of R&D and financial resources and capabilities of life science firms 
during the conceptualisation and early part of the commercialisation phase of development. 
It is more important for this study to examine how firms develop an infrastructure, rather 
than to focus solely on financial measures. 
 
2.4 The financing of life science ventures 
The discussion above indicates that capital is paramount to the development of life science 
ventures.  Often  new  ventures  will  plan  on  sustaining  many  years  without  revenues 
(Gruber, 2009). This, coupled with the capitally intensive nature of developing life science 
innovations,  makes  investment  capital  paramount.  Financing  is  one  of  the  biggest 
challenges that a life science venture faces in its early growth (Freear & Wetzel, 1990; 
Wright  &  Robbie,  1998).  Financing  is  particularly  challenging  during  the 
conceptualisation  and  early  commercialisation  stage  of  development  for  life  science 
ventures, as firms often do not have revenues to support their operations and firms are 
investing  heavily  in  R&D  at  these  stages  (Murray  and  Wolfson,  2010).  This  section 36 
 
overviews  the  sources  of  funds  and  capabilities  that  life  science  ventures  draw  on  to 
finance their development.  
 
Sources of funds 
In the early stages of growth, life science ventures demand a substantial sum of capital – 
even more so than other new technology-based firms (Deeds et al., 2000). At the seed 
stage,  capital  is  especially  difficult  to  attract  as  the  firms  often  have  not  proven  the 
research  concept.  The  capital  at  this  point  is  allocated  to  research  and  initial  product 
development.  During  the  conceptualisation  phase,  firms  often  finance  their  incubation 
through  insider  funding,  VC,  public  sector  grants  and  business  angels  (Gruber,  2009). 
However, a true taxonomy of where capital comes from has yet to emerge in the literature, 
though  it  has  noted  that  the  initial  capital  often  comes  from  the  founders  and  angel 
investors (Freear & Wetzel, 1990; Soleimani & Kharabi, 2010). Nevertheless, there is a 
lack of evidence to substantiate what percentage of life science ventures initially capitalise 
through these means.  
 
Business angels are usually informal investors made up of wealthy individuals who are 
willing  to  invest  in  high  risk  ventures  for  the  potential  of  hyper  returns  (Chesbrough, 
2000). Often angels have substantial background in the fields they invest, and they offer 
management inputs along with their capital. They typically invest amounts less than $1 
million, and seldom invest in subsequent rounds (Chesbrough, 2000; Wong, 2009).  
 
In some cases the government offers capital to early stage life science firms (Toole & 
Czarnitzki, 2009). One of the main ways the government invests in firms is through the 
Small  Business  Innovation  Research  (SBIR)  grant  program.  Through  this  program  the 
government offers grants from the range of $40,000 to $1.3 million to firms of under 500 
employees that have innovations that have the potential to help society (Bauer & Arthanat, 
2010). In 2010 approximately 6,000 SBIR grants were awarded of which approximately 
2,100 were to life science firms (Lemond, 2011). In a study of grant versus VC backed 
firms  Lerner  (1996)  found  that  SBIR  grant  firms  display  superior  performance  as 
compared to VC backed firms. He conjectured that this is because the SBIR grants are so 
competitive that only  the best  firms  receive the grants,  but  he did  not  offer sufficient 
evidence to substantiate this. Other studies have also supported Lerner‟s (1996) findings 
that grant backed firms display superior performance and that SBIR grants are helpful to 37 
 
firms (Cooper, 2003; Wallsten, 2000). However, like Lerner (1996), these studies also do 
not provide breadth on what is driving the superior performance of SBIR backed firms.  
 
One source of financing that is usually not available to new technology-based firms is bank 
loans because these companies usually do not have the credit history and are high risk 
(Donnelly & Betts, 2006). However, entrepreneurs often secure loans on their personal 
property (e.g., their homes) to finance new ventures (Han, Fraser, & Storey, 2009). This, 
however, should be viewed through insider financing rather than commercial loans.  
 
A fourth source of capital for life science ventures is VC, which is especially important to 
because of the risky nature and the potential for abnormal returns of life science ventures 
(Chakma  &  Sammut,  2011;  Cooke,  2002).  The  importance  of  VC  has  captured  the 
attention of a number of researchers (Gompers & Lerner, 2001). The literature identifies 
three main sources of VC: independent venture capital (IVC), corporate venture capital 
(CVC), and angel investors. It is clear that angel investors are markedly different than IVC 
or CVC. Angel investors are the most hands off investors. Angel investors tend to invest 
on the ground level versus investing after a venture has already been established for a 
period of time (Wright & Robbie, 1998). In contrast, IVC and CVC tend to be hands on 
and invest only after the company is established. Many IVCs and CVCs invest in early 
stage firms, but rarely will they invest in a firm that has not been formulated or is only a 
few months old because they like to have some established criteria to base their investment 
decisions on (Gompers, 1995). The difference between IVC and CVC is not as great as that 
of  angel  investors  and  IVC/CVC.  The  literature  is  well  defined  on  this  topic  and 
overviewed in Table 2-2.   
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Table 2-2: IVC and CVC differences 
Attribute  Difference 
Incentive  VCs have larger incentives tied to the performance 
of the portfolio firms than CVCs do.  
Financial risk  CVCs are more risk adverse. 
Monitoring of portfolio firms  IVCs more closely monitor their portfolio firms. 
Discovering alternative business models  IVCs  are  more  likely  to  help  their  portfolio  firms 
discover alternative business models. 
Time horizon  CVCs  have  a  longer  term  outlook  on  their 
investments.  IVCs  strive  to  get  their  investment 
returns within the established life of the portfolio. 
Investment size  CVCs can invest larger sums of money. 
Source: Author based on Chesbourgh (2000; p. 41) 
 
A  fifth  source  of  funding  for  life  science  ventures  is  industry  partners.  Smaller  firms 
sometimes sign agreements with a larger firm where the larger firm finances part of the 
smaller firms R&D. In return the larger firm is offered ownership and or access to the 
smaller  firm‟s  innovation(s)  (Higgins,  2007;  Higgins  &  Rodriguez,  2006;  Rothaermel, 
2001a). In general, life science ventures are not able to sign such agreements until they 
have developed their proof of concept  and can show that their technology has  market 
potential, and often small firms shy away from these agreements until they can protect 
their intellectual property (Dickson & Weaver, 2011; Luukkonen, 2005) .  
 
A sixth source of capital for life science ventures is public stock markets. Generally, firms 
usually do not offer an initial public stock offering (IPO) until they are in the growth stage 
of development (Pástor, Taylor, & Veronesi, 2009). Stock markets tend to embrace firms 
that  have  a  proven  revenue  model  (Lévesque,  Joglekar,  &  Davies,  2010).  However, 
recently a number of life science firms in the conceptualisation phase of development have 
launched an IPO (Williams, 2007). 
 
Financial capabilities 
Although there is some understanding on the sources of financing for life science ventures, 
there is still a large gap in understanding how new ventures obtain capital from the sources 
discussed above. The NBTF literature has touched on the process of raising capital, but it 
has not gone into great depth on what resources and  capabilities firms use to develop 
financial resources. Hsu (2007) examined the investment behaviour of VCs and found that 39 
 
the founder‟s background is a key element that factored in the investment decision process; 
i.e. VCs are more apt to invest in firms whose founders show a successful track record of 
starting  firms.  This  has  been  substantiated  by  several  other  notable  studies  (Colombo, 
Delmastro, & Grilli, 2004; Colombo & Grilli, 2005; Stuart & Abetti, 1990). It has also 
been  noted  that  the  potential  of  a  firm‟s  technology  is  an  important  criteria  in  the 
investment  decision  (Cockburn  &  MacGarvie,  2009;  Freear  &  Wetzel,  1990).  This  is 
particularly  important  to  NTBFs,  but  as  of  yet  a  way  to  gauge  the  potential  of  an 
innovation and how financiers value an infant technology has not emerged. 
 
There  are  also  studies  that  have  examined  the  importance  of  alliances  to  attracting 
investment capital. These studies have shown that firms that are well networked have more 
access to capital (Hite & Hesterly, 2001; Shane & Cable, 2002). For example, Shane and 
Cable (2002) suggest that firms with deeper industry ties are able to raise more than firms 
that are not well connected in the industry. However, this study did not shed light on how 
these  alliances  are  formed.  There  is  little  work  that  looks  at  how  the  networking 
capabilities lead to financial resources.  
 
Studies  have  also  shown  that  capabilities  in  conserving  capital  are  important  to  new 
ventures. There is an emerging body of literature on „bootstrapping‟; which Winborg and 
Landstrom    (2001,  p.  236)  refers  to  as  „the  use  of  methods  for  meeting  the  need  for 
resources without relying on long-term external finance from debt holders and/or new 
owners’. Accordingly, firms operate as lean as possible and cut all non-essential costs to 
preserve  capital.    Several  studies  have  indicated  that  bootstrapping  capabilities  are 
essential to start-up ventures because resources are almost always in short supply (Auken, 
2005; Jones & Jayawarna, 2010; Winborg & Landstrom, 2001a). However, there is little 
work  that  has  looked  at  how  bootstrapping  capabilities  affect  the  development  of  life 
science ventures. It would seem that cost containment capabilities would be critical in an 
industry where R&D expenses are high and difficult to project for.  
 
Investor relations is another capability that becomes important as firms develop and take 
on larger amounts of investment. Gorman and Sahlman (1989) found that executives‟ in 
VC backed firms spend over 100 hours a year meeting with their VCFs. Similarly, Bushee 
and Miller (2009) findings  indicate that after an IPO firm‟s CEO‟s devote up to twenty per 
cent of their time to functions related to investor relations. Moreover, research indicates 
that capabilities related to dealing with investors are critical because one of the largest 40 
 
sources of future investment capital is previous investors; it is therefore crucial to maintain 
strong relations with  investors.  Laurent-Ottomane and Weimer  (2010)  suggest  investor 
relations capabilities mainly revolve around communicating with investors on the status of 
the firm and „selling‟ the investors on investing more capital. 
 
2.5 Industry context conclusions 
The discussions in this chapter have highlighted the dynamic nature of life science firms. 
Innovation is paramount in this industry, and rapidly changing environments underscore 
the  importance  of  effectively  choosing  and  developing  resources  and  capabilities. 
Furthermore,  new  life  science  innovation  takes  millions  of  dollars  and  specialised 
scientific resources and capabilities. Despite this, there are over 2,500 life science firms in 
the US that are under 250 employees and over 300 new life science ventures are launched 
every year  (Van Beukezekom & Arundel, 2009). Even with the importance of small firms 
to  the  industry,  there  is  a  major  gap  in  the  understanding  of  how  small  resource-
constrained  firms  develop the R&D and financial resources  and capabilities  needed to 
incubate innovation. 
 
This review has highlighted that human capital, university inputs, industry partners and 
government inputs underpin the development life science ventures‟ R&D. However, there 
is still not a deep understanding of how these combine to help a firm develop its R&D 
resources and capabilities. There is also a lack of understanding of how firms obtain inputs 
from  these sources.  Furthermore,  few studies  look at  how the nature  of a life science 
innovation affects its development; i.e. do different life science innovations have different 
effects on the development of a firm?  
 
It is also apparent that life science ventures are costly to incubate and that investment 
capital is paramount to the incubation of life science ventures. The review suggests that 
this  investment  comes  from  several  sources;  insider  finance,  angel  investors,  VC, 
government  grants,  industry  partners  and  IPOs.  However,  there  is  a  real  gap  in 
understanding how firms obtain capital from these sources. More specifically, there is little 
understanding  of  the  capabilities  needed  to  attract  investment  and  mange  financial 
activities. Moreover, research does not properly identify which combinations of sources of 
capital are used early in the development of life science firms.    41 
 
 
 It is clear from this review that R&D and financial resources and capabilities are germane 
to  the  early  development  of  life  science  ventures.  The  review  also  shows  there  are 
deficiencies in the knowledge base of how life science ventures formulate these resources 
and capabilities. Because of the importance of resources and the dynamic nature of the 
industry,  the  resource-  based  view  (RBV)  and  dynamic  capabilities  offer  good  lenses 
through which to examine the development of resources and capabilities of life science 
ventures.  The  next  chapter  is  devoted  to  tracing  the  evolution  of  the  resource-based 
literature and establishing a theoretical lens through which to view this research.  
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Chapter 3 – The Resource-Based Paradigm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives: 
 
  To discuss the evolution of the resource-based literature.  
 
  To review the major conceptual and empirical studies on the Resource-Based 
View, dynamic capabilities and CAs. 
 
  To evaluate the shortcomings and identify research gaps in the resource-based 
literature. 
 
  To discuss the potential applications of dynamic capabilities in the examination of 
life science firms. 
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3.1 Introduction 
Chapter two emphasised the importance of resources and capabilities to the development 
of life science firms. Central to the strategic management of life science firms is how to 
acquire, build, use and reconfigure resources. A number of prominent theories have sprung 
up based on this. The RBV and dynamic capabilities is clearly rooted to this theoretical 
approach (Barney, 1991; Teece et. al., 1997), but resources are still paramount to other 
theories  as  well.  For  example,  Porter‟s  five  forces  model  recognises  resources  are 
important, but it emphasises this in regards to how environments shape the development of 
firms‟ resources (Porter, 1985). Upwards of ten strategic management theories touch on 
resource  development  and  use  (Aimé,  1997).  Most  of  these  are  specific  to  one  sub-
discipline within management. Following Aime (1997), the present study takes the stance 
that a strategic management issue should be isolated within one main theoretical paradigm. 
This is not to contend that one theory is necessarily better than another; rather it is better in 
a  single  study  to  isolate  a  phenomenon  under  the  umbrella  of  one  rather  than  many 
strategic management theories (Eisenhardt, 1989a). Furthermore, this is not to suggest that 
other theories should not be incorporated in a study, as multiple theoretical perspectives 
are good for comparative purposes and looking at the problem from different angles (Yin, 
2008). Rather, this  is  to suggest  that it is  important  to  have one overarching  research 
paradigm guiding a study. Because of the importance of resources and capabilities to life 
science  ventures,  this  thesis  uses  a  resource-based  paradigm  to  examine  life  science 
ventures. 
 
The RBV has gained significant scholarly attention in the last twenty years. It has become 
one of the most prominent strategic management theories, as thousands of articles draw on 
it. Out of the RBV, dynamic capabilities has developed. This theory looks at how firms 
reconfigure  their  resources  to  respond  to  rapidly  changing  environments  (Teece  et  al., 
1997). The present study is interested in the growth of life science firms, and because of 
the rapidly changing environments life science firms face, dynamic capabilities makes an 
excellent lens through which to examine life science firms. A firm displaying high-level 
capabilities is able to create complementary assets (CAs), which are the auxiliary assets 
needed in the commercialisation of an innovation (Teece, 2007). Figure 3-1 below traces 
the evolution of the resource-based literature. Starting with Penrose‟s (1959) Growth of the 
Firm, this review systematically works through this evolution. 
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Figure 3-1: Resource-based paradigm evolution 
 
Source: Author 
3.2 Penrose 
Penrose‟s (1959) growth of the firm is one of the earliest theories to address why some 
firms grow at a faster pace than others. Not only is this an important piece because it is one 
of  the  first  significant  pieces  to  look  at  firm  growth  from  a  strategic  management 
perspective,  but  it  is  also  the  basis  for  the  RBV  and  several  other  modern  strategic 
management theories. Because this thesis is directly seeded in the aforementioned theories, 
Penrose‟s early theory is where this discussion begins.  
 
According  to  Penrose  (1959),  a  firm  is  an  administrative  structure  with  productive 
resources. These productive resources are both physical and human. The physical are the 
tangible assets, such as plants and materials. Human resources are the labour that the firm 
has available. The function of the firm is to engage these resources to create outputs. In 
order to maximise outputs, the firm must recognise productive opportunities, which are the 
opportunities of output that are available to the firm (Penrose, 1959).  
 
Arguably,  Penrose‟s  largest  contribution  is  her  managerial  view  of  the  firm  (Kor  & 
Mahoney, 2004). Prior to her work in The Growth of the Firm, scholars mostly ignored the 
influence of management. She, on the other hand, saw management as one of the most 
important  resources  of the firm.  Resources  themselves are not  enough to  make a firm 45 
 
grow.  Management  is  needed  to  convert  resources  to  valuable  outputs  (Teece,  1986; 
Winter,  2003).  These  valuable  outputs  she  calls  „productive  services,‟  which  she 
differentiates  from  resources  that have no value until  they  are  converted to  something 
productive (Kor & Mahoney, 2004). A manager‟s firm-specific knowledge can adjust and 
expand, which allows a firm to grow over time; managers can be hired and trained in the 
long run. However, in the short run management expansion is limited because of the time it 
takes to hire them. This causes a bottleneck to growth, which is known as the „Penrose 
Effect‟  (Uzawa,  1969).  Penrose  also  makes  significant  contributions  to  the  process  of 
innovation within the firm. Specifically she attributes unused resources as the source of 
firm innovation. This excess capacity is one of the key variables to firm growth (Penrose, 
1959).    
 
The  variables  described  above  are  the  building  blocks  of  the  RBV.  One  of  the  main 
architects of the RBV, Barney (1991, p.103), credits Penrose‟s contributions: 
 
  ‘Her work portrayed how resources may provide long-term rent streams’. 
 
Many of the prominent theories in management trace back to Penrose‟s The Theory of the 
Growth of a Firm. Most notably are the RBV, transactions‟ costs and dynamic capabilities 
models. Penrose‟s ideas on physical and human resources provided the foundation for the 
RBV (Rugman & Verbeke, 2005). The Theory of the Growth of the Firm also lays the 
groundwork for other growth theories, as it describes firm growth happening over a series 
of steps (Rugman & Verbeke, 2005).  
 
3.3 RBV 
Penrose‟s main ideas are disseminated in her 1959 piece, but it was not until years later 
that her ideas were fully realized. Throughout the 1960‟s, 1970‟s and into the early 1980‟s, 
Industrial  Organisational  (IO)  economics  became  popular  in  the  strategic  management 
literature (Conner, 1991). This literature is concerned with the influence of the outside 
forces on the market. By far the most influential work to come out of this school is Porter‟s 
Forces  Model.  According  to  the  theory,  the  firm  holds  some  degree  of  control  in  its 
strategic  direction,  but  its  ability  to  compete  is  limited  within  the  confounds  of  its 
industrial environments (Miller & Dess, 1993). Whilst there is a sound basis for looking at 
environmental forces, critics contend that IO-related theories are overly concerned with 46 
 
outside forces and neglect firm resources and abilities. Although Hendry (1990) finds fault 
in assuming that markets work in equilibrium, many economic and political barriers show 
otherwise. Furthermore, studies have found that even firms that operate within sub-optimal 
environmental conditions are able to achieve above average economic rents (Schoemaker, 
1990). 
 
These shortcomings brought scholars back to Penrose‟s growth ideas. Wernerfelt (1984) 
and Barney (1986) extended her ideas into the RBV of the firm. These pieces, concerned 
with integral resources, examined firm competitiveness from the resource side, instead of 
the product or industrial standpoint. Accordingly, the basis of competitive advantage in lies 
in a firm‟s bundle of resources (Wernerfelt, 1984); thus firms with superior bundles of 
resources enjoy superior performance. Conceptually, this is an easy theory to grasp, but in 
practice  it  is  difficult  to  understand  clearly.  For  starters,  what  constitutes  a  resource?  
Penrose defines a resource in terms of either physical or human capital. Physical capital 
consists of the tangible property of the firm (e.g. land, equipment, etc.), and human capital 
is the knowledge and abilities of a firm are contained within it workers. Werenerfelt (1984, 
p.171)  offers  a  similar  definition:  „Those  attributes  of  a  firm’s  physical,  human,  and 
organisational capital that do enable a firm to conceive of and implement strategies that 
improve its effectiveness’. 
 
Figure 3-2 presents Maier‟s (2004) comprehensive categorisation of resources. He divides 
resources  into  tangible  and  intangible  assets.  He  then  further  breaks  each  of  these 
categories  down.  Tangible  assets  are  divided  into  two  groups:  financial  and  physical. 
Intangible assets are divided into person independent and person dependent resources. This 
is a comprehensive categorisation that is similar to several others offered in the literature 
(Black & Boal, 1994; R. Hall, 1992; Ray, Barney, & Muhanna, 2004). 
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Figure 3-2: Organisational resources 
 
Source: Maier (2004, p. 221) 
 
In  theory,  the  categories  and  definitions  of  resources  are  straightforward.  In  practice 
though, they are not as clear cut. For example, when is access to a network considered a 
resource?  If  a  life  science  firm  can  simply  join  a  large  network,  such  as  the  US  Bio 
Organisation, is this still a resource? This grey area is a large source of criticism for the 
RBV (Priem and Butler, 2001). Measuring resources has proven even more problematic, 
especially  for  intangible  ones.  For  example,  how  can  the  reputation  of  a  firm  be 
convincingly measured?  To overcome these shortcomings, a number of RBV scholars 
have created ways to measure intangibles. Bontis, et al. (1999)  suggest that there a host of 
correlations that can be looked at between intangible assets and objective measures, such 
as return on investment (ROI); these suggestions are further supported by several other 
studies (Barth & Clinch, 1998; Bowman & Ambrosini, 2003; Rodov & Leliaert, 2002). 
However,  even  these  studies  acknowledge  that  there  is  no  perfect  way  to  measure 
resources.  It is especially difficult to measure all of a firm‟s resources.  In an in-depth 
analysis of studies using the RBV, Newbert (2007, p. 141) found that 76%  of RBV studies 
only examine one resource. Furthermore, he finds that less than 5% of studies looked at 48 
 
more  than  two  resources,  perhaps  because  it  is  so  difficult  to  isolate  resources;  most 
modern firms are a web of interconnected resources, and often resources share functions 
(R. Hall, 1993). This is the central argument of Priem and Butler (2001) who contend that 
how resources create value cannot possibly be discerned. For example, how does a life 
science firm discern between the value of the scientific staff and their equipment? Life 
science  firms  usually  have  advanced  scientific  equipment,  but  it  is  rendered  useless 
without the skilled scientists who use it; so in this instance which is more valuable, the 
equipment or the scientists? As this example illustrates, it is extremely difficult to gauge 
the value of a resource. 
 
Barney (1991) and others contend that the valuable, rare, imperfectly in-imitable and non-
substitutable (VRIN) framework discerns how a resource creates value. Accordingly, a 
resource must meet the VRIN criteria for it to help the competitive position of a firm; i.e. 
the resource is valuable, rare, imperfectly imitable and non-substitutable. A number of 
scholars feel that it is too difficult to discern whether or not a resource meets these criteria, 
and for this reason have rejected, at least parts, of the theory (Priem & Butler, 2001). 
However,  many  management  scholars,  at  least  to  an  extent,  have  accepted  the  VRIN 
framework, which explains why it is such a prevalent theory in management. However, not 
all resources are a source of permanent competitive advantage, as changing environmental 
factors influence the relative value of a resource (Eisenhardt & Martin, 2000; Fiol, 2001); 
i.e.  changing  environments  and  organisational  factors  degrade  the  value  of  certain 
resources whilst increasing the value of other resources. However, some scholars contend 
that firms consistently find and better allocate resources; therefore, some types of resources 
are a source of sustained competitive advantage (Barner, 2001; Mikado, 200). 
 
Although  the  VRIN  framework  provides  a  basis  for  how  a  resource  gives  rise  to 
competitive  advantages,  it  does  not  explicitly  state  how  resources  are  obtained  or 
developed (Hoopes, Madsen, & Walker, 2003). Some contend that firms develop resources 
from superior resource picking abilities (Barney, 2001; Lounsbury & Glynn, 2001); whilst 
others contend that firms develop resources from other resources (Makadok, 2001; Teece 
et al., 1997; Winter, 2003). The lack of clarity in how resources are developed and used 
has even led to the contention that the RBV has no management implications (Priem & 
Butler, 2001). Accordingly, the RBV tells managers to obtain VRIN resources, but it offers 
no prescriptions or insights on how to obtain these resources. Furthermore, it gives little 
input on how to use the resources once they are obtained (Miller, 2003). Barney (2005) 49 
 
suggests  that  these  are  not  problematic  because  the  theory  was  never  intended  to  be 
prescriptive.  However,  Starkey  and  Madan  (2001)  clearly  show  that  there  is  a  major 
disconnect between scholars and practitioners, and that if  management research does not 
provide relevance to practitioners, then it will become irrelevant. Furthermore, Vila and 
Canales (2008) suggest that managers must have a clear picture of the issues they wish to 
address  in  the  planning  process.  In  its  current  state,  the  RBV  makes  it  difficult  for 
practitioners to define resource based issues, and for this reason the RBV needs to make 
strides to make a clearer connection to the practice of management.  
 
There  is  also  little  work  that  used  the  RBV  in  the  examination  of  small  firms  (Trott, 
Maddocks and Wheeler, 2009; Sapienza et al., 2006). Trott, Maddock and Wheeler (2009) 
call for more work to apply a RBV to the examination of small to medium size enterprises 
(SMEs). They assert that the RBV makes an ideal lens for SMEs, but work is needed to 
refine the RBV framework for these firms. This connection especially needs to be made 
within  the  life  science  industry,  and  chapter  two  surfaced  some  resources  vital  to  the 
growth and development of life science ventures. For example, the chapter underscored the 
importance  of  R&D,  scientific  human  capital,  alliances  and  specialised  financing. 
However,  the  literature  does  not  clearly  specify  how  these  resources  give  rise  to 
competitive  advantage.  Ambiguity  in  the  understanding  of  how  these  resources  are 
formulated or obtained also exists, and these are vital issues to the present study, which is 
specifically interested in how life science ventures formulate R&D and financial resources.  
 
3.4 Dynamic capabilities  
The previous discussion indicates that the RBV has become one of the most widely used 
theories in management. It also suggests that it is a useful theory, but there are several 
flaws that limit its application. The most common criticism of it is its static nature (Priem 
& Butler, 2001). This makes applying a RBV lens to a fluid industry, such as the life 
sciences,  difficult.  Life  science  resource  demands  rapidly  change,  which  changes  the 
values  of  a  firm‟s  resources  (Carayannopoulos  &  Auster,  2010).  To  get  beyond  the 
criticisms, researchers started applying a dynamic view of how resources are integrated, 
built, and reconfigured to respond to changing environments to create sources of sustained 
competitive advantage (Teece & Pisano, 1994). This view evolved into what is now called 
dynamic capabilities, which is one of the only frameworks to offer plausible insights on the 
growth of technology based firms, such as life science firms.  50 
 
 
3.4.1 Evolution of dynamic capabilities                        
Dynamic capabilities stems from the RBV (Helfat & Peteraf, 2003; Mikado, 2001; Teece 
et al., 1997). However, several other fields have also influenced its evolution; including 
organisational learning (Argyris & Schon, 1978; March, 1991), evolutionary economics 
(Schumpeter  &  Opie,  1934),  transactions  cost  analysis  (Coase  1937;  Monteverde  and 
Teece 1982)  and competencies (Patel & Pavitt, 1997; Prahalad & Hamel, 1994). Dynamic 
capabilities draws heavily on how the firm absorbs and applies knowledge. In doing so it 
makes  extensive  use  of  Nelson  and  Winter‟s  (1982)  emphasis  of  routines,  and  the 
importance of the individual on organisational routines (Cyert & March, 1992). Whilst 
dynamic  capabilities  evolved  from  the  RBV,  it  is  important  to  note  that  the  idea  of 
resources does not simply go away because of the introduction of dynamic capabilities. 
Resources are central to how dynamic capabilities are formed and what they reconfigure. 
Several  scholars  (Bowman  &  Ambrosini,  2003;  Eisenhardt  &  Martin,  2000;  Helfat  & 
Peteraf, 2003; Makadok, 2001) suggest that the traditional resource picking view is still 
important  as  well  as  complementary  to  dynamic  capabilities;  i.e.  firms  can  have  a 
competitive advantage in picking resources, but they can also use these resources more 
effectively by reconfiguring them in the most optimal manner.  
 
Collis  (1994)  is  one  of  the  first  to  explicitly  identify  dynamic  capabilities  in  his 
categorisation of static, dynamic and creative. A static capability is the ability of a firm to 
perform  basic functions, including marketing and simple manufacturing; functions  that 
almost any firm could easily become proficient at. He refers to dynamic capabilities as 
those that help the firm learn or grow. These are capabilities such as improving operational 
efficiency  through  trial  and  error.  Creative  capabilities  he  describes  as  „metaphysical‟ 
(p.146), and are used for higher-level innovation. Whilst the ideas introduced by Collis are 
not markedly different than those in the modern-day theory of dynamic capabilities, he is 
rarely  mentioned  as  a pioneer on the topic. Most  notably, he is  not  cited in  the most 
influential papers on dynamic capabilities, Teece, Pisano and Sheen (1997). This piece also 
emphasises  the  ability  of  a  firm  to  reconfigure  its  resources,  but  it  focuses  on  paths, 
positions and processes. Paths refer to the firm‟s history and future opportunities available 
to the firm. Past paths represent how it evolved, what it has learned and the major events 
that have influenced its decision-making. Future paths represent the strategic alternatives 
available to the firm. Positions refer to the resource stocks of the firm. These resource 51 
 
stocks have a large bearing on dynamic capabilities because resources are what dynamic 
capabilities  reconfigure.  Processes  refer  to  the  internal  routines  of  the  firm,  especially 
those that have a significant impact on changing the firm.  Another distinction of Teece et 
al.‟s  (1997)  ideas  on  dynamic  capabilities  is  the  emphasis  of  rapidly  changing 
environments,  especially  technical  environments.  The  next  section  further  compares 
notable dynamic capabilities‟ definitions offered in the literature.      
 
3.4.2 Definitions and frameworks of dynamic capabilities     
Most  research  follows  Teece  et  al.‟s  (1997,  p.  516)  definition:  ‘the  firm’s  ability  to 
integrate, build, and reconfigure internal and external competences to address rapidly 
changing environments’. In a different vein, Eisenhardt et al. (2000, p. 1106) emphasise 
the  importance  of  resources  in  their  definition  of  dynamic  capabilities:  ‘strategic  and 
organizational  processes  like  product  development  ,  alliancing,  and  strategic  decision 
making that create value for firms within dynamic markets by manipulating resources into 
new value creating strategies’. Solo and Winter (2002, p. 340) offer another definition 
emphasising the importance of the customer and the competition: ‘A dynamic capability is 
a  learned  and  stable  pattern  of  collective  activity  through  which  the  organization 
systematically  generates  and  modifies  its  operating  routines  in  pursuit  of  improved 
effectiveness’.    The  problem  with  these,  along  with  the  other  definitions  scattered 
throughout the literature, is that they are vague. Conceptually, most of the definitions make 
sense, but operationally it is almost impossible to pin down what a dynamic capability is 
from  these  definitions.  Zahra  et  al.  (2006)  suggest  that  three  common  elements  are 
confounded in the literature: 1) substantive capability, 2) environmental characteristics and 
3)  higher  order  capabilities.  This  problem  is  largely  because  of  the  lack  of  clear  and 
specific definitions (Salvato, 2003). There has been a movement to clarify the definition, 
but this has gone in many uncoordinated directions, highlighted in Table 2-1. From this 
table,  it  is  evident  there  are  several  inconsistencies.  A  central  problem  is  that  these 
definitions assume that a capability is only dynamic if it provides a competitive advantage. 
Tautologically this assumption is flawed. For example, the definition offered by Rind ova 
and Taylor (2002, p. 16): ‘A newer source of competitive advantage in conceptualising 
how firms are able to cope with environmental changes’. This definition does not delineate 
where competitive advantages stem from. It also fails to consider that a dynamic capability 
is often only a building block or one part of a competitive advantage.  
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In short, the definitions presented in the literature give a good sense of what dynamic 
capabilities  are,  but  they  are  still  not  specific  enough.  A  better  direction  for  defining 
dynamic capabilities is to trace it back to its ontological roots and hierarchically break it 
down. Put differently, the concept is too complicated to define in one sentence, and it 
would be better for the literature to break the definition into interrelated pieces.  
 
Table 3-1: Definitions of dynamic capabilities 
Author                                                                                   Definition 
 
Helfat (Kaplan, Murray, & 
Henderson, p. 342) 
The subset of the competences/capabilities that allow the firm to create new 
products and processes and respond to changing market circumstances. 
 
Teece et al. (1997, p. 516)  The firm‟s ability to integrate, build and reconfigure internal and external 
competences to address rapidly changing environments. 
Eisenhardt and Martin (2000, p. 
1107) 
The firm‟s processes that use resources – specifically the processes to integrate, 
reconfigure, gain and release resources – to match or even create market change. 
Dynamic capabilities thus are the organizational and strategic routines by which 
firms achieve new resources configurations as market emerge, collide, split, 
evolve and die. 
Griffith and Harvey (2001, p. 598)  A global dynamic capability is the creation of difficult-to-imitate combinations 
of resources, including effective coordination of inter-organizational 
relationships, on a global basis that can provide a firm a competitive advantage. 
Lee et al. (2002, p. 729)   A newer source of competitive advantage in conceptualizing how firms are able 
to cope with environmental changes. 
Rind ova and Taylor (2002, p. 16)  Dynamic capabilities evolve at two levels: a micro-evolution through „upgrading 
the management capabilities of the firm‟ and a macro-evolution associated with 
„reconfiguring market competencies‟. 
Zahra and George (2002, p. 186)   Dynamic capabilities are essentially change-oriented and help firms redeploy 
and reconfigure their resource base to meet evolving customer demands and 
competitor strategies. 
Solo and Winter (2002, p. 340)  A dynamic capability is a learned and stable pattern of collective activity 
through which the organization systematically generates and modifies its 
operating routines in pursuit of improved effectiveness. 
Winter (2003, p. 991)  Those that operate to extend, modify or create ordinary (substantive) 
capabilities. 
Zahra et al. (2006, p. 920)   The abilities to reconfigure a firm‟s resources and routines in the manner 
envisioned and deemed appropriate by the firm‟s principal decision-maker(s). 
Helfat (2007, p.1)   
Helfat and Peteraf (2009,  p. 91) 
The capacity of an organization to purposefully create, extend, and modify its 
resource base. 
Source: Author based on Zahra et al. 2006.  
 
Dynamic capabilities frameworks  
The unbounded definitions of dynamic capabilities are complemented by the lack of a 
coherent framework. Many different authors (most notably, Eisenhardt & Martin, 2000; 
Makadok, 2001; Zahra et al., 2006) have proposed theoretical frameworks. However, as of 
yet  not  one  of  these  has  become  commonly  accepted.  These  models  share  several 
commonalities. Almost all of the models view dynamic capabilities as a standalone theory 
that stems from the RBV. One notable exception to this is Mikado (2001), whose model 
does not substitute dynamic capabilities for resources. Instead his model views them as 
complementary; i.e. managers help firms grow by both strategically picking resources and 
using dynamic capabilities to optimise their resources. 53 
 
 
Winter (2000) develops a hierarchical conceptualisation of dynamic capabilities based on 
Collis‟ categorisation. Winter‟s conceptualisation includes an ordered level categorisation 
of zero-level, first-order and second-order dynamic capability. A zero-level capability is 
the most basic and is the operational capabilities needed to run a firm in the short term. A 
first-order capability is dynamic, the ability of a firm to reconfigure resources and respond 
to market conditions. An example is the ability of a pharmaceutical firm to recognise an 
opportunity for a new drug development opportunity. A second-order is the capability of 
learning.  This  capability  facilitates  identifying,  creating  and  modifying  dynamic 
capabilities that are most useful in the firm's operations. According to this hierarchical 
model,  all  three  are  linked  together  and  build  off  of  one  another  to  create  the  total 
capabilities of a firm. Another premise of the model is that higher-level capabilities are not 
always beneficial to a firm, and in some cases, the cost of developing them is a poor use of 
resources. Whilst this is an interesting model, there are still many holes in it. Most notably, 
this model does not clearly define each level. Furthermore, it could also be argued that 
learning is a key element to the broader concept of dynamic capabilities. For these reasons 
few  studies  have  used  this  model.  Nevertheless,  this  hierarchical  conceptualisation  of 
capabilities has the potential to unearth insights on the values of their different types of 
dynamics. It would be beneficial for future research to synthesise and further the ideas 
presented by Collis (1994) and Winter (2003) into a more specific model(s). 
 
The dynamic capabilities literature tends to emphasise three elements: (1) learning, (2) 
routines and (3) the environment. Each of these is detailed below. 
 
Learning         
The importance of learning is scattered throughout the dynamic capabilities literature. In 
their  conceptualisation  of  dynamic  capabilities,  Eisenhardt  et  al.  (2000)  suggests  that 
learning mechanisms underlie the development of dynamic capabilities. They suggest that 
firms with more experience in responding to change are more apt to develop dynamic 
capabilities. However, anecdotal and empirical evidence (Boccardelli & Magnusson, 2006; 
Macpherson, Jones, Zhang, & Street, 2004; Newbert, 2005) suggests the opposite. Take for 
example the rise of Google, Microsoft and Dell. These firms were all inexperienced and 
were in competition with well-established firms, yet all of them significantly outgrew their 
competitors  because  they  learned  quicker  and  responded  better  to  changing  business 
environments,  even  though  they  had  little  previous  learning  experience.  Furthermore, 54 
 
Autio et al. (2000) found that new ventures have an advantage in the internationalisation 
process because of their learning advantage of newness; i.e. new firms do not have the bad 
habits of established firms and respond to market conditions more swiftly. Solo and Winter 
(2002, p. 348)  propose a better view on the development of dynamic capabilities through 
three learning-related mechanisms: 1) past experience, 2) knowledge articulation and 3) 
knowledge codification processes; accordingly, these three mechanisms underpin learning 
capabilities.  
 
Winter (2000) goes against the grain of these studies to explore when learning adversely 
effects a firm‟s dynamic capabilities. In this paper she suggests that firms can focus too 
much on learning and not make the most effective use of their resources. This piece is 
unique  because  it  challenges  the  rhetoric  so  often  seen  in  the  literatures  of  dynamic 
capabilities, absorptive capacity and organizational learning that say learning always has a 
positive effect. Though learning is one of the most popular themes in dynamic capabilities, 
relatively little empirical support backs it up. Most of the learning studies cited in dynamic 
capabilities are studies from other fields that are synthesised into the analysis of dynamic 
capabilities. One notable empirical study is the Engelhard et al. (2002) analysis of the 
dynamic learning of a major pharmaceutical company. Their analysis indicates that it is 
critical for biopharmaceutical firms early on to enable learning capabilities and to create 
actionable  knowledge  based  on  what  they  have  learned.  Engelhard  et  al.  (2002)  also 
support the idea that knowledge is only important if it is actionable. In a similar study 
Swift and Hwang (2008) suggest that organisational learning requires organisation-wide 
commitment, including top managers, mid-level managers and line workers in order to 
articulate, codify, and disseminate knowledge derived. This piece is also significant in that 
it takes a holistic look at the learning approach, instead of just looking at the importance of 
top management in the learning process. In a similar vein Davies and Brady (2000) found 
in  their  study  of  telecommunication  manufacturing  firms  that  it  is  vital  to  develop 
organisational-wide learning capabilities from previous experiences.   
 
Routines    
The second reoccurring theme in the dynamic capabilities literature is routines. Teece et al. 
(1997) referred to these as processes in their conceptualisation of dynamic capabilities and 
defined this as the way things are done within the firm. This emphasis on routines is a 
central  source  of  criticism.  The  critics  note  that  this  is  tautological,  vague  and 
immeasurable  (Blomqvist,  Kyläheiko,  &  Virolainen,  2002;  Priem  &  Butler,  2001). 55 
 
Eisenhardt and Martin (2000) argue that these are criticisms of the RBV and that dynamic 
capabilities  is  differentiated  because  such  routines  are  identifiable  and  empirically 
measurable. They point to product development and strategic decision making as examples 
of identifiable and measurable routines. However, strategic decision making is an abstract 
topic to measure, and there is little empirical support of how routines influence dynamic 
capabilities; so Eisenhardt and Martin‟s (2000) arguments do not completely dispel the 
critic‟s points of contention. 
 
 Zahra  et  al.  (2006a)  propose  that  organisational  routines  are  an  antecedent  to 
organisational learning and change. This notion is supported by Inanity and Clark‟s (1994) 
study on the integration of dynamic capabilities in automobile and computer industries. 
Although an interesting and insightful study, its findings are far from conclusive because 
of  the  weak  measures  they  drew  from  secondary  data.  Another  study  by  Abuja  and 
Lambert  (2001)  concludes  that  the  routine  of  continual  experimentation  is  critical  to 
reconfiguring capabilities to respond to environmental conditions in the global chemical 
industry.  According  to  this  study,  experimental  routines  are  the  basis  of  how  new 
knowledge on which these firms compete is created. Whilst the aforementioned studies 
offer insights on the importance of routines, they do not empirically support the emphasis 
placed on routines as suggested in marquee works on dynamic capabilities (Eisenhardt & 
Martin, 2000; Teece et al., 1997; Winter, 2003; Zollo & Winter, 2002). This is not to 
suggest that routines are not important; rather more empirical work needs to isolate the 
importance of routines in dynamic capabilities.  
 
Research is especially needed in the context of life science ventures. This research needs to 
examine what routines underpin the development of life science ventures‟ key assets and 
capabilities. The previous chapter in this thesis underscored the importance of R&D and 
specialised financing to the development of life science firms. The importance of these 
resources is well-documented, but there are gaps in understanding the routines that firms 
practice to develop R&D and financial resources and capabilities. This is one area that the 
present research specifically addresses. 
 
Environment                                                                                                                                      
A third emphasis of dynamic capabilities models is the importance of the environment. 
Dynamic capabilities is an especially useful lens to examine firms in rapidly changing 
business environments (Blyler & Coff, 2003; Davies & Brady, 2000; Eisenhardt & Martin, 56 
 
2000; D. Teece & Pisano, 1994; Teece et al., 1997). The importance of responding to a 
rapidly  changing  environment  is  a  plausible  explanation  as  to  how  young  resource 
constrained firms can enter markets and outperform large and rich competitors (March, 
1991). A prime example of this is the rise of Microsoft: A young firm started by two 
college dropouts who out-performed multibillion dollar firms, Microsoft credits much of 
their success, especially their early success, to their ability to out manoeuvre and respond 
to the tremendous technical changes taking place in the software industry (Stross, 1997). 
Researchers  emphasise  the  importance  of  dynamic  capabilities  in  technology-based 
industries  such  as  software,  biotechnology  and  semiconductors  because  the  changing 
technology  in  these  industries  requires  firms  to  quickly  change  their  operations  and 
product  offerings  in  order  to  stay  competitive.  Conventional  wisdom  and  anecdotal 
evidence support the effect rapidly changing environments have on firms; however; there 
is little empirical work to fully substantiate it. Most of the studies on the influence of 
environments  cited  in  dynamic  capabilities  are  from  studies  not  specific  to  dynamic 
capabilities.  
 
The  previous  chapter  highlighted  the  rapidly  changing  environments  that  life  science 
ventures  face,  but  research  has  not  thoroughly  investigated  how  these  environments 
influence  these  firms.  One  aim  of  the  present  study  is  to  investigate  how  these 
environments impact life science ventures.   
 
Figure 3-3 conceptualises the effect that the environment has on the firm. The figure starts 
with an original resource combination that is then shocked by an outside event. Outside 
events are either new market opportunities or external shocks. Examples of external shocks 
are changing economic conditions, technological shifts or political events. The dashed line 
from external shocks to new opportunities in the figure represent the new paths that arise 
as the result of external shocks (Deeds et al., 2000; Zahra & George, 2002); thus external 
shocks either directly or indirectly impact the firm. A shock or combination of shocks 
causes a firm to respond and reconfigure its assets and capabilities. This is represented by 
the  original  resource  recombination  being  reconfigured  to  the  post-shock  resource 
combination.  Figure  3-3  below  offers  a  simple  example,  but  in  actuality  there  can  be 
hundreds, if not more, reconfigurations that a firm can go through. In this example only 
two of the three sets of resources are reconfigured post shock: AB and CD reconfigured to 
DA and BC, whilst EF stayed the same. This illustration shows that in many cases firms 
will reconfigure many operations, but some units or divisions will stay the same even after 57 
 
a shock.  The  reconfigured resources then  either lead to  superior performance,  average 
returns or poor performance. This is an important part of the conceptualisation because it 
illustrates Winter‟s (2000) notion that reconfiguration does not always lead to superior 
performance; if resources are not optimally reconfigured to respond to the external events, 
it can also lead to average or poor performance.  
 
Figure 3-3: Conceptualisation of dynamic capabilities 
 
Source: Author 
 
3.4.3 Empirical studies on dynamic capabilities 
Although the quantity and depth of empirical work is lacking, there are several notable 
empirical studies that help to substantiate the theory. Table 3-2 highlights these studies and 
shows that a broad consensus is emerging. One industry that has recently gained popularity 
for use in the empirical testing of dynamic capabilities is the life science industry (Anand, 
Oriani, & Vassolo, 2010; Ingelgard et al., 2002; Rothaermel & Hess, 2007). A  recent 
study by Rothaermel and Hess (2007) looked into the antecedents of dynamic capabilities. 
Unlike previous studies on the topic, their research factored in the interaction of the three 
antecedents (individual, firm and network) of dynamic capabilities; instead of isolating 
them  individually  as  previous  studies  have  done  (Christensen,  1997;  Henderson  & 
Cockburn, 1994; Zucker & Darby, 1997). Rothaermel and Hess (2007) suggest that there is 
important interaction between the individual, firm and networks levels in creating dynamic 58 
 
capabilities. In some cases they work as complements, but in others they can  work as 
substitutes. Their study indicates that firms can substitute superior human capital for firm-
level factors such as R&D capacity. Thus this study established that managers must weigh 
individual,  firm  and  network  resources  when  developing  an  overall  firm  strategy 
constitutes the most important contribution of this study. Although a noteworthy study, it is 
based on weak secondary data and ill-defined constructs and measurements. Therefore it 
needs further refinement and testing.  
 
Another dynamic capabilities study that uses life science firms as the sample is Zucker and 
Darby‟s  (1997)  study  on  the  influence  of  star  scientists  on  the  transformation  of  an 
organisation. Their findings suggest that star scientists greatly influence the growth and 
direction of a firm through their innovative abilities. The scientists‟ innovations set the 
direction of the organisation and force it to reorganise to commercialise the star scientists‟ 
discoveries. Zucker and Darby (1998) followed this study up with an investigation clearly 
showing  that  knowledge  spills  over  from  universities  to  biotech  firms  located  near 
universities. This tacit knowledge is a large source of dynamic capabilities for the recipient 
firms  of  the  knowledge.  Deeds  et  al.  (2000)  is  another  empirical  study  on  dynamic 
capabilities that uses life science firms as the sample; it also highlights the importance of 
human  capital  and  supports  the  notion  that  knowledge  spilled  over  from  universities 
provides important antecedents to dynamic capabilities. Another important finding from 
this  paper  is  that  it is  better  to  keep  top  scientists  in  R&D  than  to  have  them  as  top 
executives. The management duties take away from their tacit scientific knowledge, which 
serves as a driving force to creating innovations that change a firm. This study suggests 
that it is important to have a top management team with business experience and scientific 
knowledge. 
 
In  a  different  vein,  Madhok  and  Osegowitsch  (2000)  use  dynamic  capabilities  at  the 
macro-level  to  look  at  the  diffusion  of  biotechnology  around  the  world.  They  studied 
alliance and innovation flows of the US and Europe; their findings show that initially the 
technology flows  were one way from the US  to Europe, but  over time the innovative 
capabilities built up in Europe and the flow of innovation became two way. Although an 
interesting study that gives a good overview of the evolution of the cross continental flow 
of biotech knowledge, it would have been even more interesting had they included some 
firm-level examples.  
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These studies clearly demonstrate that dynamic capabilities is starting to gain the empirical 
support that it needs to become a strong theory. Also apparent from the discussion above is 
that the life science industry offers an ideal setting in which to apply a dynamic capabilities 
framework.  The  industry  fits  the  key  prerequisites  as  it  is  rapidly  changing  and  has 
constructs that lend themselves to empirical testing. For instance, the industry is heavily 
dependent on patents, which are a good proxy to measuring innovation (Acs & Audretsch, 
1989).  There  are  also  critical  technological  inflections  in  the  industry,  which  lead  to 
interesting research opportunities on how firms reorganise themselves to respond to these 
opportunities. However, empirical work as a whole on dynamic capabilities needs further 
development. Table 3-2 presents the key empirical studies done on dynamic capabilities 
from  1992-2010.  From  this  table  it  is  evident  that  Arend  and  Bromiley  (2009)  were 
justified  in  their  assertion  that  dynamic  capabilities  does  not  have  enough  empirical 
support. Specifically there is little longitudinal work, and many of the studies examine 
dynamic capabilities post hoc. There are also few studies that have used mass surveys, and 
scant work on small firms exists.  
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Table 3-2: Empirical studies on dynamic capabilities 
Study   Measurement  Research focus  Findings 
*1. Van de Ven and 
Polley (1992) 
 
Single biomedical 
innovation over a five 
year period; in-depth case 
study with multiple 
sources and on-going 
observation 
Examined the process of  trial and 
error learning in technological 
innovations by a joint venture created 
to commercialize products. 
– Observed greater escalation of commitment and 
other types of non-rational behaviour than implied 
in the learning literature 
– Suggested the following to increase adaptation 
ability:       
        • separate planning from resource funding                             
• limit „impression management‟ opportunities                    
• foster frank communication across     
departments and    levels. 
2. Eisenhardt and 
Tabrizi (1995) 
36 Computer-related 
firms, (72 projects); case 
studies – multi-
respondents per project 
Examined effects of planning, CAD 
tools, teams, supplier involvement, 
reward, and time schedules on 
product development time. 
– Found planning and CAD tools increase the time 
to develop new products 
– Cross-functional teams, frequent iterations, 
leader power, and 
trial-and-error learning decrease development time. 
3. McGrath 
(McGrath, 1995) 
 
23 Financial services 
firms; over 200 interviews 
Exploratory research to see how firms 
process and learn from poor outcomes 
in internal corporate venturing. 
– Noted three processes needed to learn from 
disappointments:                                                                   
• recognition of failure (measurement, involvement, 
communication of results)                                                     
• interpretation of  results into a business model 
that can be tested                                                                                                                   
• action taken  to change routines. 
4. Helfat (1997)  The 26 largest energy 
firms over extended 
period of time; historical 
and secondary data 
Examined if success of responses to 
changes in external conditions 
depends on existing stocks of 
complementary know-how and assets. 
– Firms with larger stocks of complementary 
technological knowledge and physical assets 
experienced greater increase in capabilities. 
– Yet, such increased capabilities could not 
compensate for the large drop in real oil prices. 
5. Brown and 
Eisenhardt (1997) 
 
6 firms in computer 
industry (41 projects); 
case studies 
Examined the ability of firms to 
change their competences 
continuously in response to high 
velocity environments. 
– Reject notion of punctuated equilibrium and 
event-based approaches in favour of time-paced 
responses. Learning and dynamic capability 
creation based on:  
• well-defined managerial responsibilities and 
project priorities                                                                                
• extensive communication                                                           
• frequent low-cost experiments and iterations. 
6. Moorman and 
Miner (1998)  
 
One electronics 
instruments firm; one 
food products firm (107 
action events over nine 
months); survey data on 
selected events 
Examined the effects environmental 
turbulence, improvisation, and 
organization memory on product and 
process efficiency/effectiveness. 
– Turbulence has a weak positive effect on use of 
improvisation. 
– When turbulence is low, improvisation  has 
negative effect on 
effectiveness; when turbulence is high, the effect is 
positive. 
– Organization memory has a negative effect on 
improvisation. 
– However, organization  memory significantly 
improves positive effects of improvisation on all 
process and product outcomes. 
7. Kazanjian and 
Rao (1999) 
 
225 Computer-related 
companies; survey data in 
two waves 
 
Hypothesis tests on 
survey data 
Examined factors influencing 
engineering capability 
institutionalization in firms highly 
dependent on this expertise. 
– Found managerial advocacy key positive factor. 
– Found mixed results with regard to CEO 
background. 
– Found institutionalization  more likely with 
smaller TMTs. 
– Found no effects of formalization or 
centralization.. 
8. Bosch et al.  
(1999) 
Publishing firms; 
illustration of two cases 
Focused on  how organization form 
and combinative capabilities mediate 
effects of prior related knowledge on 
absorptive capacity. 
– Definitive conclusions hard to draw, but 
arguments regarding organization forms are                                                      
• Functional form is + for efficiency, - for 
flexibility, - for speed.                                                                                                   
• Divisional form is - for efficiency, + for 
flexibility, + for speed.                                                                                            
• Matrix form  is - for efficiency + for flexibility, + 
for speed 
9. Majumdar (2000) 
 
39 telecommunication 
firms over 16 yrs; 
secondary data 
Examined effects of structural 
changes in the environment on 
resource accumulation, configuration, 
and utilization capabilities of firms. 
-Concludes that contrary to popular beliefs, larger 
more stable firms can indeed transform their 
capabilities in the face of overwhelming structural 
changes to the industry. 
10. Autio et al. 
(2000) 
59 electronics firms; 
panel survey data over 
four-year period, some 
validation from repeat 
surveys and secondary 
sources 
 
Hypothesis testing based 
on survey responses 
Examined the effects of early inter-
nationalization on the prospects of 
smaller firms‟ growth. Argued that 
such firms may possess learning 
advantages over older firms. 
– Found that internationalization at an early age 
was associated with greater growth both 
domestically and internationally. 
– Found product imitability to be positively rather 
than negatively associated with growth. 
– Found knowledge intensity positively related to 
growth. 
*11. Madhok and 
Osegowitsch (2000)  
Data on  international 
alliances, joint ventures, 
licensing, acquisitions and 
new Greenfield 
subsidiaries of European 
and US biotechnology 
firms  
Examined the cross national flow of 
biotechnology innovations between 
the US and Europe. 
-Found that initially biotechnology innovation was 
a one way flow from the US to Europe.  
-Found that as Europe developed capabilities, 
innovation became a two-way flow 61 
 
Study   Measurement  Research focus  Findings 
 
Hypothesis testing based 
on secondary data 
*12. Deeds et al. 
(2000) 
94 publicly held 
biotechnology firms 
 
Hypothesis testing based 
on secondary data 
Examined the effects of technological 
and management skills on new 
product development. 
-Found that location  near research based 
universities is key to developing scientific dynamic 
capabilities. 
-Found that top scientists are  more effective in a 
research role than  in a top management role. 
13. Zahra et al. 
(2000) 
 
321 high technolog y 
firms (from 12 different 
sectors); survey data with 
validation from second 
respondents and 
secondary data 
 
Hypothesis testing based 
on survey responses  
Examined the effects of international 
diversity and mode of market entry on 
technological learning and 
performance of high technology 
firms. 
– Found that international diversity had positive 
effects on the breadth, depth and speed of 
technological learning in new internationalizing 
high technology ventures. 
– Found that knowledge integration significantly 
enhanced the positive effects of diversity on the 
breadth, depth and speed of technological learning. 
- Found that modes of entry also significantly 
affected breadth, depth and speed of learning. 
– Found a positive relationship between 
international diversity and performance. 
14. Abuja and 
Lambert (2001) 
97 global chemical; 
secondary data, especially 
patent citations 
 
 
Examined how large corporations 
create breakthrough inventions and 
how exploration of  novel, emerging, 
and pioneering technology helps them 
overcome competency traps. 
– Found inverted-U shaped relationship of 
exploration of novel and emerging technologies 
with creation of breakthrough invention. 
– Found positive relationship of exploration of 
pioneering technologies with creation of 
breakthrough invention. 
– Concluded that continual activity and 
experimentation are needed for firms to renew and 
reconfigure capabilities. 
*15. Engelhard et al. 
(2002) 
Action research: 
interviews with 26 
different individuals 
involved with R&D at 
three different pharmacy 
firms. 
Examined organizational learning 
techniques in the creation of 
actionable knowledge. 
-Suggests that the learning capability of a firm  has 
to be dynamic in order to create complex 
knowledge. 
-Suggests knowledge assessment is an important 
capability. 
16. Katila and 
Abuja (2002) 
124 Robotics firms; 
secondary data, especially 
patent citations 
 
Hypothesis testing based 
on secondary data 
Examined the effects of search 
depth and search breadth on a firm‟s 
ability to create change in product 
introduction. 
– Found a positive relationship between search 
breadth and depth on  new product introduction; 
but beyond a certain level, additional depth begins 
to reduce new product  introduction. 
– Concluded that exploitation  is a broader concept 
and more beneficial than previously believed. 
*17. Rothaermel 
Hess (2007)  
A cross national sample 
of 35 pharmaceutical 
firms‟ alliances and 
innovation output; data 
collected from secondary 
sources of information 
covering 24 years    
 
Hypothesis testing based 
on secondary data 
Examined the antecedents of dynamic 
capabilities looking at the interaction 
of individual, firm  and  network 
antecedents. 
-Found that the 3 levels of antecedents are not 
always complementary. 
-Often human capital (individual level) can 
substitute for the other two levels (firm and 
network) 
18. Harreld and 
O‟Reilly (2007) 
A case study on IBM. 
Data collected from 
secondary data. 
Examined the success of IBM from a 
dynamic capabilities perspective. 
-Found IBM has been able to thrive largely based 
on the ability to reorganize itself in the face of 
rapidly changing technology and competition 
environments . 
19. Kale and Singh 
(2007)  
175 computer, 
telecommunications, 
pharmaceutical, chemical 
and electronics firms that 
have been involved in 
alliances  
 
Hypothesis testing based 
on survey responses 
Examined the process of  learning in 
alliances. 
-Found that learning that involves articulation, 
codification, sharing, and internalization of alliance 
management know-how leads to superior 
performance.  
20. Macher and 
Mowery (2009)  
93 manufacturing 
processes in 36 different 
manufacturing facilities 
from  32 different 
semiconductor firms from 
1995 to 2001.The sample 
consisted of firms from 
the US, the EU, Japan, 
Korea and Taiwan 
 
Hypothesis testing based 
on secondary data 
Examined the role of R&D and 
learning on capabilities . 
 
-Found support for the arguments of Teece et al. 
(1997), Eisenhardt and Martin (2000), Solo and 
Winter (2002) and Winter (2003) that managing 
and reconfiguring capabilities is crucial in high-
technology industries. 
-Found that deliberate learning is important to 
creating capabilities. 
-Found „learning before doing‟ is the most 
effective approach. 62 
 
Study   Measurement  Research focus  Findings 
*21. Chiaroni et al. 
(2009)  
Two step  (1) an interview 
panel of 20 industry 
experts (2) An analysis of 
the open innovation 
modes used by 20 large 
pharmaceutical 
companies  
Examined the organizational modes 
of open innovation and how these 
effect drug development.  
-Found that  the characteristics of the biotech 
industry are mitigating variables in the 
implementation of open innovation. 
22. Newey and 
Zahra (Newey & 
Zahra, 2009) 
40 interviews with multi 
informants from two firm 
case analysis and 
comparison 
Examined how dynamic capabilities 
react to changes within the individual 
firm. 
-Found  that firms build absorptive capacity in 
value networks whilst they are developing new 
products.  
-Found that learning captured at the product 
planning level is the most beneficial. 
23. McKelvie and 
Davidsson (2009)  
Sample of 108 Swedish 
new (<10years) SMEs 
from various industries 
 
Hypothesis testing based 
on survey responses 
Examined the effect the founder 
human capital, access to employee 
human capital, access to technological 
expertise, access to other specific 
expertise and access to two types of 
tangible resources had on the 
development of dynamic capabilities. 
-Found that resources and changes to resources are 
important to forming dynamic capabilities. 
-Found changes in resources have more influence 
on the development of dynamic capabilities then 
the stock of resources does. 
-Suggested that the firm is a dynamic stock of 
resources rather than a static stock. 
*24. Narayanan et 
al. (2009) 
Multiple interviews with 
several layers of 
management at one 
pharmaceutical firm 
Examined the cognitive orientations 
of key personnel, managerial action 
within the firm and the firm‟s internal 
and external contexts and how these 
effected the development of 
capabilities. 
-Suggests that key personnel have a significant 
impact on the development of capabilities; not 
because their actions were inimitable but because 
of their persistence in developing the capabilities 
led the dynamic capabilities.  
-Found that external contingencies have a major 
impact on the development of dynamic 
capabilities.  
25. Romme, Zollo 
and Berends (2010)  
Experiment simulation of 
how executives develop 
knowledge routines in the 
face of different 
environmental variables 
 
Hypothesis testing based 
on experiment results  
Examined how firms respond to 
various factors to develop knowledge.  
-Suggests that the impact of deliberate learning 
on dynamic capability is non-linear, complex, 
and in some instances counter-intuitive.  
Source: Adaptation and expansion of Zahra et al. (2006)              *Life science studies 
 
 
The table above shows that some studies are starting to surface that use hypothesis testing, 
and certain areas are justified to do so. In certain areas the theory has grown to a point 
where it can be tested. However, there are many areas related to dynamic capabilities, such 
as the development of capabilities in small firms that cannot be properly tested because of 
the lack of defined measures and constructs.  The largest problem restraining empirical 
testing in dynamic capabilities is the lack of a consistent framework. Teece et al.‟s (1997) 
paths, positions and processes framework offers a way to address this. Essentially, this 
framework  contends  that  competitive  advantage  lies  in  a  firm's  processes,  which  are 
determined from a firm's paths and positions. Previous paths are the past decisions and 
future opportunities that shape where a firm can go. Past decisions commit resources and 
often  create  rigidities  because  the  firm  is  deeply  tied  to  its  earlier  commitments.  For 
example, Deeds and DeCarolis‟ (2000) study on new life science firms shows that a firm‟s 
future development opportunities is limited by investments made in earlier research. They 
suggest that often firms invest so heavily in a technology that they drain resources that 
could be used for future projects. Future paths represent opportunities available to the firm 63 
 
and how the firm strategizes and organises its resources to pursue these opportunities. 
Positions are the resources the firm uses to leverage in their pursuit of future paths. For 
example,  life  science  firms  often  leverage  their  patents  in  the  pursuit  of  developing  a 
technology (Deeds et al., 2000; Madhok & Osegowitsch, 2000; Ziedonis, 2004). 
 
Although Teece et al.‟s (1997) paper lays out a viable framework for examining dynamic 
capabilities; i.e. probe the paths, positions and processes that lead to competitive advantage 
– little work examines all of these in a single study. As discussed above in the section on 
key empirical studies relating to dynamic capabilities, studies have examined competitive 
advantage  and  firm  growth  using  parts  of  the  framework,  but  surprisingly  little  work 
holistically examines the paths, positions and processes in a single study. Furthermore, it is 
hard to take a study that examines the paths leading to competitive advantage and then 
compare  it  to  a  study  that  examines  the  positions  that  lead  to  competitive  advantage. 
Dynamic capabilities is fundamentally process-based, and processes are hard to dissect and 
compare in multiple studies (Pettigrew, 1992). Therefore,  a sharp need for research to 
examine the paths, positions and processes leading to growth in a single study exists. In-
depth qualitative work is especially needed to unearth insights on: 
 
  What past decisions create path rigidities?  
  What future opportunities motivate reconfiguring resources and capabilities?  
  What positions do firms leverage to create key resources and capabilities? 
  What are the processes the firms use to create key resources and capabilities?  
 
Qualitative work has the potential to show how a firm develops dynamic capabilities and 
what the outputs of dynamic capabilities are. In turn, this will give quantitative scholars 
more measureable and valid constructs to work with. 
 
3.4.4 Dynamic capabilities’ shortcomings and conclusions     
Intermixed in the discussion above are several shortcomings of dynamic capabilities: lack 
of a coherent definition, weak empirical support and difficult to measure constructs. Arend 
and Bromiley (2009) note these shortcomings along with several others; they even go as 
far as to use these shortcomings as a basis to abandon dynamic capabilities. One of their 
main  assertions  is  that  the  theory  does  nothing  more  than  restate  previous  work  of 
absorptive capacity, strategic fit, first-mover advantage, organisational learning and change 64 
 
management. Accordingly, dynamic capabilities must add value beyond these theories and 
have a basis for prediction to be considered a credible theory. Their second criticism of 
dynamic capabilities is the inconsistent definitions in the literature. This is a view that is 
shared by many scholars, including those who publish on dynamic capabilities (Collis, 
1994; Williamson, 1999; Winter, 2003). Arend and Bromiley‟s (2009) third grievance is 
that dynamic capabilities lacks rigorous empirical support. They clearly show that the little 
empirical support for dynamic capabilities mainly comes from weak quantitative studies 
that do not include a longitudinal component. They also illuminate the fact that most of the 
empirical support comes from post hoc studies; i.e. research that finds successful firms that 
have  dynamic  capabilities.  A  fourth  grievance  of  Arend  and  Bromiley  is  the  lack  of 
coherent  and  logical  proxies  for  measuring  dynamic  capabilities;  there  are  too  many 
measures of dynamic capabilities, which indicate that there are incoherent constructs. The 
fifth  grievance of Arend and Bromiley  (2009)  is  the lack of practical  implications  for 
dynamic capabilities.  
 
Whilst Arend and Bromiley‟s (2009) criticisms have some merit, they do not take into 
account the entire body of work on dynamic capabilities and fail to consider that the theory 
is a young theory. Helfat and Peteraf (2009) offer a well thought out rebuttal to Arend and 
Bromiley (2009) that clearly acknowledges and addresses their concerns. They show that 
dynamic capabilities is a young theory that is just emerging from its conceptual stage; 
therefore, it will have some foundational issues to iron out. Helfat and Peteraf (2009) also 
refute the suggestion that there is weak empirical support. They point to several strong 
empirical studies (Helfat, 1997; Ingelgard et al., 2002; Zahara, Ireland, & Hitt, 2000), and 
also reiterate that because of its youth, dynamic capabilities should not be expected to have 
an established body of empirical work.  
 
In short, dynamic capabilities has the underpinnings of a strong theory. First, it can show 
causality.  For  example,  several  of  the  studies  discussed  above  show  how  dynamic 
capabilities can cause a firm to have more creative capacities (Eisenhardt & Tabrizi, 1995; 
Harreld et al., 2007; Majumdar, 2000). Second, it is measurable. For example, it can be 
measured  through  new  product  development  (Drnevich  &  Kriauciunas,  2011),  patents 
(Katila & Ahuja, 2002) and learning outcomes (Zollo & Winter, 2002). Third, dynamic 
capabilities has shown predictive powers. For example, studies have predicted that firms 
with learning capabilities can better contend with rapidly changing environments (Romme 
et al., 2010; Zollo & Winter, 2002). Furthermore, the importance of learning capabilities in 65 
 
certain settings has been disconfirmed (Kale & Singh, 2007), which shows that dynamic 
capabilities has the theoretical quality of being able to be falsified. Although dynamic 
capabilities has shown the underpinnings of a theory, it is still far from robust.  It is still in 
its nascent stage and lacks defined measures and constructs for small firms, especially for 
small life science ventures.    
 
Conclusions                                                                             
There is no perfect theory in management – whether the RBV, the five forces model, or 
transactions  cost  analysis.  Dynamic  capabilities  is  no  exception.  It  has  ill-defined 
constructs and measures and little empirical support to back it up. Although many of the 
criticisms are valid, there is potential for future research to address these. Moreover, it is 
one of the few theories that can properly account for rapidly changing environments. It 
also has a sound theoretical basis because it draws heavily on the RBV (Eisenhardt & 
Martin, 2000; Teece et al., 1997; Winter, 2003). Furthermore, Teece et. al. (1997) paths, 
positions and processes framework offers a way to tie the theory together. At the highest 
level firms are able to use their paths, positions and processes to create CAs (Teece, 1997; 
Trispas,  1997,  Rothaermel,  2001).  These  are  auxiliary  assets  needed  in  the 
commercialisation of a technology. CAs are often a large source of competitive advantage 
as they create unique competitive positions (Teece, 1986; Tripsas, 1997). The next section 
of this review delineates the literature on CAs. 
 
3.5 Complementary Assets 
This section is dedicated to further discussing one of the highest levels‟ outputs of dynamic 
capabilities – CAs. These are high level auxiliary assets and capabilities needed in the 
commercialisation of innovations (Teece, 2007). CAs are especially relevant to life science 
firms as these are needed to commercialise innovations in the field (Rothaermel, 2001a). 
This topic is also relevant to the present study because R&D has been viewed through a 
CAs lens (Gans et al., 2002; Teece, 1986). This section provides a description of CAs, 
overviews  the  empirical  work  on  CAs  and  discusses  the  shortcoming  of  the  CAs 
framework. 
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3.5.1 Description of CAs 
Teece (1986) formally introduced CAs as the auxiliary assets and capabilities needed to 
commercialise  an  innovation.  Edvinsson  and  Sullivan  (1996,  p.  360)  offer  a  slightly 
different definition specific to knowledge-based firms: „the string of assets through which 
the technology must be processed in order to reach the customer’.  Teece (1986) further 
proposes three broad categories of CAs: 1) general CAs (GCAs) 2) specialised (SCAs) and 
3)  co-specialised  complementary  assets  (CCAs).  GCAs  are  generic  assets  needed  in 
commercialisation  that  are  easily  purchased  on  the  open  market,  for  example,  general 
shipping. If a firm can ship its goods through a company like UPS or Federal Express, then 
this is a GCA; the shipping is needed for commercialisation, but it is easily obtained on the 
free market. SCAs are similar to GCAs, but they cannot be obtained on the free market. 
They are assets with a unilateral dependence that are needed for commercialisation. An 
example of an SCA is service capabilities of a medical device firm. In many cases medical 
devices require specialised service capabilities to maintain the product, and if a firm is 
unable to service the device, then the device cannot be commercialised. In many cases 
medical  device  firms  partner  with  specialised  service  firms  to  provide  the  specialised 
service for their medical device(s), which could be a unilateral dependence because the 
medical device has to have the specialised service capabilities to be commercially viable, 
but the service provider does not need the medical device firm to stay in business; they 
have other clients  that could  sustain  their business.  CCAs are assets  that  are mutually 
dependent on each other. An example of this is Microsoft and IBM in the early 1980‟s. In 
the  beginning  of  Microsoft  they  needed  IBM  for  the  hardware  platform  to  run  their 
software, and IBM needed the Microsoft software platform for programs to make their 
hardware usable and desirable. 
  
Figure 3-4 presents Teece‟s (1986) illustration of the CAs needed to commercialise an 
innovation. He identifies four areas that are usually involved with the commercialisation of 
an  innovation:  1)  competitive  manufacturing,  2)  distribution,  3)  service  and  4) 
complementary technologies. The illustration also includes „other‟ boxes to represent CAs 
not encompassed in the four other areas, an example being compliance capabilities for a 
pharmaceutical  company.  In  many  cases  biopharmaceutical  companies  have  to  have 
specialised capabilities in meeting government regulation before their products can be sold 
(Hopkins & Nightingale, 2006). This illustration gives a good conceptualisation of the CAs 
needed in commercialisation.  67 
 
 
The present  research is specifically  interested in R&D and financial  resources,  and  as 
discussed earlier, R&D has been viewed through a CAs lens. It would be interesting for 
empirical work to explicitly see where R&D fits in within a CAs framework, as there is 
little research that has looked at this. Furthermore, finance has not been viewed through a 
CAs lens, but it would be interesting to see if it could be. Capital should not be viewed 
through such a lens, but the capabilities in raising capital could be.  Conceptually they 
meet the definition of CA, auxiliary assets or capabilities needed in the commercialisation 
of an innovation (Teece, 1986); i.e. the capabilities to raise capital are auxiliary capabilities 
needed to fund the development of other assets.   
 
Figure 3-4: CAs needed in commercialisation 
 
Source: Teece (1986, p. 289) 
 
The  ideas  discussed  above  indicate  that  CAs  is  rooted  in  the  RBV.  Many  researchers 
contend that capabilities are resources that can be used to build competitive advantages 
from  (Barney  &  Hansen,  1994;  Helfat  &  Peteraf,  2003;  Mahoney  &  Pandian,  1992; 
Peteraf,  1993).  It  follows  that  SCAs/CCAs  are  resources  that  can  be  used  to  build 
competitive advantages;  they meet the criteria  of the RBV; valuable, rare, imperfectly 
imitable  and  non-substitutable  (Barney,  1991).  SCAs  and  CCAs  are  valuable  because 
commercialisation cannot happen without them. By definition, they are rare because they 
are not easily purchased on the free market. They are inimitable because they are not easily 68 
 
reproduced. Lastly, they are non-substitutable, as little else can fill the void needed for the 
SCAs/CCAs. If a CA does not meet all of these requirements, then it is a GCA. Moreover, 
SCAs and CCAs are the product of the highest level of dynamic capabilities (Teece, 2007). 
Firms must be able to either create the CCAs and SCAs needed for the commercialisation 
of  innovations  or  cooperate  with  other  firms  to  obtain  these  assets  (A.  M.  Arora  & 
Ceccagnoli, 2006; Rothaermel, 2001a). This requires firms, both internally and externally, 
to constantly manage their asset combinations and rearrange them to create the appropriate 
CCAs and SCAs needed to commercialise their innovations. Moreover, abnormally high 
profits are obtained when a firm creates a platform that other firms need as CCAs (Meyer, 
1997; Yang & Jiang, 2006). For example, Microsoft created an operating system that other 
software firms needed to commercialise their software. This platform provided a source of 
competitive advantage that yielded massive profits for Microsoft.  
 
The discussion above shows why CCAs and SCAs are at the pinnacle of the resource 
pyramid presented at the beginning of the chapter in Figure 3-1. They are the most refined 
resources needed in the commercialisation of innovations. Even though CCAs and SCAs 
offer possible insights  into how firms  obtain hyper-returns, there is  little research that 
looks at the topic. The next subsection looks into the reasons for this. 
 
3.5.2 Empirical work on CAs 
Although  Teece‟s  (1986)  seminal  work  on  CAs  is  well-noted,  there  is  relatively  little 
empirical work to support it. Numerous studies touch on CAs, but few directly examine it. 
This section highlights the noted empirical studies to date. 
 
Moorman and Slotegraaf (1999) looked  at the CAs needed for product commercialisation. 
Their  study  identifies  and  tests  a  model  of  complementary  capabilities.  The  model 
emphasises  the  interaction  between  information  and  capabilities  (namely  marketing, 
technical, R&D and distribution) of the firm. It suggests that flexibility is imperative to 
responding  to  new  information;  i.e.  firms‟  capabilities  must  be  flexible  and  work  in 
conjunction in developing the assets needed for product commercialisation. In a similar 
study,  Mitchell  (1992)  looked  at  the  role  of  CAs  in  the  medical  diagnostic  imaging 
industry.  His  research  indicates  that  the  SCAs  of  sales  and  service  buffer,  to  a  point, 
incumbents from new, more innovative competitors.  Similarly, Trispas (1997) analysed 
the typesetter industry between 1886 and 1990 and found that SCAs played a critical role 69 
 
in buffering incumbents from new competition. The new and often more innovative firms 
lacked  specialised  sales  and  service  capabilities  that  kept  them  from  overtaking  the 
incumbents that possessed these SCAs. The buffering property of SCAs is also backed up 
by Rosenbloom and Christensen (1994), who suggest firms have a whole value network 
that has to change in order for a new firm with a new innovation to enter the market.  
 
Much of the recent work on CAs focuses on alliances and networks  (e.g, Eckhardt & 
Shane,  2010;  Motohashi,  2008;  Rothaermel,  2001a;  Rothaermel,  2001b).  Rothaermel 
(2001b)  examines  the  role  of  inter-firm  alliances  and  CAs  in  the  biopharmaceutical 
industry, suggesting that incumbent firms enhance their industry position by using their 
established CAs to commercialise the innovations of new entrants. The study also indicates 
that  often  incumbents  have  well-established  positions  and  SCAs,  but  often  are  not  as 
innovative as the new entrants. In addition, the study finds new entrants lack the SCAs that 
established firms have, such as specialised manufacturing. Thus it is often better for the 
incumbent and the new entrant to form alliances to fully exploit innovations and SCAs. 
Rothaermel (2001a) came to similar conclusions from another 2001 study of CAs in the 
biotechnology industry. This study differed from his other 2001 study in that it focused on 
the alliances of large biotechnology companies, finding that firms focusing on exploiting 
CAs outperform firms focusing on creating new innovations. The study also indicates that 
the biotechnology industry focuses on establishing mutually beneficial CAs. Interestingly, 
he did not follow Teece (1986) in calling these CCAs because, in his view, it was too 
difficult to discern between SCAs and CCAs and that the difference was irrelevant for the 
study.  Similarly,  Rothaermel  (2001b)  felt  the  real  importance  is  whether  an  asset  was 
generic or specialised. In a similar vein, Rothaermel and Hill (2005) justifies using SCAs 
and CCAs interchangeably because it was not critical to the study. In this study they also 
conjecture that it is very difficult to a draw a distinction between CCAs and SCAs. Several 
other studies follow the same protocol in not distinguishing between SCAs and CCAs 
(Arora  &  Ceccagnoli,  2006;  Christmann,  2000;  Tripsas,  1997);  instead  calling  any 
specialised assets, whether and SCA or CCA, an SCA. Although the distinction between 
CCAs  and  SCAs  was  not  critical  to  these  studies,  distinguishing  them  would  have 
improved the studies by magnifying the importance of bilateral alliances.  
 
Many others have taken a similar approach as Rothaermel (2001, 2001a, 2005) and looked 
at the role of alliances in the creation of CAs. Harrison et al. (2001) notes the importance 
of  resource  complementarities  in  the  formation  of  alliances.  According  to  this  study, 70 
 
synergies are created between two firms that mutually create assets that are needed for 
commercialisation. In a similar vein, Teece (2003) notes the importance of CAs that are 
created  through  alliances  in  the  commercialisation  of  knowledge-based  innovations. 
Several others look at the importance that alliances play in establishing CAs for start-up 
firms. Most notably, Baum et al. (2000) suggest that start-ups benefit themselves by early 
along in the venture aligning themselves with alliances, integrating themselves in efficient 
alliances and aligning themselves with rivals when the opportunity for learning outweighs 
the risks of working with a competitor. Hopkins and Nightingale (2006) put forward that 
alliances offer a CA in the form of risk reduction. Their study looks at the risk-spreading of 
biotechnology firms and concludes that firms can reduce risk by creating alliances with 
firms that have specialised risk management capabilities.   
 
It is interesting that these studies note the importance of alliances to life science firms in 
creating  CAs.  However,  studies  on  CAs  and  alliances  do  not  examine  how  alliances 
interact to create the CA of R&D. The life science literature discussed in chapter two 
emphasised the importance of alliances to R&D, and the present chapter put forth R&D as 
a possible category of CA (Lowe & Taylor, 1998), yet studies have not thoroughly probed 
whether or not alliances lead to the CA of R&D. This thesis is specifically interested in 
R&D and probes whether partnerships lead to the development of CAs.   
 
The discussion in the two paragraphs above indicates that cooperation is important. Even 
firms  pursuing  competitive  strategies  will  most  likely  have  to  have  some  degree  of 
cooperation  with  other  firms;  i.e.  suppliers,  competitors  or  customers.  Teece  (1986) 
highlighted this in his conceptualisation in figure 3-5 below. This illustration shows that 
many areas (shaded) are jointly controlled through alliances (cooperative strategies), whilst 
other  areas  are  completely  controlled  by  the  innovating  firm  (competitive  strategy). 
Although this figure gives a good conceptualisation of the fact that often cooperative and 
competitive strategies are pursued at the same time, it fails to consider that individual CAs 
can  have  elements  of  cooperation  and  competition.  For  example,  R&D  can  mostly  be 
undertaken by an individual firm, but the individual firm may have partners for select 
R&D functions.  
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Figure 3-5: CAs under joint control 
 
Teece (1986, p. 291) 
 
The largest problem plaguing the empirical work on CAs is the lack of defined measures. 
The  studies  on  CAs  use  many  different  measures.  Whilst  it  is  good  to  have  different 
measures to look at the theory from different perspectives, consistent measures are needed 
for  comparative  purposes  (Johnson  &  Onwuegbuzie,  2004).  Furthermore,  the  lack  of 
consistent measures also raises reliability and validity concerns for the framework. Gans 
and Hsu (2002) developed five-point Likert scales to measure the importance and degree 
of specialisation of CAs. Their scales are the most accurate measures offered to date and 
are adapted by several others (Parmigiani & Mitchell, 2009; Pries & Guild, 2007, 2010). 
Other than the measurements offered by Gans and Hsu (2002), there have been few other 
reliable and valid independent variable measures offered to date. The dependent measures 
are not as problematic in CAs because these measures are adapted from studies in related 
areas, such as firm growth, the RBV, and transactions costs.  
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CAs and patents 
Patents  are  an  important  resource  that  influences  CAs.  Arora  and  Ceccagnoli  (2006) 
looked at the effect that patents have on CAs and found that firms with weaker patent 
protection rely more on stronger CAs to commercialise their products. They also find that 
firms with stronger patents rely more on licensing to commercialise their goods; because 
their value added activities are in the patent and not the SCAs/CCAs. This work has been 
supported by several others (Colombo, Grilli, & Piva, 2006; Deeds et al., 2000; J. S. Gans 
& S. Stern, 2003). Grauff et al. (2003) examines the effect of intellectual property in the 
mergers and acquisitions of agricultural biotechnology firms. The results from their study 
indicate  that  firms  merge  with  each  other  to  align  their  complementary  intellectual 
property portfolios. In a similar vein, Edvinsson and Sullivan (1996) suggest that patents 
themselves do not  fully protect  technology.  Instead they contend that  SCAs/CCAs are 
needed to protect novel innovation. Though patents protect innovations as a whole, some 
important processes or ideas cannot always be patented. Furthermore, processes and ideas 
can  be  exposed  in  the  licensing  process  when  information  is  shared;  the  exposed 
information  could  be used to  create competing innovations  (Lanjouw &  Schankerman, 
2001). Difficult to obtain, SCAs/CCAs offer protection that patents cannot because they 
protect knowledge and make it so other firms cannot commercialise a similar innovation. 
Edvinsson and Sullivan (1996) emphasise this in their model of innovation, which is based 
off of four major elements: human capital, structural capital, complementary assets and 
intellectual property.  
 
Size  is  another  mitigating  factor  in  the  development  of  CAs  needed  to  commercialise 
patents. Arora and Fosfuri (2003) offer a model of rent vs. revenue for patents. This model 
looks at what factors drive a firm to either license their innovations or to commercialise 
their innovations themselves. One mitigating factor is the size of the firm. Small firms 
often do not have the resources and capabilities to commercialise an innovation; instead 
they often focus on one particular process such as R&D. Because of the lack of assets and 
capabilities to commercialise an innovation, small firms often license their ideas; even 
though the rents they earn are less than if they commercialised the products themselves 
(Pries and Guild, 2010). Conversely, large firms that develop innovations often control the 
upstream and downstream activities. Not only does this allow them to earn higher rents 
from their innovations, but it also shields them from competition. Furthermore, controlling 
the  downstream  activities  also  allows  firms  to  reduce  transactions  costs  (Heller  & 
Eisenberg,  1998).  Each  company  that  is  involved  in  commercialisation  adds  layers  of 73 
 
transactions; especially in the case of patent licenses where contracts consume substantial 
time and resources in developing (Hennart, 1988; Oxley, 1997). 
 
From the discussion above it seems natural that large firms should control the upstream 
and downstream activities in developing an innovation. However, an increasing percentage 
of downstream research comes from small firms (Jones, 1999; Nicholas, Ledwith, & Perks, 
2011; Van Beuzekom & Arundel, 2009). For this reason large firms are working with 
small firms to create CCAs/SCAs to commercialise the innovations conceived by small 
firms.  The  competition  for  the  most  novel  ideas  is  intense  and  has  led  to  large  firms 
investing  in  smaller  R&D  firms  that  have  ideas  with  grand  potential  (Arora  & 
Gambardella,  1990).  This  investment  helps  secure  the  innovation  rights  for  the  larger 
company.  
 
It is surprising that small firms are often the source of knowledge and innovation needed 
for the development of CCAs and SCAs, especially in capitally intensive industries such as 
the life science industry. This phenomenon is credited to two things: the spill-over effect 
from universities and the fact that small firms are more flexible and can more quickly 
respond to changing technological environments. There is a clear correlation between the 
spill-over of innovations from universities to industry, especially to small firms. Studies 
indicate that in areas with top-tier research universities, there are  an inordinately high 
number  of  innovative  start-ups  (Anselin,  Varga,  &  Acs,  1997;  Jaffe,  Trajtenberg,  & 
Fogarty, 2000; Jaffe et al., 1993). The ideas for innovations are often birthed in universities 
and then either sold to firms located near the university or a spin off firm is created near 
the university. This is especially prevalent in life science innovations where scientists like 
to stay on the university‟s faculty whilst still pursuing the opportunity to commercialise 
innovations  (Audretsch  &  Stephan,  1999;  Zucker  et  al.,  2002).  The  second  reason 
attributed  to  the  innovativeness  of  small  firms  is  flexibility.  Small  firms  have  the 
advantage  of  newness  and  are  not  entrenched  in  bureaucratic  routines  the  way  large, 
established firms are (Autio et al., 2000). Acs and Audretsch (1987) suggest that small 
firms  have  an  advantage  in  innovating  in  industries,  such  as  life  science,  that  are 
technologically intensive. Furthermore, the literature on absorptive capacity suggests that 
new firms often have an advantage in recognising opportunities (Cockburn & Henderson, 
1998a; Stock, Greis, & Fischer, 2001). In short, small firms are often innovative because of 
their university ties and the fact that they are flexible and dynamic.  
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3.5.3 An unexplored framework 
Perhaps the reason so many researchers avoid the explicit use of the term CAs is that it is 
so  elusive  to  define  and  measure.  Teece  (1986)  describes  CAs  as  support  assets  or 
capabilities needed for the commercialisation of an innovation. Whilst in theory this seems 
clear, in practice it is much more difficult to pin down, especially for SCAs and CCAs. 
Take the example of manufacturing capabilities in the pharmaceutical industry: if a firm 
has  truly unique manufacturing capabilities, then this  would be considered an SCA or 
CCA. However, if a firm could contract the manufacturing of a drug out, would this be an 
SCA or CCA? If the contract manufacturer has truly unique capabilities and formed a 
partnership with  a pharmaceutical  firm, and both were reliant on each other, then this 
would be a CCA. But if the R&D firm in this example could set this alliance up with a few 
different  manufacturing  firms  that  had  unique  and  specialised  production  capabilities, 
would this be an SCA or CCA? As this example shows, there is clearly a grey area in 
defining  CAs,  especially  in  discerning  amongst  GCAs,  SCAs  and  CCAs.  Moreover, 
measuring  CAs  has  proven  even  more  difficult.  For  example,    Rothaermel  (2001a) 
attempted  to  measure  complementary  alliances  based  on  secondary  data  of 
biopharmaceutical  alliances  and  new  product  development.  The  results  indicate  that 
incumbents  prefer  alliances  to  leverage  CAs  over  those  to  create  new  innovations. 
However, the analysis fails to show how a coded variable based on secondary data can 
differentiate between an alliance for the purposes of obtaining a CA and an alliance for 
creating new innovations. This is not to criticise this research, as it was an excellent study 
that provided much needed insight on CAs; rather this illustrates how difficult it is to 
measure CAs. One way to overcome these difficulties is to capture the essence of CAs in 
survey and interview studies. Qualitative work is especially needed to unearth insights on 
the connections between CAs and firm growth. These insights are needed to create valid 
and reliable measures.  
 
Table 3-3 below outlines the major empirical work done on CAs. This table is much leaner 
than  the  table  presented  earlier  in  the  chapter  on  the  empirical  work  on  dynamic 
capabilities. CAs lacks the conceptual and empirical robustness of a major framework. 
However, there are several strong studies that have conceptually laid the ground work for 
the framework (e.g., Eckhardt & Shane, 2010; Edvinsson & Sullivan, 1996; Teece, 1986), 
and several other studies that provide an empirical base for it (e.g, Rothaermel & Hill, 
2005;  Tripsas,  1997).  More  studies  in  the  fields  of  strategic  management, 75 
 
internationalisation, entrepreneurship and marketing need to study the role of CAs in firm 
growth.  
 
Year over year a higher percentage of firms in developed countries are technology-based 
firms (Conway, Janod, & Nicoletti, 2005). Technology firms require ancillary assets to 
commercialise their innovations (D. J. Teece, 1986), yet the management literature has 
failed to properly investigate the topic. Stieglitz and Heine (2007) make a strong argument 
on  the  merits  of  using  CAs  in  the  study  of  strategic  management.  Specifically  they 
conjecture that CAs are an important part of the strategic direction of firms and need to be 
factored in. They also suggest that CAs should be centrally coordinated by management, 
and that controlling CAs on an ad hoc basis to the firm does not work because the whole 
firm must be integrated with the CAs, a key point that other studies on the topic have 
missed. Another area that is specifically lacking, especially with regard to new ventures, is 
how  firms  create  CAs.  Many  of  the  studies  discussed  above  note  the  importance  of 
alliances in ascertaining key CAs, but not all CAs are accessed through partners. Little 
work investigates how firms internally develop CAs. Moreover, there are few studies that 
examine the interface between creating CAs and finance; i.e. how CAs are capitalised, 
which  is  especially  relevant  for  new  ventures  that  are  resource  constrained.  Thus  the 
question remains: how do young firms overcome financial restraints to create or acquire 
CAs?  
 
 
Table 3-3: Key CAs studies 
 
Author   Area of CA Looked At  Type Of Study  Results 
Teece (1986)  Introduction and 
conceptualization of 
complementary assets 
Conceptual Paper  -Introduces GCAs, SCAs, and CCAs  
Edvinsson and 
Sullivan (1996) 
Conceptual model of 
intellectual capital 
Conceptual Paper  -Introduces a model of intellectual 
capital based on human capital, 
structural capital, complementary 
business assets, and intellectual 
property 
Tripsas (1997)  CAs as a buffer to 
competition 
Hypothesis testing 
based on historical data 
of the typesetter 
industry 
-Firms can buffer themselves from 
new more innovative firms if they 
have well established specialised CAs 
Shane (2001)  Developed and tested a 
model of firm formation 
based on four variables: the 
age of the technical field, 
effectiveness of patents, the 
tendency of market 
segmentation, and the 
importance of CAs 
Took 1,397 patents 
from MIT and looked 
at how many of these 
led to firm foundation. 
-Found that firm foundation off of 
university patents is more likely when 
technical fields are young, markets 
are segmented, patents are more 
effective, and marketing CAs are less 
important 
*Rothaermel 
(2001a) 
Alliance formation for the 
purposes of developing CAs 
Testing based on 
secondary data of 
Alliances of large 
-Incumbents that focus on developing 
networks to exploit CA outperform 
firms which focus on networks to 76 
 
Author   Area of CA Looked At  Type Of Study  Results 
international 
biopharmaceutical 
firms 
develop innovation 
*Rothaermel 
(2001b) 
Alliances formation for the 
purposes of developing CAs 
Testing of secondary 
data of alliances of 
large international 
biopharmaceutical 
firms. Focuses on 
incumbents alliances 
with new firms to 
access new 
technologies. 
It is better for firms to focus on 
developing SCAs and CCAs than on 
further developing technology. 
*Rothaermel (2002)  Alliance formation. How 
firms go about forming 
alliances  
Testing secondary data 
of 325 new 
biotechnology firm 
alliances 
New biotech attractiveness is related 
to its new product development. 
Funk (2003)   Looked at how firms can 
exploit information 
advantages to gain 
preferential access to CAs 
Examining five major 
Japanese cell phone 
producers. Collected 
data through 17 
interviews. 
Found that firms that had an 
information advantage over the 
competition were able to gain 
preferential treatment to valuable 
CAs. 
*Graff et al. (2003)  Tests an overarching 
hypothesis that the biotech 
agriculture seed industry has 
changed because of 
advanced CAs 
Taking two sets of 
mergers and alliance 
data on agriculture 
biotech firms: one set 
of 60 and one set of 46. 
Found that the agriculture biotech 
industry has reorganized itself 
through mergers and acquisitions to 
exploit CAs. 
West (2003)  Looks into the optimal 
combination of open and 
closed source code in 
software platforms 
Uingd four major 
software companies as 
case studies:  Apple, 
IBM, SUN, and 
Microsoft. 
Suggested that hybrid strategies of 
open and closed source will provide 
the highest returns. This strategy will 
enable other firms to use the 
platforms as CCAs. 
*Hopkins and 
Nightingale (2006) 
Risk management as a 
complementary asset 
Examining four 
biotechnology case 
studies. 
Found that risk management is a 
useful SCA/CCA. Firms should align 
themselves with partners that have 
complementing risk management 
capabilities.   
Swink and Nair 
(2007) 
Tested the theory of 
complementarities on 
manufacturing design and 
advanced technologies 
A survey of 224 
technical 
manufacturing firms 
Found that manufacturing design is 
important complementarily to 
advanced manufacturing. 
Stieglitz and Heine 
(2007) 
The role of CAs in strategy  Conceptual  Suggested that CAs are an important 
factor in strategy. 
Suggested that top managers must 
properly account for CAs and also 
create or secure CAs needed to be 
competitive. 
Suggested that CAs are important 
resources that fit into the RBV 
framework. 
Motohashi (2008)  Strategic use of patents by 
Japanese firms 
Secondary data testing 
of Japanese patents 
Indicated that smaller firms with 
undeveloped CAs have a higher 
propensity to license than firms with 
developed CAs.           
Indicated that large firms tend to be 
the licensor to obtain innovations so 
that they can exploit their developed 
CAs.              
Parmigiani and 
Mitchell (2009) 
Source of complementary 
manufacturing assets 
A survey of 193 US 
manufacturing firm.  
Found that firms often concurrently 
source manufacturing assets from 
several sources. 
Noted that knowledge is a key factor 
on the source of manufacturing 
assets. 
Indicated that experience firms are 
more apt to concurrently source than 
inexperienced firms.  77 
 
Author   Area of CA Looked At  Type Of Study  Results 
Eckhardt and Shane 
(2010) 
Technological innovation 
and entrepreneurial activity 
Secondary data on 201 
industries over a 15 
year period  
Found that technical innovation is an 
important driver to entrepreneurship. 
Discovered that CAs are not a big 
restraint to the dissemination of 
innovation. 
*Ceccagnoli et al. 
(2010) 
The role of CAs in 
technology outsourcing  
Secondary data from 
the pharmaceutical 
industry 
Found that firms with more CCAs 
outsource less of their technology. 
Indicated that increased transactions 
costs can stimulate the demand for 
technology from external sources. 
Source: Author                                                                                    *Life science studies 
 
 
CAs is an offshoot of dynamic capabilities, and as the name suggests, it has potential to 
complement research on dynamic capabilities. CAs offers unique insights into the auxiliary 
assets and capabilities needed in the commercialisation of innovations, especially in high 
tech  innovations.  It  has  sound  theoretical  backing,  but  unfortunately  lost  momentum 
shortly after it was introduced. However, as of late it has started to regain momentum and 
is being led by Frank Roethermel who has produced several influential pieces (2001a, 
2001b,  2005)  in  the  last  ten  years.  Several  others  have  also  joined  him  (Arora  & 
Ceccagnoli,  2006;  Ceccagnoli,  Graham,  Higgins,  &  Lee,  2010;  Colombo  et  al.,  2006; 
Helfat & Peteraf, 2003; Hopkins & Nightingale, 2006; Stieglitz & Heine, 2007; Swink & 
Nair, 2007), and the topic should see great progress in the next ten years. CAs has great 
research potential in many different fields, especially those interested in high tech firms.  
 
This section discussed several shortcomings of CAs with two notable ones being (1) it is 
difficult to empirically define and measure and (2) it lacks a clear framework. This makes 
it difficult to generate and test hypotheses and is why there is not a more robust body of 
empirical  studies  that  have  tested  CAs.  However,  CAs  is  an  off  shoot  of  dynamic 
capabilities, which allows it to be examined from a dynamic capabilities framework; i.e. 
probe the paths, positions and processes that lead the development of CAs. In the context 
of new life science ventures, work is especially needed to examine how R&D CAs are 
financed and developed. The importance of R&D resources to the development of new life 
science firms is well documented, but little work looks at how these resources are financed 
and developed.  
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3.6 Resource based paradigm conclusions  
It is clear from this chapter that Penrose‟s (1959) ideas on the importance of resources and 
management to firm growth are alive and well. Her ideas evolved into the RBV and are 
now  transforming  into  the  theory  of  dynamic  capabilities.  Findings  from  the  review 
suggest that dynamic capabilities is a unique theory rooted in the RBV that has particular 
potential for use in the study of high technology firms. This chapter also suggests that CAs 
is a complementary framework rooted in dynamic capabilities. CAs offers unique insights 
on the auxiliary assets and capabilities that are needed to commercialise innovations. It is 
an  especially  useful  framework  on  firm  growth  because  it  allows  research  to  look  at 
growth  from  several  different  angles.  In  short,  dynamic  capabilities  and  CAs  offer 
frameworks that could help unravel the growth process of high tech firms. 
 
The literature on dynamic capabilities is fragmented and difficult to bring together, largely 
because of a lack of coherent direction in the literature. There are many incongruent ideas 
and weak frameworks manifested in an undeveloped body of empirical studies; a group of 
work marked by vastly different and unsubstantiated studies. However, in the past ten 
years it has made large conceptual and empirical strides towards becoming a strong theory. 
This review clearly shows that there is potential for dynamic capabilities to become a 
powerful framework for explaining life science firm growth. Furthermore, work needs to 
use a dynamic capabilities framework to look at how key resources and capabilities are 
formed; i.e. what paths, positions and processes lead to the development of key resources 
and capabilities.  
 
3.7 Literature review summary 
The literature on life science firms suggests that they are highly innovative in high velocity 
environments. Resources and capabilities are paramount to the development of firms in the 
industry. Despite this, the prominence of smaller firms is increasing (Giovannetti, 2010). 
These small firms are contributing significantly to innovation in the industry. Surprisingly 
little  research  has  examined  how  firms  develop  their  R&D  resources  and  capabilities. 
Furthermore,  the  research  is  limited  on  how  life  science  ventures  develop  financial 
resources. Some work exists that looks at the role of alliances, universities and venture 
capital in supplying R&D and financial inputs. However, most of this examines the topic 79 
 
from the supplier side. Little work has been done on the motivations and assets that lead to 
the development of R&D and financial resources and capabilities in life science ventures. 
 
The discussion on the evolution of the resource-based paradigm suggests that resources are 
paramount to growth. In highly dynamic environments it is critical for firms to reconfigure 
their resources and capabilities in response to industry changes. The dynamic capabilities 
framework examines the paths, positions and processes that lead to the configuration and 
reconfiguration of resources and capabilities that lead to long-term competitive advantages. 
This framework is still in a juvenile state, but it has proved to be a good lens to examine 
life science firms through. It provides a particularly good lens for investigating the paths, 
positions  and  processes  that  lead  to  key  resources  and  capabilities.  The  next  section 
introduces the study‟s framework that is based on this.  
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Chapter 4 – Problem Statement                        
and Research Questions 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
  To outline the theoretical background of this study. 
  To develop the framework of this study. 
  To establish the research questions of this study. 
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4.1 Introduction 
It is estimated that over forty per cent of life science innovations stem from firms that have 
fewer than 250 employees and that there are over 300 new life science ventures formulated 
in the US each year (Van Beuzekom & Arundel, 2009). The innovations that life science 
ventures  develop  require  unique  R&D  resources  and  capabilities.  These  typically  cost 
millions of dollars to develop and often new ventures sustain years without revenues whilst 
their innovations are being developed (Murray and Wolfson, 2010). Despite this, research 
has not thoroughly investigated how firms develop the R&D and financial resources and 
capabilities to develop novel life science innovations.   
 
Although there is a growing recognition of the importance of R&D and financial resources 
and capabilities to the growth of young life science ventures, research on the development 
of these resources and capabilities is still scarce. Studies on these topics tend to focus on 
larger firms (Mittra, 2007; Rothaermel & Hess, 2007). This is largely attributed to the 
public nature of large life science firms and the fact that data is more readily available for 
large firms. Moreover, Murray and Wolfson (2010) suggest that the nature of life science 
ventures has changed drastically in the last five years. This has made studying these firms 
difficult, and this, coupled with the fact that these firms often fail, makes studying small 
life  science  ventures  difficult.  Thus  investigating  how  these  firms  develop  R&D  and 
financial resources and capabilities remains an important topic. This thesis examines it.  
 
This chapter is devoted to identifying the conceptual framework and research questions of 
the study. It starts with a discussion of the influences on the research topic. From this, the 
theoretical framework for the study is then presented. Subsequently, the research questions 
are then presented in relation to the study‟s framework.   
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4.2 Theoretical basis 
The  literature  review  emphasised  that  resources  and  capabilities  are  germane  to  the 
development of life science firms, and for this reason both the resource-based view (RBV) 
and dynamic capabilities models are particularly good lenses for looking at life science 
firms  (Coombs  &  Deeds,  2000;  Madhok  &  Osegowitsch,  2000;  Rothaermel  &  Hess, 
2007). The literature review also underscored that there are few defined measures and 
constructs on the topics related to this research. For this reason a framework is called for 
that allows the study to deeply probe how R&D and financial resources and capabilities are 
developed. The paths, positions and processes dynamic capabilities framework proposed 
by Teece et al. (1997) answers this call. This framework allows the study to isolate the 
paths, positions and processes that lead to the development of R&D and financial resources 
and capabilities.   
 
Previous paths are the past decisions and future opportunities that shape where a firm can 
go. Past decisions commit resources and often create rigidities because the firm is deeply 
tied to its earlier commitments. For example, Deeds and DeCarolis‟ (2000) study on new 
life  science  firms  shows  that a firm‟s  future development  opportunities  are  limited by 
investments made in earlier research. They suggest that often firms invest heavily in a 
technology, and this drains resources that could be used for other projects. Future paths 
represent opportunities available to the firm, influencing the firm‟s strategies. Positions are 
the resources that firms use in their pursuit of future paths. For example, life science firms 
often leverage their patents in the pursuit of developing an innovation (Deeds et al., 2000; 
Madhok & Osegowitsch, 2000; Ziedonis, 2004). Processes represent a firm‟s systems and 
routines. A firm‟s processes are determined by its paths and positions; i.e. firms develop 
processes based on the available opportunities, the restraints caused by past decisions and 
resources available to them. Examples of processes are learning and sensing. Life science 
firms  require  competencies  in  sensing  out  technologies  and  learning  from  their  earlier 
research (Kaplan, Murray and Henderson, 2003). 
 
The paths, positions and processes framework allows this research to deeply probe how 
R&D  and  financial  resources  and  capabilities  are  formulated.  Figure  4-1  presents  the 
framework this study draws on. The paths aspect allows the study to develop questions 
pertaining to the decisions and opportunities that influenced the development of the firms‟ 
R&D  and  financial  resources  and  capabilities.  For  example,  what  investments  in 83 
 
technology influenced the development of a firm‟s financial resources and capabilities? 
The positions aspect allows questions to probe the resources that the firms used in the 
pursuit of developing R&D and financial resources and capabilities, such as whether or not 
a firm‟s scientists were an important resource that helped in the development of R&D. The 
processes aspect of the model allows questions to be developed that probe the routines that 
proved  important  to  the  development  of  the  firm‟s  R&D  and  financial  resources  and 
capabilities.  For  example,  whether  or  not  learning  routines  were  important  to  the 
development of the firm‟s R&D. In turn, the study is then interested in how R&D and 
financial resources and capabilities help a firm grow. The two loop-backs in the figure 
represent the resources and capabilities feeding back into the paths and positions of the 
firm; i.e. the new resources and capabilities will affect the positions and strategic paths 
available. For example, a firm with initial paths, positions and processes that lead to the 
development  of  advanced  R&D  resources  and  capabilities  will  be  affected  by  these 
resources and capabilities. The newly created resources and capabilities provide the firm 
additional positions on which to compete and open new research and market paths. In turn, 
the firm leverages its expanded paths and positions to broaden its R&D and finances, and 
ultimately this perpetuates the firm‟s growth.    
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Figure 4-1: Research framework 
 
Source: Author 
 
 
4.3 Research objectives and questions 
The literature review indicates that existent theory does not offer deep insight into the 
R&D  and  financial  resource  and  capability  development  of  life  science  ventures. 
Moreover, the existing theory does not provide strong constructs on this topic. Thus the 
overarching objective of this study is to close the gap in the deficiency of knowledge 
related to the R&D and financial resources and capabilities of life science ventures. Based 
on the topic and discussion above, two research objectives are set forth:  
 
Objective 1 
To explore and examine how R&D and financial resources and capabilities are developed.  
 
Objective 2 
To explore and examine the effect of R&D and financial resources and capabilities on the 
growth of life science ventures. 
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Each of these is discussed below along with the research questions for each objective. The 
questions are defined by the findings from the literature. These questions focus the study; 
however, they are purposely asked in order to allow for flexibility in the findings. This is 
important in qualitative research where interviews are used to collect data (Yin, 2008). The 
next chapter further elaborates on this point.     
 
4.4 Objective 1 
The first objective stems from the fact that little research investigates the development of 
R&D  and  financial  resources  and  capabilities  in  life  science  ventures.  Despite  its 
importance,  this  topic  has  not  properly  been  examined.  The  literature  underscores  the 
importance of R&D (Kenney, 1986) and financial (Baum & Silverman, 2004; Powell et al., 
2002) resources and capabilities of larger life science firms, but little work examines these 
from a small life science firm‟s perspective. There is a real gap in understanding how life 
science ventures develop R&D and financial resources and capabilities. This objective is 
examined under the guise of the study‟s paths, positions and processes framework. 
 
4.4.1 Paths and positions 
The defining trait of life science firms is innovativeness. From 1980 to 2006 the industry 
had more patents than any other; in 2008 almost eight percent of the total patents filed in 
the US were life science patents, over 11,000 (Van Beuzekom & Arundel, 2009). A survey 
of life science executives found the number one goal of R&D is to discover breakthrough 
products (Deloitte & Touche, 2009). Decarolis and Deeds (1999) suggested that innovation 
in the life science industry is measured and stored in the forms of academic citations and 
patents.  They also  note that greater stocks  of  patents  and citations  are correlated with 
superior  performance.  The  high  patenting  and  publishing  propensity  demonstrates  the 
creative destruction that is so widespread in the industry, with new and better innovations 
constantly  replacing  old  ones  (Kenney,  1986;  Powell  et  al.,  1996;  Roijakkers  & 
Hagedoorn, 2006). Other than noting that life science ventures are often created to pursue a 
novel  innovation,  the  literature  has  not  provided  great  depth  on  the  influence  that 
innovation has on the development of life science ventures. Further knowledge is needed 
as to how innovation affects the development of firms. More specifically, little work has 
explored how the type and source of knowledge affect the development of a firm‟s R&D 
and financial resources and capabilities. The first set of questions aims to address this gap: 86 
 
 
Q1) How does an innovation affect the development of life science ventures? 
 
1a) Does the source of an innovation affect the development of R&D and 
financial resources and capabilities? 
 
2a)  Does  the  type  of  innovation  affect  the  development  of  R&D  and 
financial resources and capabilities? 
 
In the context of this research framework these questions are viewed through a paths lens. 
The decision to pursue a technology is a past decision that influences the development of 
firms; whilst future technological opportunities influence the future paths that a firm takes.  
 
Another  distinctive  trait  of  life  science  firms  is  their  reliance  on  alliances 
(Carayannopoulos  &  Auster,  2010;  Powell  et  al.,  1996).  Often  life  science  firms  are 
lacking  the  scientific  or  commercialisation  resources  and  capabilities  to  develop  their 
product(s), and for this reason they turn to other firms to fill these gaps. Calabrese and 
Silverman‟s (2000) study found that establishing strong alliances is especially important to 
start-up life science firms. They suggest that small life science firms align themselves with 
partners that have complementing capabilities. One important source of these alliances is 
universities. Zucker et al (1998) looked at the importance that top university researchers 
play in new life science companies. They found that star university researchers are often 
the driving force behind new life science firm formation, an idea that is further evidenced 
by the fact that life science firms tend to cluster spatially near top research universities 
(Owen-Smith et al., 2002; Zeller, 2001). Although there is little work specific to small life 
science firms, it follows from the discussion above that partnerships provide important 
inputs to life science ventures, which leads to the second set of questions: 
 
Q2)  Do  partnerships  have  a  major  bearing  on  the  development  of  R&D  and 
financial resources and capabilities? 
 
2a)  How  do  life  science  ventures  know  what  inputs  they  have  to  offer 
potential partners? 
 
2b) How do life science ventures identify what partners have to offer? 87 
 
 
In the context of the framework of this study these can be viewed through both a paths and 
a positions lens. Previous work has shown that partnerships in the life science industry 
open research opportunities  that influence strategy  (Haeussler, Patzelt, &  Zahra, 2010; 
Rothaermel, 2001a); thus it follows that alliances can have an influence on paths. Alliances 
also provide important resource inputs, such as scientific knowledge (Powell et al., 1996; 
Rothaermel, 2001a), and thus they can supply important resources (positions).    
 
The literature review also underscored the capitally intensive nature of the life science 
industry.  It  takes  years  from  the  time  an  innovation  is  conceived  until  the  time  it  is 
commercialised (Hall, 2002; Murray & Wolfson, 2010). This lag time from innovation to 
commercialisation forces life science ventures to sustain long periods without revenues 
whilst they are developing their innovations. During the conceptualisation phase, firms 
often  finance  their  incubation  through  insider  finance,  VC,  public  sector  grants  and 
business angels (Fraer, 1990; Murray & Wolfson, 2010).  
 
Furthermore, the amount and type of financing that a firm acquires will have a major 
bearing on its development. For example, VC has been shown to have a major impact on 
the development of their portfolio firms (Sapienza, Manigart, & Vermeir, 1996). Raising 
VC requires substantial effort, and the VCs have a major impact on their portfolio firms‟ 
management; furthermore, the capital they supply is a catalyst to firm growth (Gompers & 
Lerner, 2001; Unger, Greiman, & Leybourne, 2010). In comparison, firms that bootstrap 
their operations do not exert great effort in attracting outside investors, but it also limits 
them  in  the  capital  that  they  have  to  invest  in  the  development  of  their  innovation 
(Winborg & Landstrom, 2001). It logically follows that financing has a major bearing on 
the development of a life science firm, which leads to the third set of research questions. 
 
Q3) How does  the pursuit of financing impact  the development  of life science 
ventures? 
3a) How do different financial strategies impact the financial trajectories of 
the firms?  
 
In the context of this study‟s framework both these questions can be viewed through a 
paths lens. The pursuit of financing is a major event that firms devote substantial resources 
to. It takes time and effort to obtain the investment capital needed to finance a life science 88 
 
venture. Moreover, once investment capital is obtained, it opens up future opportunities, as 
it allows firms to invest in new areas (Chakma & Sammut, 2011; Gompers & Lerner, 
2004).  
 
Another important finding from the literature review is the importance of human capital to 
life science ventures. Zucker et al (1998) note the importance of star researchers to the 
growth and development of life science firms, which is further supported by Boxeman et 
al‟s (2001) findings that human and social capital are two of the most important building 
blocks of new technology-based companies. The clustering of life science companies near 
top  universities  also  supports  this  idea  (Blumenthal  et  al.,  1996;  Zucker  et  al.,  1998). 
Furthermore, an industry survey of life science executives placed attracting scientific talent 
as  one  of  the  biggest  challenges  in  the  industry  (Deloitte  &  Touche,  2009).  From  a 
financial standpoint, investment in a new technology-based business is often determined 
by the key individuals involved in a venture (Murray and Wolfson, 2010). Similarly, Baum 
and  Silverman  (2004)  found  that  an  important  criterion  that  investors  look  at  in  life 
sciences ventures is the background of the top managers.  
 
The discussion above underscores the importance of key individuals to developing a firm‟s 
R&D  and  financial  resources  and  capabilities.  It  follows  that  key  individuals  are  the 
drivers to the development of R&D and financial resources and capabilities, which leads to 
the fourth set of research questions:  
 
Q4)  Are  highly  trained,  skilled  and  experienced  individuals  driving  the 
development of R&D and financial resources and capabilities? 
 
 4a) Are star scientist playing an important role in the development of a 
firms R&D?  
 
In the context of this study‟s framework this question is viewed through a positions lens. 
Key  individuals  are  resources  that  firms  draw  on  to  develop  their  R&D  and  financial 
resources and capabilities. From an R&D standpoint, scientists provide vital inputs from 
their scientific abilities that allow firms to develop their R&D (Zucker et al., 2002). From a 
financial standpoint the TMTs‟ backgrounds supply a resource that firms use to attract 
investment capital. Furthermore, the TMTs in new ventures are the ones who use their 
skills and abilities to secure investment capital (Colombo & Grilli, 2009).  89 
 
 
4.4.2 Processes 
The literature review emphasised the importance of a firm‟s processes to the development 
of their resources and capabilities. Two processes of particular emphasis are sensing and 
learning.  The  importance  of  learning  is  scattered  throughout  the  dynamic  capabilities 
literature.  In  their  conceptualisation  of  dynamic  capabilities  Eisenhardt  et  al.  (2000) 
suggest that learning mechanisms underlie the development of dynamic capabilities. They 
suggest that firms with more experience in responding to change are more apt to develop 
dynamic capabilities. Autio et al. (2000) found that new ventures have an advantage in the 
internationalisation process because of their learning advantage of newness; i.e. new firms 
do not have the bad habits of established firms and learn from changing market conditions 
more swiftly. Helfat (1997) is one of the few studies that have directly looked at learning 
in life science firms. This study found that learning from experimentation is vital to the 
progress of a firm‟s R&D. Although few studies have directly looked at learning in life 
science firms from a dynamic capabilities perspective, studies in other areas have also 
indicated that learning is important to the development of R&D (Cohen & Levinthal, 1989; 
Powell et al., 1996). Similarly, studies have indicated that learning from earlier financial 
investment decisions is an important process for NTBFs. That is, firms must learn how to 
better use their capital and how to attract additional investment (Unger et al., 2010).   
 
Processes relating to sensing opportunities is another area that has been emphasised in the 
literature  (Teece,  2007).  In  an  in-depth  study  on  the  IBM  Corporation  Harreld  and 
Tushman (2007) found that sensing opportunities is a process that IBM has mastered, and 
this has been one of the firm„s main sources of competitive advantage. IBM„s sensing 
processes have allowed them to find unique innovations to develop, and these innovations 
have been important  to the firm„s  competitive  position.  Similarly, Trispas  and Gavetti 
(2000) in an in-depth study of the Polaroid corporation find that sensing new technological 
opportunities was an important process that the firm developed and  has been one of the 
this firm‟s main competitive advantages. In a similar vein, Kaplan, Murray and Henderson 
(2003) took an in-depth statistical look at fifteen pharmaceutical firms‟ TMTs ability to 
recognise  scientific  opportunities.  Their  findings  suggest  that  sensing  is  a  process  that 
gives firms a competitive advantage by allowing them to develop drugs that have unique 
and desirable characteristics.  
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A third set of processes that have been found to be important to NTBFs is networking 
routines.  As  discussed  above,  partners  provide  important  inputs  to  small  resource- 
constrained firms in dynamic environments. In order to develop partnerships, small firms 
must develop a number of formal and informal processes. They must identify partners, 
negotiate  partnership  agreements  and  develop  working  relationships  with  partner 
organisations.  The  literature  has  shown  that  these  processes  can  lead  to  alliances  that 
provide access to inputs such as R&D (Rothaermel, 2001a) and capital (Bygrave, 1988; 
Sengupta, 2011).  
 
Although there is little work that has examined the processes that lead to the development 
of life science ventures‟ R&D and financial resources and capabilities, from the discussion 
above it follows that several processes, including learning, sensing and networking, are 
important to the development of R&D and financial resources and capabilities, which leads 
to question five: 
 
Q5) What processes are important  to  the development of life science  ventures‟ 
R&D and financial resources and capabilities?   
 
4.5 Objective 2 
The second objective stems from the fact that little research examines the effect of R&D 
and financial resources on the early development of life science ventures. It is clear from 
the  entrepreneurship  literature  that  new  firms  are  often  at  a  disadvantage  because  of 
resource constraints and liability of newness  (Singh et al., 1986). Life science ventures 
face particularly large constraints, as the industry requires substantial financial and human 
capital (Baum & Silverman, 2004). Despite this fact, scores of life science ventures have 
successfully sprung up all around the globe (Giovannetti, 2010), and scholarly research 
fails to properly examine how life science ventures‟ R&D and financial resources  and 
capabilities  help  them  overcome  large  resource  constraints  to  successfully  grow  and 
prosper.  This objective is examined through the second part of the model presented in 
Figure 1 (above) and it examines what the impact of R&D and financial resources and 
capabilities are. 
 
The literature review suggests that R&D and financial resources and capabilities are at the 
heart of a life science ventures development. Often a unique innovation is the motivation 91 
 
for the start-up of a life science firm (Audretsch, 2001), and innovation sets the strategic 
path  of  life  science  firms.  For  this  reason  R&D,  coming  in  the  form  of  scientific 
capabilities and resources such as advanced laboratories, is paramount to the growth of 
these firms. .   
 
Often life science ventures are focused on the development of innovation at the onset and 
do not have revenues to support the firm‟s operations (Baum & Silverman, 2004). For this 
reason, investment capital is crucial to the firm‟s growth, and frequently this capital comes 
from VCs (Gompers & Lerner, 2001; Powell et al., 2002). A new firm without a track 
record requires a compelling case to attract the capital that is required to develop a novel 
innovation. In order to attract this investment, firms must have a business that offers the 
potential  for  great  return  and  the  firm  must  have  capabilities  in  attracting  investment 
capital (Gompers & Lerner, 2001). From the arguments above it follows that R&D and 
financial resources and capabilities are central to the development of life science ventures 
and are closely linked. This leads to the sixth set of research questions: 
 
Q6) How are R&D and financial resources integral to life science ventures? 
                   6a) How closely linked are R&D and financial resources and capabilities? 
  6b) Do R&D and financial resources co-evolve? 
 
The literature review emphasised that a number of resources and capabilities are needed in 
the  development  of  new  firms.  Research  has  noted  the  importance  of  CAs  to  the 
development  of  life  science  innovations  (Eckhardt  &  Scott  Shane,  2010;  Rothaermel, 
2001a). CAs are the auxiliary assets and capabilities required for the commercialisation of 
an innovation (Trispas, 1997). R&D has been put forth as a CA but has not yet been fully 
substantiated. Teece (1986) suggests that a complementary technology is a category of 
CAs; i.e. technologies that go along with the core technology that a firm is attempting to 
commercialise. Similarly, Gans et al. (2002) suggest that the research assets needed to get 
through government approval is a category of CA. Moorman and Slotegraaf (1999) discuss 
product  development  capabilities  and  allude  to  R&D  as  a  potential  category  of  CA. 
Similarly, Lowe and Taylor (1998) allude to R&D as a CA, but do not explicitly call R&D 
a CA. It follows from these studies that R&D can be a CA. 
 
Although financial resources and capabilities have not been looked at through a CAs lens, 
it follows that they could be viewed as such. Financial capital is needed for the growth of a 92 
 
life science firm, but the capital itself is not a CA. In management research capital is 
generally viewed as a generic proxy or transactional tool. However, financing is much 
more encompassing than just being a transactional tool or a proxy. The capital is a generic 
asset, but it follows that capabilities in raising capital could be viewed through a CAs lens, 
as these are auxiliary capabilities needed to develop an innovation. Although the extant 
research does not explicitly look at finance through a CAs lens, financing lends itself to 
being a CA.   
 
From the discussion in the two paragraphs above it follows that both R&D and finance can 
be viewed through a CAs lens. This leads to the seventh question: 
 
Q7) Can R&D and financial resources and capabilities serve as a CA? 
 
Specialised complementary assets (SCAs) are the auxiliary assets and capabilities that are 
not  easily  developed  or  contracted  for  that  are  needed  in  the  commercialisation  of  an 
innovation.  These  can  serve  as  a  source  of  competitive  advantage  (Teece,  1986; 
Rothaermel, 2007). An example of an SCA is service capabilities of a medical device firm. 
In  many  cases  medical  devices  require  specialised  service  capabilities  to  maintain  the 
product,  and  if  a  firm  is  unable  to  service  the  device,  then  the  device  cannot  be 
commercialised. These capabilities are such that they require sophisticated and often tacit 
knowledge that cannot easily be replicated.  Likewise, little work has explored whether 
financial capabilities are SCAs; as discussed above, it follows that capabilities in raising 
and managing capital could be an SCA. These are capabilities that are not easily created 
but can serve as a source of competitive advantage, especially true in the context of new 
life science ventures where there is hyper-competition for investment capital (Chakma & 
Sammut, 2011).  
 
From  the  discussion  in  the  paragraph  above  it  follows  that  both  R&D  and  financial 
resources and capabilities in certain circumstances serve as SCAs. This leads to the eighth 
question: 
 
Q8) Can R&D and financial resources and capabilities serve as a SCA?  
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4.6 Summary of framework and research questions 
There is a gap in the understanding of how small resource constrained life science ventures 
create advanced R&D and financial resources and capabilities that allow them to develop 
novel innovations. There are few defined constructs and measures on this topic, which 
calls for a framework that allows it to deeply probe the matter. The paths, positions and 
processes framework answers this call. The paths aspect allows questions to be developed 
that focus on the motivation for developing R&D and financial resources. The positions 
aspect allows for questions to focus on the positions that are leveraged to create these 
resources  and capabilities, and the processes aspect  allows for questions  to  isolate the 
important routines firms use.  
 
This  section  develops  a  dynamic  capabilities  research  framework.  This  framework 
underpins the eight main research questions of this study, which are summarised in Table 
4-1 below.  
 
This  research  is  embedded  in  an  era  of  massive  shifts  in  technology,  a  new  age  in 
innovative life science ventures, and is at the forefront of a very important topic, as young 
life science firms are having a profound effect on the life science industry. Moreover, it is 
a critical topic as R&D and finance are central to the development of life science ventures. 
The two sets of questions set forth in this chapter allow the research to examine how R&D 
and financial resources and capabilities are formulated and what affect they have on the 
development of life science ventures. The framework and research questions presented in 
this  chapter  dictated  the  research  methods  of  this  study.  The  next  chapter  details  the 
specific methods used to address this research. 
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Table 4-1: Research questions 
Q1) How does an innovation affect the development of firms? 
1a) Does the source of an innovation affect the development of R&D and 
financial resources and capabilities? 
2a)  Does  the  type  of  innovation  affect  the  development  of  R&D  and 
financial resources and capabilities? 
 
Q2)  Do  partnerships  have  a  major  bearing  on  the  development  of  R&D  and 
financial resources and capabilities? 
2a)  How  do  life  science  ventures  know  what  inputs  they  have  to  offer 
potential partners? 
2b) How do life science ventures identify what partners have to offer? 
Q3) How does  the  pursuit of financing impact  the development  of life science 
ventures? 
3a) How do different financial strategies impact the financial trajectories of 
firms?  
 
Q4)  Are  highly  trained,  skilled  and  experienced  individuals  driving  the 
development of R&D and financial resources and capabilities? 
 4a) Are star scientists playing an important role in the development of a 
firm‟s R&D? 
 
Q5)  What  processes  are  important  to  the  development  of  life  science  ventures, 
R&D and financial resources and capabilities?   
 
Q6) How are R&D and financial resources integral to life science ventures? 
            6a) How closely linked are R&D and financial resources and capabilities? 
        6b) Do R&D and financial resources co-evolve? 
 
Q7) Can R&D and financial resources and capabilities serve as a CA? 
 
Q8) Can R&D and financial resources and capabilities serve as an SCA?  
 
Source: Author 
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Chapter 5 – Research Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
  To overview the philosophical assumptions underlying the study. 
  To identify the appropriate research paradigm for the study. 
  To justify the research methods chosen for the study.
  To discuss the techniques used to ensure the reliability and validity of the study.
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5.1 Introduction 
Chapters two and three introduced the relevant literature to this study and chapter four 
presented the research questions based on this review. This chapter introduces the methods 
used to explore these questions.  
 
This  thesis  aims  to  generate  insights  on  how  life  science  ventures  develop  R&D  and 
financial resources and capabilities, and how these resources and capabilities affect the 
early growth of these ventures. Initially the research was intended to explore the research 
questions through quantitative techniques. However, a look into the literature found few 
defined constructs and measures with which to properly conduct an empirical, positivist 
study. The dynamic capabilities framework that this thesis draws on also made a positivist 
study difficult to conduct, as it is a young theory that does not have many well-defined 
constructs and measures (Helfat & Peteraf, 2009). Furthermore, in positivist social science 
research the phenomenon of interest is separated from it social setting (Easterby-Smith, 
Thorpe, & Lowe, 2002). After further information on the research questions were gathered, 
the researcher came to the determination that to unearth insights on the research topic, the 
phenomenon of interest could not be separated from its social setting. Put differently, life 
science firms should be examined in their setting to find insights on the research questions. 
For  this  reason,  the  research  adopts  a  phenomenological  approach  that  stresses  that 
meaning stems from the interaction with the phenomenon of interest (Bryman and Bell, 
2003).  
 
Regardless of the research method used, reliability and validity is a major issue. For this 
reason  the  present  study  kept  reliability  and  validity  at  the  forefront  of  this  research. 
Reliability  and  validity  in  qualitative  work  refers  to  the  trustworthiness  of  the  study 
(Lincoln and Guba, 1985). From the onset this study established dependability from proper 
design, well-crafted questions, appropriately selected cases and reliable data collected from 
multiple sources. Another challenge of qualitative work is to properly apply the findings 
from  the  study.  This  study  adopts  Miles  and  Huberman‟s  (1994)  data  reduction  and 
packaging to produce themes related to the research topics. Data was collected, compared 
across cases and funnelled into themes through multiple data reduction steps. To manage 
the massive amount of data, the researcher used case record and qualitative data analysis 
software to aid in the reduction of the data. The resulting themes were then compared 
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There are no perfect research methods in business (Bryman and Bell, 2003). All research is 
contextually based, and the proper methods depend on the research setting. Furthermore, 
methodology is restrained by time and budgets (Easterby-Smith & Lowe, 2002). It is not 
the purpose of this chapter to review all of the literature on research methods. An effort 
such as this would take years to complete and volumes of manuscript. Rather this chapter 
focuses on the methods that were considered and used in this study. The research process 
is  generally  illustrated  in  a  linear  fashion  (Bell  &  Bryman,  2003;  Creswell,  2008). 
However,  Edmondson  and  McManus  (2007)  suggest  that  whilst  research  ultimately 
follows a sequential process, it often happens in an iterative manner. Figure 5-1 presents 
the iterative process followed in this study.  
 
To  summarise:  the  research  started  with  a  broad  interest  (1)  on  the  resources  and 
capabilities important to life science ventures and then the researcher discussed the interest 
with topic experts (2). Followed by this the researcher reviewed the literature and designed 
the  study  based  on  the  literature  and  discussion  with  topic  experts.  The  study  then 
underwent an iterative process of collecting data (5, 7 and 9), then analysing the data (6, 8 
and 10) and then comparing the data to the literature. In the last step (11) the results were 
written up. Figure 5-1 serves as the framework for this chapter.   
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Figure 5-1: The study's research process 
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5.2 Steps 1-3: background 
The literature review in chapters two and three examined the major literatures (i.e. RBV, 
dynamic  capabilities,  CAs,  life  science,  and  VC  value  added)  most  relevant  to  this 
research. Dynamic capabilities is the overarching theory used here because this work is 
fundamentally  concerned  with  how  life  science  ventures  respond  to  changing 
environments to develop key resources. More specifically, this thesis is concerned with the 
paths, positions and processes that lead to the development of R&D and financial assets 
and capabilities (D. J. Teece, 1986, 2007).  
 
The literature review clearly showed that the central focus of this thesis was still early on 
its theoretical development. There is little empirical support for many of the constructs and 
propositions, and there are several grey areas that need clarification. Furthermore, little 
work has attempted to tie together the theory of dynamic capabilities with firm growth. 
The main research questions emerged from the review and discussion with industry and 
scholarly experts.  
 
5.3 Step 4: Study Design 
Steps 1-3 established the background of the research and positioned where the research 
questions are in terms of their theoretical development. Prior to establishing a research 
paradigm it is important to establish the philosophical stance of the research (Edmondson 
& McManus, 2007). In Step 4 this stance was established and the research framework was 
created based on this stance.  
 
5.3.1 Method choice for the present study 
Bell and Bryman (2003) suggest that there are five forces that influence a study towards a 
quantitative or qualitative paradigm. Figure 5-2 illustrates the major influences on business 
research, and how each of these influenced this work towards qualitative or quantitative 
methods.  Each  influence  from  figure  5-2  is  analysed  below,  and  then  the  research 
paradigm chosen for this study is presented based on this analysis.  
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Figure 5-2: Research influences 
 
Source: Author 
 
The theories involved in this research favour a qualitative approach. The literature review 
chapters established that dynamic capabilities is beyond its nascent stage of development, 
but it is still far from developed and it is in need of further empirical refinement. Further 
knowledge on the understanding of the underpinnings of how life science ventures develop 
R&D and financial resources and capabilities is what is most needed at this point. These 
are best gleaned from qualitative work (K. M. Eisenhardt, 1989b). The second influence 
from  above,  values,  neither  favours  a  quantitative  or  qualitative  approach.  Bell  and 
Bryman (2003 p. 27) define values as „either the personal beliefs or the feelings of the 
researcher’.  Values  have  a  large  impact  on  the  outcome  of  research  –  especially 
interpretive research. Bias can result at any stage of research. Just because a researcher 
does not have preconceived biases does not mean that these cannot be formed (Easterby-
Smith et al., 2002; Yin, 2008). Bias is prevalent in all types of research, both quantitative 
and qualitative, and it is the job of the researcher to minimise the effect of bias in the 
research (K. M. Eisenhardt, 1989b). The validity and reliability section later on in this 
chapter further elaborates on how biases were minimised for the present study. Overall, 
bias  did  not  have  a  major  influence  on  the  philosophical  stance  of  this  research  and 
therefore is placed in the middle. 
 
The  third  major  influence  on  business  research  is  practical  considerations.  Ideally 
researchers in business should capture both great depth and generalisibility. However, it is 
usually not practical to capture both of these in a single study (Creswell, 2008). There are 101 
 
time, cost and feasibility constraints that inhibit a researcher from being able to obtain 
everything he would like to. For this reason practical considerations are a major influence 
in designing a research project. The context and philosophical stance of the research, plus 
the  previous  research  on  the  topic(s)  dictate  the  practical  considerations.  (Hurmerinta-
Peltomaki  &  Nummela,  2004).  Put  differently,  practical  considerations  are  what  the 
research is trying to accomplish, its main objectives. On the highest level this is concerned 
with whether the research is theory building, theory testing or both. The present study is 
concerned primarily with unearthing new insights on how life science ventures develop 
R&D and financial resources and capabilities. Therefore an interpretive approach is more 
appropriate for this and the reason why practical considerations in figure 5-2 are towards 
the qualitative end of the spectrum.    
 
The fourth influence on business research is epistemological influences. For this study the 
epistemological  influences  slightly  favour  a  qualitative  approach.  Pettigrew  (1992) 
emphasises  that  organisational  processes  are  embedded  in  an  organisation.  This  is 
especially true in the growth process of the firm; it would be extremely difficult to unearth 
insights on the growth process of life science firms if the researcher did not interact with 
the  firms  themselves.  Furthermore,  it  would  be  difficult  for  the  researcher  to  take  an 
objective stance on the  key  R&D and financial  resources needed  for life science  firm 
growth because there are few defined and tested constructs and measures on the topic. 
Therefore the epistemological influences on this study favoured a qualitative approach. 
 
The fifth influence on business research is ontology. This refers to what social entities exist 
and whether their  existence is  driven by  established principles or if the social  entities 
themselves  drive  the  establishment  of  the  principles.  The  latter  is  known  as 
constructionism,  which  sees  the  social  actors  as  the  ones  constantly  constructing  and 
reconstructing the principles that guide the actors (Bell & Bryman, 2003). In the context of 
a business organisation the actors (managers, employees, customers, and suppliers) drive 
the guiding principles of the firm. These principles constantly change depending on the 
interaction of the actors. The opposite view is objectivism, which sees the principles of the 
organisation as the guiding force of the actors. In the case of the firm, the established 
principles  of  the  organisation  guide  the  actors.  For  example,  established  work  hours 
determine the actions of employees. The present study takes the stance that the managers 
in  the  firms  are  the  ones  that  construct  and  guide  the  growth  process.  Because  the 102 
 
constructs  related  to  the  social  entities  (i.e.  the  managers)  in  this  study  are  not  well-
developed, a more qualitative approach is favoured.  
 
The analysis of the forces influencing the present study indicates that overall a qualitative 
approach is more appropriate for this thesis. However, the analysis from Figure 5-2 above 
shows that mixed approaches could also be appropriate. Table 5-1 summarises the main 
types of research designs. This table shows that there are three main research paradigms: 
qualitative, quantitative and mixed methods.  
 
Table 5-1: Methodological approaches 
Paradigm   Types of Studies 
Quantitative   Survey, hypothesis testing using primary or secondary data, 
experiment, quasi experiment 
Qualitative  Case studies, ethnography, action research, grounded 
research  
Mixed methods: with 
equal emphasis 
Combination of quantitative and qualitative with equal 
emphasis 
Mixed: with quantitative 
emphasis 
Combination of quantitative and qualitative with the 
quantitative being more dominant  
Mixed with qualitative 
emphasis 
Combination of qualitative and quantitative with the 
qualitative being more dominant  
Source: Author 
 
It would seem since the present research is towards the middle of qualitative-quantitative 
spectrum, that mixed methods would be ideal. Mixed methods give a good alternative to 
strictly quantitative or qualitative approaches and are often good for research in the middle 
of the qualitative-quantitative spectrum. They are not without flaws though. One of the 
main weaknesses of mixed methods is that it is difficult for a single researcher to execute. 
A second major weakness of mixed methods is that it tends to be expensive (Perry, 1998).  
 
5.3.2 Method Considerations  
After sifting through the many possible methods that could be used for this research, two 
general approaches surfaced as the most appropriate: 1) mixed methods and 2) the case 
method. This is based on the philosophical influences discussed above and that the topics 
in the research had some theoretical underpinnings, but still needed further development. 
Mixed methods and the case method are the most appropriate for topics in this stage of 
development  because  they  both  can  serve  to  further  develop  constructs  into  a  more 103 
 
quantifiable  state  (Bell  &  Bryman,  2003;  Edmondson  &  McManus,  2007;  Eisenhardt, 
1989b).  
 
In  recent  years  the  use  of  mixed  methods  in  the  social  science  has  become  accepted 
(Creswell, 2008; Jick, 1979; Johnson & Onwuegbuzie, 2004). Mixed methods is especially 
useful  when  the  phenomenon  of  interest  is  neither  at  the  nascent  stage  of  theoretical 
development nor at the advanced stage of theoretical development (Greene & Caracelli, 
1997). In instances such as this, qualitative research adds insights that extend the prior 
empirical  base. Kuhn (1961) suggests that qualitative work is  a prerequisite to quality 
quantitative work. Before jumping into a research paradigm, McManus and Edmonson 
(2007) emphasise that fit between the methods and the state of theory is the most important 
element of a research design. Theories fall between a developmental spectrum of nascent 
to  mature.  Nascent  theories  call  for  a  qualitative  approach  because  the  constructs  and 
measures  needed  to  quantitatively  test  the  theory  are  not  available;  thus  a  qualitative 
approach is needed to develop these constructs and measures. Mature theories call for a 
quantitative approach to reaffirm or disconfirm theory. Because the theories of interest to 
this study have some defined constructs and measures, a purely qualitative approach is 
repetitive, unless it is intended to look at the topic from a different angle. Theories in the 
intermediate stage of development can use a qualitative, quantitative or mixed approach. 
Qualitative work can further establish constructs and measures, which then can be tested 
using  quantitative  techniques.  It  is  critical  to  pair  the  right  methods  for  the  stage  of 
development that a theory is in; pairing the wrong methods for the development that a 
theory  is  in  has  become  endemic  to  management  research  (Edmondson  &  McManus, 
2007). Table 5-2 summarises the problems associated with this.  
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Table 5-2: Methods and theoretical maturity 
Prior work on research 
question 
Data collection and analysis  Problems encountered  Outcome 
Mature: Extensive literature 
complete with constructs 
and previously tested 
measures  
Qualitative only  Reinventing the wheel; 
Study findings risk being 
obvious or well known. 
Research fails to build 
effectively on prior work to 
advance knowledge about 
the topic 
  Hybrid  Under status of evidence; 
Paper is lengthened but not 
strengthened by using 
qualitative evidence. 
 
Intermediate: One or more 
streams of literature 
offering some but not all 
constructs and measures 
needed 
Quantitative only  Uneven status of empirical 
measures; New constructs 
and measures lack 
reliability and external 
validity 
Results are less convincing, 
producing potential 
contribution to the 
literature. 
  Qualitative only  Low opportunity; 
Insufficient provisional 
support for a new theory; 
Lessens papers‟ 
contribution 
 
Nascent: Little or no prior 
work on the constructs and 
process under investigation 
Qualitative only  Fishing expeditions; 
Results vulnerable to 
finding significant 
associations among novel 
constructs and measures by 
chance 
Research falls too far 
outside guidance for 
statistical inference to 
convince others of its 
merits 
  Hybrid  Quantitative measures with 
uncertain relationship to 
phenomena; Emergent 
constructs may suggest new 
measures for subsequent 
research, but statistical tests 
using same data that 
suggested the constructs are 
problematic 
 
 
Source: Edmonson and McManus (2007, p. 1170) 
 
According to Yin (1981, p. 59) the distinguishing characteristics of a case study are ‘that it 
attempts to examine: (a) a contemporary phenomenon in its real world context, especially 
when (b) the boundaries between phenomenon and context are not clearly evident’. Unlike 
many other approaches, especially strictly quantitative methods, case study research has 
the potential to uncover novel theory (Eisenhardt, 1989); the unique and flexible nature 
allows  fresh  insights  to  emerge.  Case  studies  are  also  particularly  useful  for  the 
development  of  hypotheses.  They  provide  a  sound  basis  for  defining  constructs  and 
measures (Eisenhardt, 1989). There are no defined rules for case study research. They can 
use qualitative methods, quantitative methods, or a combination thereof. Although there 
are no defined rules or set protocols for case research, it is important for a case study to be 
properly designed based on the study‟s objectives  (Eisenhardt, 1989a;  Yin, 2008). Put 
differently, the objectives should determine the research protocols.  
 105 
 
Researchers must first establish what a case study‟s purpose is. Case studies serve multiple 
purposes. They can be exploratory, descriptive, explanatory or a combination thereof. An 
exploratory case study looks at „what‟ is happening around the phenomenon of interest; 
e.g. what motivates life science firms to start up? A descriptive case study is intended to 
categorise events and paint a portrayal of the phenomenon. An explanatory case study 
seeks to establish and explain causal relationships. In many instances, including the present 
study, a combination of these is appropriate.  
 
This study adopted a strictly qualitative research approach for two main reasons: (1) the 
major theories and other major research influences involved with the research favoured a 
qualitative approach and (2) there were time and resource constraints that would not have 
allowed a proper mixed-methods study to be conducted. Case studies make an ideal bridge 
between qualitative and quantitative research (Eisenhardt, 1989a; Larsson, 1993; Miles & 
Huberman, 1994). The rich insights from the cases can be used to develop constructs and 
measures for quantitative studies. Gilmore and Coviello (1999) suggest that in qualitative 
entrepreneurial  research  a  study  design  should  allow  for  refinement  through  multiple 
stages and multiple techniques; this allows for new themes to emerge. Case studies answer 
this call and allow for research to unfold over multiple stages, and it also allows for the use 
of multiple techniques in a single study. Furthermore, Coviello and Jones (2004) call for 
research to integrate positivist and interpretivist methodologies, whilst at the same time 
incorporating time as a key dimension. Case studies also answer this call because of their 
ability to incorporate different data and method techniques over specified time periods. For 
the reasons outlined above, the present study used a qualitative case method.   
 
It  is  important  before  conducting  a  study  to  establish  the  philosophical  stance  of  the 
research. The case method can use either positivist or phenomenological assumptions. In 
positivist paradigm the extraneous variables are attempted to be minimised so the observed 
variables can be isolated (Bell & Bryman, 2003). In a positivist study, results usually come 
from statistical testing of hypothesis. Generally speaking this type of research does not 
allow for  great  flexibility  (Easterby-Smith  et  al., 2002).  In contrast,  phenomenological 
research  observes  the  variables  of  interest  within  their  wider  context.  Variation  and 
flexibility in the study design are accepted. The basis for moving data to theory stems from 
comparison. In the context of cases, this is comparison is to both other cases in the study 
and to the literature (Eisenhardt, 1989a). The present study establishes a phenomenological 
paradigm that is inductive in nature. This decision was based on the researcher‟s stance 106 
 
that the best means to unearth insights on the research questions stemmed from unearthing 
fresh insights from life science ventures in the context of their operations.    
 
Although the case approach taken in this study is inductive, it is not purely inductive. 
There are few instances when research is truly inductive or deductive (Miles & Huberman, 
1994; Reichertz, 2004). Langley (1999, p. 694) sees „rigid adherence to purely deductive 
or  inductive  strategies  as  unnecessarily  stultifying‟.  The  present  study  started  with  an 
inquiry based on existing literature; thus from the start it was not truly inductive. If it were 
truly inductive it would have followed a grounded approach where no information was 
gathered on the topic prior to the start of the study. On the other hand, and as discussed 
previously, the study is not purely deductive. A better classification of the approach used 
in this study is abductive, which Reichertz (2004, p. 305) defines as „a cerebral process, 
an  intellectual  act,  a  mental  leap,  that  brings  together  things  which  one  had  never 
associated with one another‟.  
 
Abduction is in between induction and deduction, but does not necessarily fall exactly in 
the middle. It can follow ontological assumptions that are more inductive, but it also can 
follow ontological assumptions that are more deductive (Dubois & Gadde, 2002; Kovács 
&  Spens,  2005).  For  the  present  study  the  ontological  drivers  were  more  inductive; 
therefore the study used an abductive approach more towards the inductive side of the 
spectrum. Abduction also emphasises an iterative process of refining theoretical prospects 
and concepts (Dubois & Gadde, 2002).  
 
This thesis follows Bonoma (1985) in using four iterative steps in the research process: 1) 
drift,  2) design, 3) prediction  and  4) disconfirmation.  In the first  stage  the problem is 
defined;  that  is,  its  nature  and  scope.  Essentially  this  stage  is  concerned  with  getting 
intimately familiar with the topic. The drift stage then becomes the design stage. At this 
point  data  collection  begins,  the  major  areas  of  inquiry  are  further  refined,  and 
conceptualisations are fleshed out. The design stage then becomes the prediction stage 
where  ideas  are  further  refined  and  compared.  The  prediction  stage  then  becomes  the 
disconfirmation stage where the findings are attempted to be refuted.  
 
Whilst  the  present  study  followed  the  steps  outlined  above,  it  also  still  followed 
Eisendhardt‟s (1989b) suggestion not to follow a rigid research structure when using the 
case method. Instead this thesis uses the four steps in a dynamic manner. This research 107 
 
continually iterated backwards and forwards between the four steps, redefined concepts 
and questions and gathered additional data from multiple sources. Figure 5-3 depicts the 
iterative  steps  of  this  research.  Each  step  taken  is  shown  in  the  diamond  and  the  bi-
directional arrows between and across the diamond represents the backward and forward 
iteration that occurred amongst all of the steps in the process. Each of the steps taken in 
this research is further discussed below.  
 
Figure 5-3: The dynamic process of the research 
 
 
Source: Author 
 
In the drift stage research topics are probed. This research started with informal interviews 
with industry and subject experts, and these were followed by an overview of the literature. 
This helped to further refine the research questions and focus. At this stage the research 
established the broad research questions and objectives. This stage established the context 
of the phenomenon; including the industry terminology, trends and industry concepts. 
   
In the design stage ideas were further fleshed out and the framework for the research was 
constructed  and  refined.  Following  Eisenhardt  (1989)  and  Bonoma  (1985),  this  study 
constantly referred back to the theory in a theory/data/theory fashion. This led to using 
dynamic capabilities as the overarching framework. It also led to the further refinement of 
the concepts  of this  study. Furthermore, the major concepts  that surfaced aided in  the 
selection of the case firms and the development of the first formal interview schedule. The 108 
 
analysis from the exploratory interviews in this stage led to the further refinement of the 
studies direction. Most notably, analysis of the first round of interviews also underscored 
the  importance  of  R&D  and  financial  resources  and  capabilities  in  early  growth.  In 
summary, in the design stage the research concepts and ideas were refined to narrower but 
still relatively broad categories.   
 
In the prediction  stage,  ideas  from the design stage were again referenced  against the 
literature and the previous findings of the study. This led to the further refinement of the 
research  concepts  and  the  development  of  a  second  interview  schedule  and  then 
subsequently the second round of interviews. This stage led to the development of general 
propositions related to the research questions.  
 
In the disconfirmation stage, the data from the interviews was scrutinised. Researchers 
often fixate on data that supports their notions and ignore data that might disconfirm their 
notions (Spiggle, 1994). This is especially problematic in interview analysis, and because 
this research relied heavily on interview data, it was important to include a step in the 
research process to disconfirm or refute findings. This study relied on three main refutation 
techniques. The first was in the data analysis where the data was attempted to be refuted. 
This  was  accomplished  by  going  back  through  the  data  once  major  themes  had  been 
abstracted and looking for data to refute them. This process is further detailed later in this 
chapter in the data analysis discussion. The second refutation technique involved gathering 
data  from  multiple  sources.  The  third  refutation  technique  involved  triangulating  the 
findings  with  the key informants  from  each firm.  This  process  it detailed later in  this 
chapter.  
 
5.4 Steps 5, 7, and 9:  data collection 
Steps 1-4 established the background of the research and laid out a paradigm for the study. 
Steps 5, 7, and 9 were devoted to collecting the data. In case study, research data can be 
qualitative, quantitative, or both (Miles & Huberman, 1994). Data can come from many 
places, but in qualitative case studies common sources of case data include documents, 
observation and interviews with key informants. The present study utilised all three of 
these sources. However, the core of the data came from interviews with the key informants 
from the focus firms of the study. The researcher conducted a total of eighteen formal 
interviews, which totalled over twenty hours and produced over 500 pages of transcripts.   109 
 
 
In qualitative case research it is helpful to establish the unit of analysis prior to selecting 
the case firms (Yin, 2008). This allows for the selection of firms that provide the richest 
information  for  the  research  questions  and  objectives.  In  this  study  the  main  unit  of 
analysis is R&D and financial resources and capabilities. This unit of analysis is complex 
because of the many factors that influence the development of R&D and financial assets 
and capabilities needed in growth. However, properly selecting case firms that isolate the 
unit of analysis can allow for complex ideas to be captured (Eisenhardt, 1989a; Yin, 2008). 
Because  the  process  is  so  central  to  the  unit  of  analysis  of  the  present  study,  it  was 
important to isolate firms in a particular stage of growth.  Following this logic, the present 
study identified firms that were at the commercialisation stage of development. Firms at 
this stage of development were chosen because it is a critical stage to survival and growth 
(Kazanjian  &  Drazin,  1989).  Furthermore,  Perry  (1998)  suggested  that  replication  and 
validity is enhanced by purposeful sampling where results can be compared. Having firms 
in the same stage of development allowed for a basis of comparison for the present study.  
 
The literature and informal interviews with industry experts were instrumental in choosing 
the unit of analysis. It is clear from both of these that the R&D and financial resources and 
capabilities  needed  in  growth  are  best  captured  from  high  level  executives  who  are 
intimately familiar with the firm‟s history and development, so this research follows suite. 
Isolating the firms to capture the unit of analysis through this lens also helped to delimit 
the study. It is not possible for one researcher to capture the all of the data relevant to a 
research topic from all possible sources (Bonoma, 1985; George & Bennett, 2005); this 
produces far too much data to process.    
 
Another important factor in the collection of data for this project is its longitudinal design. 
A longitudinal design is important in research involving growth because it allows complex 
processes  to  be  captured  and  broken  down  into  steps  (Johanson  &  Wiedersheim-Paul, 
1991; Welch & Luostarinen, 1988). By definition, process studies are looking at change 
over time; therefore, studies that capture a static snapshot cannot convincingly explain 
processes.  Longitudinal  studies  help  increase  the  reliability  and  validity  of  a  study  by 
capturing the steps that make up the processes. Thus qualitative studies, such as the present 
one,  increase  their  trustworthiness  by  imploring  a  longitudinal  design,  ensuring  that 
important events that may have affected processes are not overlooked (Pettigrew, 1990). A 
longitudinal design is appropriate for the present study because it is interested in the R&D 110 
 
and financial resources needed in firm growth.  Longitudinal studies are more complex, 
especially in qualitative studies where thousands of pages of data can be collected (Yin, 
2008). It is therefore essential to collect and analyse data systematically. Consequently, 
this study collected and analysed data in three systematic steps to ensure reliability and 
credibility. These steps are further detailed later in section 5.5.  
 
Table 5-3 overviews the data collected for this study. The data was collected over a three 
year period and chiefly came from interview data, but other sources were used as well. 
This section further elaborates on the data, the sources of data and how it was collected.  
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Table 5-3: Kinds of data  
 
                                                                                                                         Case firm 
 
Data type  BA1  BA2  DD1  DD2  MD1  MD2 
 
Interview    Aug 2008: 55 
minutes 
  Mar 2009: 65 
minutes 
  Feb 2011: 52 
minutes 
  Aug 2008: 63 
minutes 
  Feb 2009: 71 
minutes 
  Dec 2010: 38 
minutes 
 
 Aug 2008: 71 
minutes 
 Mar 2009: 77 
minutes 
 Dec 2010: 37 
minutes 
 Sept 2008: 52 
minutes 
 Feb 2009: 45 
minutes 
 Jan 2011: 65 
minutes 
 Sept 2008: 65 
minutes 
 Feb 2009: 45 
minutes 
 Feb 2011: 52 
minutes 
  Sept 2008: 50 
minutes 
  Jan 2009: 55 
minutes 
  Dec 2010: 62 
minutes 
 
Archive   7 news 
articles: 2,800 
words 
 4 websites: 
9,000 words 
 8 news articles: 
2,600 words  
 5 websites: 
17,000 words    
 1 industry brief: 
1,600 words                                                            
 12 news 
articles: 4,200 
words 
 6 patent 
records: 35,000 
words   
 12 websites: 
18,000 words                                                               
 
 21 news 
articles : 6200 
words  
 14 patent 
records: 
45,000 words    
 6 websites: 
15,000 words                                                       
 3 news articles: 
900 words    
  3 patent 
records: 11,000 
words 
 2 websites: 
4,000 words                                                                        
  8 news articles: 
2,700 words 
  3 patent 
records: 6,000 
words  
   2 websites: 
2,000 words                                                                                          
Direct observation   August 2008: 
90 minutes 
 March 2010: 
40 minutes 
 Feb 2011: 50 
minutes 
       Feb 2010: 60 
minutes 
 Feb 2011: 60 
minutes 
 
Source: Author112 
 
 
5.4.1 Case selection 
Ensuring research design to acquire an accurate sample used to represent the population is 
especially  challenging  in  qualitative  work,  where  sample  sizes  are  usually  small  (Yin, 
2008). On the other hand, qualitative studies are not used to create law, and therefore these 
studies  can  afford  to  have  more  latitude  in  their  sampling  accuracy.  The  lack  of 
randomness does not mean that case studies should not represent the population though. 
Seawright and Gerring (2008, p. 296) suggest that ‘a case should provide useful variation 
on the dimensions of theoretical interest’. The present study is particularly interested in the 
R&D and financial resources of firms in rapidly changing environments. Therefore life 
science firms were deemed as appropriate cases for this study: life science firms are high 
tech and have a high propensity to use VC (Gompers & Lerner, 2001; Mayer, Schoors, & 
Yafeh, 2005).  
 
Eisenhardt  (1989b)  suggested  using  between  four  and  ten  cases  because  this  number 
allows for an in-depth analysis within a reasonable amount of time. Following Eisenhardt 
(1989),  twelve  firms  were  selected  for  the  research.  Case  selection  was  based  on  the 
following criteria: 
 
1.  Is a life-science firm. 
2.  Is in the early stages of the commercialisation phase of development.  
3.  Has less than 250 employees.   
 
These  criteria  were  chosen  based  on  the  research  topic.  Life  science  firms  make  an 
excellent  choice  because  of  their  dynamic  nature,  and  the  life  science  industry  is  the 
industry that the research has practical experience in and was most interested in. For these 
reasons firms from this industry served as the sample for this study. The E.U definition of 
small business as 250 or fewer employees was used. Firms were chosen at various points 
within the size spectrum (i.e. 4-225) to examine the effects of the various sizes of firms on 
the research question; e.g. do micro firms of four employees have different experiences 
than firms of 225 employees.  
 
Figure 5-4 depicts the steps taken to identify and select the case firms for this study. In the 
first step the potential population of firms that met the study‟s requirements was identified, 113 
 
which  was  believed  to  be  approximately  1,500  (Van  Beuzeken  and  Arundel,  2008). 
Because most firms that fit these criteria are private firms, they are not transparent with 
their operational information. This made it difficult to find firms.  
 
In the second step of the selection process potential firms from with the population were 
identified. The areas of San Diego, San Francisco, and south Florida were targeted because 
of the large number of life science companies present in those areas. In order to find the 
names of the firms and the contact name of the founders and/or the senior management, 
several databases were cross referenced. The main databases crossed referenced are: 1) 
Grow Think Research (www.growthinkresearch.com), 2) Bio Space (www.biospace.com), 
3) Jigsaw (www.jigsaw.com) and 4) 411 Lead (www.411lead.com). 
 
The first of these databases, Grow Think Research, is dedicated to collecting research on 
early stage technology ventures. Several noted studies used such a database for filtering 
firms (e.g. Deeds, 2002; Lynsay, 2009; Rothaermel, 2001). The Grow Think Research 
database attempts to track all of the information available on high technology ventures. 
The website has a built-in search engine to locate companies that have received venture 
funding.  It  also  has  further  options  to  narrow  the  search  down  by  industry,  size  of 
company, size of investment received, age and location. Once the inputs are entered, a 
query is run, and the results are listed alphabetically. The user can then click on each firm 
to find out more information on the company, including its product or service offering. For 
this research the following inputs entered were 
 
  Industry: Life science  
  Company Size: <250 employees 
  Age: <15 
  Investment Received: Early Stage 
  Location: San Francisco, California; San Diego, California; and Miami, Florida  
 
The query yielded 262 companies. Subsequently, all 262 firms‟ profiles in the Grow Think 
database were reviewed. The objective of the review was to further weed out firms that did 
not meet the criteria of the exploratory study. The review disqualified 87 firms, which 
reduced  the  number  of  firms  to  175.  The  relevant  information  for  the  175  firms  was 
recorded in a tracking database the researcher used as part of the research records.  
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The qualifying companies were then cross-referenced in the Biospace database; which is a 
database of life science firms in the U.S that has been used to glean information on life 
science firms in several noted studies (e.g. Deeds, 2002; Rothaermel, 2001; Smith, 1999). 
Each  company  was  entered  into  the  Biospace  database,  and  the  reference  found  no 
significant  discrepancies  from  the  information  found  in  the  Grow  Think  database. 
However,  for  seventy-nine  of  the  companies  it  found  additional  information  that  was 
useful and which was added to the information in the tracking database.  
 
The resulting firms were then cross-referenced in the Jigsaw database, which contains the 
names of  employees  at  companies.  For each  company the names, phone numbers  and 
email  address  of  the  founders  and/or  the  key  executives  was  recorded  in  the  tracking 
database.  A  similar  process  was  followed  in  the  811  Lead  database,  one  with  similar 
information and function as Jigsaw. This process yielded the names and phone numbers of 
exectutives at 176 firms. These names and numbers were then recorded in the tracking 
database.  
 
In the third step (Figure 5-4, step 3), all of the founders and or key executives that met the 
parameters for the exploratory study were contacted via telephone to see if they would be 
willing to participate in the study. This yielded seventeen executives who consented to 
participate in the study. After the phone calls, emails explaining the research and asking 
for help were sent out to the forty-two firms that were unable to be contacted by phone. 
The emails resulted in seven more firms expressing interest in assisting with the study; 
thus a total of twenty-four firms consented to participate in the study. These firms were 
then contacted a second time and asked a series of filtering questions to see which firms 
would be best for the study. From these questions twelve firms emerged as optimal for the 
study and were subsequently interviewed.  
 
The initial round of interviews was then conducted, and the data for these interviews was 
analysed. At that point the researcher decided to further focus on six firms (focus firms) in 
order to allow for more depth with each.   
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Figure 5-4: Case selection 
 
Source: Author 
 
Firm groups 
All  of  the  firms  were  coded  to  keep  their  identities  anonymous;  to  help  protect  the 
proprietary  information  of  the  firms  and  to  also  make  the  firms  more  comfortable  in 
participating in the study. These codes are based on the firms‟ subsectors (Senker & Sharp, 
1997), and they categorised the firms into three groups: 1) Biological Analysers (BAs), 2) 
Drug  Development  (DDs)  and  3)  Medical  Device  (MDs).  Previous  studies  have  used 
industry  subsectors  to  classify  firms  for  comparative  purposes;  subsectors  provide 
variation that is a good basis for comparative purposes (Dewick, Green, & Miozzo, 2004; 
Feldman, 2005; Hendry & Brown, 2006). The firms used in the present study were small 
life science firms in the commercialisation phase of development.  
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Table 5-4 highlights the revenues and financing obtained of each of the firms examined in 
this study.  
 
Table 5-4: Case firm profiles 
Firm   Year Founded  Revenues in 2009.  Specialised financing obtained as 
of December 2010. 
BA1***  2004  <$1 million  $1.1 million 
BA2***  2003  <$1 million  $4 million 
BA3  2005  $8 million  $75 million 
BA4  2005  $42 million  $40 million 
DD1***  2001  <$1 million  $28 million 
DD2***  2001  <$1 million  $8 million 
DD3  2000  $15 million  $105 million 
DD4  2000  $60 million  $70 million 
DD5  2000   $25 million  $450 million 
MD1***  2000  <$1 million  $10 million 
MD2***  2003  <$1 million  <$2 million 
MD3  2004  <$1 million  <$14 million 
Source: Author 
*** Focus firm 
 
The  noticeable  differences  amongst  these  firms  were  the  revenues  and  the  amount  of 
capital raised. Although these differences are in some cases significant, these firms are still 
relatively similar. Furthermore, some variation amongst cases is desirable for the sake of 
comparison (Eisenhardt, 1989a; George & McKeown, 1985). Thus the bounded variation 
in the cases is ideal.   
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5.4.2 Interviews 
The bulk of the data for this study came from interviews. These interviews transpired over 
a five-year period (2006-2010) and consisted of informal and formal interviews with key 
personnel. There were three rounds of interviews, and each round of schedules was based 
on the literature and the previous round of interviews analysis. The researcher developed 
the  interview  schedules  based  on  the  Jones,  Wheeler,  Vlachos  and  De  Opacua  (2008) 
interview  schedule;  which  was  originally  designed  to  explore  the  growth  and 
internationalisation of Scottish life science firms.   
 
The  interviews  started  with  open-ended  questions  to  allow  the  interviewee  to  offer 
unsolicited insights. Close-ended questions then captured specific points. The interview 
schedule for each round of interviews is detailed later in this section. The interviews took 
place  with  key  personnel  from  each  firm  who  had  been  with  the  firm  from  or  near 
inception; which is ideal in the field of management because intimate knowledge of the 
firms‟ operations is needed to capture deep insights (Eisenhardt, 1989a). Each interview 
was  taped,  transcribed  and  field  notes  were  taken.  Subsequently,  a  second  round  of 
interviews ensued with the firms to narrow down the generalisations found from the first 
round of interviews. These interviews were transcribed, analysed and compared to the data 
from the first round of interviews. Next a third round of interviews was conducted. This 
round  was  different  in  that  it  aimed  to  validate  the  first  two  rounds.  This  time  the 
respondents were asked to validate findings from their firm.   
 
Interviews  are  one  of  the  best  methods  for  studies  intending  to  unearth  fresh  insights 
(Kvale & Brinkmann, 2008). Gillham (2000) suggests that one of the biggest benefits of 
interviews is the flexibility to probe new paths that were not originally considered, whilst 
still  capturing  specific  information.  Interviews  using  open-ended  and  close-ended 
questions encourage two-way conversation between interview and interviewee, allow for 
flexibility to further probe for relevant information and allow the interviewers to offer 
insights  that  may  not  have  been  considered  before  the  interview.  These  insights  are 
captured  through  interpretive  content  analysis  of  the  interviews,  whilst  close-ended 
questions allow for specific points to be captured (Seawright & Gerring, 2008). The close-
ended responses also help with in-site validation of key issues and are useful for cross-case 
comparisons.  The  research  topics  in  the  present  study  are  in  the  earlier  stage  of 
development, but there is some theoretical development on the topics. For this reason an 118 
 
open and close-ended interview schedule provided the best means to capture new concepts 
whilst still capturing specific data to compare to existing theories.  
 
The  interviewer  is  an  essential  part  of  the  research  process,  especially  in  open-ended 
interviews (Yeung, 1995). Researchers should first make the interviewee comfortable. For 
the present study this was particularly important as the case firms were all high tech, which 
tend to be sensitive about divulging information about their operations (Unikel, 1997). In 
order to gain the confidence of the interviewee, three main tactics were used: 1) a thorough 
description of the research project and its aims and objectives was given to the interviewee, 
2) a confidentially agreement was given to each of the interviewees before the interview 
was conducted and 3) the questions in the interview avoided asking specifics about trade 
secrets. Another challenge for an interviewer is asking appropriate questions to probe for 
information; if appropriate questions are not asked, then irrelevant or no information would 
emerge from the interview (Benjamin, 1974). To overcome this challenge, the interview 
schedules stemmed from the existing literature, the informal interviews, and information 
gathered on the case firms.  
 
A third challenge for the interviewer is to make sure that the interviewee understands the 
questions being asked (Easterby-Smith et al., 2002). The present study ensured that the 
questions  were  clear  and  concise;  all  possible  unfamiliar  terms  were  defined  and  the 
respondent was encouraged to ask the interviewer clarifying questions. Furthermore, the 
interviewee first told his or her own story of the firm and its growth, allowing for fresh 
insights to emerge and helping to increase the credibility of the interview by reducing the 
possibility of directing the respondent towards certain responses (Gillham, 2000). Multiple 
interviewers also helped ensure the emergence of accurate and meaningful information. 
The primary researcher and his supervisor, Professor Marian Jones, conducted the first 
round of interviews. A fourth challenge for interviewing is eliminating the interviewer‟s 
bias. The researcher attempted to eliminate all preconceived biases; mainly though the 
development of unbiased interview schedules.  
 
Another mechanism used to eliminate bias was to get feedback on the interview schedules 
from  subject  experts  before  the  interviews  were  conducted.  Furthermore,  a  number  of 
triangulation techniques, which are discussed in the next section, were employed to help 
eliminate researcher bias.  The fifth  challenge in interviewing and arguably the biggest 
challenge for a researcher conducting interviews is listening (Benjamin, 1974; Yin, 2008). 119 
 
Interviews  yield  massive  amounts  of  data,  and  during  the  open  interview  process,  the 
interviewer  must  filter  the  most  relevant  data  to  use  for  probing  questions  during  the 
interview. In order to filter information during an interview, Kvale and Brinkmann (2008) 
suggest  taking  field  notes,  listening  for  key  terms  and  asking  clarifying  questions 
throughout. The present study followed this advice. Furthermore, at the end of the session 
the interviewer presented the respondent key points taken from the interview to verify 
(Yin, 1983).    
 
5.4.3 Interview Design 
Conducting multiple interviews and designing the subsequent interviews from the prior is 
an  ideal  method  to  capture  specific  theoretical  concepts  (Hurmerinta-Peltomaki  & 
Nummela, 2004). Based on the first round of interviews, a second round of interviews on a 
narrower  set  of  topics  was  conducted  with  the  six  focus  firms.  This  set  of  interviews 
intended to draw further information on what had emerged from the first set of interviews. 
The third set of interviews confirmed findings from the first two rounds of interviews with 
the focus firms, but also left room for new insights.   
 
Interviewing  respondents  intimately  familiar  with  the  phenomenon  of  interest  helps  to 
increase the validity and reliability of the data gathered from an interview (S. Kvale & 
Brinkmann,  2008).  Qualitative  research  in  management  often  involves  gathering 
information from high-level executives because they are knowledgeable in all of the firm‟s 
operations (Harrigan, 1983); thus they are able to offer data which is more reliable. To 
increase the reliability and validity, many studies on small firm growth (e.g., J. Bell, Crick, 
& Young, 2004; Boter & Holmquist, 1996; Burgelman, 1983; Knight & Cavusgil, 2004) 
have  used  interviews  with  executives  as  a  source  of  data.  The  fact  that  all  of  the 
interviewees in the present study were with the firm from (or really close to) its inception 
also  helped  increase  the  trustworthiness  of  the  data.  Table  5-5  further  details  each 
informant‟s relationship with the firm. 
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Table 5-5: Data collected from 
Firm  Informant(s)  Notes 
BA1***  CEO; Board member  Founder 
BA2***  CEO  Founder 
BA3  CEO  Founder 
BA4  Operations manager  His father started the 
business, and he has worked 
there since inception. 
DD1***  CEO 
Chairman  
Director of research 
CEO is not technically a 
founder but has consulted 
with the firm since the 
beginning and owns a 
significant amount of the 
firm. 
DD2***  CEO 
Chairman 
Founder 
DD3  Chief scientific officer  Founder 
DD4  Chief operating officer  Came on within three 
months of the firm‟s 
founding. 
DD5  CEO  Founder 
MD1***  CEO  Founder 
MD2***  CEO 
Founder 
 
CEO is not a founder, but 
has been with the firm since 
year 2. 
MD2  CEO  Founder 
 Source: Author 
*** Focus firm 
 
First round of interviews 
At the time of the first round of interviews the research had four objectives: 1) gaining a 
background on the firms, 2) exploring the resources and capabilities needed in growth, 3) 
probing out what general effects the VCs non-financial resources had on the firms and 4) 
giving the interviewees a chance to offer unsolicited insights on the research topic (from 
the general open-ended questions) to draw themes from. The first point of interest in the 
study was the development of key resources. In order to examine it, the first interview 
schedule looked at six areas: 
 
A.  The firm‟s current position 
B.  The foundation process of the firm 121 
 
C.  The critical events of the firm 
D.  The impact of international activity 
E.  The firm‟s boldness, creativity, and innovativeness 
F.  The firms R&D and product portfolio management  
 
The first category of questions intended to provide an overview of the firm‟s competitive 
positions in both domestic and international markets. These questions were designed to 
establish the competitive position of the firm and what the important contributors to getting 
in that position were. The interview schedule consisted of a series of open and close-ended 
questions.  This  category  stemmed  from  the  assets  and  capabilities  literature,  which 
suggests that several factors such as unique resources (Oviatt, McDougall, & Loper, 1995), 
R&D  spending  (Burgel  &  Murray,  1998),  executives  with  international  backgrounds 
(Westhead, Wright, & Ucbasaran, 2001), important CAs (Teece 1986; Rothaermel 2001) 
and growth orientation (Autio, Yli-Renko, & Salonen, 1997) affect firm growth.  
 
In the second category of questions respondents were asked to 1) provide a history of the 
firm, 2) establish why the firm was founded, 3) establish how the firm was funded, 4) see 
if there were any international activities that were important in the foundation of the firm 
and 5) see what the aims and objectives of the founders were when they started the firm. 
This set of questions was aimed at probing what the main drivers of the firm‟s foundation 
were in  order  to  probe the motivation  of the firm‟s  foundation and what  major assets 
influenced the firm‟s early growth.  
 
The  third  category  of  questions  probed  the  significant  milestones  that  influenced  the 
direction of the firm. This category gave the interviewee an opportunity to discuss any 
major events that affected the growth and development of the firm. There were probing 
questions asked to get the respondent to discuss the effect that equity investors had on the 
process. Studies suggest that VC is an important milestone in the development process of 
firms (Gompers, 1995; Timmons & Bygrave, 1986); the questions were designed to see the 
importance of the VC, especially relative to other major milestones. In a similar vein, the 
questions  in  category  four  explored  the  important  activities  that  impacted  the  firms‟ 
development.   
 
Categories five and six aimed to unearth insights on the influence of innovation on the 
development of the firms. Innovation is critical to the growth of new technology-based 122 
 
firms (Löfsten & Lindelöf, 2002). The main purpose of these questions was to see what the 
effect of innovation was, as well as to see what the sources of innovation were. Moreover, 
innovation is a driver of internationalisation (Bloodgood, Sapienza, & Almeida, 1996), and 
studies indicate that VC has a significant positive impact on innovation (R. Florida & 
Smith Jr, 1990; R. L. Florida & Kenney, 1988; Kortum & Lerner, 2000;  Timmons & 
Bygrave,  1986).  Thus  these  questions  also  explored  the  impact  of  VC  on  the  firm‟s 
innovation and internationalisation.     
 
Second round of interviews 
A second round of interviews was conducted with the case firms. The interview schedule 
was based largely on the analysis of the first set of interviews. The first round of interviews 
established the background on the case firms in this study and also raised three major 
themes: 1) R&D and financial assets and capabilities are at the heart of early growth, 2) 
unique  paths,  positions  and  processes  lead  the  development  of  R&D  and  financial 
resources and capabilities and 3) VC has various effects on the growth of life science 
firms, but these effects are not always positive.  
 
Results from the first round of interviews suggest that R&D and financial resources and 
capabilities are vital to the firms‟ foundation and growth. The second and closely related 
theme that emerged is that R&D and financial  resources and capabilities come from a 
variety  of  sources:  internal  resources,  industry  partners,  university  partners,  the 
government and VCs. Furthermore, there are a unique set of paths, positions and processes 
that lead to the development of R&D and financial resources and capabilities. The third 
theme that emerged from the first round of interviews is that the VC business model is 
inherently flawed. There is little extant literature on this topic. Therefore the questions 
were drawn on the basis of the first round of interviews. Although this topic is not directly 
related to the first topic, it does have an effect on the development of firms.  
 
Like the first round of interviews‟ schedule, the second round schedule used both open and 
close-ended questions. This type of interview schedule allows for new themes to emerge, 
whilst  still  being  able  to  capture  specific  points  (Labaw,  1981).  The  questionnaire 
consisted of five sections. It started off with questions pertaining to the R&D and financial 
assets and capabilities important to the firms‟ growth. It then moved into questions about 
where  R&D  and  financial  assets  and  capabilities  stem  from.  Subsequently,  the 123 
 
questionnaire  asked  questions  relating  to  the  effect  of  the  VCs  business  model.  Each 
section of the interview schedule is further explained below.  
 
Section A 
This section hones in on the key resources important to the firm‟s early growth, namely, 
which R&D and financial resources are paramount. The open-ended questions in section A 
provided  the  respondents  an  opportunity  to  provide  fresh  insights  on  these  questions; 
whilst the questions in section A1 captured specific information relating to paths, positions 
and  processes  leading  to  the  development  of  key  resources  and  capabilities.  Another 
objective of this group of questions was to probe the source of the key  resources and 
capabilities.  Questions  1.1-1.16  in  A1  specifically  ask  about  how  alliances  led  to  the 
development of the key resources and capabilities. These questions were developed on the 
basis of alliances literature (Coombs & Deeds, 2000; Lindsey, 2008) and the resources and 
capabilities literature (Teece, 1986; Trispas, 1996). 
 
Section B 
This section follows a similar rationale to section A in that it aimed at going into further 
depth on the events that led to the development of key resources by focusing on the major 
milestones. Miles and Huberman (1994) suggest that insights on major events in time can 
help to establish important facts in theory building. Similarly, Yin (2003) suggests critical 
events are important to establishing the context of a case. Thus the purpose of the open-
ended questions in this section was to probe the time frame and events that led to the 
development of the critical resources and capabilities. Moreover, this section also included 
some questions to probe the effect that resources and capabilities had on the growth of the 
firm. 
  
Section C 
The first two sections aimed to establish the resources and capabilities important to firm 
growth. Section C goes into more depth on the role of VC. The rationale for this section 
comes from the literature on VC networks (Lynsey, 2009; Sorenson  and Stuart, 2001; 
Wright and Lockett, 2003) and VC value-added literature (Gompers and Lerner, 1996; 
HSU, Hellman and Puri, 2002). However, this literature is vague and there is only specific 
coverage on the value of VC networks in aligning future financing. For this reason the 
section starts out with open-ended questions to let the respondents offer new insights on 
the influence of VC on the firms‟ growth. These were followed by a set of more specific 124 
 
questions  on  whether  resources  and  capabilities  were  created  from  VC  inputs  or  VC 
networks.  
 
Section D 
The  first  round  of  interviews  suggested  that  firms  tended  to  have  a  few  partners  that 
provide inputs. This section presents a table to capture data relating to these partners. It is 
intended to see if any patterns from the top partners emerge. This table is based largely on 
resources literature, which suggests that partners are important sources and that firms tend 
to have a few key partners (Arora & Gambardella, 1990; Graff et al., 2003; Rothaermel, 
2001a, 2001b). The table captures specific points relating to how the partners influenced 
the firms‟ growth.  
 
Section E  
One of the themes that emerged from the first round of interviews is the inherent flaws in 
the VC business model. Almost no literature exists on this topic. For this reason the section 
starts off with open-ended questions that are based on the results of the first round of 
interviews.  The  questions  in  section  E1  ask  close-ended  questions  to  capture  specific 
points about the problems with the funding models available to life science firms.  
 
Third round of interviews 
This round of interviews was intended to validate the findings of the first two rounds of 
interviews. Pragmatic validation, a powerful means to triangulate findings, is a form in 
which the perspective of the findings is judged by the sample of interest (Kvale, 1987), 
which in this study is the case firms. One of the main validation techniques that this study 
uses is a survey on the major findings. Each of the major influences that the study found 
important  to  the  development  of  R&D  and  financial  resources  and  capabilities  was 
presented in a survey to each of the case firms in this study, and the respondents rated the 
importance of each influence. This data does not serve for statistical testing, but instead 
each response is compared to the analysis from the qualitative data for each of the firms. 
This serves to validate the findings. In general, most of the findings were validated, but 
there were a few small discrepancies. In those instances more information was gathered to 
clarify the discrepancy, and an explanation for the discrepancy was established.   
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Archives and observation 
The  research  supplemented  the  data  collected  from  the  interviews  with  all  publicly 
available data for each of the case firms. This  included new articles, websites, analyst 
reports, patent records and articles in scholarly journals. All of this data was recorded in a 
case record for each firm. Case  records help to organise a study, keep track of information 
and provide a common framework for tracking data for each case in a study (Stake, 1999). 
Observation was also utilised in the data collection. The researcher spent a total of twelve 
hours (four hours each at three different case firm sites) observing the operations, sitting in 
top management meetings and touring facilities. Copious observation notes were taken and 
recorded in the case records for each of these visits. Collecting data from multiple sources 
is a good way to triangulate a study. Data from other sources offer potential new insights 
and  can  confirm  or  disconfirm  ideas  from  other  sources  of  data  (Yin,  2008);  the 
supplementary data collected in this study served this purpose.  
 
5.5 Steps 6, 8, 10: data analysis 
The analysis of case research depends on the type of case study, the number of cases used 
and the objectives of the study. The present study used six case studies, is concerned with 
unearthing new insights on the development of life science ventures and relied primarily 
on qualitative data. Eisenhardt (1989b) suggests that for qualitative case research there are 
two main approaches to analysis: within-case and cross-case. In within-case analysis the 
goal is to narrow down the massive amounts of data into manageable amounts that can be 
properly  analysed  in  a  scientifically  valid  manner;  whereas  cross-case  analysis  is 
concerned  with  comparison  and  theme  narrowing  and  replicating  (Eisenhardt,  1991). 
However, using both within-case and cross-case analysis is often the preferred choice for 
research involving multiple cases (Miles and Huberman, 1994; Yin, 2008). That this study 
used multiple cases as well as the nature of the study made using both approaches of 
analysis  appropriate.  Each  case  was  analysed  individually  and  the  emergent  data  was 
recorded for each case. Data was then analysed across groups and cases. The within-case 
allowed the findings from each to be analysed individually, whilst the cross-case provided 
a means of replication. 
 
The core of the data for this study emanated from a series of interviews that consisted of 
three  separate  rounds  of  interviews.  However,  the  study  also  captured  numerical  data 
consisting of financial and operations data (e.g., number of employees, revenues, etc.) and 126 
 
is presented in tables. Rather than being statistically tested, it is used to help construct case 
histories. The cross-case analysis tables were constructed for each major category with 
each case represented.  
 
5.5.1 Data coding 
Before discussing the reduction and packaging of the data, it is important to discuss the 
techniques used to identify the codes. These codes emanated from the literature (priori 
codes)  and  the  emergent  inductive  themes  found  throughout  the  analysis.  Below  the 
multiple step process used to code the qualitative data is described.  
 
In the first step, coding of the text, transcripts and the field notes was done using four 
techniques outlined by Ryan and Bernard (2003): 1) identifying repetitions, 2) looking for 
transitions, 3) identifying similarities and differences and 4) cutting and sorting notable 
quotes. For each of these techniques the data was uniquely read (i.e. the transcripts were 
read four separate times during this step), and the elements were coded along the lines of 
the particularities of each technique, and were then recorded on a coding sheet.  Repetition 
is  one  of  the  most  basic  ways  to  identify  themes  and  was  the  first  technique  used. 
Essentially the researcher is looking for ideas that reoccur throughout the text (Silverman, 
2006). Examples that reoccurred throughout the first set of interviews were the importance 
of finances; several key R&D and financial resources and capabilities critical to growth; 
and that the VC business model is flawed. The second data analysis technique searched for 
transitions in the data. Abrupt pauses or shifts in a interviewee‟s thoughts often indicate 
significant events or issues, and these are often a basis for themes (Ryan & Bernard, 2003). 
The third analytical technique used in this study identified similarities and differences. 
Glaser and Strauss (1967) call this constant comparison, which is essentially comparison 
occurring across units of data. There are several approaches to constant comparison. The 
most detailed is line-by-line analysis where every line is  compared. The least  detailed 
constant comparison technique is comparing blocks of texts. The text block method is 
much less time intensive than the line by line method, and because of the large amount of 
data collected, this study used the text comparison technique. Notes were taken for each 
section of text and compared to each other. Cutting and sorting of notable quotes is the 
fourth text analysis technique used in this study. These were placed into categories based 
on themes. There are many techniques to sort amongst themes, ranging from sorting into 
many different themes to sorting into broad themes. This study used a relatively broad 127 
 
sorting system of twelve categories for the emergent themes. A comparison of the four 
analytical techniques produced the broad categories of themes for the study‟s framework.  
 
The first four coding techniques yielded almost twenty-five themes, but in order to more 
finely  glean  the  data,  two  more  coding  techniques  suggested  by  Russell  and  Bernard 
(2003) were used. The first is theory matching. In this step the interviews were searched 
for  themes  relating  to  prior  and  emerging  theory.  Sections  of  text  were  analysed  and 
compared to the existing literature on life science firms, the RBV, dynamic capabilities and 
CAs. The second step taken in  the second stage of the refinement process  looked  for 
missing data. Often respondents will intentionally or unintentionally leave out pertinent 
information  in  responses  that  are  important  to  a  topic  (Taylor  &  Bogdan,  1984). 
Entrepreneurs are known to overemphasise their role in a venture (King & Roberts, 1992). 
Since most of the interviewees in the present study are the entrepreneurs who started the 
firm,  it follows that the interviewees  may have left  important information  out  of their 
responses to emphasise their role in the firm‟s development.  
 
5.5.2 Data categorising, reduction and structure 
The coding processes described above serve to identify the themes of the study. Figure 5-5 
depicts the steps in the analytical process used to summarise, reduce and aggregate the 
data. In the first part the researcher gathered data from interviews and secondary data and 
analysed each part using Miles and Huberman‟s (1994) three level analytical abstraction 
process. At the first level major themes were summarised and packaged together in major 
categories.    At  the  second  level  data  was  abstracted  and  categorised  along  narrower 
themes. At the third level data was reduced to major themes and an explanatory framework 
was developed. Part II then deductively validated the findings from the first part.  128 
 
Figure 5-5: Data categorisation, reduction and structure 
 
Source: Author 
 
Part I of the data analysis began with the coding techniques described in section 5.4.1 
above.  Seventeen  of  these  codes  stemmed  from  literature  (a  priori  codes)  and  twelve 
inductive codes emerged during the analysis (Appendix A, Table A1). At this stage in the 
analysis  it  emerged  that  R&D  and  financial  resources  and  capabilities  drove  the  early 
development of the firms, as was evidenced in over seventy-five per cent of the codes 
related to R&D and finance, despite the fact that only a few of the questions asked in the 
interview directly probed these areas. Consequently, step two of the analysis repackaged 
the data along the lines of R&D and financial resources and capabilities (Appendix A; 129 
 
Table A2). At level three of the analysis the research then further refined and created a 
structure for the data categorising it into two main groups (R&D and financial) with each 
of the groups having three sub-group: paths, positions and processes (Appendix A: Table 
A3). At the third level in the data analysis Miles and Huberman (1994) suggest that data 
should be tested. In order to do this the study then presented the findings to the respondents 
(Part II of Figure 5-5).   
 
In  part  II  the  research  created  a  questionnaire  (Appendix  D)  aimed  at  validating  the 
findings. The questionnaire is based on pragmatic validation, which is a powerful means to 
triangulate findings. This is a form of validation, which the perspective of the findings is 
judged by the sample of interest (Kvale, 1987). The  respondents from  each firm were 
presented with each of the themes produced from the first part of the study on a scale of 1 
(not important) to 7 (very important). Based on the first two parts of the analysis, the 
questions were pre-coded for each of the firms. These codes were then compared to the 
responses  from  the  key  informant  from  each  firm.  The  researcher  then  gathered  more 
information  on  any  major  discrepancies  between  the  pre-coded  responses  and  the 
responses by the respondents.   
 
The careful coding and analysis techniques described above are important, as researchers 
often have no systematic approach to coding data; they often rely on intuition to come up 
with categories whilst they are reading through the transcripts (Ryan & Bernard, 2003). 
This is often a good initial technique, but it limits the information that can be gleaned from 
the transcripts. Even in a grounded study a more structured approach to analysing data is 
needed.  The  systematic  approach  taken  in  the  coding  of  the  data  in  the  present  study 
helped to uncover ideas, and it also added to the credibility of the study by ensuring that 
the themes and ideas were drawn from all angles of the data.  
 
One particular challenge for researchers analysing qualitative data is managing their data.  
To aid in this, the present study used software and a case database. RDQA is a qualitative 
data analysis program. This relatively new program has powerful functions to store, trace 
and  query  data.  Qualitative  data  analysis  software  such  as  this  is  quite  popular  in 
qualitative management studies (Yin, 2008). A custom-created database by the researcher 
also aided in tracking the key case information for all of the firms. On top of the electronic 
filing, the researcher printed, labelled and filed each page of data.  
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5.5.3 Reliability and credibility 
There are several shortcomings of the methods implored for this study. Quantitative purists 
might  fault  it  for  the  lack  of  generalisability.  However,  this  is  not  one  of  the  main 
objectives of the study. Rather the main objective is to capture rich insights on the R&D 
and financial resources and capabilities needed in the growth of life science ventures, and 
as discussed earlier, these are best captured through qualitative techniques such as the case 
methodology  used  in  this  study  (Bell  &  Bryman,  2003;  Easterby-Smith  et  al.,  2002). 
Qualitative research is also criticised for lack of rigor. However, even quantitative purists 
recognise that a properly designed and executed qualitative study can be just as rigorous as 
the best quantitative study. Closely related to rigor, and the source of the third and biggest 
criticism of qualitative work is the lack of reliability and credibility. In many cases this 
criticism is valid: qualitative researchers often dismiss the importance of reliability and 
credibility.  
 
Reliability is an elusive term to define in qualitative research. In quantitative research it 
refers to the ability of the results to be replicated (Bell & Bryman, 2003). By the nature of 
qualitative work it is difficult, if not impossible in many instances, to produce results that 
are  completely  replicable.  For  this  reason  reliability  takes  on  another  meaning  in 
qualitative  research.  Lincoln  and  Guba  (1985,  p.  317)  contend  that  reliability  is  best 
described as „dependability‟ in qualitative research. Dependability comes from the quality 
of the processes and products of the work. To capture dependability, the present study took 
careful consideration to create consistent measures and processes to explore the research 
questions. The first way dependability is captured is through the design. The study used 
consistent processes throughout the research, the three most important being the design of 
the interview schedule, the selection of the case firms and the analysis of the data. The 
interview schedule was carefully crafted on the basis of the literature and discussions with 
industry experts. This produced theoretically sound questions. The selection of the case 
firms is the next major process that was carefully controlled for. As discussed previously in 
this chapter, the study used life science firms, which are used extensively as samples in 
studies on the major theories related to this project. The study also carefully controlled for 
the analysis of the data. As discussed above, the study used several commonly accepted 
and  rigorous  techniques  to  draw  themes.  To  further  ensure  reliability,  the  study  took 
careful consideration to use the same techniques for all of the case firms‟ data. 
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The reliability discussed above is a prerequisite to the validity of the study (Lincoln & 
Guba, 1985); i.e. the findings could not be valid unless the reliable processes discussed 
above were used to find them. Like reliability, validity in qualitative work is elusive to 
define. Denzin (1970) sees validity scales as dependent on the accepted body of knowledge 
in the research community. He says they ‘are only symbolic – they have no meaning other 
than that given by the community of scientists’ (p. 106). The main way that validity is 
established in this study is through using reliable processes and basing the work off of 
existing theories and methods that are accepted in the literature. Ultimately validity and 
reliability in qualitative work is judged by how credible and trustworthy a study is.  
 
Table 5-7 summarises the steps taken in this study to establish trust. These steps were 
taken from the beginning to the  end of the study to ensure trustworthy  findings were 
produced. Often qualitative researchers only consider reliability and credibility issues in 
certain parts of a study, such as in the data collection or analysis, but unless a concerted 
effort  is  made  throughout  a  study,  the  results  are  not  seen  as  trustworthy  (Denzin  & 
Lincoln, 2005; Yin, 2008). For this reason the present study made a concerted effort to 
keep reliability and credibility at the forefront of each step of the research process. One of 
the best ways to increase the credibility and trustworthiness of a qualitative piece is to use 
strong  triangulation  techniques.  The  next  section  further  delineates  the  triangulation 
techniques used to establish trustworthiness in this study. 132 
 
Table 5-6: Trustworthiness approaches 
Steps  Approaches taken to ensure 
trustworthiness 
Steps 1-3: Research background  -A thorough literature review was conducted, 
which helped to identify and properly position 
the study.  
-Scholarly and industry experts were 
consulted to establish an appropriate research 
paradigm.  
Step 4: Study design  -Systematic approach was designed from the 
onset. 
-All philosophical influences were properly 
analysed before the study was designed. 
-Design peer was reviewed by multiple 
experts.  
Steps 5,7, and 9: Data collection  -Triangulation through an iterative data 
collection process from multiple sources. 
-The bulk of data came from high level 
executives intimately familiar with the firm‟s 
history. 
-Six cases used; a sufficient number for 
comparative purposes, but still a manageable 
size to analyse.  
Steps 6,8, and 10: Data analysis  -A systematic approach to analysing the data: 
  Data triangulated by analysing it through 
different approaches 
  Looking at the data through multiple 
theoretical lenses  
  In site validation 
-Results presented in different formats, which 
allows for different angles of comparison.  
 Source: Author 
 
5.5.4 Triangulation 
Triangulation  is  one  of  the  main  tools  that  qualitative  researchers  have  to  establish 
reliability  and  validity.    O‟Donoghue  and  Punch  (2003,  p.  78)  see  triangulation  as  a 
„method of cross-checking data from multiple sources to search for regularities in the 
research data’. Denzin and Lincoln (2005) identify four main types of triangulation: 1) 
data, 2) multiple researcher, 3) multiple theory and 4) multiple method. The present study 
utilised all four.   
 
Collecting  data  from  multiple  sources  is  one  means  to  triangulate  case  research  (Yin, 
2008). Data for the present study emanated from several sources. The main data source of 
data came from the interviews with key informants from the firms. The secondary sources 133 
 
of data came  from  news  articles,  patent records,  industry reports, SEC  filings  and the 
internet. The internet data was collected from the case firms‟ websites, life science industry 
websites  and  life  science  web  blogs.  The  web  can  provide  rich  qualitative  data  for 
academic research (Robinson, 2001; Romano Jr et al., 2003; Sixsmith & Murray, 2001). 
For this study web data served for comparative and confirmatory purposes; i.e. the study 
compared the secondary data to the data from the interviews. Until recently data collected 
from the web has not been used in academic research. However, Herring (2001) provides 
strong evidence that the web is becoming an accepted place for academic studies to draw 
from. Furthermore, the prolific use of the web has made it a large and rich source of data 
appropriate  for  academic  research  (Lefever,  Dal,  &  Matthiasdottir,  2007).  Few 
management studies use netnography or secondary data from the web as a source of data. 
Liu and Arnett (2002) is one of the few examples; this study assesses the web content of 
the  fortune  five  hundred  companies  by  using  the  firms‟  websites  as  a  means  of  data 
collection.  Feinberg  and  Kadam  (2002)  also  used  web  sources  in  their  assessment  of 
customer service. Jones (1999) suggests it is especially useful to triangulate primary data 
with web data. However, he also emphasises the ethical concerns involved with using the 
web to glean data. Using only web data for the present study would have been hard to 
justify. However, using it for comparative and triangulation purposes is well justified.  
 
A second way this study is triangulated is through the multiple theoretical perspectives that 
were taken to look at the research. Often researchers fixate on one theoretical lens and 
thereby miss insights from other theories (Denzin and Lincoln, 2005). The present study 
looked at the research questions from three main theoretical perspectives:  RBV, dynamic 
capabilities/CAs,  and  VC  value  added;  which  provided  additional,  multiple  angles  for 
examining  the  questions.  The  third  means  of  triangulation  that  this  study  draws  on  is 
validation. As discussed above, the findings were validated by a questionnaire that the case 
firms completed, which provided another powerful means of triangulation (Kvale, 1987; 
2004). 
 
5.6 methods conclusions 
The purpose of this chapter is to detail the methods implored to investigate the research 
questions  of  this  study.  These,  as  well  as  the  case  methodology  used,  are  relatively 
complex. To simplify this, the complex process was broken down into manageable steps 134 
 
that are outlined in Figure 5-1 (at the beginning of the chapter). Investigating the questions 
in this research was very similar to a detective investigating a crime (Yin, 1981). It took 
many sources of data and many hours of collecting and analysing clues, and piecing all of 
the clues together in a coherent way to produce a compelling argument for the themes that 
emerged from the study. The case method taken in this research is inductive in nature but 
also drew on some deductive techniques. It relied on interviews as the primary source of 
data, but several other sources of data also helped to supplement the interview data. The 
methods implored allowed the researcher to uncover important insights on the R&D and 
financial resources and capabilities important to the early growth of life science ventures.  
 
The methods used in this study are not perfect. There are no perfect research methods in 
business  (Bell &  Bryman, 2003). Quantitative  purist  might  argue that  this  study lacks 
validity and generasability. Whilst some qualitative experts may argue the case method 
lends itself to narrow and idiosyncratic theory. However, the methods are well justified 
given the current state of development for the theories of interest to this study. Moreover, 
the methods produced trustworthy findings that contributed to the literature on the research 
topics. The next chapter discusses these findings.  
   135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 – Results and Analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
  Present the structure of the analysis. 
  Present the findings from the within-group-analysis. 
  Present the findings from cross-case analysis. 
  Present the triangulation questionnaire responses. 
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6.1 Introduction 
This chapter and chapter seven present the findings of the study. Following Senker and 
Sharp (1997) the firms are divided into three groups for analysis purposes. The analytical 
framework is constructed based on the firms‟ industry subsector: medical device (MDs), 
drug development (DDs) and biological analysers (BAs). A within-case and within-group 
analysis is presented in the first part of this chapter. Followed this is the responses from the 
questionnaire  that  was  administered  to  the  case  firms  is  presented.  This  serves  as  a 
framework  for  the  cross-case  analysis  and  to  present  the  findings  from  a  different 
perspective.   
 
A within-case analysis  presents  data in  meaningful and logical  manner and allows for 
capturing depth (Miles and Huberman, 1994). However, it does not give a contextual base 
for comparison. Information from a within-case analysis is often used as basis for a cross-
case analysis where such comparisons are made. Although this is common practice, depth 
is often lost in the transfer from the within-case analysis to the cross-case analysis (Yin, 
1981). To minimise this, the present study first presents a short within-case analysis and 
then presents an in depth analysis of the main themes from the study in a cross-group 
analysis. The within-case analysis provides a contextual basis for each firm and the small 
number of firms in the cross-group analysis allows for a basis for comparison, but still 
allows depth in the analysis (Miles & Huberman, 1994). The findings for each group are 
presented in terms of the major themes that were identified in the study. The structure of 
the analysis is outlined below. 
 
A. Within case analysis 
A within case analysis for each firm from the group is presented in this section. A narrative 
of  the  major  events  and  motivations  behind  the  development  of  R&D  and  financial 
resources and capabilities is presented. This section serves to provide a contextual basis for 
each firm, which underpins the cross-group analysis.  
 
B. Cross-group analysis of R&D resources and capabilities development 
This section identifies and discusses the key paths, positions and processes that led to the 
development of the firms‟ R&D resources and capabilities. The matrix of the key paths, 
positions and processes that led to the development of the firms R&D is first presented. 
These matrices are not intended to quantify the data from the study; rather the intent is to 137 
 
present  the data in  a structured manner (Miles and Huberman, 1994;  Yin, 2008). The 
development  of  these  matrices  was  detailed  in  the  research  methods  chapter,  but  to 
summarise,  each  matrix  was  developed  from  each  case  using  an  abductive  approach 
drawing  on  the  data  techniques  offered  by  Ryan  and  Bernard  (2003)  and  Miles  and 
Huberman (1994). The ideas in the table were initially formulated based on the qualitative 
data; i.e. the interviews. Themes were coded and the software RDQP was used to compare 
codes along multiple lines.  
 
Followed by this the paths, positions and processes are each individually analysed. This 
part  of  the  analysis  follows  Maitlis  and  Lawerence  (2007)  and  Lawerence  (1998)  in 
presenting evidence trails to support the analysis. These evidence trails consist of textual 
representations,  close-ended  questions  and  secondary  data  that  supports  the  finding 
(Lawerence, 1998; Maitlis & Lawrence, 2007).    
 
C. Cross-group analysis of financial resources and capabilities development 
This section identifies and discusses the key paths, positions and processes that led to the 
development of the firms‟ financial resources and capabilities. It follows the exact format 
as Section B and is based on the same analytical techniques. 
 
Code blocks corresponding to the themes from the study are presented throughout the 
chapter to help connect the major themes of the study with the analysis. Table 6-1 presents 
the  code  blocks  for  the  themes  that  were  yielded  from  the  data  reduction  techniques 
discussed in section 5.4.2. For example: 
 
The pursuit of this technology cost the firm over $15 million in the first five years 
[Fin-pa – costly innovation].   
 
In this example the code block identifies that this text relates to the theme of innovation 
having an influence on the financial paths of the firm.  
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Table 6-1: Themes and text coding 
  Text Code 
R&D PATHS 
Core technology R&D demands  R&D-pa core tech  
Path – university partnerships  R&D-pa uni partners 
Government partnerships  R&D-pa govt partners  
Industry partnerships  R&D pa industry partners 
New technologies influenced firm‟s direction  R&D-path new tech 
Government approvals: e.g. patent or FDA  R&D-pa govt approval 
Scientific developments  R&D-pa scientific dev 
R&D POSITIONS 
Core Technology  R&D-pos core tech 
Patents  R&D-pos patents  
Founders  R&D-pos founders 
Skilled scientists  R&D-pos scientists 
Star scientists  R&D-pos star scientists 
Industry partnerships  R&D position industry 
inputs 
University partnerships  R&D-pos uni input 
Government partnerships  R&D-pos govt input 
R&D facility and research equipment  R&D-pos facilities  
R&D PROCESSES 
Sensing and seizing scientific opportunities  R&D proc S&S 
Finding and developing research partnerships  R&D proc partnering 
Navigating government approval  R&D-proc  patenting 
Filing patents  R&D-proc patenting 
Learning from earlier research  R&D-proc learning 
Transforming R&D   R&D-proc transforming 
FINANCIAL PATHS 
Costly innovation   Fin-path costly innovation 
Raising capital  Fin-pa – raising capital 
Public stock offering  Fin-pa IPO  
VC  Fin-pa VC  
Revenues  Fin-pa revenues 
FINANCIAL POSITIONS 
Scientific capabilities  Fin-pos scientific cap 
Founders   Fin pos founder  
Executive staff  Fin-pos TMT  
Core innovation  Fin-pos  core tech 
Firm‟s staff  Fin-pos– staff  
FINANCIAL PROCESSES 
Raising capital  Fin-proc  RC 
Integrating financial resources   Fin-proc int 
Dealing with Investors  Fin-proc inv rel 
IPO  Fin-proc IPO 
Transforming financial resources and operations  Fin-proc trans 
COMLEMENTARY ASSETS 
R&D complementary asset  R&D CA 
R&D specialised complementary asset  R&D SCA 
R&D co-specialised complementary asset  R&D CCA 
Financial complementary asset  Fin CA 
Financial specialised complementary asset  Fin SCA 
Financial co-specialised asset  Fin CCA 
Source: Author 
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The chapter is structured as follows: 
 
6.2 Drug development firms 
6.3 Medical device firms  
6.4 Biological analyser firms 
6.5 Triangulation and cross-case analysis 
6.6 R&D and finance interdependence 
6.7 Analysis conclusions 
 
This chapter presents the findings of the study. For the sake of parsimony, the findings are 
not at this point compared to the literature; this is done in chapter seven.  
 
6.2 Drug development firms 
This  section  overviews  the  evolution  of  the  drug  development  firms.  This  group  is 
constituted  by  two  small  drug  development  firms  that  are  pursuing  novel  drug 
technologies. In this section a narrative of each case is presented followed by an in-depth 
cross group analysis. 
 
6.2.1 Drug development firm one (DD1) 
DD1 is a small drug development and diagnostic firm. The firm‟s core technology revolves 
around cardiovascular disease treatment and prevention. The firm was founded in 2000 by 
two  scientists  and  a  medical  practitioner.  Currently  the  firm  employs  eighteen  staff 
members and is generating less than $1 million in revenues. However, the firm has mainly 
focused on R&D in the first ten years and has just started selling its first product.  
 
The core technology that the founders conceptualised set the central direction of the firm; 
as the CEO puts it, 
  
Our technology has driven all of our major decisions and is still driving everything 
that we do today. (DD1‟s CEO) [R&D-pa and fin-pa core tech] 
 
The founders came up with the idea of combining multiple cardiac techniques together into 
a drug platform [R&D-po founder]. In 2000 they formed DD1 to pursue its development 140 
 
[R&D-pa core tech]. The initial capital for the development came from personal funds 
[Fin-pos founder]. After the founders developed the model for their technology, they then 
started to seek outside capital. To help with this process and to structure the firm, the 
founders hired a highly experienced CEO in the second year of the firm‟s operations. The 
CEO‟s first priority was raising capital. In order to do this he created processes to raise 
money from physicians. The firm created routines of finding, contacting and presenting the 
companies technology to physicians and then asking the physicians to invest in the firm 
[Fin-proc RC]. At the time the main positions that the firm leveraged to „sell‟ the potential 
investors was the market potential of the core technology and the experience the CEO had 
in developing young firms [Fin-pos TMT]. These processes quickly yielded $3 million.  
 
In the first four years the capital went primarily to developing their drug technologies. The 
initial R&D assets and capabilities emanated from the founders, a small staff and research 
partners. Early on the firm did not have any major research partners, but instead developed 
routines for identifying researchers doing complementary work [R&D-proc partnering]. 
They looked for these researchers through their work in scholarly, scientific journals and 
conferences. Once DD1 identified potential researchers, they then presented the prospect 
of using DD1‟s technology and research to attract them, which turned out to be a mutually 
beneficial arrangement, as the researchers got access to useful information and technology 
from DD1, and DD1 received inputs from the independent researchers [R&D CCA]. These 
routines proved highly beneficial to DD1 as they were able to forge important relationships 
with independent researchers. 
 
The  independent  researchers  were  very  important  to  helping  us  advance 
technology for a low cost. Several of their studies advanced our technology and 
provided important independent research backing. (CEO, DD1) 
 
A partnership in year three with the U.S. FDA also had a major impact on the firm‟s R&D 
path [R&D-pa govt partnerships]. This partnership was on a joint study for the firm‟s main 
drug application. The study looked into the estimated development time and cost of the 
drug. Results from the study suggested it would take four years and $10 million to develop. 
At about the same time the firm ran into issues on its patent applications; most notably, it 
was taking longer to obtain the patents than the firm had anticipated [R&D-pa scientific 
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put their project on hold and focus on an application for a diagnostic device. According to 
the CEO,  
 
The patents were taking too long and we did not have the time or money to get the 
drug to market [R&D-pa govt app]. For this reason we focused on developing a 
diagnostic device from our technology. We focused on this because it could be 
brought to market more rapidly. (DD1‟s CEO) [R&D-pa core tech] 
 
Due to the high development costs of the core technology, the firm has had to constantly 
raise capital. In the first four years this came primarily through private investors, but in 
year four the firm needed substantial capital to finance the change in the firm‟s R&D focus 
[Fin-pa costly innovation]. The firm turned to a public stock offering for this. Although a 
complex ordeal [Fin-pa IPO], the firm was able to navigate it based on the CEO‟s vast 
experience in taking companies public: 
 
I have taken four companies public, so I knew how to do this. I knew that a reverse 
public offering from a shell company would be the fastest and best way to raise a 
large amount of capital. (DD1‟s CEO) [Fin-pos TMT] 
 
Due to the CEO‟s experience the firm successfully raised over $10 million from its first 
stock offering. This capital went to focusing on the development of their diagnostic device. 
The capabilities in raising capital proved vital as the capital that they yielded allowed the 
firm to continue its R&D. These advanced capabilities proved to be important auxiliary 
assets throughout the development of the firm [Fin SCA].   
 
Developing the diagnostic device also proved difficult. The firm expanded its research 
staff  and  continued  to  forge  relationships  with  independent  researchers  [R&D-proc 
partnering].  The  firm  also  established  a  relationship  with  the  government  on  a  joint 
research  project.  From  the  agreement  with  the  government,  DD1  received  $1  million 
dollars for the research and access to some government labs and research inputs [R&D-pos 
govt inputs]. This helped advance the firm‟s technology, but did not help as much as they 
hoped it would, largely because the government bureaucracy slowed the research and the 
government  wanted  too  much  ownership  of  the  IP  that  was  yielded  from  the  study. 
Because of these problems the firm has not looked to enter into other research agreements 
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The  government  is  too  difficult  to  deal  with  and  wants  too  much  of  the  IP 
(intellectual  property)  from  the  research.  So  we  are  not  going  to  be  pursuing 
partnerships with the government. (DD1‟s CEO) [R&D-pa govt partners]  
 
DD1 formed another important  partnership with the University of Mississippi  Medical 
Centre in the fifth year [R&D-pa univ partners]. It emanated from a relationship with one 
of the firm‟s private investors, a physician there. The physician lobbied the chancellor to 
enter into a joint research agreement with DD1. The agreement established a relationship 
whereby the university got access to DD1‟s technology in exchange for research services 
[R&D CCA]. This proved vital to DD1‟s development as the research inputs from the 
university greatly helped the firm advance their diagnostic device [R&D-pos Uni inputs]. 
The  fact  that  the  firm  received  the  inputs  from  the  university  at  almost  no  cost  was 
particularly beneficial as the firm was in a very tight cash flow situation. This relationship, 
along with inputs from the firm‟s scientists, greatly helped progress the firm‟s device in 
years seven and eight.  
 
These  advancements  helped  the  firm  in  year  eight  to  raise  an  additional  $10  million 
through  a  combination  of  an  additional  stock  offering  and  private  investment.  This 
investment  proved  vital,  as  the  firm  needed  it  to  navigate  their  device  through  FDA 
approval [Fin-pa costly innovation]. Moreover, all of this transpired in the midst of the 
economic downturn of 2008 when capital became in short supply. 
 
The capital markets dried up. The VCs pulled out and nobody wanted to invest in 
early stage biotech firms. So we were lucky to get the capital to keep us afloat. 
(DD1‟s CEO) [Fin-pa VC]       
 
The firm successfully navigated FDA approval and received clearance for their device in 
2010  [R&D-pa  govt  approval].  This  was  a  long  and  strenuous  process,  but  the  firm 
successfully leveraged its scientific capabilities and strategic partnerships to get over this 
hurdle. In 2010 the firm also received full clearance on five patents. The firm just started 
marketing its device in 2010 and is hoping that revenues will pick up so that it can start to 
refocus on the drug development path that it set out to pursue. These scientific capabilities 
to progress the core technology and navigate the patenting processes proved instrumental 
in the firm‟s early development [R&D SCA].  143 
 
 
Although the firm is generating less than $1 million in revenues, it has still enjoyed growth 
since its inception in 2010. The growth is seen in its five domestic and thirty international 
patents; a fully developed device with FDA approval; staff of eighteen employees and a 
relationship with a major university and its network of independent researchers. From a 
financial perspective its growth is most evident from the $28 million that the firm raised 
from 2000 to 2010.  
 
6.2.2 Drug development firm two (DD2) 
DD2 is  a small drug development  firm  that is pursuing a platform technology for the 
prevention  and  treatment  of  disease.  Their  technology  is  based  on  toxins  from  snake 
venom.  The  firm  was  founded  in  2001  by  a  scientist  to  pursue  the  development  of  a 
technology that was being developed by a firm that went  bankrupt. As of 2010, DD2 
employed eleven people and was generating less than $1 million in revenues. In 2009 the 
firm  just  started  marketing  its  first  product,  and  it  anticipates  revenues  to  jump 
substantially. Moreover, it has several applications that will be ready in 2010 and 2011.  
 
The core technology that the firm is pursuing has provided the central path for the firm‟s 
R&D and its overall strategic direction. To date almost all of DD2‟s resources have been 
dedicated to this technology.  
 
This technology has been in development since the late 1980‟s. Two other firms developed 
and worked on it, but both of these ceased operations, largely due to mismanagement. Both 
had scientists leading them who were not doing a good job from a business perspective. As 
the CEO put it, 
 
DD2  came  about  primarily  as  a  motivation  from  a  failure  of  a  predecessor 
company to that one. Our interpretation, or my interpretation, the motivator behind 
the whole thing really was that a lot of what was previously done, failed more due 
to bad management than to a poor product. And frankly I thought that they’d do a 
better job. (DD2‟s founder and CEO) [R&D –pa core tech] 
 
The founder of DD2 worked for the second firm that advanced the technology. He was the 
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had considerable potential [R&D-pa core tech]. For this reason he decided to create a firm 
to pick up where the last firm left off. In order to capitalise the firm, the CEO used a 
relationship he had with a VC that had invested in the predecessor firm [Fin-po founder]. 
He had worked closely with the VC, and the VC felt that he could revive the technology. 
Without this relationship with the VC, DD2 might not have ever gotten started: 
 
I had a contact with a New York group who were willing to look at financing the 
initial phase of the company. That clearly is one of the biggest breaks that we 
needed. If I did not have this contact, then we would not have got going. Just trying 
to figure out how you’re going to launch this thing and start the revenue generation 
part of  it, or  at  least  attracting  the investment  because very rarely do you get 
revenue depending on the type of product. Thus, this prior relationship proved as 
an  important  position  to  obtaining  the  capital  needed  to  get  the  firm  started. 
(DD2‟s founder and CEO) [Fin-po founder; Fin-pa VC] 
 
Once DD2 was started, the main challenge was reviving the technology and the research. 
The research sat dormant for a few years, and DD2 needed to revive what had been done 
and construct a strategy for their R&D. The founder provided the main scientific position 
to accomplishing this: 
 
So it came from experience. I didn’t jump into it blind. I was very well aware of the 
history,  I  was  very  aware  of  the  potential  asset  of  the  potential  product  to  be 
developed. (DD2‟s founder and CEO) [R&D-po founder]  
 
This scientist is widely considered one of the main snake venom experts in the world, and 
he was able to use his knowledge to jump start the firm‟s research [R&D-po star scientist].  
To help him the firm hired three other highly trained scientists who helped with this task 
[R&D-po scientist]. Their routines revolved around their vast scientific experience. Put 
differently, the scientists possessed tacit routines on strategizing and executing research. 
This allowed the firm to make several steps toward proving the efficacy of their drug 
technology. However, they burned through a greater amount of capital than expected and 
within two years had to attract another $1 million investment [Fin-pa core tech].  
 
For this round of investment the firm leveraged the background of the founder and the 
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founder]. This capital allowed the firm to continue its technological development, which 
drove the need to establish a partner for specialised testing. More specifically, the firm 
required  specialised  research  equipment  and  capabilities  [R&D  SCA].  The  firm‟s 
founder‟s  relationships  provided  access  to  the  university  facilities;  from  his  previous 
dealings with the universities he was able to swiftly forge agreements for testing DD2‟s 
drugs  [R&D-po  uni  inputs].  Moreover,  the  firm  also  established  research  relationships 
through activity in the scholarly community. Through scientific journals they were able to 
locate several other researchers looking at snake venom. The researchers agreed to work 
with DD1 because of the firm‟s unique technology and the fact that this technology had 
been backed by independent tests. In the third year of operations a high profile scientist 
became a director for the firm. He is associated with several top universities and is highly 
experienced in the field. His inputs have opened access to the wider scientific community 
and have helped the firm establish important research links; including links with research 
partners in Europe and China. These inputs have already helped in the firm‟s growth by 
providing science that has helped progress DD2‟s technology, but more importantly, they 
have opened up future research paths and market opportunities.  
 
Its progress and the new director‟s networks allowed the firm to forge a relationship with a 
partner  firm  in  the  field  [R&D-pa  industry  partner].  The  partner  firm  was  developing 
similar technologies that complemented DD2‟s research.  DD2 formed a relationship with 
the firm to share resources and technologies. Capital is a particularly important resource 
that DD2 received from the partnership. In the fourth year of operations the partner firm 
infused around $2 million, which kept DD2 viable. At the time, capital was hard to obtain 
in South Florida where the firm is based because of the tight venture capital markets: 
 
Florida has a huge potential for biotech, the financial support isn’t there.  And so 
all  these  universities  have  great  science,  but  because  there’s  no  mechanism  to 
allow for funding to allow companies to take out the technologies and see if they 
can  commercialise  these  innovations,  it’s  made  raising  capital  difficult  for  us. 
(DD2‟s founder and CEO) [Fin-pa VC] 
 
The cash infusion also provided the capital to sanction the firm‟s first clinical trial in the 
UK. DD2 made a conscious effort not to first apply for FDA approval because of the costs, 
time and bureaucracy involved [R&D-pa govt approvals]. The CEO drove this decision as 
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He has worked and negotiated with drug regulatory agencies in the US, Canada, 
EU, South America, South Africa, and China, enabling companies to move ahead, 
save millions on research and testing in clinical trials, and gain IND approvals. 
(Chairman of DD2) [R&D-po founder] 
 
Based on his experience he felt the UK would be the best place to start clinical trials 
because  of  their  favourable  testing  procedures  for  drug  applications  such  as  theirs. 
Furthermore,  the  founder  held  important  relationships  in  the  UK  that  helped  facilitate 
testing procedures; he is Irish and received his PhD from the Imperial College in the UK. 
His background and relationships helped navigate the clinical trials in the UK [R&D-po 
founder].  
 
The clinical trials helped the firm raise an additional $500,000 from private investors [Fin-
po scientific cap]. The firm used this capital to further develop and test their drug for HIV 
and multiple sclerosis applications. These tests revealed that the firm‟s applications for 
these diseases are effective and inexpensive treatments for these diseases. This provided 
validation to  the firm‟s research, which the firm  built  on in  the sixth  year when they 
clinically proved their drug‟s effectiveness for analgesic applications. These applications 
spurred more interest in the firm and allowed it to continually develop important research 
relationships. Amongst these relationships were several with elite universities and labs. 
The breakthroughs created interest from other firms as well. Most notably, this interest led 
to a merger in the eighth year of DD2‟s existence [R&D-pa industry partner].  
 
Although the firms merged they still operated autonomously. However, the two firms share 
some important resources like scientific assets; the firms have access  to  one another‟s 
scientists, facilities and networks [R&D CCA]. Shared financial resources are even more 
important, and the partner firm is the one that handles most of the financial matters for 
DD2.  This  merger  has  provided  the  important  resources  that  DD2  needed  in  order  to 
continue its research [Fin CCA]. However, raising capital still remains important to DD2. 
 
The  increased  R&D  and  financial  resources  allowed  DD2  to  expand  its  clinical 
development. In late 2009 the firm introduced an over the counter pain medication. Even 
though the firm had a more potent version of the drug that could realise higher profit, the 
firm  chose  to  pursue  this  version  because  approval  is  much  more  streamlined  and 147 
 
inexpensive for over-the-counter drugs [R&D-pa govt approval]. Its approval is significant 
because it marked the beginning of commercialisation for the firm. Another milestone in 
year nine came in the form of one its major patent approvals [R&D-pa govt approval]. This 
patent protects one of the main applications that the firm had worked on for over eight 
years. In year ten the firm received another important patent approval. These are major 
milestones because they give the firm more leeway in how they can license and distribute 
their drugs.   
 
These milestones are building blocks to the firm‟s future. It is anticipating rapid growth 
over  the  next  five  years.  They  have  proven  their  technology  and  have  market-ready 
applications and a network of partnerships and financial resources to back the firm‟s future 
growth. In the first ten years the firm‟s growth is evidenced in its two key patents; full 
FDA approval for two drugs and UK approval for one drug; network of partnerships and 
the $5 million in outside investment capital that the firm has received.  
 
6.2.3 DDs cross-group analysis 
The narratives above provide a contextual basis for the evolution of the DD1 and DD2‟s 
R&D and financial  resources  and  capabilities. This section delves deeper into the key 
paths, positions and processes that led to the development of the firms‟ R&D and financial 
resources and capabilities. It analyses and compares the paths, positions and processes that 
led to each firm‟s R&D resources and capabilities. A similar approach has been taken to 
explore the financial assets and capabilities developed in the early stages of growth.  
 
 6.2.4 R&D resources and capabilities development 
In the early stages of growth both firms focused on the development of their technology, 
the impetus of developing R&D resources and capabilities for both firms. This section 
highlights the paths, positions and processes central to the development of the firms‟ R&D 
resources  and capabilities; the paths  are the past  decisions and actions,  and the future 
opportunities that influenced the firms‟ strategic pursuits; the positions are the resources 
that the firms leveraged in their development; and the processes are the routines that the 
firms used to leverage their positions in order to take advantage of their paths (Teece, 
2007; Winter, 2003). Table 6-2 presents the matrices of the paths, positions and processes 
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chapter, and this collates with the text code table presented at the beginning of the present 
chapter. Based on the analysis of the interviews and the close-ended questions, each path, 
position and process for each firm is placed in one of four categories based on its influence 
on the firm‟s development: high (H), medium (M), low (L) or no (N) influence. The major 
paths, positions and processes are discussed in detail below. 
 
Table 6-2: DDs' R&D paths, positions and processes 
  D1  D2 
INFLUENTIAL ON FIRMS’ PATHS 
Core technology conceptualised at a university  N  N 
Core technology conceptualised at another firm  H  N 
Core technology conceived by the firm  L  H 
Government partnerships  L  L 
Industry partnerships  M  L 
New technologies influenced firm‟s direction  H  M 
Government approvals: e.g. patent or FDA  H  H 
Scientific developments  H  H 
IMPORTANT POSITIONS 
Patents  L  H 
Skilled scientists  H  H 
Star scientists  H  H 
Industry partnerships  L  H 
University partnerships  L  L 
Government partnerships  L  L 
R&D facility and research equipment  L  L 
Core technology  H  M 
KEY PROCESSES 
Sensing and seizing scientific opportunities  H  H 
Finding and developing research partnerships  M  L 
Navigating government approval  H  M 
Filing patents  M  H 
Learning from earlier research  H  H 
Transforming R&D   H  M 
Source: Author 
 
Paths 
Several  paths  influenced  the  strategic  R&D  pursuits  of  the  firms.  Table  6-3  presents 
evidence depicting the importance past decisions and future opportunities that dictated the 
development of DD1 and DD2‟s R&D resources and capabilities has had.  
  
 The most prominent path for the firms emanated from their core technologies. Table 6-3 
(1-6) below provides sample evidence depicting this and also depicting that both firm‟s 
strategic  direction  was  firmly  established  by  the  technology  that  the  firms  set  out  to 
develop  and  commercialise  [R&D-pa  core  tech].  DD2‟s  technology  was  initially 
discovered and developed at other organisations, and the efforts of those organisations set 
the research path for the firm (Table 6-32; 1, 2 and 5). The early stage technologies that 
DD1 conceived and incubated set the central path for the firm‟s R&D, but unlike DD2, the 
firm‟s technology was totally new. The technologies impacted the R&D  resources and 149 
 
capabilities needed [R&D-pa core tech]. However, R&D proved vital for both firms, but 
the exact combination of resources and capabilities required differed. DD2‟s technology 
moved  the  firm  to  primarily  focus  on  developing  specialised  testing  resources.  In 
comparison,  DD1‟s  path  dictated  that  the  firm  develop  R&D  resources  for  creating  a 
technology.  Simply  put,  the  technologies  that  the  firms  pursued  set  their  strategic 
directions and dictated the R&D resources needed for growth.  
 
Future research opportunities also greatly influenced the R&D paths of the firms. Table 6-
3 (7-9) presents a representative sample of the evidence supporting this. Opportunities to 
develop new applications motivated the firms to develop the research capabilities that were 
needed to develop these applications [R&D-pa new tech]. An opportunity to develop a 
diagnostic device changed the strategic path of DD1 (Table 6-3; 7) [R&D-pa scientific 
dev]. The firm needed to find a product that could quickly be brought to market, and an 
application using their technology for a diagnostic device presented an opportunity for this. 
Thus, in the fifth year of the firm‟s operations it changed R&D paths to focus on this 
device. DD1 almost completely stopped working on drug applications and devoted all of 
its  resources  to  this  product.  In  year  eight  several  progressions  related  to  the  firm‟s 
diagnostic device brought them to FDA clearance [R&D-pa govt approval]. This clearance 
allowed the firm to start marketing their device and allowed them to refocus their resources 
on their original path of developing drug applications.  
 
Similarly,  DD2  pursued  the  development  of  four  new  applications  for  their  drug 
technology [R&D-pa scientific dev]. These new drugs greatly affected the firm‟s R&D 
paths: the firm developed research resources and capabilities to test and commercialise 
these drugs. Moreover, motivated by the need to quickly generate revenues, DD2 pursued 
the development of an over the counter drug in year eight of their existence (Table 6-3; 8 
and 9). The firm pursued development of this drug because of how quickly an over the 
counter  drug  could  be  brought  to  market  [R&D-pa  govt  approvals].  This  new  path 
stemmed largely from the need to show investors the firm could produce a drug that could 
generate revenues. This made DD2 devote a significant amount of revenues to this project. 
Several of their other research projects on their other drugs were slowed or halted so that 
they could focus on the over the counter drug.    
 
Gaining  government  approval  (FDA  or  other  government  clearance)  has  also  greatly 
influenced the paths of the firms‟ research (Table 6-3; 10-15) [R&D-pa govt approvals]. 150 
 
Initially  both  firms  pursued  drug  applications  that  required  high  level  government 
approval. This forced the firms to devote significant resources to pursuing it. DD1 invested 
over $250,000 in a joint research project with the FDA to try to streamline the approval 
process of their main drug application. The results were less than desirable and indicated 
that  the  drug  would  take  more  time  and  capital  to  bring  to  market  than  originally 
anticipated. The fact that a diagnostic device could more readily be brought through FDA 
approval  triggered  the  firm  to  refocus  their  R&D  on  applying  their  technology  to 
developing a device (Table 6-3; 7) [R&D-pa govt approval]. Although the device required 
a less rigorous FDA process, the firm still devoted several million dollars towards getting 
the device through FDA approval. 
 
Government approvals have also had a major impact on DD2‟s R&D paths, as the firm has 
put several drugs through government testing (Table 6-3; 13-15) [R&D-pa govt approvals]. 
Interestingly, government approvals have motivated the firms down an internationalisation 
path. In order to save on costs and streamline the approval process, DD2 went for their first 
major approval in the UK because of their more efficient approval processes for drugs like 
DD2‟s. The firm has also put three drugs up for FDA approval in the US, which has 
greatly influenced the strategic direction of the firm.  This  forced the firm  to  devote a 
significant portion of its R&D resources to FDA-related functions. It has also made the 
firm develop routines for meeting FDA processes. There are dozens of processes that the 
firm has to follow in order to stay in compliance with FDA approval.  
 
Path rigidities have also resulted from the substantial resources invested in government 
approvals (Table 6-3; 10-13). Both firms committed a substantial amount of their resources 
to FDA approval, which limited the investment that they could make in other areas related 
to  their  technology.  The  commitment  to  government  approvals  made  success  in  these 
endeavours  paramount.  DD2  enjoyed  success  in  their  approvals,  but  the  resources  the 
processes consumed also restrained the firm from making investments in other areas of 
R&D that they would have liked to have pursued. DD1, on the other hand, had some major 
FDA setbacks that forced the firm to reconfigure its R&D to focus on the development of a 
device instead of the drug it originally set out to pursue.  
 
Government approval also presented opportunities for both firms. Major milestones in the 
approval process helped the firms attract additional capital and resources needed for their 
technology. It also helped the firms develop several key relationships. For example, DD1 151 
 
entered into an important research collaboration with a university medical centre that was 
largely  facilitated  because  of  FDA  milestones  [R&D-pa  uni  partners].  Similarly,  DD2 
entered into a strong partnership with another firm within the industry [R&D-pa industry 
paths]. These relationships proved influential on the firms‟ R&D paths.  
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Table 6-3: DDs' R&D paths 
FIRM                 The core technology drove R&D demands of the firms. 
 
DD1  1.  The technology set the stage for the firm. It drove all of our basic functions. Our R&D and 
entire company revolves around it. (DD1‟s CEO) 
 
2.  The technology has been everything to us. All of our functions revolve around it and we 
wouldn’t be here without it. (DD1‟s CEO) 
 
3.  One hundred per cent of the $28 million invested in the firm went directly or indirectly to 
developing the firm‟s core technology. (Close- ended question; analysis of firm‟s financial 
statements) 
 
DD2  4.  DD2 came about primarily as a motivation from a failure of a predecessor company to that 
one.  Our interpretation, or my interpretation, the motivator behind the whole thing really 
was that a lot of what was previously done failed more due to bad management than to a 
poor product.  And frankly I thought that they’d do a better job. (DD2‟s founder and CEO) 
 
5.  So we tried to revive the innovative property, that’s perceived to be the asset to the 
company.  (DD2‟s founder and CEO) 
 
6.  Ninety per cent plus all of DD2‟s capital expenditures in the first nine years went to 
developing their core technologies.  (Close-ended question; analysis of firm‟s financial 
statements) 
 
                            New scientific opportunities impacted the strategic direction of R&D. 
DD1  7.  The cumbersome approval procedure is one of the main reasons that we decided to re-
strategize on developing a device. We hated to shelf the drugs, but we needed to get a product 
to market, and we found that our technology could get approved much quicker and cheaper 
through a diagnostic device.  (DD1‟s CEO) 
 
DD2  8.  We re-focused on an over the counter drug because these could more readily be brought to 
market. (Close-ended question; analysis of firm‟s financial statements) 
 
9.  Marketing not only generates revenue, but it also helps to give us credibility. For this reason 
we decided to refocus for a short tem attention on developing an OTC drug. (DD2‟s founder 
and CEO) 
 
              FDA and government approvals have impacted the strategic direction of R&D 
DD1  10.  We have put a lot into FDA and have had to make our products work because of this 
tremendous investment. (DD1‟s CEO) 
 
11.  When you’re a small firm, and you commit $10 million to FDA, you have to make sure that it 
works. (DD1‟s CEO) 
 
12.  In the first nine years the firm has invested over $4 million in FDA related matters. (Analysis 
of financial statements) 
 
DD2  13.  FDA approval is costly, lengthy and consumes the firm. (DD2’s Chairman) 
 
14.  We were familiar with the UK and knew that this process would be more streamlined and 
more efficient. (DD2‟s founder and CEO) 
 
15.  That (UK approval) was a major success from that perspective to kind of get on the board 
with regard to demonstrating that our products are worthy of administration.  A certain level 
of credibility is garnered from this. It is helpful in developing relationships and looking good 
to investors. (DD2‟s founder and CEO) 
Source: Author153 
 
Positions 
The firms leveraged several positions in their strategic R&D pursuits. Table 6-4 presents 
sample evidence supporting the most important resources that the firms leveraged in the 
development of their R&D.  
 
The most ubiquitous resource for both  firms was their core technology [R&D-po core 
tech]. Table 6-4 (1-5) depicts a representative sample of evidence that underscores the 
importance  of  the  firms‟  technologies  to  the  firms  R&D.  Both  firms  leveraged  their 
technology to help them attract important inputs. Capital proved to be one of the most 
important  assets  that  the  core  technology  helped  the  firms  attract  [R&D  and  fin  co-
specialisation]. The firms‟ core technologies have also allowed them to attract research 
partners that have been vital to progress their technologies [R&D-po core tech].  
 
DD1‟s technology complements research related to many areas of cardiac disease, and this 
has  been  a  resource  that  has  allowed  the  firm  to  enter  into  many  different  mutually 
beneficial partnerships with independent researchers who gained access to inputs that help 
in their studies. DD1 benefited from important independent testing that helped progress 
their technology (Table 6-4; 1) [R&D CCA]. DD1‟s technology also allowed them to enter 
into a partnership with a large university that was interested in gaining access to DD1‟s 
science (Table 6-4; 2) [R&D CCA].  
 
Quite similarly, DD2‟s technology is a resource that has helped the firm attract inputs from 
a number of universities and independent researchers (Table 5-2; quotes 3, 4 and 5) [R&D-
pos core tech]. Many of these relationships were facilitated through scholarly journals and 
conferences.  The  researchers  were  motivated  to  work  with  DD2  largely  because  their 
technology  had been verified in  the scientific journals. Moreover, it also  provided the 
impetus to the firm‟s most important partnership; a firm that they later merged with in year 
7. DD2‟s R&D resources and capabilities complemented the partner firm‟s research [R&D 
CCAs]  and  thus  was  the  motivating  factor  to  the  partnership,  which  has  provided 
invaluable inputs that have helped the firm to grow and develop.  
 
A second position that has been vital to the firm‟s development is their scientific staff. 
DD1‟s staff is made up of five scientists of whom three are PhDs. These scientists have 
made consistent contributions that have helped advance the firm‟s technologies (Table 6-4; 
6) [R&D pos scientists]. The founders‟ provided particularly important early resources to 154 
 
the firm‟s R&D. They are the ones who conceptualised the technology and developed the 
drug prototype [R&D-pos founder]. All three of the founders have had substantial success 
as scientists. One of the founder‟s publication records put him in the top five per cent of all 
research scientists, and the other two hold multiple patents for innovations that have gone 
on to great commercial success. 
 
The founders‟ designed the firm‟s research and hired the scientific staff from whom for the 
first two years most of the firm‟s inputs came (Table 6-4; 7). The firm‟s scientific board, 
which is also made up of several noted scientists, has also helped the firm progress its core 
technology.  
 
In a slightly different vein, DD2‟s R&D revolved around the founder who is a star scientist 
(Table 6-4: 8 and 9) [R&D-pos star scientist; R&D-pos founder]. The founder is the one 
who came up with the main progressions for the firm‟s technologies. He is well-published, 
holds six patents and is recognised as one of the leading experts on snake venom. His 
knowledge and talents provided vital resources that contributed significantly to the firm‟s 
innovations.  DD2  also  had  a  small  team  of  scientists  who  helped  the  CEO  on  the 
technology,  and  their  contributions  were  important  [R&D-pos  scientists]  but  were  not 
specialised in the sense that they could not have been performed by other trained scientists.  
 
Another important resource for DD2‟s is their specialised research facility. DD2‟s lead 
scientists designed and fitted a facility specific to their operations [R&D-pos facilities]. It 
is highly advanced and customised for their research purposes. Although research facilities 
are important to DD1, they are not highly specialised since the building and equipment 
were readily available on the free market. Some of the testing equipment for DD1 required 
some customisation, but this only constituted one small part of the research facility. Put 
differently, a specialised R&D facility has been an essential resource to DD2, but such a 
facility has not been essential to DD1.  
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Table 6-4: DDs' R&D positions 
                
FIRM  The firm’s core technology helped attract and develop other resources. 
DD1  1.  We were able to develop a following of independent researchers because they were 
interested in our technology. This was crucial as they made contributions to our product 
that did not cost us anything. Having these free researchers was important to the firm’s 
development. (DD1‟s CEO) 
 
2.  The medical college was interested in being a part of what we are trying to do. They saw 
that our technology could help some of their research projects. (DD1‟s CEO) 
 
 
DD2  3.  This discovery is significant to our continued research and development, as it identifies the 
mechanism of action for RPI-78M. We believe that our drug is the first to induce the 
expression of IL-27, which represents a novel way to approach the treatment of several 
autoimmune diseases. This makes it of interest to a wide variety of firms and organisations. 
(DD2‟s founder and CEO) 
 
4.  The biotechnology research and development field is extremely competitive and is 
characterized by rapid change. Our competitors have substantially greater financial, 
scientific, and human resources, and as a result, greater research and product 
development capabilities. Our competitors have competitive advantages with greater 
potential to develop revenue streams. Our competitors are located in the United States as 
well as around the world. We attempt to compete by establishing strategic partners or 
alliances with pharmaceutical companies, academic institutions, biotechnology companies 
and clinical diagnostic laboratories which will enter into joint ventures, emphasizing our 
drugs’ superior properties. (DD2 Chairman)  
 
 
5.  A 2007 article discussing the importance of DD1‟s technology to entering into an 
important partnership with a Chinese biotech firm: DD2’s technology shows great promise 
to helping the 1.3 million people living with tuberculosis. (November 23, 2005 Business 
Wire)  
 
                              The scientists provided important inputs to the firms’ R&D. 
DD1  6.   Our scientists have continually made progressions that have moved the technology along. 
The staff had not made any ground-breaking findings, but they have consistently moved 
things along.  (DD1‟s CEO) 
 
7.  The founders were the ones that came up with the breakthroughs. Their novel ideas is what 
got the research going and what we have based all of our products on. One founder in 
particular had worked in a number of fields and used his knowledge and capabilities to 
bring together all of the science needed to develop our platform. (DD1‟s CEO) 
 
DD2  8.  We have a small firm here and I guess without me it would never have happened. I’ve been 
more of the driving force on directing the R&D projects. (DD2‟s founder and CEO) 
 
9.  By leveraging his comprehensive understanding of regulatory requirements, he has guided 
us on new projects through the correct protocols at a minimum budget, advancing products, 
positioning for licensing, and setting up manufacturing. The application of his knowledge of 
laboratory practices to select new technologies that enhance production, quality control, 
and product formats. (DD2‟s Chairman) 
 
 
Source: Author 
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Processes 
The  firms  relied  heavily  on  processes  related  to  identifying  and  integrating  scientific 
innovations and techniques. Table 6-5 (1-5) presents a representative sample of evidence 
that underscores the importance of sensing, filtering and integrating processes.  
 
Both  firms‟  founders  had  vast  experience  in  identifying  and  evaluating  scientific 
technologies for DD1 and DD2 [R&D-proc S&S]. These processes were held uniquely 
within the founder‟s own scientific and conceptual knowledge and could not be replicated 
(Table 6-5; 3 and 4) [R&D-pos founder]. They could not explain how they are able to 
evaluate technologies other than that it is intuitive based on their years of experience in 
evaluating them.  
 
As the firms developed, sensing complementary technologies also became important. The 
firms created processes for finding scientific inputs for their R&D. For example,  DD1 
developed  routines  for  identifying  potential  researchers  working  on  complementary 
research [R&D-proc S&S]. These routines revolved around scouring journals to look for 
researchers  working  in  similar  areas.  Once  a  researcher  was  located,  the  firm  then 
contacted the researcher(s) about the prospect of joint research projects. This yielded over 
fifty relationships that led to important contributions to DD1‟s technology. Moreover, this 
routine helped the firm conserve capital as the firm had received important inputs, but it 
also had minimal related expenses.  
 
Learning processes from their daily operations also helped advance the firm‟s R&D (Table 
6-5; 6-8) [R&D-proc learning]. Every day they moved their technology forward based on 
what  they  had  previously  accomplished.  Both  firms  have  systems  for  tracking  their 
progress, but these are relatively common [R&D-proc leaning]. More than anything the 
firms‟ learning was held within their scientific staff whose knowledge and insight came 
from their previous experience (Table 6-5; 6 and 7) [R&D-pos scientists].  
 
Another  area  where  learning  routines  proved  important  to  the  two  firms  was  with 
government approval [R&D-proc govt approval]. Both firms learned how to better prepare 
themselves for dealing with FDA. DD1 learned from its major FDA setback that drugs are 
expensive and time consuming to clear through FDA approval. Similarly, DD2 learned 
from their early FDA dealings that this process takes a long time and the FDA approval 
decision can be erratic. For this reason for some of their future drugs the firm pursued 157 
 
approval  with  other countries  first.  The other countries,  such as  the UK, have a more 
streamlined and predictable approval processes. 
 
Both firms also learned from their experience with the patent process that it takes longer to 
pursue  than  they  had  originally  intended.  DD1‟s  core  patents  took  over  nine  years  to 
execute, whilst two of DD2‟s most important patents took over eight years to execute 
[R&D-proc  govt  approval]. Moreover, the firms learned that upholding patents  is  also 
difficult. For this reason both firms made future strategic choices to pursue applications 
that did not completely depend on patents.  
 
Transformation related processes have also been important to both firms (Table 6-5; 9-12) 
[R&D-proc  transform].  In  the  fourth  year  of  existence  DD1  realised  that  because  of 
changing conditions in the pharmaceutical industry, they would not be able to progress 
their  drug  applications  to  market  (Table  5-3;  9).  The  FDA  had  changed  its  approval 
procedures and the firm‟s drugs were taking longer than originally expected to develop. 
This triggered DD1 to reconfigure its R&D resources to focus on the development of a 
diagnostic device that could more readily be passed through FDA approval [R&D-proc 
govt approval]. At that point they also they also had to focus more on new R&D routines 
and partnerships.  
 
In a similar vein, DD2 came to a point where it needed a new drug that could be brought to 
market quickly, and used its transformational routines to reconfigure its R&D to focus on 
the development of an over the counter drug (Table 6-5; 10 and 11) [R&D-proc transform]. 
Several of its projects were stopped and those resources were then devoted to the new 
drug.  Transformational  routines  proved  highly  beneficial  to  both  firms,  as  these 
reconfigurations led to marketable products that kept both firms viable. These products 
allowed  the  firms  to  generate  revenue  and,  more  importantly,  showed  their  ability  to 
develop  a  marketable  product,  which  helped  attract  more  investment  capital  and  other 
resources.  
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Table 6-5: DDs' R&D processes 
 
FIRM   Identifying and sensing technologies 
DD1  1.  At the beginning we had to pull together a number of science to try to make our idea work. 
Finding the technologies was vital to making this happen. One of our founders had 
experience in several areas and was important to bringing everything together. (DD1‟s 
CEO) 
 
2.  Finding the technology comes from years of experience. There is no formula or set way of 
looking at a technology. You look at some objective things, but in an infant science the 
judgement comes from experience. (DD1‟s CEO) 
 
3.  Finding science is important. We have routines in place to find research that can help us. 
One of the most important sources of this is the independent researchers that we reach out 
to. (DD1‟s CEO) 
 
 
DD2  4.  It was up to me to collect all these assets together and form a plan to develop products using 
the resources we had and finding what we needed – all in an expeditious way of getting to 
market revenues. (DD2‟s founder and CEO) 
 
5.  The firm has entered into dozens of partnerships with organisations with offerings that could 
help us. We have systems of searching within the community and finding these people.  
(DD2‟s founder and CEO) 
 
                              Learning routines have helped advance the firms R&D 
DD1  6.  Our scientists have routines for sharing information. It is hard to pinpoint them. I mean we 
have standard reporting and all, but it is the scientists who just know how to take and look at 
their work and figure out what to do with it. This is where the learning happens.  (DD1‟s 
CEO) 
 
DD2  7.  The systems we have in place for learning come from the fact that we’re all experienced 
researchers, you know PhD’s, advanced degrees, so it’s just experienced research. (DD2‟s 
founder and CEO)   
 
8.  Our learning relies heavily on the existing data for the direction and determined the 
pathway for what type of R&D we still needed to do in order to move forward. (DD2‟s 
founder and CEO) 
 
                              Transforming R&D has proved vital to the firms’ growth and survival 
DD1  9.  In year four we saw that FDA approval was getting more difficult and that our drug was not 
progressing as well as we had hoped. This prompted us to focus on the development of a 
diagnostic device. (DD1‟s CEO) 
 
10.  We had to change direction. To stay above water we changed to a diagnostic firm. We had 
the resources in place, but they had to change things around. (DD1‟s CEO) 
 
DD2  11.  So  effectively  operations  were  fairly  low  key,  low  numbers  of  staff  until  2009  when 
effectively  we  existed  for  the  best  part  of  eight  years  just  researching  before  we  really 
started to get any traction.  And the only way we started to get traction was to develop a 
product that was on the market. (DD2‟s founder and CEO) 
 
12.  The 2009 quarter fourth report for the SEC has an entire section dedicated to the importance 
of the over the counter drug market and the fact that the firm dedicated a substantial amount 
of its resources to this effort. (Q4 2009 SEC 10k Report) 
 
 
Source: Author 
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6.2.5 Financial assets and capabilities 
The  firms‟  R&D  demanded  significant  capital  to  get  their  products  to  a  point  of 
commercialisation. For the most part, generic financing was not available. For this reason, 
the firms turned to specialised investment sources for the needed capital, which required 
the firms to leverage a unique set of paths, positions and processes to obtain the needed 
capital.  This  section  highlights  the  paths,  positions  and  processes  central  to  the 
development of the firms‟ financial assets and capabilities. Based on the coding and close-
ended questions, each path, position and processes for each firm is placed in one of four 
categories based on its influence on the firm‟s development: high influence (H), medium 
influence (M), low influence (L) or no influence (N). The analysis for the major paths, 
positions and processes is detailed below. 
 
Table 6-6: DDs' financial paths 
  D1  D2 
INFLUENTIAL ON FINANCIAL PATHS 
Costly innovation   H  H 
Raising capital  H  H 
Public stock offering  H  M 
VC  L  L 
POSITIONS 
Scientific capabilities  H  H 
Founders with strong industry background  H  H 
Executive staff  H  L 
Core innovation  H  H 
Firm’s staff  L  L 
PROCCESSES RELATED TO 
Raising capital  H  H 
Integrating financial resources   H  H 
Dealing with Investors  H  M 
IPO  H  M 
Transforming financial resources and operations  H  M 
Source: Author 
 
Paths 
Table 6-7 highlights the paths important to the development of the firms‟ financial assets 
and capabilities. There were several past decisions and future opportunities that impacted 
the strategic pursuits of the firms.  
 
In general, the largest influence on the firms‟ financial paths was their technology. The 
impetus  for  developing  financial  assets  for  the  firms  stemmed  from  the  high  cost  of 
developing a novel drug technology, which is supported by the representative evidence in 
Table 6-7 (1-7) [Fin-pa costly innovation]. DD1 and DD2 required substantial investment 
during the conceptualisation phase. Most of this investment focused on R&D. Over time 160 
 
developing a platform technology proved quite costly as DD2 spent over $25 million on 
the development of their drugs in the first nine years of existence, whilst D3 spent over $5 
over that same span. The discrepancy in investment is largely attributed to the fact that 
DD2‟s  technology  was  based  on  an  existing  drug  platform,  whilst  DD1‟s  was  freshly 
created by the firm.  
 
The only viable early financing path for DD2 was VC. Capital from a VC financed most of 
the firm‟s early development. In contrast DD1‟s seed capital came from a small group of 
angel investors. This angel investment exhausted quickly as the drug technology proved 
expensive to develop. The firm looked at VC but could not raise capital there because of 
the changing VC funding model (Table 6-7: 3).This triggered the firm  to  go down an 
alternative  path  to  securing  capital.  At  this  point  the  firm  implemented  elaborate 
mechanisms for raising funds from physicians familiar with their cardiac technology.  
 
For DD1 and DD2 raising capital through public stock offerings was also an important 
path in the firms‟ development. However, the two firms‟ paths to an IPO were markedly 
different. DD1‟s CEO took the company public on a small public stock exchange through a 
reverse  merger  where  the  firm  took  over  another  public  firm  that  had  gone  bankrupt, 
essentially just taking over their stock ticker. By taking over another firm, DD1 expedited 
the public offering process; most notably, it allowed the firm to avoid many of the filings 
that are required for public offerings. This proved successful as it allowed the firm to 
quickly list on a public exchange and raise over $20 million in capital over a five year 
period. In contrast, DD2 merged with another firm that already held a public stock ticker. 
This merger was largely motivated by the access to public funding that would result from 
the merger. The merger provided access to over $3 million in funds in the two years from 
the date of the merger.  
 
For DD1 the public offering path did have a downside in that it consumed and continues to 
consume  a  tremendous  amount  of  the  key  executives‟  time  (Table  6-7;  9).  The  TMT 
spends hours filing reports, dealing with investors and dealing with regulatory procedures. 
This is time that could be devoted to more productive means. In contrast, DD2 does not 
have to deal with these processes. This is primarily because the firm DD2 merged with 
handles most of these dealings. Moreover, the merger has freed up DD2‟s executives by 
taking care of most of the financial issues. This has allowed DD2 to focus on the scientific 
end of the business.    161 
 
Table 6-7: DDs' financial paths 
 
IRM  The core technology drove the strategic direction of the firm. 
DD1  1.  The technology has cost millions to develop. We knew it was going to be expensive, but in 
this business you never know exactly what it is going to cost you. In the last nine years we 
have spent well over $25 million on it. (DD1‟s CEO) 
 
2.  Even with the low cost inputs we have received from partners, this has been an expensive 
ordeal. Here we are almost ten years later and raising capital to develop the technology 
remains the main issue that we have to deal with. (DD1‟s CEO) 
 
3.  Venture capitalised would not look at us. The model has changed and they no longer look at 
early stage companies. They want all of the return without any of the risk. Venture capital is 
not what it used to be. (DD1‟s CEO) 
 
4.  On hundred per cent of the $28 million invested in the firm went directly or indirectly to 
developing its core technology. (Close-ended question; analysis of firm‟s financial 
statements) 
 
DD2  5.  Just  trying  to  figure  out  how  you’re  going  to  launch  this  thing  and  start  the  revenue 
generation part of it, or at least attracting the investment because very rarely do you get 
revenue depending on the type of product. (DD2‟s founder and CEO)  
 
6.  It’s not cheap to apply for patents to protect your technology, and it is an important and 
costly step to undertake, especially when you go international. (DD2‟s founder and CEO) 
 
7.  Ninety per cent plus all of DD2’s capital expenditures in the first nine years went to 
developing their core technologies.  (Close-ended question; analysis of firm‟s financial 
statements) 
 
               IPOs have influenced the direction of the firms. 
DD1  8.  Because of the dry VC markets we had to go public. The VCs wanted to come along too late 
in the company’s development and still wanted too much equity. This made the public 
markets an important option for us.  (DD1‟s CEO) 
 
9.  I have to spend a lot of timing dealing with the stockholders and issues related to that, but 
we needed to go public to get the capital. If I had my choice, I would rather get the capital 
from other places so that I could avoid all of those headaches. (DD1‟s CEO) 
 
DD2  10.  We have had to commit resources to going public and it has affected our operations, but it 
has been a needed source of capital for us. (DD2‟s founder and CEO) 
 
11.  The hope of (IPO) financing was to meet our near-term budgets and the financial leverage 
to allow us to become revenue generating and fund the clinical trials of our biotech 
investment. (DD2‟s Chairman) 
 
 
Source: Author 
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Positions 
The firms leveraged several unique positions to develop their financial endowments. The 
most ubiquitous position was their superior technology [Fin-core tech]. Table 6-8 (1-4) 
provides  representative  evidence  illustrating  that  one  of  the  biggest  factors  that  their 
investors looked at in their investment decisions was the potential profitability of the firms, 
and this potential profitability was driven by the firms‟ technologies.   
 
The founders‟ and executives‟ backgrounds supplied another important resource that the 
firms leveraged in raising capital. Both firms had founders who had successfully started 
drug development firms in the past, and they used this to entice investors (Table 6-8; 6, 7 
and 8). DD1‟s three founders leveraged their networks to raise the seed capital needed to 
get  the  firm  started.  To  do  so  the  firm  then  relied  heavily  on  the  networks  and  the 
competencies of the CEO. In comparison, DD2‟s founder had a previous relationship with 
a VC that provided the central position that led to the VC funding of DD2. Put differently, 
had DD2‟s founder not had this relationship, then there would have been little chance the 
firm would have been created to pursue the technology (Table 6-8; 9).  
 
Partners also provided important financial resources. As discussed above, DD2 developed 
a close partnership with a publicly traded firm that resulted in a merger. This merger gave 
DD2 access to capital and financial capabilities (Table 6-8; 13 and 14). The partner firm 
has a highly experienced CFO who has taken away much of the financial responsibilities 
from DD2. This has allowed DD2 to focus on developing their technology. Prior to the 
merger DD2‟s CEO, who is the firm‟s main scientist, devoted a significant amount of his 
time to financially related matters, which diverted him from time in the lab where he is 
most  valuable.  In  contrast,  DD2  has  only  directly  received  cash  from  the  FDA,  but 
partners‟ organisations have provided research inputs that have saved the firm substantial 
financial resources (Table 6-8; 11).  
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Table 6-8: DDs' financial positions 
 
FIRM                 Core technology proved critical in the development of financial resources. 
DD1  1.  We went out and sold what the potential of our product was. This application has the 
potential to make a big dent in a multi-billion market.  (DD1‟s CEO) 
 
2.  They have to see that the technology is going to make money. To invest in a risky business, 
they have to see there is something with big potential. (DD1‟s CEO) 
 
 
DD2  3.  The potential of our science is what the investors are looking at. This is why we have been 
able to get the money that we have. (DD2‟s founder and CEO) 
 
4.  The assumption is you’re many years away from revenue, you’re delayed from revenue.  So 
you’re going to be relying on earning cash for the product every five years or longer. So the 
investors have to believe that his technology is going to take off and that you have the 
capabilities to get it to market.  (DD2‟s founder and CEO) 
 
                             The founders proved critical to developing the firms’ financial assets and capabilities. 
DD1  5.  The founders were the main source of capital early on, and on an on-going basis their 
backgrounds and networks have helped us get more investment.  (DD1‟s CEO) 
 
6.  We (the founders) have been the main reason why the firm has been able to raise $28 
million. (DD1‟s CEO) 
 
7.  I had experience raising capital and knew how to do it. Sure my access to financiers helps, 
but more importantly I have done it many times in the past. (DD1‟s CEO) 
 
DD2  8.  Management is the key element to get money in. It’s best to have a track record, in order to 
give investors comfort factor. Myself and Rik are highly experienced and have helped with 
this. (DD2‟s founder and CEO)   
 
9.  Had I not had the existing relationships with the investors the company may not have been 
viable; the product may have never gotten off the ground. (DD2‟s founder and CEO) 
 
10.  The Chairman of the firm has personally invested over $2 million in the firm and has also 
lent the firm in excess of $2 million. (10k SEC filing 2010).  
                             Partner firms contributed important financing. 
DD1  11.  We got a million from the FDA that was helpful. It financed one of our key research projects 
on our drug platform. (DD1‟s CEO) 
 
12.  Partners have not really contributed much cash, although the partnership with the medical 
school has provided us with valuable research inputs. It is hard to quantify how much those 
inputs are worth, but it could be worth millions. For that matter the independent researchers 
have also provided some valuable inputs that would have cost us a lot to develop. (DD1‟s 
CEO) 
 
DD2  13.  The merger gave us access to large sums of capital. That has been quite helpful to us. 
(DD2‟s founder and CEO) 
 
14.  The firm has entered into five different partnerships that have contributed in access of $3 
million towards the firm’s research. (Closed ended question with CEO) 
 
 
Source: Author 
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Processes 
The  firms  developed  several  processes  that  led  to  the  development  of  their  financial 
endowments. The first set revolved around prospecting and securing capital. Both firms‟ 
paths of developing a platform technology were quite costly [Fin-pa costly innovation]. 
Table 6-9  (1-4) depicts representative  evidence of how the firms  developed skills  and 
competencies in prospecting and negotiating for capital. Developing these routines proved 
critical as the economic downturn of 2008 adversely affected the firms‟ ability to raise 
capital.  
 
The  shortage  of  capital  also  made  the  firms  develop  routines  for  reconfiguring  their 
financial resources to focus on fewer and more immediate projects [Fin-proc trans]. This 
shortage of capital was one of the main motivators behind DD1 reconfiguring its resources 
to focus on the development of a diagnostic device. Similarly, DD2 abruptly refocused its 
research efforts in year seven to focus on the development of an over the counter drug. The 
firm cut funding to other projects and focused its investment on this [Fin-pa core tech].  
 
A closely related set of processes that the firms developed revolved around integrating and 
conserving capital (Table 6-9; 6-9) [Fin-proc int]. The firms ran into serious problems 
early  on  because  of  miss-forecasting  their  budget  needs.  They  received  what  they 
anticipated  as  a  sufficient  amount  of  capital,  but  burned  through  it  quicker  than  they 
projected. This made them develop systems for monitoring their cash flows and projected 
spending. Closely related, the firms religiously practiced routines in cost savings. They 
operated with as few employees as possible, purchased as little equipment as possible and 
outsourced many non-essential functions.   
 
Similarly, both firms developed routines for strategically investing their capital in the most 
appropriate areas. This was particularly difficult early on as the firms were not certain 
which technological paths they would pursue. Both firms pursued platform technologies 
that had many potential paths. The experience of founders provided an important position 
for these firms in this process. These founders possessed knowledge in this area from their 
experience in start-up life science firms, and they used this to help strategically guide their 
new firm in investing and budgeting their capital.  
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Table 6-9: DDs' financial processes 
 
FIRM  Prospecting for capital has been vital to the firms. 
DD1  1.  From day one raising capital has been the most important routine. We are 
constantly seeking more investment from our current investors and seeking 
new investors. (DD1‟s CEO) 
 
2.  I am the main fundraiser, but I have a few staff members to help with this. 
The board also helps with this on occasion. My title is CEO, but it might be 
more appropriate to call me Chief Fundraising Officer. (DD1‟s CEO) 
 
 
DD2  3.  On an on-going basis has raising capital been important. Raising capital 
becomes an all-consuming event in a start-up operation. (DD2‟s founder 
and CEO)  
 
4.  Our ability to continue into our tenth year of operations relies on our ability 
to raise capital. Raising capital is vital. (DD2‟s Chairman) 
 
                            Conserving capital is a vital routine. 
DD1  5.  In this business there is only enough cash on hand for a few months. It is 
important to pick and choose the best place to invest this money. This 
decision is made off of what has the biggest impact. There is no way to 
describe how we do this other than it comes from our experience in start-
ups.  (DD1‟s CEO) 
 
6.  We had to pick where to invest our money. In a perfect world we could have 
kept the drug and diagnostic research both going, but because of the limited 
funds, we have to choose one. (DD1‟s CEO) 
 
DD2  7.  The public markets helped us raise capital to invest in our research. We 
have had to commit resources to going public, and it has affected our 
operations, but it has been a needed source of capital for us. (DD2‟s 
founder and CEO) 
 
8.  This (IPO) financing provides us with the capital to meet our near-term 
budgets and the financial leverage to allow us to become revenue 
generating and fund the clinical trials of our biotech investment. (DD2‟s 
Chairman) 
 
 
Source: Author 
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6.2.6 Drug development firms’ conclusion 
DD1 and DD2 were started to develop and commercialise drug technologies. This path 
made R&D and financial resources and capabilities paramount during the early phases of 
growth. The strategic R&D pursuits drove the need for specialised financing: the firms‟ 
technologies were costly and time consuming to develop, which caused the firms to sustain 
years from inception without any revenues. Thus the firms required specialised financial 
resources and capabilities to acquire investment capital.  
 
In order to pursue the path of developing a novel technology, the firms leveraged their 
scientific  talents  and  founders‟  experience.  From  these  the  firms  created  processes  to 
develop the needed financial and R&D resources and capabilities. Generally speaking, the 
firms  relied  on  sensing,  seizing,  learning  and  organising  processes  to  leverage  their 
positions to take advantage of the strategic paths available to them. Although there were 
distinguished similarities in the development of the firms‟ R&D and financial resources, 
there were also numerous differences. The most noticeable difference was the amount of 
capital  obtained  and  the  different  IPO  paths  that  the  firms  went  down.  D1  raised 
substantially more capital than D2 did, and D2 went public through a merger, whereas D1 
filed for an IPO.  
 
Despite the differences, both firms successfully leveraged a unique set of paths, positions 
and  processes  to  develop  the  R&D  and  financial  resources  and  capabilities  needed  to 
navigate  the  early  growth  process.  Moreover,  key  individuals  were  the  driving  force 
behind the firm‟s growth. The founders of DD1 and the CEO are the ones that discovered 
the technology, raised the needed capital and provided access to networks. Similarly, the 
founder of DD2 discovered their technology, attracted the early investment, established 
key relationships and made scientific breakthroughs that advanced the firm‟s technology.  
 
6.3 Medical device firms (MDs) 
This section overviews the development of the medical device firms. This group consists 
of two firms that are pursuing the development of novel medical devices. In this section a 
narrative of each case is presented followed by an in-depth cross- group analysis. 
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6.3.1 Medical device firm one (MD1) 
MD1 is a small firm that was founded in 2000. Since then it has developed a device for 
back  and  spinal  treatment.  Their  device  elongates  the  spine,  which  alleviates  muscle 
tension and back pressure, and in many instances, this relieves pressure that otherwise 
would  require  invasive  surgery.  Currently  the  firm  employs  a  staff  of  seven  and  is 
generating  less  than  $2  million  in  revenue.  In  the  first  six  years  it  focused  on  the 
development of the device. In year six the firm started generating revenues.  
 
An idea for a device that allows for greater flexibility in spinal treatment motivated the 
inception of the firm. The founder had been a practicing physician for many years and had 
conceived the device whilst working with patients on another device. He noticed that there 
might be a way to give the patient greater flexibility. From this he sketched out some ideas 
and started working on a prototype in his basement. After a couple of years he developed a 
working prototype, which led him to formalise MD1. The initial idea for the device has 
driven the path of the firm: 
   
The idea for the machine is the whole business. This is why we are here (MD1‟s 
founder and chairman) [R&D-pa core tech].  
 
Initially the founder was the only one working on the product‟s R&D. After he formalised 
the firm, he then contracted a couple of engineers to help him develop a prototype. The 
founder provided all of the inputs to the engineers, and they worked with him on designing 
the device and guiding him on what would be practical [R&D-po founder]. Over a three 
year  period  this  iterative  process  yielded  two  different  prototypes.  The  prototypes 
functioned and proved more effective than other devices on the market, but the founder 
still felt the device could be improved. Up until  that point the founder worked on the 
project part time and financed the development out of personal funds [Fin-po founder].  
 
In the third year the founder decided to make a more substantial commitment to the device. 
Specifically, he decided he needed to dedicate himself full time to this project, hire a full 
time engineer and lease a production facility. To finance this commitment he liquidated his 
assets: 
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And  here,  we  liquidated  and  moved  from  Florida,  I  mean,  from  New  York  to 
Florida, partnered with a colleague, hired new engineer, and began new prototype. 
(MD1‟s founder and chairman) [R&D and fin transformation] 
 
He also decided to move the firm‟s operations to Florida where substantial cost savings 
could be realised [Fin-pa costly innovation]. Florida had much less expensive facilities 
available, and contractors in the area were also much less expensive.  When he moved to 
Florida, he re-connected with a former colleague who had also moved there. Eventually he 
decided to bring the colleague on as a partner. This was a big boost to the company as the 
new  partner  is  highly  experienced  in  developing  devices  and  has  two  doctorates:  a 
physician  doctorate  and  a  PhD  in  electrical  medical  science.  The  partner  brought 
knowledge in developing the device and also committed financial resources to the firm.    
 
Upon moving to Florida, the priorities for the firm were establishing the R&D facility, 
hiring  an  engineer  and  developing  a  new  prototype.  They  quickly  accomplished  these 
goals,  and  in  the  fourth  year  they  developed  a  new  prototype  that  they  pursued  FDA 
approval for.  
 
The firm was not experienced in the FDA approval process, so the founder took it upon 
himself to navigate it himself [R&D-pos founder]. He quickly became proficient in FDA 
procedures and successfully filed all of the paperwork and had the testing done for the 
device. In less than two years the firm traversed the FDA process and gained full approval 
for the product. What also aided the firm in this is the fact that this is not an invasive 
device, so the FDA approval is not as long or as entailed as it is for invasive devices.  
 
The FDA approval triggered the firm to start its first production run in year six. They 
contracted with a manufacturer to build the devices for them. Based on the successful test 
results of the device, the firm was able to pre-sell ten units. This provided capital to the 
firm that allowed it to avoid outside financing. Sales quickly expanded in the seventh year, 
but then when the economic recession hit in year eight, the firm‟s sales quickly dropped 
off: 
 
In fact, the series tipped after that one, and then in 2008 the economy went boom.  
Everything fell.  (MD1‟s founder and chairman) 
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The sudden decrease in sales adversely affected the firm and forced the owners to open up 
a medical practice to help subsidise it. As the recession carried on, practitioners were not 
making large capital investments in devices such as MD1‟s, which continued to weigh on 
MD1 as they had substantial overhead to pay for: 
 
Doctors suddenly didn’t want to spend anything for equipment, unless it was cheap, 
cheap, cheap, and this was an expensive machine.  This stuff is expensive to make 
and our R&D is expensive to maintain. If you don’t sell a certain volume, you can’t 
support this.  So we have managed to hold on. (MD1‟s founder and chairman) 
[R&D-pa costly innovation] 
 
In year eight a financial break came from foreign sales [Fin-pa revenues]. The firm had 
done no overseas marketing, but physicians from outside of the US had learned of the 
technology and solicited MD1 to purchase devices. In year nine the firm quickly received 
and filled orders from Asia, the Middle East, Europe and Canada. This forced the firm 
down an internationalisation path. The firm does not have substantial overseas operations, 
but they do have to provide training to the overseas customers. The firm either had to fly to 
the overseas location or they have had to bring in the overseas customers to train them at 
their Florida headquarters. These sales are helping to finance the firm‟s continued growth.  
 
MD1 is constantly improving their product and production techniques. Every week they 
spend  time  brainstorming  on  how  to  make  it  better  by  experimenting  with  new  ideas 
[R&D-proc learning]. Due to these routines, in year nine the firm received ISO 13485 
certification, which is extremely difficult  to  obtain and  which is  significant  because  it 
indicates a high degree of quality for medical devices. Having the certificate itself has been 
a boost to the firm‟s marketing efforts. 
 
In year ten the firm leveraged its international sales to help with its domestic operations: 
 
But, we feel confident that the international market is going to keep this company 
going  until  the  domestic  market  regains  its  momentum.  (MD1‟s  founder  and 
chairman) [Fin-pa revs] 
 
It is also for the first time actively seeking outside investment. The founder had looked into 
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nature of the device. However, now that the device is fully developed and market-proven, 
they are confident that they will be able to obtain an equity investment of some type. 
Moreover, the increased activity in international markets is helping to finance the firm, and 
at the time of the study, the economy had started to pick up and domestic demand had 
increased.  
 
Although the firm is not generating significant revenues, it has still enjoyed considerable 
growth. The growth is most evident in an FDA approved and market-tested device. It is 
also evident in the six patents the firm holds, the eleven employees working at the firm and 
the many independent tests that have validated their device‟s efficacy.   
 
6.3.2 Medical device firm two (MD2) 
MD2 is a small firm developing a diagnostic technology that tests for infectious diseases. 
Their technology detects active markers of diseases in infections, and their technologies‟ 
main advantage is the ability to identify active infections, unlike the competitions tests, 
which cannot discern between active and inactive. This is a platform technology, but to 
this point MD2 has been forced to cut back their scope and focus on the development of 
one application. The firm was founded in 2003 to further develop and commercialise an 
innovation that was created at the University of Florida. Currently the firm employs ten 
staff members and as of 2010 was not generating revenues. However, the firm has just 
received approval for its first application and will be generating revenues in 2011.  
 
The technologies that the firm licensed have set the strategic direction of the firm. 
 
Without these innovations we would we would have no business.  (MD2‟s CEO) 
[R&D-pa core tech] 
 
In 2003 the firm‟s founder came across the patents because of his connection with the 
University of Florida. In previous dealings he had worked with the university on acquiring 
technology. He reached a favourable deal for the access to the patents whereby a small 
upfront fee was paid, and a portion of the future profits would be paid. Although the 
patents already had shown clinical promise, they were still far from a market-ready state. 
This  created  a  path  that  demanded  substantial  R&D  and  financial  resources  and 
capabilities [R&D-pa core tech].  171 
 
 
Raising capital became the firm‟s first priority. The University of Florida helped them 
engage  with  an  angel  investment  network.  This  resulted  in  an  individual  investing  $2 
million dollars, and the initial capital funded the development of the firm‟s R&D.  Initially 
the  owner  and  a  couple  of  scientists  worked  on  the  chemistry  needed  to  further  the 
technology. They made several progressions that helped the firm raise an additional $4 
million in 2008. Even so this capital proved extremely difficult to raise because the capital 
markets had tightened up due to the recession.  
 
I think we began seeing it in late 2006.  Certainly through 2007 the capital markets 
were drying up because you could see bad things were coming, and they would see 
that  based  on  that  part  of  the  business…  I  think  that  part  of  the  financial 
community sees it first.  And so from that period of time until literally 2009, it was 
extremely difficult to get capital. (MD2‟s CEO) [Fin-pa VC] 
 
Despite  the  tight  capital  markets,  the  firm  successfully  raised  the  amount  needed  and 
continued  to  develop  the  core  technology.  The  research  progress  also  helped  the  firm 
attract  additional  research  partners.  In  2008  the  firm  forged  an  important  international 
research partnership with the University of Toronto [R&D-po uni]. This partnership was 
facilitated largely through the scholarly community. MD1 knew of the work the university 
was conducting because of the great number of papers that they were producing. Similarly, 
the university had seen some publications related to MD1‟s technology and was interested 
in sharing resources [R&D CCA]. This partnership provided important inputs that helped 
the firm develop the chemistry that they needed for their technological development.  
 
At  the  same  time  the  firm  received  important  inputs  from  a  star  scientist  who  was 
consulting  for  the  company  [R&D-po  star  scientist].  He  holds  over  ten  patents  and  is 
widely regarded as one of the top researchers in the field, and he contributed important 
findings  that  helped  the  firm  develop  a  saliva  application  for  their  technology.  This 
breakthrough opened up several opportunities for the firm such as creating an interest in 
their technology that helped attract research inputs from a number of research institutions. 
However,  the  firm  needed  to  develop  a  complementary  device  to  deliver  the  new 
technology. At the time there was not an exact device on the market to satisfy this need. In 
order to find such a device the CEO, who had previously lived in Scotland, turned to a 
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develop one. This proved to be a vital partnership as the firm was able to quickly develop 
the needed device for MD2 [R&D CCA].  
 
The quick advancement of the device triggered the firm to start the government clearance 
procedures for it. Due to the CEO‟s previous experiences with the US FDA, the firm 
decided first to seek approval for their saliva-based device in Europe. The CEO had much 
better experiences with the EU than he did with the FDA: 
 
The FDA is becoming more difficult, less predictable, and actually I think selling is 
slowing technology down, which is why we’re going to be launching in Europe first 
because of that. (MD2‟s CEO) [R&D-pa govt approval] 
 
The advancement of the technology towards a state of commercialisation greatly helped 
the firm attract an additional $8 million in private equity financing in 2010. Like the earlier 
rounds of financing, this one proved difficult to obtain. The firm‟s CEO leveraged the 
progress in the technology and the networks of the previous investors in order to obtain the 
capital needed to progress their device. However, the firm would have preferred to raise a 
much greater amount of capital to progress several applications. Their core technology has 
many different potential applications in many different areas.  
 
However, the changing capital markets prohibited the firm from raising the capital needed 
to develop more than one application at a time. Furthermore, the CEO represents the main 
fundraising capability and is constrained by the amount of time he must devote to dealing 
with the current investors and other operations of the firm. 
 
Now that the firm is at a point of commercialisation, they are projecting that the revenues 
from  their device will help  subsidise the development of other applications.  However, 
raising capital is still a top priority for the firm as they still project to consume substantial 
sums of capital. The CEO emphasises the importance of raising capital: 
 
Raising  capital  is  always  important  in  this  business.  You  are  always  burning 
through capital, so it is important to have a continual supply coming in. (MD2‟s 
CEO) [Fin-pa costly innovation] 
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Although the firm has not started to generate revenues, it has still enjoyed considerable 
growth.  One  of  its  proudest  accomplishments  is  advancing  its  technology  through  the 
economic downturn of 2008. Small firms in this industry were particularly hit hard by the 
downturn,  as  they  are  reliant  on  VC  and  other  forms  of  risk  capital  to  develop  their 
technologies. Growth to this point is also evident from the growth of their staff to ten 
employees, over twenty publications on their research and the development of a strong 
network of partners.  
 
6.3.3 MDs cross-group analysis 
The narratives above provide a contextual basis for the evolution of the firms‟ R&D and 
financial resources and capabilities. This section delves deeper into the key paths, positions 
and processes that led to the development of the firms‟ R&D and financial resources and 
capabilities. Following this the financial resources and capabilities development will be 
presented in the same fashion.  
 
 6.3.4 R&D assets and capabilities development 
In the early stages of growth both firms focused on the development of their technology. 
This was the impetus to developing R&D assets. In the same fashion as the last section, 
Table 6-10 presents the matrices of the paths, positions and processes that were yielded 
from the data reduction techniques discussed in the research methods chapter. Based on the 
analysis of the interviews and the close-ended questions concerning each path, position and 
processes for each firm is placed in one of four categories based on its influence on the 
firm‟s development: high (H), medium (M), low (L) or no (N) influence. The major paths, 
positions and processes are discussed in detail below. 
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Table 6-10: MDs' R&D paths positions and processes 
  MD1  MD2 
INFLUENTIAL ON FIRMS’ PATHS 
Core technology conceptualised at a university  N  H 
Core technology conceptualised at another firm  N  N 
Core technology conceived by the firm  N  N 
Government partnerships  L  L 
Industry partnerships  L  M 
New technologies influenced firm‟s direction  H  H 
Government approvals: e.g. patent or FDA  H  H 
Scientific developments  H  H 
IMPORTANT POSITIONS 
Patents  H  M 
Skilled scientists  H  H 
Star scientists  H  H 
Industry partnerships  L  H 
University partnerships  L  H 
Government partnerships  L  L 
R&D facility and research equipment  M  M 
KEY PROCESSES 
Sensing and seizing scientific opportunities  H  H 
Finding and developing research partnerships  L  M 
Navigating government approval  H  H 
Filing patents  M  M 
Learning from earlier research  H  H 
Source: Author 
 
 
Paths 
Three main paths influenced the development of the firms‟ R&D. Table 6-11 presents 
evidence depicting the importance of the firms‟ core technology, government approvals 
and  research  setbacks  to  the  development  of  MD1  and  MD2‟s  R&D  resources  and 
capabilities.  
 
The  firms‟  technologies  dictated  their  R&D  paths  (Table  6-11;  1-5)  [R&D-pa  tech 
demands]. Although both firms‟ technologies dictated their strategic paths, the two firms‟ 
technologies evolved in different fashions.  
 
MD1‟s technology was conceptualised and developed by a practicing physician who had 
no R&D or business experience. The idea for the device emanated whilst treating patients 
where he had an idea for a more effective back treatment device. Thus MD1 had to come 
up  with  the  idea  from  scratch.  In  contrast,  MD2‟s  core  innovation  was  created  at  a 
university. This idea had been worked on for several years at there and had reached a point 
where it became commercially attractive. At this point MD2‟s founder licensed the rights 
to  it  and  formed  a  company  to  further  pursue  its  development.  The  relative  state  of 
development of the firms‟ innovations had a bearing on the research paths of the firms. 175 
 
MD2‟s more developed technology required testing and refining; whereas, MD1‟s device 
required conceptualisation and development.  
 
Although MD1‟s device needed more development, it still came to market quicker than 
MD1‟s device did. MD1 was able to bring their device to market within six years, whilst 
MD2‟s took over eight. This is largely attributed to the difference in technology that the 
two  firms  pursued.  MD1‟s  technology  is  not  an  invasive  device  or  chemically  based, 
whereas MD2‟s device is. Invasive and chemically-based devices take longer to develop 
and have more government regulation to contend with.  
 
It is evident from these two cases that the technology that a life science venture is created 
to pursue can come from different sources, but regardless of source, the technology drives 
the R&D paths of the firm. Furthermore, these cases show that novel technology can have 
varying development time horizons, even from firms in the same field. 
 
Government approvals had a large bearing on the firm‟s strategic paths (Table 6-11; 6-11) 
[R&D-pa  govt  approvals].  Both  firms  had  to  dedicate  substantial  resources  to  gaining 
government approval. MD1‟s founder was inexperienced, but still led the firm‟s product 
through government approval (Table 6-11; 7). In comparison MD2‟s founder was highly 
experienced  in  gaining  government  approval  for  medical  devices,  so  he  chose  to  first 
pursue government approval in Europe (Table 6-11; 9 and 10). The net effect of the of 
government approvals is that both firms strategized around this and devoted significant 
resources to it, and it drove MD1 down an internationalisation path.  
 
In a similar fashion, the patent process influenced the R&D paths of the firms [R&D-pa 
govt approvals]. Both firms applied for and received several patents. For both firms the 
commitment  to  patents  tied  up  substantial  resources,  which  created  path  rigidities. 
Unfortunately this limited other R&D related activities that they could invest in.  
 
The third major path that influenced the firms‟ R&D is research setbacks (Table 6-11; 11-
13). MD1‟s first prototype did not perform as well as they would have liked, which forced 
the firm to significantly increase their R&D efforts (Table 6-11; 11). This triggered the 
founder of MD1 to sell his physician practice and liquidate his personal finances to invest 
in MD1‟s R&D resources so that the firm could build a better prototype. Similarly, MD2 176 
 
ran into some troubles getting through the patent application process and also had some 
setbacks in their testing.  
 
These setbacks forced both firms to reorganise their R&D. MD1 cut back on the number of 
projects they pursued, whilst MD2‟s setbacks led them to recreating their entire prototype. 
 
The two firms‟ reorganisation paths were markedly different. MD1 cut back its R&D to 
conserve resources. In contrast, MD2 expanded its R&D; the firm hired additional staff 
and leased a larger research facility. Despite the fact that MD1 cut back its R&D spending 
whilst MD2 increased its R&D spending during their reorganisations, resources provided 
the central motivation behind the new paths the firms pursued. MD1 cut R&D spending 
and focused on developing one application, instead of the three applications it had initially 
pursued. This move was aimed to save resources to keep the firm viable. In contrast, MD2 
increased spending because they felt the only way to keep the firm viable was to come up 
with a new prototype for their device. Consequently, the new prototype required the firm 
to expand its R&D.  
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Table 6-11: MDs' R&D paths 
 
FIRM   The core technology drove R&D demands of the firms. 
MD1  1.  The idea for the machine is the whole business. This is why we are here. (MD1‟s chairman) 
 
2.  We are the only articulating 10-way adjustable positioning spinal elongation system in the 
world. We are the first major evolutionary improvement to spinal traction and elongation 
in the last 50 years. (MD1 co-chairman) 
 
3.  One hundred per cent of the $2 million invested in the firm went directly or indirectly to 
developing the firm’s core technology. (Close- ended question) 
 
MD2  4.  Without these innovations we would we would have no business.  (MD2‟s  CEO) 
 
5.  Almost all of MD2’s $10 million capital expenditures in the first seven years went to 
developing their core technologies.  (Closed ended question; analysis of firm‟s financial 
statements) 
 
                                FDA and government approvals have impacted the strategic direction of R&D. 
MD1  6.  We had to learn how to navigate FDA approval. This was important to the development of 
our device. Without it, it cannot be used.  (MD1‟s Chairman) 
 
7.  I did not have experience in FDA, but it is essential, so I took the time to familiarise myself 
with the process and navigated it for the company. (MD1‟s Chairman) 
 
8.  There is a lot that went into the patents. It is important to devote the resources to this 
because the patents protect the device. (MD1‟s Chairman) 
 
MD2  9.  The FDA is becoming more difficult, less predictable, and actually I think selling 
technology is slowing down, which is why we’re going to be launching in Europe first 
because of that. (MD2‟s CEO) 
 
10.  The regulatory process is tedious. It’s unpredictable now.  The agency is inconsistent and 
erratically changes directions.   It’s now kind of coming back to a more centred position, 
but what used to take in our industry for relatively safe products you could predict that if 
you made your submission, then within 90 days you got an answer.  It’s much less 
determinant (sic) now.  (MD2‟s CEO) 
                              Scientific setbacks impacted the strategic direction of R&D. 
MD1  11.  I said to him, You know, I see what’s going on here.  I think this whole prototype needs to be 
redone.  I said, Okay.  Let’s re-do the whole thing. That’s what we did. (MD1‟s Chairman) 
 
12.  The firm developed three prototypes and went through over twenty designs. (Close- ended 
questions with CEO)  
 
MD2  13.  We’ve had to restrict our expenditure R&D to focus on the first product that we hope to 
launch later this year. (MD1‟s CEO) 
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Positions 
Table 6-12 presents evidence supporting the most important positions to the development 
of the firms‟ R&D resources and capabilities.  
 
Both firms‟ founders proved to be both direct and indirect critical resources to their firms‟ 
R&D (Table 6-12; 1-4) [R&D-pa founder]. MD1‟s founder came up with the idea for the 
technology  He  was  also  the  driving  force  behind  the  early  prototype.  The  partner  he 
brought in, skilled in many technical areas, provided inputs that allowed the firm to refine 
the prototype with regard to the computer interface.   
 
In a slightly different vein, MD2‟s founders drove the development of their R&D. He did 
not conceptualise the technology, but instead he used his technical and business skills to 
sense it out (Table 6-12; 3) [R&D-po founder]. He then used his experience to put together 
a staff and a plan to further develop and pursue the commercialisation of the technology. 
Although the founders‟ inputs were substantially different, the founders of the two firms 
were the key resources behind the R&D.  
 
Scientists  are  another  position  that  significantly  contributed  to  the  development  of  the 
firms‟ R&D (Table 6-12; 5-9). MD2‟s scientific staff is made up of seven researchers as 
compared to MD1‟s staff of three, and both firms‟ scientific staff proved to be important 
resources. Moreover, both firms received large contributions from star scientists (Table 6-
12; 6 and 8) [R&D-po star scientist]. The co-owner of MD1 is an accomplished scientist in 
the field and has substantial experience in developing devices. His contributions, along 
with the contributions of the founder‟s inputs, are what enabled the firm to create and 
progress  their  core  technology.  Two  star  scientists  renowned  in  the  field  proved 
particularly important to MD2‟s  technology.  
 
The firms‟ core technology also provided an important resource to the firms‟ R&D (Table 
6-12; 10-13) [R&D-pos core tech]. MD1‟s technology quickly progressed to a state of 
commercialisation in year six. At this point they used the revenues from the sale of the 
devices  to  supplement  the  R&D  of  the  firm  (Table  6-12;  11).  In  contrast,  MD2‟s 
technology  took  over  nine  years  to  get  to  market,  but  the  technology  proved  more 
beneficial  to  attracting  other  R&D  inputs  than  MD1‟s.  More  specifically,  MD2‟s 
technology  complemented many  areas  of research related to  the treatment  of infection 
(Table 6-12; 12) [R&D CCA]. This triggered several key research partnerships that led to 179 
 
important R&D resources. For example, the firm developed a close relationship with the 
University  of  Toronto,  which  wanted  access  to  MD1‟s  technology.  This  relationship 
proved mutually beneficial as MD1 received important testing and access to specialised 
technology,  and  the  university  received  access  to  MD2‟s  technology,  which  helped  in 
several  of  their  research  projects  [R&D  CCA].  In  addition  the  firm  developed  a 
relationship with a Scottish firm that proved mutually beneficial.  
 
The different effects the firms‟ core technologies had on the development of their R&D is 
largely  attributed  to  the  nature  of  their  innovations  and  the  protection  status  of  the 
innovations. By its nature MD2‟s technology complements several areas, whereas MD1‟s 
technology does not. Also MD2‟s technology is harder to copy, and it is easier to defend 
their  intellectual  property  than  MD1‟s  technology  is.  For  this  reason  MD2  was  more 
relaxed about working with partners. They were not afraid that their technology would be 
stolen.  Despite  these  differences,  both  firms‟  technologies  proved  to  be  important 
resources that aided in the development of their R&D resources and capabilities. 
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Table 6-12: MDs' R&D positions 
 
FIRM      The founders provided important R&D inputs. 
MD1  1.  So, I started to fabricate, in my basement, a prototype to test certain positions’ postures 
and movements.  And when I felt that this was something that could work, I then hired an 
engineer and I had some drawings done, and I went back and forth with the engineer on 
the drawings, to fine tune what I wanted,  and I had a, actually two prototypes in New 
York, made.  (MD1‟s Chairman) 
 
2.  Oh yes, I was the one driving the design of the device. (MD1‟s Chairman) 
 
MD2  3.  He evaluated the patents and saw that they had large profit potential. He is a PhD and 
has many years of experience in the industry that helped with this. (MD2‟s CEO) 
 
4.  The founder and Chief Scientific Officer holds over twenty patents and has helped three 
other companies successfully develop and commercialise medical devices in the past. 
(Information taken from firm prospectus.) 
               The scientists provided important inputs to the firms R&D. 
MD1  5.  The new engineer actually built the new working prototype. He took those prototype 
drawings and made it out of extruded aluminium, and from this we got patents  and made 
it into production material drawing that could brought to a and made.  (MD1‟s 
Chairman) 
 
6.  He (co-owner) has extensive experience and was able to make some critical 
contributions right away. He has an extensive electronics background that was a big 
help to creating the controls. (MD1‟s Chairman) 
 
MD2  7.  The company’s technical progressions could not have been made without our scientists.  
(MD2‟s CEO) 
 
8.  There is a researcher we have in California who has made some significant 
contributions to our technology. He is well known and has a substantial scientific 
background.  (MD2‟s CEO) 
 
9.  The company has a scientific advisory board made up of top scientists and researchers 
who are leaders in their fields. The scientific advisory board provides input and 
advice. (MD2‟s CEO)  
 
                    The core innovation proved important to R&D. 
MD1  10.  We have interest from hospitals from all over the world that are interested in working 
with us because of it is a revolutionary device. (MD1‟s founder) 
 
11.  We were able to get to start selling it in 2006, and these revenues really helped with the 
continued development of the device.  (MD1‟s founder) 
MD2  12.  There are a number of organisations that are interested in our technology because of its 
ability to identify active infections. (MD2‟s CEO)  
 
13.  We have been able to reach out to a number of universities because of their interest in 
using our science. They want to stay at the cutting edge, and our product is at the cutting 
edge.  (MD2‟s CEO) 
Source: Author 
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Processes 
Table 6-13 presents a representative sample of evidence depicting the important processes 
that led to the development of MD1 and MD2‟s R&D resources and capabilities. They 
relied on several of the same routines with some small differences.  
 
One set of routines that both firms developed is transformational capabilities (Table 6-13; 
1-4). Early on in the venture MD1 had to rapidly redefine its R&D to produce a new 
prototype  that  could  effectively  treat  spines  and  get  through  FDA  testing  [R&D-proc 
trans]. The firm quickly reorganised its R&D resources to focus on this development. It 
hired new staff members, brought a new partner into the ownership structure and came up 
with a drastically different design (Table 6-13; 1 and 2). The founder orchestrated the 
transformation as he saw the need for a new prototype. 
 
 Similarly,  MD2  ran  into  some  early  research  issues  that,  coupled  with  financial 
constraints, forced the firm to refocus its R&D on its main application (Table 6-13; 3 and 
4). Similar to MD1, the founders and the CEO drove this transformation. They saw this 
need and redesigned the firm‟s research to focus on just one application. 
 
Clearly the ability to reconfigure R&D resources and capabilities is critical. Had these 
firms not adjusted, then they would not have survived. MD1 would not have been able to 
get their device through FDA approval and MD2 would have exhausted their resources 
trying to develop four applications and would not have gotten them to market.   
 
In addition  the firms‟  R&D revolved around learning daily  from  their earlier research 
(Table 6-13; 5-8) [R&D-proc learning]. Neither firm had an advanced system for this but 
instead relied on the tacit abilities of their staff. MD1‟s learning mainly emanated from the 
two  owners  and  the  engineer  they  employed.  They  did  not  have  a  formal  system  but 
instead  shared  ideas  and  independently  worked  on  tasks  aimed  at  progressing  their 
technology. Likewise, MD2‟s scientific staff did not have many formalised procedures. 
Rather they  worked independently and shared ideas and updates relevant to the firm‟s 
research.  
 
One  set  of  processes  important  to  MD2,  but  not  MD1  is  sensing  complementary 
technology  (Table  6-13;  9-11)  [R&D-proc  S&S].  MD2  was  established  through  the 
founder‟s abilities to sense out technology. The routines they developed relied heavily on 182 
 
the networks of the founders and CEO. The firm also developed systems for scouring 
scientific journals to find complementary technologies. In contrast, MD1 did not have such 
routines  in  place. The founder is  where the core technology  emanated, and the firm‟s 
scientific progressions came almost exclusively from internal sources.    
 
These differences are largely attributed to the difference in the two firms‟ technologies. 
MD2‟s technology complemented many other areas related to infectious disease [R&D 
CCA]; whereas, MD1‟s technology is unique and does not have widespread application. 
Some of the difference in the importance of technology sensing is also attributed to the 
background of the founders. MD2„s founders and TMT are highly connected and these 
connections  resulted  in  access  to  complementary  technologies.  In  contrast,  MD1„s 
founders  are  not  highly  experience  and  connected  (Table  6-13;  9).  This  is  one  of  the 
reasons that they did not have access to complementary technologies, and did not take in 
knowledge from outside sources. 
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Table 6-13: MDs' R&D processes 
                             Transforming R&D has proved vital to the firms’ growth and survival. 
MD1  1.  You know, I see what’s going on here.  I think this whole prototype needs to be redone.  I 
said, Okay.  Let’s re-do the whole thing. That’s what we did and within a year we had an 
FDA cleared device. (MD1‟s Chairman) 
 
2.  This needed to be formalised, so I brought in an engineer and brought an old colleague on 
board to really refine the machine.  (MD1‟s Chairman) 
 
MD2  3.  We have reorganised our research to focus on our main application. Ideally we would like 
to focus on three applications, but because of resource constraints, we have had to focus on 
one application. (MD2‟s CEO) 
 
4.  I think we were fortunate to just make it through there and stay alive, which is why it has 
taken us as long as it has for what should have been out in three years instead of six years; 
primarily because of the inability to raise capital. This has forced us to reorganise and focus 
on one application. (MD2‟s CEO)  
 
               Learning routines have helped advance the firms’ R&D. 
MD1  5.  It was an iterative process of seeing what worked and what didn’t. It was a continual 
learning process.  (MD1‟s Chairman) 
 
6.  It was a long process to develop the first prototype. They say, Well, how about?  No, I want 
the machine to do this.  Well, then they show me something.  Well, how about we do it like 
that? and I was, Well, well, that will work. Or That won’t work. You need to make it go like 
this.  And we’d go back and forth, until what I wanted was achieved. That started probably 
2000, up until 2003. (MD1‟s Chairman) 
 
MD2  7.  We have a chief scientific officer who coordinates all of the scientific activity. There are 
many different things going on, so it is important to coordinate these things. We learn from 
our earlier tests and apply these to refining our device. (MD2‟s CEO)   
 
8.  Our learning routines have led to several significant progressions of our technologies. 
(MD2‟s founder and CEO) 
 
               Sensing and taking in outside knowledge proved vital to R&D. 
MD1  9.  I am a doctor (medical physician) and I have never developed anything before, so I did not 
have any contacts with alliances that could help me out. All of this came from my practical 
experience and experimentation with the machine. (MD1‟s Chairman) 
 
 
MD2  10.  The rest of the technologies were either developed here at Gene Ex in Miami or through 
partners and consultants that we have used under contract. We have taken in knowledge for 
our product from a number of source. (MD2‟s CEO) 
 
11.  We’re really bringing a bunch of science together.  Some of it is fairly new here, but much of 
what we like so much—I think innovation—is bringing a kernel of new stuff together with 
other stuff, but I’ve found over the years the most successful accomplishments are the things 
that have been developed in other spaces and you bring them together; and we’ve done a bit 
of that. (MD2‟s CEO)  
Source: Author 
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6.3.5 Financial assets and capabilities 
Table 6-14 highlights the paths, positions and processes central to the development of the 
firms‟ financial resources and capabilities. Based on the coding and close-ended questions, 
each path, position and the processes for each firm is placed in one of four categories based 
on its influence in development: high influence (H), medium influence (M), low influence 
(L) or no influence (N). The analysis of the major paths, position and processes is detailed 
below. 
 
Table 6-14: MDs' financial paths, positions and processes 
  MD1  MD2 
INFLUENTIAL ON FINANCIAL PATHS 
Costly innovation   H  H 
Raising capital  L  H 
Public stock offering  N  N 
VC  L  L 
POSITIONS 
Scientific capabilities  M  H 
Founders   H  H 
Executive staff  H  H 
Core innovation  H  H 
Firm’s staff  L  M 
PROCCESSES RELATED TO 
Raising capital  L  H 
Integrating and conserving financial 
resources  
H  H 
Dealing with Investors  N  M 
IPO  N  N 
Transforming financial resources  H  h 
Source: Author 
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Paths 
Table  6-15  highlights  the  paths  important  to  the  development  of  the  firms‟  financial 
resources and capabilities. There were several past decisions and future opportunities that 
impacted the financial demands of the firms. 
 
The  core  technology  had  the  largest  bearing  on  their  financial  paths  [Fin-pa  costly 
innovation]. Both firms‟ financial strategies revolved around their core technology. MD2‟s 
core  technology  required  $3  million  in  the  first  three  years.  This  investment  went  to 
developing important chemical technology and testing for the device. Moreover, the firm 
has also invested substantially in items related to government approval for their device; 
most notably, patents and EU product approval. The substantial costs forced the firm down 
a path of attracting outside investors. Early on an angel investor emerged to provide most 
of the early capital. Followed by this a VC investment came in. Throughout the first nine 
years of existence MD2 has invested over $10 million in their technology. In consequence 
of choosing to develop costly technology, raising funds has been at the forefront of MD2‟s 
strategic direction (Table 6-15; 5). The firm‟s research is dependent on it, and the firm‟s 
ability to raise capital is dependent on progressions in its research (Table 6-15; 6) [R&D 
and finance co-specialisation].   
 
In contrast, MD1‟s technology was less expensive to develop, largely because of the path 
of developing a non-intravenous device and the fact that the founder provided most of the 
early scientific inputs. This allowed the founder to self-finance the early development of 
the firm. The nature of the core innovation also made raising capital difficult, as they could 
not get a lot of interest in the device because of its niche nature (Table 6-15; 2) [Fin-pa 
VC]. It has profit potential, but it does not have the large scale profit potential that VCs 
look for in a potential investment, yet another reason the firm went down a self-financing 
path. 
 
The device‟s continued development consumed hundreds of thousands of dollars, which 
triggered the founder to bring on a partner in year four. In year six the firm started selling 
its device and these revenues opened up new financial paths for the firm [Fin-pa revs]. 
These revenues helped finance the development of the firm‟s technology. This also helped 
to deter the need for outside investment. The firm also got a big boost in year eight when 
the technology helped them attract international customers. In that year several foreign 
customers solicited MD1 to purchase their device. Their interest stemmed from MD1‟s 186 
 
superior technology. At that point the firm had done no overseas marketing, but the foreign 
customers  had  heard  of  MD1‟s  technology  and  located  the  company  on  the  internet. 
Consequently, the firm received revenues that have essentially kept the firm viable.  
 
Apparent in these cases is that the owners‟ experience levels influenced the financial paths 
of the firms. MD2‟s  experienced founders sought  out  and found early  stage investors, 
which helped to minimise the personal investment they had to contribute to the venture. In 
comparison, MD1‟s founder was not experienced in starting a device firm and was not 
familiar with raising capital. However, both firms‟ strategies proved effective, as they both 
successfully financed the development of a marketable device.   
 
These cases also show how external events can greatly influence the financial paths and 
outlooks of small life science ventures. The recession of 2008 greatly hindered the firms‟ 
abilities to finance their R&D, and because of this both firms had to drastically change 
their financial strategies (Table 6-15; 8-11). For MD1 the sales of their device greatly 
dropped off. This adversely affected their ability to finance their R&D (Table 6-15; 9). 
Moreover,  it  left  them  with  great  overhead  costs  that  proved  difficult  to  meet.  This 
triggered the owners‟ of MD1 to open new financial paths including opening a clinic to 
generate revenues. 
  
In comparison, MD2 found it more difficult to raise the capital in the midst of the recession 
(Table 6-15; 10 and 11) [Fin-pa VC]. The markets had largely dried up because of the 
recession forcing MD2 to downsize its operations and focus on the development of only 
one of its applications, instead of the four that it had originally set out to develop.   
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Table 6-15: MDs' financial paths 
 
FIRM                The core technology drove the financial strategies of the firm. 
MD1  1.  The machine took a significant dollar amount to develop. The costs for the design and 
development have cost a substantial amount. (MD1‟s Chairman) 
 
2.  The main word that the venture capital people use is scalability. See, scalability.  A 
machine like mine, you may have a few thousand treating doctors in the world, and only a 
percentage of those might buy the machine. So, it’s not a big scalability. So, it’s a real 
boutique-y market.  (MD1‟s Chairman) 
 
3.  But we feel confident that the international market is going to keep this company going 
until the domestic market regains its momentum.  (MD1‟s Chairman) 
 
4.  One hundred per cent of the capital invested in the firm went directly or indirectly to 
developing the firm‟s core technology. (Close-ended question) 
 
MD2  5.  The core technology has driven our need to raise capital.  (MD2‟s CEO)  
 
6.  So, the sell to the investors has been this is great technology.  It’s a great market.  If we 
can finance it we should have a very successful commercial enterprise.  (MD2‟s CEO) 
 
7.  Because of the cost of developing the innovation - that makes raising capital paramount.  
(MD2‟s CEO) 
 
                             Environmental factors have influenced the firms’ financial strategies. 
MD1  8.  In fact, the series tipped after that one, and then in 2008, the economy went boom.  
Everything fell.  (MD1‟s Chairman). 
 
9.  Doctors suddenly didn’t want to spend anything for equipment, unless it was cheap, cheap, 
cheap, and this was an expensive machine.  This stuff is expensive to make and our R&D is 
expensive to maintain. If you don’t sell a certain volume, you can’t support this.  So, we have 
managed to hold on. (MD1‟s founder and chairman). 
 
MD2  10.  And so from that period of time until literally 2009, it was extremely difficult to get capital.  
I think we were fortunate to just make it through there and stay alive. (MD2‟s founder and 
CEO) 
 
11.  We saw it first. The capital markets dried up and many of the investors were on the side line. 
Then when things got better, investors went to the stock market because it was so easy to get 
great returns as the market rebounded. This made it difficult for firm like to get the high risk 
– high reward capital.  (MD2‟s CEO) 
 
 
 
Source: Author 
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Positions 
The  firms  relied  on  two  main  positions  to  develop  their  financial  resources  and 
capabilities; their top management team (TMT) and their technology. However, the way 
the firms leveraged these varied substantially.  
 
The TMTs of the firms provided the most important positions in the development of the 
firms‟  financial  resources  and  capabilities  [Fin-po  TMT].  Table  6-16  (1-7)  depicts  a 
representative sample of evidence that underscores the importance of the firms‟ TMT to 
developing its financial resources and capabilities. MD1‟s founder provided all of the seed 
capital to fund the firm in the first three years. He then brought on a partner who also 
contributed financial resources. MD1‟s founders‟ capabilities in conserving capital also 
provided an important position because it saved money that otherwise would have had to 
come from outside investors; the founders used their scientific capabilities to reduce the 
amount that had to be spent in the development of the firm‟s product. For example, the 
founder navigated the FDA approval process for the firm, which saved the firm upwards of 
a million dollars. The founder and his partner also opened a clinic in the ninth year to 
generate  more  revenues  for  the  firm.  This  proved  vital  as  these  revenues  provided 
resources that allowed the firm to stay viable during the economic recession.    
 
Similarly,  MD2‟s  TMT  provided  the  important  inputs  to  the  financial  resources  and 
capabilities of the firm, but in a different way than MD1‟s did (Table 6-16; 5-7). MD2‟s 
founder‟s background proved vital to the early investment that the firm received. He is 
well  known  and  well  connected,  and  he  used  this  to  help  the  firm  attract  the  early 
investment the firm needed to get started. In year two the firm hired a highly experienced 
CEO who has been its main fundraiser. He used his experience and networks to attract $10 
million in capital. Moreover, MD2‟s TMT‟s capabilities in reorganising and cutting costs 
have kept the firm viable (Table 6-16; 7) [Fin-po TMT].  
 
Interestingly, the two firms‟ TMTs had drastically different backgrounds and approached 
the financing of their respective firms drastically differently (Table 6-16; 8-11), but both 
firms‟ TMTs supplied vital resources that significantly contributed to the capabilities of 
their firms [Fin-po TMT].    
 
Technology  is  the  second  position  that  the  firms  drew  on  to  develop  their  financial 
resources  and  capabilities,  but  like  the  TMTs,  the  firms  leveraged  their  technology  in 189 
 
different  ways.  MD1  quickly  moved  its  product  to  commercialisation  and  used  the 
revenues  the  technology  generated  to  help  finance  the  continued  development  of  the 
technology. In contrast, MD1 used its technology to help attract investors. The technology 
showed promise to lead in a highly profitable market, which MD1 used to help attract 
investors. Although the two firms‟ technology differed greatly and had different impacts 
on the firms‟ finances, both technologies proved to be vital resources.    
 
 
Table 6-16: MDs' financial positions 
 
FIRM   The founders and top managers provided key financial positions. 
MD1  1.  I paid for all of the early development of the firm. (MD1‟s Chairman) 
 
2.  Since he came on board, we have shared the expenses in developing the machine. (MD1‟s 
Chairman) 
 
3.  I was able to keep costs down by doing a lot of the functions of the firm myself and 
strategically finding the lowest cost inputs. (MD1‟s Chairman) 
 
4.  One hundred per cent of the capital has been provided by the founder and his partner. 
(Close-ended question) 
 
MD2  5.  The founders were important to bringing in the capital. They knew some key people and had 
a background in business that the investors liked. (MD2‟s CEO)  
 
6.  It is important to know how to find investors and work with them. Myself and our CFO are 
experienced in this, and this has helped us bring in the capital that we need to continue the 
technology’s development. (MD2‟s CEO) 
 
7.  The board had to sit back and make some cost cutting decisions to stay viable. (MD2‟s 
CEO) 
                              The firms’ technology helped develop financial resources. 
MD1  8.  The sales of the machine took off initially, and this helped us develop the company.  (MD1‟s 
Chairman) 
 
9.  In 2008 the international revenues picked up and these have given us a big boost. These 
have really helped us through the recession. (MD1‟s CEO) 
 
MD2  10.  The investors look at how profitable a device can be, and ours is in a profitable market, so 
that’s one of the tools that we used to attract investors. (MD2‟s CEO) 
 
 
Source: Author 
 
 
Financial processes 
Both firms relied on a number of routines to develop the financial resources necessary for 
their firm‟s growth. Table 6-17 presents a representative sample of evidence of the key 
processes that the firms used to develop their financial resources and capabilities. For the 190 
 
most  part  the  firms‟  routines  were  quite  similar,  but  there  were  also  some  noticeable 
differences.  
 
One  of  the  main  differences  is  the  importance  of  routines  in  prospecting  and  raising 
capital. This proved highly important to MD2, whereas these processes did not play a 
major part in MD1‟s operations. The routines that MD2 developed for raising capital came 
from  the tacit knowledge and abilities of the founders and the TMT. They had  raised 
capital for new life science ventures in the past and knew how to prospect and negotiate 
with early stage investors (Table 6-17; 3 and 4). The outside investors that MD2 brought in 
also  made  the  firm  develop  investor  relation  routines,  the  most  important  of  which 
revolved  around  communications  with  investors  [Fin-proc  inv  rel].  This  was  handled 
primarily through the efforts of the CEO and CFO.  
 
It is evident from these two cases that new innovations are costly to develop and that 
capital is paramount to the development of innovation, but this capital can emanate from 
different sources. The source of capital has a major bearing on the processes that a firm 
must develop. MD1 self- financed the venture and did not have to develop routines related 
to raising capital. In contrast, MD2 financial strategy revolved around attracting outside 
capital, which made routines related to prospecting capital paramount. There are merits 
and demerits of each source of capital. Outside investment capital lessens the risk to the 
founders, but it takes a substantial resource commitment to processes related to raising it 
and  dealing  with  the  investors,  especially  the  time  the  TMT  has  to  devote  to  these 
functions. Regardless of the source of capital, it is evident that key individuals – i.e. the 
founders and TMTs – are the ones who drive the processes related to raising it.   
 
One set of routines that both firms relied heavily on revolved around conserving funds 
(Table 6-17; 6-8) [Fin-proc int]. Because of the costly nature of their products and their 
shortage of capital, both firms had to save  money in every way possible. This proved 
difficult,  as  the  firms‟  innovation  was  expensive.  To  conserve  funds  MD1  internally 
performed as many design functions as possible. This was led by the firm‟s two owners 
who contributed most of the R&D functions. The owners even attempted several functions 
that they were not versed in. For example, they produced the technical drawings for some 
of the designs, and the founder navigated the FDA approval process for the firm‟s device, 
even though he had no experience in these areas. MD1 also constantly looked for ways to 
save capital in their production. They constantly negotiated with suppliers and found new 191 
 
ones (Table 6-17; 5 and 6). In a similar vein, MD2 developed processes for keeping their 
operations as lean as possible. Whenever possible they outsourced functions to university 
partners who would perform the functions for little to no costs. MD2 also learned how to 
use cost effective contract researchers for many functions (Table 6-17; 7 and 8).  
 
Clearly  cost  cutting  routines  are  vital  to  the  development  of  a  life  science  venture‟s 
financial resources and capabilities. Cutting costs in every way possible without adversely 
affecting R&D greatly helped both of these firms, as both firms successfully developed a 
medical device whilst still controlling for costs.  
 
Closely related to conserving funds, the firms also developed routines for transforming 
their  financial  resources  (Table  6-17;  10-13)  [Fin-proc  trans].  In  year  three  MD1 
transformed  from  a  relatively  informal  operation  of  just  one  founder  to  a  formal 
organisation. The firm hired a staff and leased an R&D facility. The firm‟s owner had to 
come  up  with  capital  to  finance  this  transformation,  which  he  did  by  liquidating  his 
personal assets and moving the firm to Florida because of lower operational costs that the 
state offered (Table 6-17; 11). MD1 also had to transform its finances again in year eights 
because of the recession of 2008, which caused MD1‟s sales to quickly drop off, greatly 
affecting their ability to finance their R&D and operations. In response the firm‟s owners 
opened a medical clinic to help finance the firm. After seeing the recession would have a 
prolonged effect on the firms, the owners quickly leased a facility for a medical clinic and 
started  generating  revenues  from  this  to  supplement  the  firm‟s  financial  resources.  At 
about the same time MD1 started receiving international orders, which helped to augment 
the financial resources of the firm [Fin-pa revs]. Then the firm quickly reorganised its 
operations to focus on international markets by ramping up their international sales and 
marketing efforts, which helped to increase revenues.  
 
Similarly, the recession of 2008 forced MD2 to use it transformational routines to alter its 
financial strategy. The firm‟s CEO knew that they did not have the capital to sustain four 
major  research  projects,  and  that  additional  investment  would  be  difficult  to  raise.  In 
response the CEO and the board of directors made the decision to cut three of the R&D 
projects and scale back the firm‟s operations. Although this hurt the firm, as the three 
projects  that  were  cut  showed  great  commercial  potential,  the  quick  move  proved 
beneficial because it allowed it to stay viable during the recession that loomed from 2008 
until the time of this study (winter 2010-2011). The firm also transformed itself when a 192 
 
major  investment  of  $6  million  in  year  seven  was  received,  allowing  it  to  expand  its 
operations, causing it to revamp its financial strategy. Moreover, this capital allowed the 
firm to bring their device to a point of commercialisation, which has made the firm invest 
in related areas.  
 
These two cases demonstrate how life science ventures have to create processes to adjust 
their financial resources and reorganise their financial strategies in response to internal and 
external events. It is also evident that these processes are driven at the individual level; i.e. 
the TMTs are the ones leading the processes related to financial transformation. They are 
the ones  that recognise  the need for change, and they  are the ones  that determine the 
strategic changes to be made.    
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Table 6-17: MDs financial processes 
 
FIRM               Prospecting for and dealing with investors has been vital to MD2. 
MD1  1.  We just sent a few VC prospectuses out, but it had been all self- financed to this 
point. (MD1‟s CEO) 
 
2.  Close-ended question: has the firm spent significant effort pursing outside 
investment: No. (Close-ended question) 
 
MD2  3.  Raising capital is critical in this business. We are consistently meeting with our 
investors and new investors to raise capital. (MD2‟s CEO) 
 
4.  We have experience and know how to raise capital. It is something that we know 
how to do from our experience.  (MD2‟s CEO) 
 
5.  We have routines in place for dealing with investors. They want updates and there 
is a good amount of time that goes into working with them. (MD2‟s CEO) 
  
                             Conserving capital is a vital routine. 
MD1  6.  We constantly looked for ways to keep our costs down. From performing functions 
ourselves to finding lower cost suppliers. We are always looking to do things more 
efficiently. (MD1‟s CEO) 
 
7.  Lean and mean is how we operate. Self-financing a business forces you to keep 
costs down in every possible way. (MD1‟s CEO) 
 
MD2  8.  It is easy for costs to run up in this business. For this reason you have to watch 
costs closely and constantly look for the most cost-efficient but still effective way of 
doing things. (MD2‟s CEO)   
 
9.  There are a number of things that we do on a regular basis to keep costs down, such 
as having partners and research contractors provide certain functions. (MD2‟s 
CEO)  
                    Transformation capabilities have been important to the firm’s financial resources. 
MD1  10. We constantly looked for ways to keep costs down. (MD1‟s CEO) 
 
11. I decided to cash in my chips, liquidate all my assets, and cut my living expenses 
down by coming to Florida. I cut my engineering and fabricating cost down by 
coming to Florida. (MD1‟s Chairman) 
 
MD2  12. We had to focus on only one project. We needed to control costs where we could. 
(MD2‟s founder and CEO) 
 
 
Source: Author 
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6.3.6 MDs conclusion 
Both firms had a similar end goal: to develop and commercialise a novel medical device. 
This decision made R&D and financial resources and capabilities paramount during the 
early phases of growth. Although there are noticeable similarities in the development of 
the  firms‟  resources  and  capabilities,  there  are  also  numerous  differences.  The  most 
noticeable  difference  is  the  type  of  financing  that  the  two  firms  obtained.  MD1  was 
financed by the owners and proceeds from the revenues from their device, whilst MD2 
acquired its capital from private investors and VCs. Consequently, MD1 did not have to 
devote substantial time to investor-related matters. In contrast, MD2 developed advanced 
capabilities in raising capital and working with investors. The most striking similarity of 
MD1  and  MD2‟s  resources  and  capabilities  was  the  importance  of  key  individuals  in 
driving the development of the firms‟ R&D and financial resources and capabilities.  
 
6.4 Biological analyser firms (BAs) 
This section overviews the development of the biological analyser firms, which consist of 
two firms that are pursuing the development of instruments that analyse biological and 
molecular matter. In this section a narrative of each case is presented followed by an in-
depth cross group analysis. 
 
6.4.1 Biological analytics firm one (BA1) 
BA1  is  an  engineering  micro-firm  that  has  developed  an  instrument  for  detecting  and 
analysing  biological  materials  and  particles.  They  have  a  platform  technology  with 
widespread applications. One of the applications with the most potential is for identifying 
viruses and bacteria: from a cheek swab on a human their technology can break the sample 
into simple particles that can be analysed within minutes. The main advantages of this are 
twofold: one is that the sample takes minutes to analyse, which is unlike the current testing 
procedures which can take weeks. The second main advantage is that, unlike the current 
testing procedures, every virus a person has can be identified; whereas with the current 
testing procedures only the viruses being tested for will be detected. Another application 
for the machine is for testing for explosive and biological materials, which is especially of 
interest to security agencies.    
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The  company  is  a  spin-off  from  Yale  University.  However,  the  technology  was  not 
actively marketed by Yale. Rather the professor who founded the technology at Yale was 
contacted by the founder of  BA1 who was  a  former student who had stayed in close 
contact.  BA1‟s  founder  knew  of  the  innovation  because  of  his  relationship  with  the 
professor, and because of recent events in global terrorism, he saw that the technology had 
the potential to help in the defence of bioterrorism. Specifically he envisioned that the 
technology could be coupled with electronic systems to quickly identify harmful biological 
agents. Based on this vision he convinced the professor to commercialise the innovation, 
which in turn has driven the entire strategic direction of the firm: 
 
The idea for the device has set the entire stage for the company. This is what we 
have been doing for the last seven years. (BA1‟s CEO) [R&D-pa core tech] 
 
After licensing the technology from Yale in 2004, he then opened an R&D facility in south 
Florida. There he and a small team of two other engineers have further developed the 
device. They formed an early research partnership  with the US  Army  that  has  proven 
critical as the Army has supplied important inputs from a biotechnology standpoint. The 
firm‟s product pulls together three areas: biology, physics and electronics. BA1‟s founders 
held advanced knowledge in electrical engineering and physics, but not biotechnology. In 
this area the Army researchers have provided most of the main inputs needed to construct 
BA1‟s instrument:  
 
We complement one and another. They need our instruments’ ability to break down 
and analyse particles and we need their biotechnology to understand what to look 
for in the particles. (BA1‟s CEO) [R&D CCA] 
 
Initially BA2 financed the development of the device mostly from personal funds and a 
small amount of investment from friends and family. Due to the small amount of capital 
that the firm started with, keeping costs down became an important routine:  
 
It has been a struggle. We have boot-strapped and cut costs in every way possible. 
(BA1‟s founder and CEO) [Fin-proc int] 
 
At the end of the first year the firm received a boost in funding from a SBIR grant for 
$183,000 to aid in the R&D of their instrument. The firm had been able to quickly navigate 196 
 
the small business innovation research (SBIR) grant process because of the founder‟s skill 
and experience. Previously he had applied and been awarded dozens of SBIR grants. He 
used the capabilities and skills to help BA1 quickly get a grant: 
 
I  have  filed  over  150  grants,  so  I  could  complete  one  of  these  applications 
blindfolded. This was  not  a problem because of  my experience.   (BA1‟s CEO) 
[R&D-po founder] 
 
Even though the firm spent less than $500,000 on R&D in the first two years, they were 
still  able  to  develop  an  instrument  that  successfully  particalised  and  analysed  several 
viruses. The efficacy of the tests helped the firm develop several partnerships. Because of 
this  they  received  interest  from  some  of  the  largest  and  most  prominent  research 
organisations in the world, such as Scripps and the National Institute of Health. The firm 
received  some  important  inputs  from  these  organisations,  but  kept  their  distance  from 
larger  organisations  in  order  to  protect  their  ideas  and  technology;  several  of  the 
breakthroughs for the firm‟s device are not patented because the firm wanted to preserve 
its capital for functions other than patenting. The firm does have several patents they will 
file for, but at the time they were able to protect their innovations without patents by not 
sharing too much information with partners. The only partner the firm shared information 
was  with  the  US  Army,  but  only  because  of  a  very  strong  non-disclosure  agreement 
between them.  
 
The firm quickly refined and improved their main instrument, and in year two came out 
with a miniaturised version that is less than four inches by four inches [R&D-pa new tech]. 
Its portability increased the interest in the product. Several more defence agencies became 
interested in it because such a device could be used where there could be harmful biologic 
agents. In addition, this device also captured the interest of the US agriculture department 
because at that time several harmful diseases had started to enter the US from agriculture 
imports. The agency had had to kill many animals and destroy large stocks of fruits and 
vegetables  that  were  suspected  of  having  certain  diseases.  BA1‟s  instrument  had  the 
potential to quickly test and identify whether or not the disease is present, and if it is not, 
then the agriculture product would not have to be destroyed.  
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Because  of  these  potential  government  uses,  BA1  received  several  small  government 
research contracts from years three to five that totalled over $500,000 [Fin-po govt]. In 
addition, in years four and five the firm received over $200,000 in orders from universities 
for  components  related  to  their  devices  technology  [Fin-po  revs].  They  received  these 
orders  because  components  of  BA1‟s  device  are  useful  with  certain  lab  machines. 
Interestingly, BA1 did not actively market these components, but the universities found out 
of the firm‟s components through networks. Also interesting is that over half of these sales 
were to foreign universities.  
 
This additional funding went to further refining the technology. In collaboration with the 
Army,  the  firm  successfully  developed  an  electro  spray  aerolisation  source,  which 
increased the range of bacteria and viruses that the firm‟s instrument could analyse [R&D-
pa new tech]. Prompted by this the firm and the Army decided to apply for a major grant to 
further develop and apply the technology to defence applications. This grant would be for 
over $7.6 million of which BA1 will receive $5.3 million. At the time of this study the firm 
was a month away from hearing from the grant committee. If the firm receives the grant, it 
will drastically change the direction of the firm: 
 
This grant will transform the company. It will bring in resources that will allow us 
to fully execute the technologies  potential. Five million dollars is an incredible 
boost to a small company. (BA1‟s CEO) 
 
Simply put, the firm will have the financial resources to patent the technology, which will 
allow it to quickly and drastically increase its revenues. Moreover, it will afford the firm 
the capital needed to develop other applications for the instrument that have even greater 
market values. For example, the medical applications have market potential well into the 
billions. To this point the firm has not pursued that path because the defence path they 
have  taken  has  provided  them  access  to  grants  and  contracts  that  have  financed  the 
development of the technology. In addition, the medical path will require FDA approval, 
which  is  costly  and  lengthy  to  obtain  [R&D-pa  govt  approval].  However,  if  the  firm 
receives this grant, it will open up several potential paths, and medical applications is one 
of the first the firm will look to pursue because of its market potential. 
 
By traditional measures the firm has not seen much growth since its inception seven years 
ago.  Its  revenues  are  less  than  $250,000;  it  has  a  small  R&D  facility  and  only  three 198 
 
employees. However, the firm has developed and proven a revolutionary device that has 
the potential to have a major impact in several large and profitable areas. Moreover, it has 
developed several key relationships and built a strong image in the industry. So although 
the traditional measures of growth are not significant, the firm has still seen significant 
development.  
 
6.4.2 Biological analytics firm two (BA2) 
BA2 is small firm that makes instrumentation for analysing molecular agents. The firm‟s 
core  technology  revolves  around  the  ability  to  measure  chiral  drugs  and 
biopharmaceuticals. Initially the firm was founded in 2000 by a PhD graduate student in 
chemistry along with a professor to pursue the commercialisation of the graduate student„s 
chiral research; she had come up with a unique technique for analysing chiral drugs, and 
saw that this could have major market potential. This innovation has been the driving force 
behind the firm„s strategic direction: 
 
We  were  working  on  my  research  and  I  suggested  that  we  commercialise  the 
technology.  So  I  did  the  marketing  study  and  wrote  the  business  plan  and  the 
business formed around it. (BA2‟s CEO) [R&D-pa new tech] 
 
Early resources for the firm came from the university [R&D-po uni]. She had access to 
labs and one of the professors provided important inputs. From these resources the firm 
was able to develop a successful prototype for an instrument that could finely measure 
chiral drugs. This triggered her to start BA2. Because of the policy of her university on her 
particular type of research, she was able to maintain full rights of the innovation.  Initially 
the firm was funded out of personal savings; the founder drew on her credit cards and took 
a loan of $150,000 from her mother [Fin-po founder]. She used these resources along with 
inputs from universities to develop her product. The professor who had worked with her 
during her  research had moved to  one of the top universities in  chiral  science,  which 
opened up inputs for BA2. At this point the professor became a partner in the firm, and he 
and  his  new  university  offered  valuable  inputs.  From  a  scientific  standpoint  BA2  got 
access to a wide variety of equipment and personnel, which provided important inputs to 
progressing BA2‟s technology. Moreover, the university also had an incubation program 
for helping small technology firms grow. This helped the young firm in strategic planning 199 
 
and  making  connections.  These  early  resources  enabled  BA2  to  develop  a  functional 
prototype in year two that they were able to patent. 
 
The patent proved vital as it afforded the firm the intellectual property protection to form a 
partnership to commercialise the instrument. The founder was able to strike an agreement 
with a large biopharmaceutical for producing the instrument, whereby BA2 provided the 
intellectual  capital  for  the  instrument  and  the  partner  firm  produced  and  marketed  it. 
According to the terms of the agreement each firm was given fifty per cent of the revenues. 
This event proved critical to BA2‟s development, as it provided important revenues that 
helped finance the continued development of the firm‟s technology [Fin-po revs].  
 
The increase in revenues afforded the firm capital to continue to develop applications from 
their technology. It allowed them to hire additional scientists and develop a network of 
relationships that helped the firm make several developments in their applications. One 
particular  relationship  that  the  firm  formed  was  with  the  University  of  Glasgow‟s  life 
science department where one of the leading researchers in chiral drug technologies was 
based [R&D-po uni]. He provided important inputs that in conjunction with the firm‟s 
internal  developments  allowed  them  to  develop  a  revolutionary  new  instrument.  This 
instrument was named in R&D Magazine’s „Top 100 for 2004‟. This prestigious award 
given on the basis of a rigorous review process is particularly impressive because it is 
amongst every type of innovation – not just life science innovations.  
 
This award gave BA2 a big boost of credibility within the scientific community. It helped 
in marketing their products and it also helped them attract research partners: 
 
It gave us a lot of credibility because it’s a very prestigious award. It gave us a lot 
of credibility. So that gave us credibility. So sales with big companies came shortly 
after. (BA2‟s CEO) [Fin-po core tech] 
 
The award also helped the firm relocate to south Florida. A city in south Florida was 
actively recruiting firms to move there with tax incentives, and this award made BA2 
attractive to the town. Moreover, the award aided the firm in landing its first government 
grant. In year six the firm applied for a small business innovation research grant (SBIR) 
and was awarded $500,000 [Fin-po govt]. The SBIR grants are for small firms that have 
innovative products that have great potential to help society and the US economy. This 200 
 
$500,000  research  grant  provided  a  big  boost  to  the  firm  and  has  provided  capital  to 
expand BA2‟s research staff and spending on needed equipment and testing.  
 
In year six the firm also received an important patent that allowed it to market its second 
instrument. The boost in revenues provided financing to continue the development of two 
more applications of BA2‟s technology [Fin-po revs]. To develop these applications the 
firm relied on their founder‟s inputs along with their scientific staff. By that point their 
staff had grown to twelve researchers who were almost all PhDs. These scientists provided 
important support, but the two founders provided the main scientific inputs to the new 
applications: 
 
We (the founders) have provided essential science to our products. (BA2‟s CEO) 
[R&D-po founder] 
 
Not only were the founders‟ scientific inputs vital, but so was their access to networks. 
Both were well-connected within the greater scientific community. The second founder is 
one of the leading experts in chiral drug science. He is one of the most cited professors in 
the field, is the head of the department at the top university in the field and is the editor of 
one of the top scientific journals in field. From this he has gained name recognition that 
has benefited BA2.  
 
The first founder is also well-connected, but she became so in a different fashion. She 
attends over twenty tradeshows a year where she participates in networking events [R&D-
proc net]. In addition, she chairs many industry-related organisations. From these she has 
become well known in the life science community: 
 
I served as the president of the society for our field of spectroscopy and I got to 
know a lot of people. I serve on many different committees, I chair a conference 
and the people recognize my name. (BA2‟s CEO) [R&D-po founder] 
 
These connections have provided access to partners that have provided important inputs. 
One important input that came from her networks in year eight is angel investment. Her 
networks also helped the firm expand sales and service capabilities in Europe in year nine. 
This has proved vital to the firm‟s growth as European sales have quickly picked up and 
are helping to finance the firm‟s continued growth [Fin-po revs].  201 
 
 
At the time of this study (year ten) the firm had just come out with an updated version of 
their  chiral  measurement  instrument  that  is  even  more  effective  than  their  current 
instrument. The firm is confident that it will see sustained growth in the next few years as 
they have four fully developed products and several new applications under development.  
 
Until this point growth is evidenced in the over $3 million in annual sales, the four patents 
the firm holds, the staff of fifteen and the extensive relationships they have with other 
firms and research institutions.  
 
6.4.3 BAs cross-group analysis 
The narratives above provide a contextual basis for the evolution of the firms‟ R&D and 
financial resources and capabilities. This section delves deeper into the key paths, positions 
and processes that led to their development. It analyses and compares the paths, positions 
and processes that led to each firm‟s R&D resources and capabilities. Following this the 
financial resources and capabilities development is presented in the same fashion.  
 
6.4.4 R&D assets and capabilities development 
In the early stages of growth both firms focused on the development of their technology. 
This was the impetus of developing R&D assets and capabilities for both firms. In the 
same fashion as the last section, Table 6-18 presents the matrices of the paths, positions 
and  processes  that  were  yielded  from  the  data  reduction  techniques  discussed  in  the 
research methods chapter. Based on the analysis of the interviews and the close-ended 
questions,  each  path,  position  and  processes  for  each  firm  is  placed  in  one  of  four 
categories based on its influence on the firm‟s development: high (H), medium (M), low 
(L) or no (N) influence. The major paths, positions and processes are discussed in detail 
below. 
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Table 6-18: BAs' R&D paths, positions and processes 
  BA1  BA2 
INFLUENTIAL ON FIRMS’ PATHS 
Core technology conceptualised at a university  H  H 
Core technology conceptualised at another firm  N  N 
Core technology conceived by the firm  N  N 
Government partnerships  H  L 
Industry partnerships  L  M 
University partnerships  L  H 
New technologies influenced firm‟s direction  M  M 
Government approvals: e.g. patent or FDA  M  M 
Scientific developments  H  H 
IMPORTANT POSITIONS 
Patents  M  M 
Skilled scientists  M  M 
Star scientists  H  H 
Industry partnerships  L  M 
University partnerships  L  H 
Government partnerships  H  L 
R&D facility and research equipment  L  L 
KEY PROCESSES 
Sensing and seizing scientific opportunities  H  M 
Finding and developing research partnerships  H  H 
Navigating government approval  L  L 
Filing patents  L  M 
Learning from earlier research  M  M 
Transforming R&D  M  M 
Source: Author 
 
Paths 
Several paths influenced the strategic R&D pursuits of the firms. The most ubiquitous path 
emanated  from  the  firms  core  technology.  Table  6-19  (1-4)  presents  a  representative 
sample of evidence illustrating the importance of the core technology to the firms R&D.  
 
Both firms' technologies came from universities [R&D-pa uni partners]. For both of these 
firms the technology that emanated from a university set the central R&D path of the firm 
(Table 6-19; 1-4). BA2‟s founder created the technology whilst she was at graduate school; 
whereas, BA1‟s founder convinced his former professor to release a technology developed 
some years past. BA1‟s technology required the firm to develop competencies to bring 
together  techniques  from  the  areas  of  electronics,  physics  and  biotechnology.  In 
comparison,  BA2  developed  competencies  revolving  around  measuring  and  analysing 
chiral drugs. Both firms‟ technologies required substantial resource investment and forced 
them  to  acquire  specialised  financing  to  pay  for  their  R&D  [R&D  and  Fin  co-
specialisation].  
 
Internal and external events also impacted the firms R&D paths (Table 6-19; 5-9). For 
BA1 the fear of global terrorist attacks triggered a demand for an instrument that could 
quickly detect and analyse harmful biological agents (Table 6-19; 5). This outbreak also 
provided government resources that influenced the direction of BA1‟s R&D. Similarly, a 203 
 
change in drug technology increased the demand for chiral drugs and created the main path 
for BA2‟s technology.  
 
Internal breakthroughs by the firms also influenced the strategic paths of their R&D (Table 
6-19; 5 and 9); i.e. the firm made substantial discoveries that greatly affected their R&D. 
For example, BA1 successfully miniaturised its instrument, which opened up new potential 
applications for their product [R&D-pa new tech]. Likewise, BA2 found new applications 
for its technology that opened up R&D opportunities. Thus it is apparent from these cases 
that environmental factors can have a major impact the strategic path of a life  science 
venture.  
 
The pursuit of partnerships had a major bearing on the firms R&D paths (Table 6-19; 14-
17). An opportunity with the US Army allowed BA1 to synthesise their electronic and 
physics capabilities with the Army‟s biotechnology [R&D CCA], which enabled BA1 to 
develop  a  device  that  could  detect  and  analyse  viruses  and  bacteria.  Without  this 
partnership the firm‟s R&D would have taken a much different direction.  
 
Slightly less drastic, BA2 received R&D inputs from one of the leading universities in 
chiral chemistry allowing them to progress their chiral instrument technology [R&D-pa uni 
partner]. This partnership had a particularly large bearing in the firm‟s early R&D paths as 
it supplied the resources needed to develop the firm‟s core technology. Another partnership 
with  the  University  of  Glasgow  allowed  the  firm  to  develop  their  second  application 
enabling them to pursue this path.   
 
BA1 clearly was more reliant on partners then BA2; however; both firms‟ strategic R&D 
paths were significantly affected by partners. Had these firms not had these partnership 
opportunities, then their R&D would have evolved in a much different fashion, and there is 
a good chance that the firms might not have been able to have successfully developed their 
products. From these two cases it is apparent that partners affect the R&D paths of the 
firms. Nevertheless, path rigidities can prevail from partnerships. For example, BA1 had 
strong  agreements  in  place  with  the  US  Army  that  have  limited  the  latitude  of  the 
applications that it can pursue. These constraints are partly contractual and partly a result 
of the substantial resource commitment that BA1 has made to the Army. Such narrow path 
rigidities have not resulted from BA2‟s partnerships.  
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Government approval processes, particularly patenting, also affected the firms R&D paths 
(Table 6-19; 10-13) [R&D-pa govt approval]. BA2 pursued and received four patents. To 
get the patents the firm had to devote substantial resources, particularly scientific ones, to 
the application process. An advantage that the patents provided was affording the firm the 
protection  to  introduce  new  products  and  develop  new  research  partnerships.  In 
comparison, BA1 licensed four patents that their core technology is based on, and they 
have several ideas that they plan to patent. However, in order to conserve resources they 
decided to wait to start the patent application for these newer ideas in order to conserve 
resources for other functions. It has also challenged the firm to choose strategically whom 
they work with in order to protect their ideas. In other words, they do not want too many 
close partners, especially industry partners, because they  fear that their ideas  could be 
stolen.   
 
Another path that has impacted the firms‟ R&D paths is the FDA (Table 6-19; 14 and 17) 
[R&D-pa  govt  approval].  Both  firms‟  technology  has  human  applications,  but  the 
cumbersome FDA approval process has driven the firms away from these. Rather than 
committing substantial resources, they chose instead to focus on applications that do not 
require approval. Although the FDA has not directly influenced the strategic pursuits of the 
firms, it has had an impact on their strategies.     
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Table 6-19: BAs' R&D paths 
FIRM             The core technology drove the R&D demands of the firms. 
BA1  1.  The idea for the device has set the entire stage for the company. This is what we have been doing for the 
last seven years. (BA1‟s CEO) 
 
2.  The patents from Yale are what it all started with. The product has revolved around those patents. 
(BA1‟s CEO) 
BA2  3.  We were working on my research and I suggested that we commercialise the technology. So I did the 
marketing study and wrote the business plan and the business formed around it. (BA2‟s CEO) 
 
4.  Almost all of BA2‟s $3 million capital expenditures in the first seven years went to developing their core 
technologies.  (Close-ended question) 
 
              Internal and external events impacted the firms R&D endowments. 
BA1  5.  Bioterrorism has become a big problem and has created a need for a device like ours that can quickly 
analyse biological agents.  (BA1‟s Chairman) 
 
6.  Now, the hallmarks of it (BA1’s instrument after it was redone) are; it’s very fast. Like, in five minutes, 
you have results, and there’s (sic) no chemicals involved. So, for a variety of reasons, it’s very attractive 
to virologists, biologists and we confirmed that presentation of impressive test results. (BA1‟s CEO) 
 
7.  There is a lot that went into the patents. It is important to devote the resources to this because the patents 
protect the device’. (BA1‟s Chairman) 
 
BA2  8.  Chiral drugs are becoming the standard in the pharmaceutical industry. I saw this and knew that a 
technology that complemented chiral drugs would be a good market to get into. It has as almost 80% of 
drugs are chiral based. (BA2‟s CEO) 
 
9.  We have been able to adapt our technology to create ideas. This has opened up new research paths that 
have led to new products.  (BA2‟s CEO) 
           The pursuit of partnerships had a major bearing on the firms’ R&D. 
BA1  10.  The Army has been a very important partner. We have a key patent from them that has really affected our 
instrument. (BA1‟s CEO) 
 
11.  The Army has really helped shape the firm. Their biotech inputs are important and having them as a 
partner has helped to get grants.  (BA1‟s CEO)  
 
BA2  12.  The partnership with Syracuse has been very important. It provides a lot of science that has helped the 
firm develop. (BA1‟s CEO) 
 
13.  Networking is important to getting inputs that we need. We have established a wide variety of partners, 
which has helped us in developing our technology. (BA2‟s CEO) 
           Government approval processes affected the firms R&D.   
BA1  14.  We have several applications that will need FDA approval. We have strategically stayed away from these 
to avoid the cost and time associated with this. (BA1‟s CEO)  
 
15.  There are several ideas that could be patented, but the patenting process triggers a series of events and 
forces us to invest in this. Instead the ideas are protected because we control all of the information and do 
not share it with anyone who might try to take it. (BA1‟s CEO) 
 
BA2  16.  The pursuit of the patents has been an important influence on our R&D. We have had to put a lot into 
these, and gaining these patents has opened up opportunities for us. (BA2’s CEO) 
 
17.  Our products do not require FDA approval, so that has allowed us to avoid having to devote R&D 
resources to this. (BA2‟s CEO) 
Source: Author 
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Positions 
Several positions proved important to the development of the firms‟ R&D. Table 6-20 
presents evidence supporting the most important ones.   
 
The firm‟s core technology is one of the most important resources that the firms used to 
develop  their  R&D  resources  and  [R&D-po  core  tech].  Table  6-20  (1-4)  depicts  a 
representative  sample  of  evidence  that  underscores  the  importance  of  the  firms‟ 
technologies  to  the firms  R&D. One important  input that the firms‟ core technologies 
helped with is attracting research partners. Both firms‟ technologies are ground-breaking 
and  have  the  potential  to  fundamentally  influence  the  industry,  motivated  other 
organisations to reach out to BA1 and BA2.   
 
BA1„s technology has potential to change homeland security procedures. Specifically their 
technology can quickly identify and analyse diseases from a sample of small particles, 
which could allow homeland security to become more effective in looking for biological 
weapons. This ability is a position that the firm has leveraged to enter into several key 
relationships – most notably with the US Army and the US department of Agriculture. 
 
In a similar fashion, BA2‟s technological positions facilitated several key relationships. 
Their relationship with a top university stems largely from the universities desire to be 
attached to a leading edge technology. Moreover, the firm has attracted relationships with 
several of the top biopharmaceutical firms in the world who want to use BA2‟s technology 
to aid in the development of their drugs.  
 
The firms‟ scientists have also proven important resources to the firms‟ R&D [R&D-po 
scientists]. BA1‟s is constituted primarily by the two founders who have developed many 
innovations in the industry and have a combined fifty years in new product development 
experience.  They  have  drawn  on  this  experience  to  help  progress  BA1‟s  instrument. 
Moreover, they have deep connections that allow them to draw on the knowledge of others 
when they have questions about their research (Table 6-20; 10 and 11). 
 
In a similar vein, BA2‟s founders have been critical resources to BA2‟s R&D (Table 6-20; 
12  and  13)  [R&D-po  founders].  The  founders  came  up  with  the  idea,  and  one  of  the 
founders is renowned in the field. He is the chair of the department at a university that is 
widely regarded as one of the top in this field [R&D-po star scientists]. Moreover, the 207 
 
founders of BA2 are well-connected, and their networks and networking abilities have 
been an important resource that has contributed to the development of their technology. 
For example, their relationship with a University of Glasgow professor provided access to 
science that allowed them to develop one of their main applications. Unlike BA1 though, 
BA2 also has a scientific staff of fifteen members that is an important asset to the firm‟s 
R&D [R&D-po scientists].The staff has not made any breakthrough discoveries, but they 
are versed in many areas and make incremental contributions that have collectively made a 
large impact on the development of BA2‟s technology.   
 
It is evident from these cases that founders are an important resource to the development of 
life science ventures. The founders of BA1 and BA2 contributed much of the key research 
inputs, and drove the development of the other R&D resources that their firms needed.   
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Table 6-20: BAs' R&D positions 
FIRM                 The core innovation proved important to R&D. 
BA1  1.  Our technology is why the Army wanted to work with us. It has the potential to greatly help 
with what they are doing with terrorism. (BA1‟s CEO) 
 
2.  An Army report showing BA1‟s instruments superior technology and recommending to the 
government enter into a research partnership with BA1 because of this technology. 
(Government report) 
BA2  3.  All these big organisations wanted to work with us because of our superior technology. 
(BA2‟s CEO)  
 
4.  Over the last several years the vibrational circular dichoism (BA2’s core technology) 
technique has dramatically revitalised the utility and spectroscopy within pharmaceutical 
drug discovery. (Dr. Don Pivonka, research director of a large multinational 
biopharmaceutical firm) 
 
                                Partners provided vital R&D inputs. 
BA1  5.  We got important inputs from a number of partners. The patents come from Yale and the 
Army has provided all of the biotech inputs.  (BA1‟s Chairman) 
 
6.  Without partner inputs we would not have been able to put it (their instrument) together. 
(BA1‟s Chairman) 
 
BA2  7.  We have gotten important help from a number of different places. Syracuse has certainly 
been important, but Glasgow and a number of other places have been important as well.  
(BA2‟s CEO) 
 
8.  We have a network of strong partners that provide information and testing that have been 
critical to the firm. (BA2‟s CEO) 
 
9.  The firm has relationships with ten of the top biopharmaceutical organisations in the world.  
(Information from company prospectus)  
 
                 Founders have provided critical R&D inputs. 
BA1  10.  I was the one who found the core patents and had the idea to bring everything together. 
(BA1‟s founder) 
 
11.  My partner and I have been the ones developing the device. We have help from a number of 
partners, and we have some part- time staff, but it is us driving this.  (BA1‟s founder) 
BA2  12.  My partner and I were the ones that came up with the science for the technology. This is 
the basis of the products.  (BA2‟s CEO)  
 
13.  We (the two founders) are still important to the research. He performs a lot of research 
and is involved and comes up with a lot of our scientific ideas, and I am overseeing 
everything and bringing a lot of different science together.  (BA2‟s CEO) 
Source: Author 
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Processes 
Four main processes proved to be important to the development of BA1 and BA2‟s R&D 
endowments:  sensing  technology,  networking,  transforming  and  learning.  Table  6-21 
depicts  a  representative  sample  of  the  evidence  supporting  the  importance  of  these 
processes.  
 
One  of  the  most  important  set  of  processes  revolved  around  sensing  and  seizing 
technological opportunities [R&D S&D]. Table 6-21 (1-4) demonstrates this. BA1 and 
BA2‟s  founders  sensed  out  opportunities  that  had  great  market  potential.  
However, the two  firms  sensed their opportunities out  in  much different  ways.  BA1‟s 
founder was highly experienced in industry and used one of his connections to find the 
technology for his firm; whereas  BA2‟s founder was very inexperienced and used her 
academic  knowledge  and  skills  to  sense  out  an  opportunity  arising  due  to  changing 
science.  
 
On a continual basis technological sensing capabilities have been important to both firms, 
as they have both continually sought out and found complementary technologies that have 
contributed  to  their  core  technologies.  BA1  found  complementary  biotechnologies  that 
have  proven  vital  to  the  development  of  their  instrument.  Similarly,  BA2  has  found 
complementary drug and electronics technologies that have aided in the progression of 
their instruments. 
 
Most  of  these  complementary  technologies  have  surfaced  from  the  firms‟  founders‟ 
networking routines (Table 6-21; 1-4) [R&D-proc network]. Both founders have developed 
advanced networking capabilities that have resulted in complementary technologies and 
important  research  inputs.  However,  the  two  firms‟  networking  routines  are  markedly 
different. BA2‟s founder participates in over twenty trade shows a year where she often 
speaks and attends networking events. She is also active on the board of several industry-
related organisations. In addition she has made a routine of staying in contact with her 
important industry contacts. The second founder of BA2 is also highly networked, but his 
networks emanate from his prestigious position as the head professor of chemistry at a top 
university. Because of this position many people interested in his research contact him.  
 
BA1‟s founders are also well-networked but these have developed from a much different 
set of processes than BA2‟s did. The main founder of BA1 has made connections from his 210 
 
experience in the industry (Table 6-21; 5). He is also able to make key contacts from his 
informal networking routines. These routines are based on finding and contacting people 
whom he believes can help with his firm‟s research. Moreover, BA1 also has an advisory 
board member who is extremely well-connected.   
 
These cases show that networking routines can be important to the development of a firm‟s 
R&D. It also shows that a firm‟s networks and networking capabilities can vary greatly, 
but still have a similar end result.  
 
A third important set of processes revolves around learning and communicating (Table 6-
21;  9-12)  [R&D-proc  learning].  These  processes  proved  vital  to  both  firm‟s  R&D. 
However, BA2 has more formalised systems in place for this than BA1 does. On a regular 
basis BA2‟s staff meets to discuss their research objectives. They also have routines for 
sharing  information,  and  their  sub-departments  have  formalised  research  routines.  In 
contrast,  BA1  does  not  have  such  formalised  systems.  Instead  their  small  staff  meets 
sporadically and communicates with their research partners on an ad hoc basis. Although 
the two firms‟ routines differ in their formality, they are still important to both firms. These 
cases illustrate that different learning and communication routines can be effective.  
 
Transformational-related processes are the fourth set of processes that have been important 
to both firms‟ R&D (Table 6-21; 13-15) [R&D-proc learning]. Early on BA2 realised that 
the changing conditions in the pharmaceutical industry would pose a large opportunity for 
instruments that specialise in chiral drugs. This motivated the firm to focus its R&D on 
developing instruments for these types of drug applications, and they devoted almost all of 
their resources to this.  
 
In a similar vein, BA1 focused its R&D on the development of a technology that could 
answer the call for help from homeland security to find a device that could quickly detect 
harmful biological agents. Thus the firm focused its R&D processes on developing such a 
device  and because of this,  successfully developed a prototype within two  years.  In a 
similar scenario, BA1 responded rapidly when an agricultural disease outbreak created a 
great demand for an instrument that could quickly detect the disease. The firm reorganised 
its R&D resources to focus on this application, and in consequence, this helped the firm 
land a research grant, and has sparked interest in a large order for the firm‟s instruments 
from the US Department of Agriculture.   211 
 
 
It is evident from these two cases that the ability to respond to changing industrial and 
environmental  factors  is  important  to  staying  viable  and  creating  a  product  that  is  in 
demand. Both firms recognised and responded to outside factors and their growth to date is 
largely attributed to the capabilities to reorganise themselves in response to these factors.  
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Table 6-21: BAs' R&D processes 
FIRM           Sensing and seizing technological opportunities proved important. 
BA1  1.  I have had to find technology that complements ours. I have ways of staying informed in the scientific 
community that provides this information. (BA1‟s CEO) 
 
2.  I knew of the patents and saw that this could be a big opportunity. I have been in industry for years and 
knew when I heard of this that it was going to have a lot of potential. Being able to sense the technology 
comes from an innate feeling based on experience. (BA1‟s CEO) 
BA2  3.  We were working on the technology in my school’s lab, and I saw that the competing professor’s work 
and knew that what we had could commercialise. I knew from my research that the industry was moving 
towards a chiral model. (BA2‟s CEO) 
 
4.  We have processes for staying in touch with the scientific community. Our staff stays on top of research. 
We have connections with several top universities and we attend over twenty trade shows a year. These 
allow us to find emerging technologies and stay abreast on everything. (BA2‟s CEO) 
            Networking has proved vital to the firms’ R&D endowments. 
BA1  5.  I have networks in place from my years of experience. These are helpful when I have a question or need 
something done.   (BA1‟s Chairman) 
 
6.  Networking capabilities are still important. I have learned how to find key people and reach out to them. 
Sometimes this is just making some calls and sometimes I network through conferences. (BA1‟s CEO) 
 
BA2  7.  Networking is very important to us. We attend over twenty shows a year and make contacts with 
everyone that we can. These have led to important partnership. (BA2‟s CEO) 
 
8.  My partner and I are well- networked. He is a distinguished professor and knows many people through 
this. He is the editor of a journal, and people know him because of his stature in the field. I, on the other 
hand, have gotten involved in many organisations and attend many networking events. From the last ten 
years of doing this people know me. (BA2‟s CEO) 
           Learning and communication have been important to R&D. 
BA1  9.  We consistently see what we can do to improve it (BA1’s instrument). We learn from the earlier prototypes 
and then bring in new parts and pieces and ideas. (BA1‟s CEO) 
 
10.  It is important to get input from the users. From this we can learn what we need to change. So it is 
important to reach out to them.  (BA1‟s CEO)  
 
BA2  11.  We have formal meetings where we get the staff together to share ideas and update everyone on what is 
going on. Each unit also meets on a regular basis to strategize on what they have learned. (BA1‟s CEO) 
 
12.  Learning also happens at the individual level. We have PhDs who are all trained and know how to go 
about their research and learn from what they did earlier. (BA2‟s CEO) 
           Transforming capabilities has proven important to R&D. 
BA1  13.  We knew that the device had to become smaller. So we set out to develop a miniaturised version. This 
made us devote a significant amount of resources, but we were able to accomplish this.  (BA1‟s CEO)  
 
BA2  14.  We saw the changes going on in the drug industry and focused our product on a technology that could 
help with this. (BA2’s CEO) 
 
15.  We saw a need to develop a new product and quickly devoted resources to this, and from this we were able 
to come out with a new unit. (BA2‟s CEO) 
Source: Author 213 
 
6.4.5 Financial assets and capabilities 
The  firms‟  R&D  demanded  significant  capital  to  bring  their  products  to  a  point  of 
commercialisation. For this reason, the firms leveraged their paths, positions and processes 
to  obtain  the  capital  needed  to  finance  their  growth.  Table  6-22  highlights  the  paths, 
positions and processes central to the development of the firms‟ financial resources and 
capabilities.  Based  on  the  coding  and  close-ended  questions,  each  path,  position  and 
processes for each firm is placed in one of four categories based on its influence on the 
firm‟s development: high influence (H), medium influence (M), low influence (L) or no 
influence (N). The analysis for the major paths, positions and process is detailed below. 
 
Table 6-22: BAs' financial paths, positions and processes 
  BA1  BA2 
INFLUENTIAL ON FINANCIAL PATHS 
Costly innovation   H  H 
Raising capital  L  L 
Public stock offering  N  N 
VC  L  L 
POSITIONS 
Scientific capabilities  M  H 
Founders   H  H 
Networks with investors  L  L 
Investors were connected within financial 
community 
L  L 
Executive staff  H  H 
Core innovation  H  H 
PROCCESSES RELATED TO 
Raising capital  L  L 
Conserving capital  H  H 
Dealing with Investors  L  L 
IPO  N  N 
Transforming financial assets and capabilities  H  H 
Grant writing  H  M 
Source: Author 
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Paths 
Several past decisions and future opportunities guided the financial needs of the firms. 
Table 6-23 highlights the paths important to the development of the firms‟ financial assets 
and capabilities.  
 
The core technology had the largest bearing on the financial demands of the firms. Both 
firms‟ financial strategies revolved around their core technology. The firm‟s respective 
novel technology required substantial capital to develop. BA1 spent over $2 million in 
developing their core innovation, whilst BA2 spent over $3 million [Fin-pa core tech].  
 
Early on the firms made the strategic choice to follow a path of financing their incubation 
through  personal  investment  (Table  6-23;  6  and  7).  However,  the  firm‟s  strategies 
stemmed from a much different set of factors. BA1 decided to pursue this strategy because 
they wanted to avoid VC because of past experiences [Fin-pa VC]. They knew that VC is 
hard to deal with, and they could access capital from other places that did not require 
equity or control in the firm. In comparison, BA2‟s main founder was very inexperienced 
and did not know how to finance a venture. The only thing she thought she could do was to 
self-finance. This led her to obtain a $150,000 loan from her mother to start the business. 
In hindsight she wished she would have considered other financial strategies, but at the 
time she did not know any better and she was too busy concentrating on the other functions 
of the business. 
 
Both firms‟ strategies proved successful, as they acquired the capital needed to start their 
firms. These two cases suggest that previous experience influences the financial strategies 
of  a  life  science  venture;  with  the  more  experienced  founder  knowing  how  to  source 
capital for a new venture, and the inexperienced scientist having to learn how to finance a 
venture throughout the process of starting the firm. 
 
Closely  related,  SBIR  grants  also  influenced  the  strategic  financial  paths  of  the  firms 
(Table 6-23; 5 and 9) [Fin-pa govt], but in different ways. From the onset BA1‟s strategy 
revolved around obtaining an SBIR grant to finance the early development of the firm. The 
firm  successfully  obtained  $180,000  in  the  first  year,  which  effectively  launched  the 
venture; this provided them the capital boost to focus full time on the venture. In contrast, 
BA2 did not receive an SBIR grant until year six. This is largely because the firm did not 
know how to obtain such a grant. After learning of the grant the firm looked into the 215 
 
process  and  decided  to  apply  for  one.  This  proved  beneficial  as  the  firm  received  a 
$500,000 grant that greatly helped the firm. For both firms‟ grants provided critical capital 
inputs that had a substantial impact on their financial paths (Table 6-23; 5 and 9).  
 
The initial commercialisation of the firms‟ products is another area that impacted their 
financial paths (Table 6-23; 10 and 13) [Fin-pa revs]. In year three BA2 started generating 
revenues that provided capital to further invest in the firm‟s technology. Likewise, BA1 
started generating revenues in year four that contributed capital to the firm‟s research.  
 
Large capital infusions or the potential for large capital infusions have had a bearing on the 
financial paths of the firms (Table 6-23; 11 and 14) [Fin-pa raising cap]. In year eight BA2 
received an angel investment of over $1million. This has allowed the firm to expand its 
R&D resources and invest in several new applications that have large market potential. 
Similarly, BA1 at the time of this study was in the final steps of a major grant application. 
This  grant  would  award  BA1  $5.3  million  for  the  continued  development  of  their 
instrument, and it would offer many new financial paths to the firm. More specifically, it 
would afford the firm capital to invest new applications and it would allow the firm to 
apply for several patents.  
 
It is evident from these cases that major R&D breakthroughs opened up new financial 
paths that have had or will have a major bearing on the firms‟ R&D.  
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Table 6-23: BAs' financial paths 
 
 FIRM             The core technology drove the financial demands of the firms. 
BA1  1.  This has cost a lot of money, so we have had to put a lot of thought and effort into financing 
the development of the technology. (BA1‟s CEO) 
 
2.  We have had to boot strap and cut costs whenever possible to develop this technology. It has 
been a struggle, but we have been able to develop the device. (BA1‟s CEO) 
BA2  3.  So we had to come up with money to develop it. Initially I took a loan from my mother and 
paid for things on my credit cards. (BA2‟s CEO) 
 
4.  Almost all of BA2‟s $8 million capital expenditures in the first seven years went to developing 
their core technologies.  (Close-ended question) 
 
                           Strategic financial choices have influenced the firms’ development. 
BA1  5.  The grants have provided the bulk of the funding. This has allowed us to develop our product. 
It has also made us devote time to the grant process.   (BA1‟s CEO) 
 
6.  We choose to self-finance and get grants. We knew that this was going force us to boot strap 
and cut costs. (BA1‟s CEO) 
 
BA2  7.  I made the choice to self- finance the venture because I didn’t know any other way to finance 
the business. (BA2‟s CEO) 
 
8.  A friend of mine put me in touch with a venture capitalist, and he started asking me a bunch of 
questions about business models that I had no idea what he was talking about. So I hung up 
because I had no idea what he was talking about and decided that I did not need venture 
capital. So I continued to pay for the venture through self- finance.  (BA2‟s CEO)  
 
9.  I wish I would have used SBIR grants earlier. I just did not know what they were. Once we 
found out about them we applied and got them. They have been a big help to the firm’s 
finances. (BA2‟s CEO) 
                         New financial resources have influenced the firms’ financial paths. 
BA1  10.   We started getting some revenues in that have been helpful to financing some of our other 
operations. (BA1’s CEO) 
 
11.  If we get this grant, it will transform our financial picture. It will allow us to invest in many 
different areas and will financially transform the firm. (BA1‟s CEO) 
 
12.  The $5.3 million will go to us and will allow us to move forward with several different 
applications. (BA1‟s CEO) 
 
BA2  13.  The revenues really helped generate money that we used to invest back in the company. (BA2‟s 
CEO) 
 
14.  In 2008 we got the angel investment, which has helped us get a few more projects going and 
was especially beneficial to our European expansion. (BA2‟s CEO) 
Source: Author 
   217 
 
Positions 
The firms leveraged several positions to develop their financial resources and capabilities. 
Table 6-24 presents evidence supporting the main ones.  
 
The founders of the firms proved to be important resources to the development of financial 
assets and capabilities [Fin-po founders]. Table 6-24 (1-5) depicts a representative sample 
of  evidence  that  underscores  the  importance  of  the  firms‟  founders.  BA1‟s  founder 
provided much of the early seed capital and is the main reason the firm secured early grant 
money (Table 6-24; 1 and 2). In a similar fashion BA2‟s main founder also provided most 
of the early capital.  Furthermore, both  firms‟ founders proved important to conserving 
funds to keep their young ventures viable (Table 6-24; 3 and 5). They both operated on a 
„shoestring budget‟ where they cut costs and obtained as many free or low cost inputs as 
possible. It is evident that the founders were the ones who were driving the early financial 
positions of the firm.  
 
The second main position that the firms drew on to develop their financial resources and 
capabilities  is  their  core  technology  (Table  6-24;  6-10)  [Fin-po  core  tech].  BA1‟s 
technology helped it attract funding grants that allowed the firm to finance a large portion 
of  its  operations.  Likewise  BA2‟s  technology  helped  them  attract  grants  and  an  angel 
investor. The firms‟ technology showed large potential to help society, which is what the 
firms leveraged to attract the grants. For BA2 the large profit potential of the technology is 
what attracted the angel investor.  
 
Both  firms  technology  started  generating  revenues  early  on  that  helped  to  finance  the 
firms‟ development. This revenue provided important financial resources that the firms 
used  to  supplement  their  development.  It  is  evident  from  these  two  cases  that  the 
technology‟s cost of development is a central path that drives the demand for capital, but 
potential profitability of the technology provided a resource to leverage in attracting grants 
and  investment.  Moreover,  these  cases  illustrate  that  technology  that  comes  to  market 
quickly can greatly help the firm by providing financial resources that supplement the 
firms‟ development.  
 
Closely related, the firms‟ technology helped attract partners who provided capital and 
money saving inputs (Table 6-24; 1-14). For example, interest in a technology to help in 
bioterrorism defence led to a partnership between the BA1 and the US Army. The Army 218 
 
provided some funds, but even more importantly they provided R&D inputs worth millions 
of dollars. Had BA1 had to internally develop these competencies, then the firm would 
have had to have acquired additional capital. 
 
Similarly, BA2‟s technology helped them attract several important relationships (Table 6-
24; 13 and 14). These relationships helped the firm save capital by providing low cost 
R&D inputs. For example, the technical inputs from one of their university relationships 
would have cost millions of dollars to develop.  
 
It is evident from these cases that partnerships influence financial resources. These cases 
show that partners have a major direct and indirect effect on the firm‟s financial resources. 
In some instances partners directly infuse capital into the firms, and in some cases the 
partners  indirectly  supplement  a  firm‟s  financial  resources  from  the  inputs  that  they 
provide. In some instances, such as BA1, these indirect financial contributions can be one 
of the most important financial positions of a firm.  
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Table 6-24: BAs' financial positions 
 
FIRM  The founders and top managers provided key financial positions. 
BA1  1.  A good portion of the funds have come from personal savings, and I have been the one that 
has sought out the grants. (BA1‟s CEO) 
 
2.  I am the one that has gone after the grants and completed the applications. (BA1‟s CEO) 
 
3.  I have been reaching out to partners and keeping costs down in every possible way. Because 
of my inputs we have been able to save a substantial sum of capital. (BA1‟s CEO) 
 
BA2  4.  I went out and got a 150K loan from my mother and put a bunch of expenses on my credit 
cards. (BA2‟s CEO)  
 
5.  I have kept the costs down and this is how we were able to get the business going without a 
big upfront investment. I was doing everything at first and was operating out of my school’s 
lab. (BA2‟s CEO) 
 
                              The firms’ technology helped develop financial resources. 
BA1  6.  One of the main reasons that we got the grants is because the technology filled the need the 
grant was looking for. They put requests out for certain areas and our technology fit.  (BA1‟s 
CEO) 
 
7.  We are in the running for this major grant because our technology is superior. Our product 
analysed the particles many times faster than the other applicant’s product did. This has 
given us a big leg up. (BA1‟s CEO) 
 
8.  The firm won three SBIR grants, which totalled $925,000. These grants are based on the 
potential of a technology to help the US government solve a problem, and these grants are 
ultra-competitive as less than 15% of applicants are awarded a grant (NIH, 2011). 
 
BA2  9.  Our technology is why we were able to get the two SBIR grants. The committees look at the 
potential of an innovation and award money largely on the potential of a technology. (BA2‟s 
CEO) 
                              Partners indirectly provided financial resources. 
BA1  10.  The Army provided a lot of valuable inputs. It could have cost us in the millions to develop 
the biotechnology inputs that we got from them. (BA1‟s CEO) 
 
11.  The partners provided inputs that we could not have afforded to develop. (BA1‟s CEO) 
BA2  12.  Our partners have been a big help to saving us money. The university has been a big help. 
The science and labs we had access to was (sic) worth a lot of money. (BA2‟s CEO) 
 
13.  It is hard to exactly quantify the value of the resources that the partners have contributed, but 
it would be quite large. From the inputs to the testing to the access to researchers. It is a lot. 
(BA2‟s CEO) 
Source: Author 
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Processes 
A number of routines proved important in the development of the financial resources and 
capabilities necessary for the firms‟ development. For the most part the firms‟ routines 
were quite similar, but there were also some noticeable differences. Table 6-25 presents a 
representative  sample  of  evidence  illustrating  the  most  important  financially-related 
processes. 
 
Processes revolving around conserving capital have proven vital to the firms‟ financial 
resources (Table 6-25; 1-4) [Fin-proc conserve]. These were especially important early on. 
BA1 has „boot-strapped‟ most of its operations. It has a small staff of three who perform 
all of the main scientific and functional duties of the firm. They have been paid at under 
market wages with the intent that they will receive large dividends once the firm grows. 
Furthermore,  BA1  has  operated  out  of  low  cost  operational  facilities  to  cut  down  on 
overhead expenses. The main motivation for cost savings stems from the lack of large 
capital reserves, which is a result of the firm‟s strategic decision to avoid equity investors 
such as VCs. Driving the cost-saving routines is the CEO who has drawn on his many 
years of experience to implement cost-cutting routines without losing essential functions 
(Table 6-25; 1-4).  
 
Comparatively,  BA2  has  also  developed  an  advanced  set  of  routines  in  cutting  costs. 
Initially the firm was run out of the university lab where the founder was finishing her 
PhD. Even after completing her doctorate, she kept the business housed there to cut down 
on costs. For the first couple of years she was the only employee. There was ample need 
for other employees, but she performed all of the tasks in order to conserve capital. As the 
firm has grown, it has kept to its cost-cutting ways. The firm currently operates in an area 
that has incentivised them to be there, and it operates as lean as possible in all areas of its 
operations. 
 
These two cases demonstrate clearly that cost cutting routines are especially important to 
life science ventures – especially in the early operations and particularly to firms that are 
incubated out of personal savings. 
 
The second set of processes that the firms have become proficient in is grant writing (Table 
6-25; 6-7). Their proficiencies stem from different sources however. BA1‟s grant writing 
abilities come primarily from the main founder who has written dozens of grants in his 221 
 
career (Table 6-25; 5). He has used his knowledge and capabilities in this area to land over 
five grants for BA1. These grants have provided the bulk of the capital that has financed 
the firm‟s development.  
 
In contrast, BA2 had to learn processes related to finding, applying and executing a grant. 
The firm‟s main founder did not know what an SBIR grant was until four years into the 
firm‟s operations (Table 6-25; 6). After learning about the grant, she created systems to 
apply for SBIR grants, which proved successful, as the firm has landed over $900,000 in 
grant funds. These grants provided a big boost to the firm‟s R&D and allowed them to 
expand from two product offerings to four.  
 
The evidence from these two cases illustrates how influential the SBIR grants can be on 
small firms. Although the grants required the firms to invest substantial time and develop 
routines for navigating the application and maintenance processes, the capital from the 
grants proved vital to their early growth.  
 
Processes related to transforming financial strategies also played an important role in the 
firms‟ growth (Table 6-25; 8-11) [Fin-proc transform]. BA1 went through several periods 
where they had to adapt their operations because of cash flow problems. This required the 
firm to cut back operations and strategically choose the areas to invest their limited capital. 
Most recently the firm has had to prepare for its largest possible transformation from the 
$5.3 million  grant  that  they  are anticipating  receiving. This  capital  will fundamentally 
change  the  firm‟s  financial  operations  and  strategies.  The  person  leading  the 
transformation processes for the firm has been the CEO. He has drawn on his experience 
and  successfully  found  a  way  to  manipulate  the  firm  around  to  accommodate  the 
drastically changing financial situations of the firm. If BA1 receives this grant, they will 
have to create more formalised systems for accounting and operating the firm. Because of 
the size of the grant, the firm will have to put more sophisticated routines in place for 
reporting on how the funds have been used.    
 
Similarly, BA2 has undergone several organisational transformations that have influenced 
the firm‟s financial resources. The firm‟s main founder was the only employee in the first 
couple of years, and she performed almost every one of the firm‟s functions. In the third 
year  the  firm  started  generating  revenues,  and  the  firm‟s  operations  expanded  rapidly. 
Within a few months the firm realised a growth path and quickly went from a firm of one 222 
 
employee to a firm of over ten employees. This growth forced them to develop routines for 
managing  cash  flows and strategizing  for larger investments.  The main founder and a 
couple of the staff members  designed a reporting system  that has  allowed the firm  to 
navigate its increased financial complexity.  
 
These  two  cases  illustrate  how  quickly  financial  situations  can  change  in  life  science 
ventures. Cash flows quickly come and go in this industry, and it is important that firms 
rapidly respond and adapt their financial resources and strategies to accommodate this 
rapid  change.  When  new  capital  is  introduced,  firms  must  introduce  processes  for 
managing  their expanded financial  resources,  and when cash  flows  become tight, it is 
imperative that firms implement routines for strategically conserving capital.   
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Table 6-25: BAs' financial processes 
FIRM                Conserving capital is a vital routine. 
BA1  1.  It has been a struggle. We have constantly kept costs down in every way that we 
can. Paying ourselves very little, only purchasing the necessities and getting things 
done as cheaply as possible.  (BA1‟s CEO) 
 
2.  Boot-strapping is imperative when trying to keep costs down like we have. Since 
the beginning we have been operating bare bones. We have grown accustomed to 
saving money. It has become ingrained in us. (BA1‟s CEO) 
 
MD2  3.  When you are paying for things on credit cards you have to watch every expense 
and get things done as cheaply as possible. (MD2‟s CEO)   
 
4.  We have processes for keeping costs down and strategically outsourcing to save 
capital. We are small and keep our operations highly efficient. (MD2‟s CEO)  
                           Grant writing processes have proved vital. 
BA1  5.  I have applied for over 150 grants, so I know how the process works. For the 
company these processes have importance. First you have to present your product 
so that it meets the need. Then you have to convince the committees that it does this. 
Once you receive the grant you then have to have processes in place for making the 
government happy with you.  (BA1‟s CEO) 
 
MD2  6.  I did not even know what the grants were. Once we found out about them we then 
created systems for finding the appropriate grants, applying for them and then 
maintaining them. (MD2‟s CEO)   
 
7.  Grant processes have served us well. Finding and writing grants has been 
important to learn. (MD2‟s CEO)  
Transformation capabilities have been important to the firm’s financial  
resources. 
BA1  8.  When we got the larger grant in this it changed the way we did things and how we 
approached our products development. (BA1‟s CEO) 
 
9.  If we get this $5 million we will revamp our operations. We will be able to move 
forward with initiatives such as our patents and it will make us formalise our 
operations. (BA1‟s Chairman) 
 
MD2  10. The  increased  capital  changed  the  company.  We  had  to  put  in  systems  for 
accounting and HR and had to more formally strategize about how and where to 
invest. (MD2‟s CEO) 
 
11. As your financial situation changes, so does the company. Our systems have 
expanded and the strategic outlooks change as well. (MD2‟s CEO) 
 
 
Source: Author 
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6.4.6 BA firms’ conclusion 
Financial and research resources and capabilities drove the firms‟ early growth. The R&D 
resources and capabilities demanded substantial investment: the firms‟ technologies were 
costly to develop and took a long time to develop, which made the firms sustain several 
years from the inception without any revenues. This coupled with the strategic choice of 
both  firms  to  self-finance  the  venture,  made  saving  capital  and  obtaining  government 
grants paramount. In order to pursue the path of developing a novel technology, the firms 
leveraged their scientific talents and founders‟ experience. From these the firms created 
processes to develop the needed financial and R&D resources and capabilities. In general 
the firms relied on sensing, seizing, learning and organising processes to leverage their 
positions to take advantage of the strategic paths available to them. Although there were 
distinguished  similarities  in  the  development  of  the  firms‟  R&D  and  financial 
endowments, there were also numerous differences. The most apparent difference was the 
relative experience level of the two firms‟ founders; BA1 had a highly experienced founder 
whilst BA2 had a very inexperienced founder. These experience levels had a major bearing 
on the firms‟ R&D and financial resources and capabilities development. 
 
In the final analysis though, both founders successfully navigated a unique set of paths, 
positions and processes to develop and commercialise a novel instrument for analysing 
particles and biological agents.  
 
6.5 Triangulation and cross-case analysis 
This  section  presents  the  responses  to  the  validation  questionnaire  that  each  firm 
completed in the final step of this research. It serves to triangulate the earlier analysis, and 
it also serves as a framework for the cross-case analysis. Each major path, position and 
process that surfaced is discussed along with any discrepancy that arose between the earlier 
analysis of the interview data and the response to the questionnaire. 
 
The questionnaire that the firms completed is based on pragmatic validation, which is a 
powerful  means  to  triangulate  findings.  This  is  a  form  of  validation  in  which  the 
perspective of the findings is judged by the sample of interest (Kvale, 1987). In in the 
present study it is the key informant from the case firms. Each of the major influences 
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was presented in a survey to each of the case firms in this study, and the respondents rated 
the importance of each influence. This data does not serve for statistical testing, but instead 
each response is compared to the analysis from the qualitative data for each of the firms. 
This serves to validate and triangulate the findings. In general, most of the findings were 
validated,  but  there  were  a  few  small  discrepancies.  In  those  instances  the  researcher 
gathered  more  information  to  clarify  the  discrepancy,  and  an  explanation  for  the 
discrepancy is offered.   
 
The  questions  are  divided  into  two  sections;  one  for  R&D  and  one  for  finance.  Each 
section is further broken into three groups of questions. The first group of questions asks 
about  the  important  paths  that  led  to  the  development  of  the  firm‟s  resources  and 
capabilities. The second group of questions asks about the important positions used in the 
development of the firm‟s resources and capabilities. The third group of questions asks 
about  the  important  processes  leading  to  the  development  of  the  firm‟s  resources  and 
capabilities. The results from all of the firms‟ responses are presented below along with a 
discussion of how the results of the survey compared to the findings from the qualitative 
analysis.     
6.5.1 Triangulation of R&D paths 
The first set of questions looked at „to what extent did opportunities and past decisions 
have on the development of the firm‟s R&D?‟ It is evident from the earlier analysis and 
Table 6-26 that innovation is the most ubiquitous influence on the R&D path of the firms. 
University partnerships also proved influential on the firms R&D paths. Several other past 
decisions and future opportunities also influenced the development of the firms‟ R&D 
resources  and  capabilities,  but  these  influences  varied  amongst  the  firms.  The 
discrepancies that surfaced from the responses and the earlier analysis are noted in the 
discussion below. 
 
All of the firms rated the core technology as very important (Table 6-26; 1). This is in line 
with the earlier analysis and is one of the most important themes of this study. The firms‟ 
strategies revolved around a novel technology. The pursuit of this technology drove the 
firms to develop a unique set of R&D resources and capabilities in its pursuit. Thus the 
core technology has clearly been an important path in the development of the firms‟ R&D.   
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In general, VC did not have a major influence on the firms R&D paths (Table 6-26; 2). 
Three of the firms (BA1, DD1, and MD1) did not receive VC, so it is to be expected that 
VC did not have an influence on these firms R&D. However, only DD1‟s VC, of those that 
drew  on  VC,  had  a  major  influence  on  R&D  paths.  Their  VC  provided  capital  and 
management inputs that greatly affected the firm‟s strategic R&D pursuits; i.e. it afforded 
them the capital to develop their R&D resources and capabilities.  
 
The firms ranking of the importance of industry partners on their R&D paths varied greatly 
(Table 6-26; 3). However, for the most part this is in line with the data gathered in the first 
part of this study. BA1 and BA2 relied heavily on partners for inputs, and these industry 
partners had a major impact on the firms‟ R&D paths, whereas the other firms did not have 
strong relationships with firms in the field and in some of the cases purposely avoided 
partnerships. The response from DD1 did vary somewhat from the analysis of the earlier 
data. For DD1, it seemed apparent that industry relationships were important to their R&D 
paths, but there was only one partner firm that influenced the strategic path of DD1, and 
they merged with this firm. Thus the respondent to this survey did not see them as  a 
partner firm, but instead a part of DD1. The relative importance of partners seemed to 
revolve  around  the  firm‟s  strategy  and  availability  of  partners.  Moreover,  whilst  the 
importance of partners varied, the study did show that partners can have a profound effect 
on a firm‟s R&D evolution. For example, industry partner inputs to BA2‟s R&D had a 
significant impact on their R&D.     
 
An important theme from this study is the importance of university partnerships to the 
R&D  paths  of  the  firms  (Table  6-26;  4).  Three  of  the  firms‟  (BA1,  BA2  and  MD2) 
innovations  emanated  from  universities,  and  for  almost  all  of  the  firms,  university 
partnerships opened up research opportunities that influenced the strategic pursuits of the 
firms. MD1 is the one exception to this, as they had no university relationships. Overall 
university science opened up R&D opportunities for the firms and university partnerships 
influenced the direction of the firms R&D. This is one of the major themes to surface from 
this study.   
 
For the most part government partnerships did not influence the strategic direction of the 
firms‟ R&D (Table 6-26; 5). The two exceptions to this are BA1 and BA2. Both of these 
firms entered agreements that greatly influenced their firms R&D paths. BA1 had a couple 
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had been driven by research partnerships with the government. Thus the opportunity for 
government partnerships has had a major bearing on these firms‟ R&D paths.   
 
Scientific discoveries by the firm had a large bearing on the strategic paths of the firms‟ 
R&D (Table 6-26; 6). All of the firms made progressions that changed the outlook of their 
R&D and motivated the firms to reorganise their resources to accommodate the scientific 
discoveries.  The  one  discrepancy  from  the  earlier  data  is  with  BA1  ranking  this  a  4. 
Further information revealed that this is because the founder clearly thought this was a 
major progression for the firm, but he did not view this as a scientific breakthrough on a 
large scale. However, further information clarified that internal scientific discoveries did 
have a major bearing on the firm‟s R&D paths by opening up new R&D paths for the firm. 
Overall scientific progressions by the firms had a major impact on the R&D paths of the 
firms. More specifically, these opened up new research avenues that affected the strategic 
pursuits of the firms.  
 
Scientific developments in the wider industry are seen as having a low influence on the 
R&D paths of the firms, except for BA1 and MD2, which marked these as high (Table 6-
26; 7). For the five firms there were no major events in the industry that presented great 
opportunities  or  adversely  affected  the  firms  R&D  paths.  MD1‟s  rating  of  scientific 
breakthroughs as extremely high came as a slight surprise, as the earlier data suggested that 
these events had an impact, but not a vital impact. The follow up revealed that there were a 
couple of developments in the industry that allowed MD1 to develop its device, and this is 
why scientific discoveries in the industry was rated so highly. In general, discoveries in the 
industry did not have a major impact on the firms, but BA1 and MD1 show that these 
discoveries can have a bearing on the on a firm‟s R&D paths.  
  
Five of the firms rated „FDA, EU or other government approvals‟ as high to extremely 
high; whereas, DD1 rated this as influential and BA1 rated this as not influential at all 
(Table 6-26; 8). DD1‟s response differed a little from the results found earlier in the study, 
which is largely explained by the respondents‟ experience in the industry where FDA and 
government approval are simply part of the drug development process. Further information 
revealed that these approvals in fact have been highly influential on the strategic R&D 
pursuits of the firm. BA1‟s view of this category as having a low influence was driven by 
the fact that the firm has invested almost no resources in FDA approval. However, further 
clarification indicates that the firm has strategically planned around FDA approval, so this 228 
 
did have an indirect effect on BA1‟s R&D paths. Overall, FDA and other government 
approvals have been highly influential on the strategic paths of the firms. The firms have 
strategized  around  FDA  and  in  most  cases  devoted  significant  resources  to  these 
procedures. Moreover, in many cases the substantial resources devoted to FDA limited the 
other areas the firms could focus their R&D. 
 
The respondents rated patents as influential to highly influential on the development of 
their R&D (Table 6-26; 9), which reaffirms the earlier findings that patents and the pursuit 
of patents have an impact on R&D paths. In general the firms developed their R&D based 
on patents or the pursuit of R&D affected what decisions were made in regards to R&D; 
e.g. three of the firms (BA2, DD1 and MD1) strategized largely around obtaining patents.  
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Table 6-26: R&D paths triangulation 
      1= to no extent  7 = to a very great extent 
      1  2  3  4  5  6  7 
1.  Your firm‟s core innovation(s)  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
2.  VCs  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
3.  Industry partnerships  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
4.  University partnerships  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
5.  Government partnerships  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
6.  Scientific breakthroughs by your firm  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
7.  Scientific breakthroughs in the industry  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
                   
8.  FDA, EU or other approvals  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
9.  Patenting  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
Source: Author 
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6.5.2 Triangulation of R&D positions 
Table 6-27 summarises the important positions that the firms leveraged in the development 
of their R&D resources and capabilities. From this it is evident that four resources proved 
important  to  the  firms‟  entire  R&D:  (1)  core  technology,  (2)  scientific  staff,  (3)  star 
scientists  and  the  (4)  founders.  Several  other  resources  also  proved  important,  but  the 
relative importance of these resources varied amongst the firms. The results that surfaced 
in the first part of the study are consistent with the responses below.  
 
A central theme to emerge from this study is that the core technology is an important 
resource  that  the  firms  leverage  in  the  development  of  their  R&D  resources  and 
capabilities. This theme recurred throughout the interview analysis and is validated by 
Table 6-27 (1) below. It is apparent that the firms leverage their core technology to attract 
other R&D inputs; specifically partner opportunities arise because other firms want access 
to the unique technology. Moreover, discoveries in the technology allow the firms to build 
other R&D assets such as patents from discoveries in their core technologies.   
 
Another important resource that all of the firms leveraged in the development of their 
R&D  are  their  scientists.  The  respondents  rated  their  scientific  staff  as  „important  to 
extremely important‟ (Table 6-27; 2). This is in line with the earlier analysis findings that 
scientists  contribute  important  inputs  to  a  firm‟s  R&D.  Specifically,  they  contributed 
knowledge resources that allowed the firms to progress their R&D. Not surprisingly, these 
cases show how vital of a resource scientists are to the development of a firm‟s R&D.  
 
If their scientific staff is a core resource, this is even more so for their leading scientists.  
With their record of scientific discovery, as evidenced by patenting and academic citations, 
they are core resources to the development of life science innovations. This theme emerged 
from the earlier analysis and is confirmed by the rankings of this category below in Table 
6-25 (3). For most of the firms the star scientists made contributions that greatly helped in 
the  progression  of  the  firms‟  technologies.  For  example,  a  star  scientist  for  BA2 
contributed several  chemical  techniques that allowed their instrument  to  analyse chiral 
chemicals. All of the responses to this question aligned with the analysis from the earlier 
part of the study that star scientists can be important resources to the development of novel 
life science innovations.  
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One  of  the  central  themes  to  come  from  the  earlier  analysis  is  the  importance  of  the 
founders to the development of the firms‟ R&D (Table 6-27; 4). This is validated by the 
very  high  responses  the  respondents  put  for  the  importance  of  the  founders  to  the 
development of R&D. All of the firms had founders who were critical resources to their 
firm‟s R&D. Specifically, they made large contributions to the development of their firms‟ 
technology.  The  firms‟  founders  created  or  sensed  out  the  core  innovation  and  then 
continued to use their scientific knowledge and skills to help progress their firm‟s R&D.  
 
The respondents‟ ratings on the inputs of their executive staff and board varied, which 
collates with the earlier analysis (Table 6-27; 5). MD1, MD2 and BA3 executive staff and 
board  members  are  important  resources  to  the  firms  R&D.  They  provided  scientific 
knowledge and access to other scientific inputs that have been vital resources to these 
firms‟ R&D. In contrast the other three firms‟ (BA1, DD1 and DD2) executives and board 
members have been important but have not provided critical R&D resources. They have 
mainly contributed ideas and occasionally helped the firms make contacts that help in the 
firm‟s research.   
 
The firms rating of the importance of university resources varied, which reflects the earlier 
findings from the study (Table 6-27; 6); three of the firms (BA1, BA2 and DD1) rated the 
importance of university resources as high to extremely high, two of the firms (DD2 and 
MD1) rated this as moderately important and one firm rated this as of no importance. The 
firms  that  relied  on  university  resources  received  important  scientific  inputs  from 
universities. These resources proved vital to the firms. For example, BA2 had research 
performed in a university lab that had capabilities that few labs in the world have. Firms in 
which university partnerships were of moderate importance mostly used the universities 
for testing inputs. Interestingly, the universities provided resources to all of the firms, but 
the relative importance of these inputs varied. There was no theme as to what drove the 
importance  other  than  that  prior  strong  connections  with  a  university  influenced  the 
relative importance of university resources. BA1, BA2 and DD1‟s strong connections with 
the universities resulted from either the firm‟s founder being an alumnus of the university 
or the firm‟s founder having worked with the university in the past. 
 
The responses to the importance of industry partner resource inputs varied amongst the 
firms (Table 6-27; 7), but this is in line with the earlier findings. There was not a general 232 
 
theme to emerge on the discrepancy of the relative importance of partners. Each firm had a 
unique motivation for either working or not working closely with industry partners.  
 
The  importance  of  government  resources  to  the  firms  varied  amongst  the  respondents 
(Table 6-27; 8), but collated with the earlier analysis. Only one of the firms received vital 
resource inputs from the government – BA1. This firm‟s development revolved around 
these resource inputs. In comparison BA2 and DD1 received some inputs on a couple of 
R&D projects that helped the firms, but overall the government resources did not prove 
vital; whilst DD2, MD1 and MD2 received no resources from the government. Overall 
government resource inputs did not have a major bearing on the firms‟ R&D, but in certain 
circumstances  government  inputs  did  provide  a  boost,  as  was  the  case  of  BA1  where 
government resources contributed substantially to the firm‟s R&D.  
 
The respondents rating of the importance of patents as a resource to the firms‟ R&D varied 
greatly (Table 6-27; 9). Three of the firms  (BA1, BA2 and MD1)  rated patents  as an 
important resource. For these firms patents provided protection, which allowed them to 
move  their  product  to  a  point  of  commercialisation  without  fear  of  losing  intellectual 
property. For DD1 and MD2 the patents were not of critical importance, but they did prove 
to be resources that the firms leveraged to develop research opportunities. Patents proved 
to be of no importance to DD2‟s early growth. This firm applied for patents, but it took 
eight years to get them, so the firm‟s patents did not provide important R&D resources. 
However, the follow-up with the firm indicates that now that the firm has the patents, they 
will become important resources to their R&D. Interestingly, the importance of patents 
varied  amongst  the  firms  and  the  reason  for  the  variation  differed.  The  one  theme  to 
emerge on this is that the relative ability of the firm to protect the intellectual property 
without patents influenced the relative importance of patents. However, the cases only 
provided some indications of this, and there is not substantial evidence to put this forth. 
Also interesting is that patents and the patenting process was highly influential on the 
firms‟  R&D  paths;  i.e.  the  pursuit  of  obtaining  patents  affected  their  R&D  strategies. 
However, the relative importance of the patents as a resource varied in importance. 
 
Specialised research facilities are a resource varied in terms of its importance, which for 
the most part is in line with the earlier findings. The firms that rated this as extremely 
influential needed facilities that are very rare and have highly sophisticated equipment. The 
high rating for this from BA1 was stronger than had emerged in the earlier interviews, but 233 
 
further information revealed that the Army facility where they conducted a lot of research 
proved vital as there are almost no other research facilities in the world that have the 
capabilities to bring together the three sciences that the firm‟s technology is based on; thus 
this  has  been  a  vital  resource  to  BA1.  Specialised  research  facilities  provided  some 
important inputs for MD1 and MD2, but these were for select R&D functions. In other 
words, a specialised R&D facility has only been important resource for certain functions. 
For BA2 and DD2 most of their research could be conducted at just about any laboratory, 
so specialised R&D facilities did not prove important to them.   
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Table 6-27: R&D positions triangulation 
      1= to no extent  7 = to a very great extent 
      1  2  3  4  5  6  7 
1.  Your firm‟s core technology  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
2.  Your firm‟s  scientific staff  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
3.  Star scientists  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
4.  Founders  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
5.  Executive staff and board of directors  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
6.  University inputs   BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
7.  Industry partners inputs  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
8.  Government inputs  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
9.  Patents  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
10.  Specialized R&D facility***   BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
Source: Author 
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6.5.3 Triangulation of R&D processes 
Table  6-28  presents  the  important  processes  used  to  help  develop  the  firms‟  R&D 
resources and capabilities. It can be summarised that by trend each firm relied on a unique 
set  of  processes  to  develop  its  R&D.  However,  sensing  technology  and  learning  are 
important processes that all of the firms used to develop their R&D. Only a few minor 
discrepancies surfaced from the responses and the earlier interviews. These are discussed 
below. 
 
One of the main themes from the earlier analysis is that sensing out technology has clearly 
been  an  important  set  of  routines  for  the  firms.  This  is  validated  here  as  all  of  the 
respondents marked this question as extremely high (Table 6-28; 1). All of the firms had 
routines in place that allowed them to identify a technology to develop and commercialise. 
Some of the firms sensed out technologies that were already in development, whilst the 
others used sensing routines to find an idea for a novel life  science innovation. These 
routines revolved around scanning the scientific community for emerging science, staying 
in  contact  with  people  in  the  industry  and  being  abreast  of  industry  trends  and 
developments.  These  routines  happened  at  the  network  and  firm  levels,  but  on  the 
individual level is where these routines transpired the most; i.e. each of the firms in this 
study had an individual or a small group of individuals driving their technological sensing 
routines. 
 
The responses on the importance of networking routines varied amongst the firms (Table 
6-28; 2), which collates with the earlier findings. These routines proved very important to 
BA1 and BA2. Both of these firms received important R&D inputs from their networks, 
and their networks resulted from their networking capabilities. For three of the firms (DD1, 
MD1 and MD2) networking routines proved moderately important. These firms are fairly 
well networked and have used their networking capabilities to capture some key R&D 
inputs. Lastly, networking routines did not prove important to DD2‟s R&D.  
 
Key individuals (i.e. the founders and TMTs) drove the networking for the firms. Their 
networking processes ranged from as simple as picking up and calling a contact that might 
be able to help the firm to as complicated as BA2‟s CEO‟s system for embedding herself 
into  a  network  through  trade  show  attendance,  volunteering  in  industry  events  and 
participating in formal networking events.  236 
 
 
Learning processes have proven to be important to the firms‟ R&D (Table 6-28; 3). The 
earlier  findings  indicated  that  these  processes  helped  the  firms  progress  their  core 
technology, which aided in  attracting new resources.  This  is  substantiated by the high 
ratings that the respondents marked for this question. These processes transpired at the 
network,  firm  and  individual  levels.  BA1  and  BA2  practised  learning  routines  at  the 
network level. They worked with their partners on joint research where they learned from 
earlier research paths. For example, with their partners they dissected why certain projects 
did not work.  
 
Similarly, learning in R&D took place in all of the cases  at the firm level. The firms 
worked with everyone within the organisation as to what progressions had been made and 
as to what could or could not be done based on their earlier research. The results for all of 
the cases also indicated that learning routines are most evident at the individual level. All 
of the firms have researchers who work autonomously on their individual projects and 
have their own systems in place for how they dissect problems and take in new information 
from their earlier findings.      
 
The responses on the importance of routines related to tracking and sharing information 
varied amongst the firms (Table 6-28; 4), which is in line with the earlier findings. For four 
of  these  firms  (BA,  BA2,  DD1  and  MD2)  these  routines  allowed  the  firms  to  share 
information amongst the various researchers working on the firm‟s technology. In general, 
the routines relied on written and oral communication, and in BA2‟s case they have a 
formalised system for tracking and sharing scientific information amongst their research 
team. All the firms‟ information-sharing routines helped their researchers collaborate and 
strategize on the most effective way to progress their R&D. For DD2 and MD1 these 
routines did not prove important. This is largely because these firms‟ technologies were 
developed by a very small group of individuals that did not need to share information to a 
wide audience.    
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 Table 6-28: R&D processes triangulation 
    1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Finding (sensing) the core technology  BA1             
    BA2             
    DD1             
    DD2             
    MD1             
    MD2             
                 
3.  Networking  BA1             
    BA2             
    DD1             
    DD2             
    MD1             
    MD2             
                 
4.  Learning from previous research paths  BA1             
    BA2             
    DD1             
    DD2             
    MD1             
    MD2             
                 
5.  Tracking and sharing information  BA1             
    BA2             
    DD1             
    DD2             
    MD1             
    MD2             
Source: Author 
 
6.5.4 Triangulation of financial paths 
The responses to the important paths are presented in Table 6-29. It is evident from this 
table that the core technology and government-related processes had a major impact on the 
development of the firms‟ financial resources and capabilities. Several other opportunities 
and past decisions also influenced the firms‟ financial demands, but the relative importance 
of these varied amongst the firms. In general the responses to the questionnaire aligned 
with the earlier analysis. This confirms the detailed discussions in sections, 6.2, 6.3 and 6.4 
above.  
 
An important theme from this study related to the development of financial resources and 
capabilities is that the costly nature of developing a novel technology dictated the firms‟ 
financial strategies and outlooks (Table 6-29; 1). DD1 is the one respondent who did not 
mark this  as  a highly influential  path.  Instead he marked this  as  low. This  came as  a 
surprise as the earlier analysis indicated that the great cost involved with developing a drug 238 
 
technology drove DD1 to develop advanced financial resources and capabilities. However, 
further information revealed that the drug technology itself was not overly expensive to 
develop, but the activities involved with developing the drug were expensive. Items such 
as FDA testing and developing production capacities did create a demand for specialised 
financial resources and capabilities. Thus the core technology indirectly drove the financial 
paths of the firm.  
 
In short, all of these firms were new life science ventures that were financially constrained 
yet pursued the development of costly technology. This dictated the financial paths that the 
firms went down. 
 
Table 6-29 (2) depicts that raising capital proved as an important path to three of the firms 
(DD1, DD2 and MD2), but not to the other three firms (BA1, BA2 and MD1). Further 
information  gathered  from  the  firms  which  raising  capital  was  not  highly  important 
revealed that this is because of these firms‟ decision to self-finance a large portion of their 
early growth; this meant they did not have to spend a lot time and effort on raising capital.  
 
Only two of the respondents (MD2 and DD1) rated investor relations as influential on the 
financial paths of the firms (Table 6-29; 3). This is not a surprise as these responses are in 
line with the findings from the interviews. For the most part the firms did not have to 
expend considerable time dealing with investors. Interestingly, MD2 is the only one of the 
three VC-backed firms that had investors that impacted the financial paths of the firm. 
They along with DD1 had to spend considerable time meeting with investors. This has 
been time that has drawn from the TMTs time and has had an effect on the firms‟ financial 
paths.  
 
For the most part an initial public stock offering (IPO) has not had a large impact on the 
firms‟ financial paths (Table 6-29; 4). Four of the firms are not publicly traded and have 
not looked into the process of going public. DD1 and DD2 are publicly traded, and this has 
greatly  affected  their  financial  paths.  The  need  for  public  financing  for  these  firms 
stemmed from the great cost in developing novel drugs. Surprisingly DD1 rated IPO as 
having no influence. However, further information revealed that this is because the firm 
did not go public on their own accord, but instead merged with a publicly traded firm. 
Further information also revealed that the public stock markets have had an effect on the 
firm‟s strategic path; mainly through the capital that it offers.  239 
 
 
Another important theme relating to this study comes from the impact that government 
approvals have on the financial paths of life science firms. The earlier findings put forth 
that these approvals have had a major bearing on the firms‟ financial paths, and Table 6-29 
below confirms this. These approvals are expensive and time-consuming and have had a 
major impact on the financial paths of the firms; i.e. they have had to strategically acquire 
the capital needed for this. Had the firms not have had to contend with these government-
related processes, then they could have avoided considerable financial demands; which 
would have had a significant impact on their financial paths. BA1 is the one firm that these 
processes did not affect. This is because BA1 made the strategic choice not to pursue 
applications that required government approval. However, these processes still indirectly 
influenced  BA1‟s  financial  paths  as  the  firm  strategized  largely  around  avoiding 
applications that required FDA or other government approvals.  
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Table 6-29: Triangulation of financial paths 
       1= to no extent  7 = to a very great extent 
      1  2  3  4  5  6  7 
1.  Costly to develop innovation(s)  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
2.  Raising capital  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
3.  Dealing with investors  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
4.  Initial public stock offering (IPO)  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
5.  Costly government approvals such as patents or FDA   BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
Source: Author 
 
6.5.5 Triangulation of financial positions 
Table  6-30  summarises  the  responses  to  the  questions  about  the  important  positions 
(resources) that the firms leveraged in the development of their financial resources and 
capabilities. It is evident from this table that the firms relied on a unique set of resources to 
develop their financial resources and capabilities. Only a few discrepancies surfaced from 
the responses and the earlier analysis. These are noted in the discussion below.  
 
One of the main themes to come from the earlier analysis is the importance of the founders 
to the development of the firms‟ financial resources and capabilities. For the most part this 
is  validated  by  the  very  high  responses  the  respondents  put  for  the importance  of  the 
founders  to  R&D  (Table  6-30;  1).  All  of  the  firms  had  founders  who  were  critical 
resources to their financial resources and capabilities. The one exception to this is DD1 
who rated this as very low. Further information from the firm reveals the initial founders 
were not influential in raising capital, but instead the CEO is the one who did most of the 241 
 
fund raising. However, the CEO has been a part of the company almost since inception and 
holds significant stock. After further consideration the firm sees him as a founder, and thus 
with him included as a founder, the firms‟ founders did provide critical resources to the 
firm‟s financial resources and capabilities.   
 
The founders‟ resource contributions came in the forms of the capital they invested, access 
to their network of investors and their capabilities in raising capital. In all of the cases the 
firm‟s founders made substantial resource contributions in these forms that greatly aided in 
developing their firm‟s financial resources and capabilities.  
 
The responses to the question about the impact of the executives and board member‟s 
resource contributions to the development of the firm‟s financial resources and capabilities 
varied (Table 6-30; 2). This reflects the earlier findings that demonstrated how some of the 
firms had significant financial resource inputs from their executives and board members. 
Four of the firms‟ (BA1, DD1, MD1 and MD2) executives and boards made substantial 
resource  contributions.  More  specifically,  they  contributed  capital,  access  to  financial 
networks, and capabilities in raising capital. BA2 is the only one to mark this category as 
low, as their executives and board members did not contribute financial resources.   
 
For  the  most  part  VCs  did  not  contribute  many  resources  that  helped  the  case  firms 
develop  their  financial  resources  and  capabilities  (Table  6-30;  3).  Even  the  firms  that 
received VC (DD1, DD2 and MD2) only rated VC resources as having a low to moderate 
impact on the development of financial resources and capabilities. These firms received 
some capital from the VCs, and the VCs also opened up networks, but these resource 
inputs did not prove critical to these firms. The other three firms did not receive VC, which 
explains their low rating of VC influence. Interestingly, all of the firms, even the ones that 
received VC, expressed their displeasure with the VC model. This is largely why the firms 
have tried to stay away from VC resource inputs. Specifically the firms felt that VCs no 
longer want to invest in risky ventures and that it has become overly difficult to attract VC 
investment.    
 
In general the firm‟s core technology helped them attract investment capital (Table 6-30; 
4).  All  of  the  firms,  except  MD1,  received  some  form  of  outside  capital,  and  the 
technology is one of the reasons why the outside capital was invested. Put differently, 
outside investors saw the large profit potential of the technology and invested largely based 242 
 
on  this.  For  BA1  and  BA2  the  grant  committees  saw  that  their  technologies  had  the 
potential to help fill a government need. 
 
It  came  as  a  bit  of  surprise  that  both  DD1  and  DD2  only  rated  the  technology  as  a 
moderately important resource to attracting capital, as the earlier analysis indicated that the 
technology provided important positions to developing the firms‟ financial resources and 
capabilities. However, further information reveals that in fact the technology did help raise 
capital, but there were a few times when the firms‟ technology hindered attempts to raise 
capital because it had not progressed as far as it should have. For example, DD1 ran into 
some delays with patent approval, and this hindered their ability to raise capital. Because 
of this, the investors feared the technology might not make it to market. Thus DD1 and 
DD2‟s  technology  did  help  attract  capital,  but  there  were  also  instances  in  which  it 
hindered the firms‟ abilities to raise funds. 
 
Overall  all  the  firms‟  technologies  provided  an  important  resource  that  helped  them 
throughout their early growth. Progressions in the firms‟ technologies towards a state of 
commercialisation provided an additional resource that the firms used to attract additional 
capital.  For  example,  developing  the  saliva-based  instrument  made  MD2‟s  product 
marketable, which greatly aided the firm in attracting a major investment in 2009.  
 
There is a polarised difference in how important a resource the firms‟ respective staff has 
been to the development of their financial resources and capabilities (Table 6-30; 5); with 
some of the firms‟ staff proving to be an important resource and some of the firms‟ staffs 
proving not to be. Four of the firms‟ (BA1, DD1, DD2 and MD2) staff was critical to the 
company because they lent their expertise that the firms used to help attract investment 
capital. BA1 and DD2 also had staff members who directly made financial contributions to 
the firms. On the other end, BA2 and MD1‟s staffs did not prove important to the firms‟ 
financial resources and capabilities. They did not help the firm attract financing and did not 
directly contribute financial resources.    
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Table 6-30: Triangulation of financial positions 
      1= to no extent  7 = to a very great extent 
      1  2  3  4  5  6  7 
1.  Founder(s)  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
2.  Executive staff‟s and board members 
experience 
BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
3.  Venture capital investor(s)  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
4.  Core technology  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
5.  Company‟s staff  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
Source: Author 
 
 
6.5.6 Triangulation of financial processes 
Table  6-31  presents  the  important  processes  used  to  help  develop  the  firms‟  financial 
resources and capabilities. This table shows that processes related to conserving capital and 
learning from earlier financial decisions had a major bearing on the development. Only a 
few minor discrepancies surfaced from the responses and the earlier interviews. These are 
noted in the discussion below. 
 
The importance of routines related to prospecting for capital varied (Table 6-31; 1). These 
processes proved highly important to DD1, DD2 and MD2, and can largely be attributed to 244 
 
the vast amount of money that these firms‟ innovations demanded. In order to obtain the 
needed capital, DD1, DD2 and MD2 had to develop advanced routines related to finding 
and selling the idea of investing in the firm and negotiating terms. For example, DD1 has a 
system where they contact physicians about the possibility of investing. If a physician is 
interested, then the CEO meets with the potential investor. Similarly, these firms have 
systems in place for negotiating with the potential investors. These routines have also been 
important to BA1 and BA2, but these are not systems that they use on a regular basis. 
Instead  there  have  been  select  times  when  they  have  relied  on  these.  For  MD1  these 
routines have been of no importance because the firm has made little attempt to draw in 
outside investors, which is a result of the founder‟s decision to self-finance the venture. All 
of the firms‟ innovations have been capitally intensive to develop, but BA1, BA2 and 
MD1‟s have been less expensive, and these firms were able to source the capital for their 
innovations with less effort than the other three firms have been able to.  
 
Processes revolving around dealing  with  investors (Table  6-31;  2) have had a varying 
effect  on  the  firms‟  financial  assets  and  capabilities.  DD1  and  DD2  have  developed 
advanced routines for dealing with their investors. This has involved meeting with the 
investors, creating reports and completing compliance paperwork. For the most part these 
are lower-level routines that have become ingrained in the firms. These processes have had 
some influence on BA2, but the firm‟s TMT only devotes a small amount of time to these 
routines. For three (BA1, MD1 and MD2) of the firms these routines were reported to have 
had almost no influence on their financial resources and capabilities. In the cases of BA1 
and MD2 this is largely because the firms have taken in a limited amount of capital from 
outside investors. The low response from MD2 contrasts to the earlier analysis. However, 
further information clarified that the respondent did not view this question correctly and 
that this has been influential on the firm‟s development.    
 
An important finance-related theme from this study is the importance of budgeting and 
conserving capital. Table 6-31 (3) shows that the firms saw these as important processes to 
their  financial  pictures,  which  reflects  the  earlier  findings.  The  firms  have  developed 
routines for saving capital that revolve around sensing out low cost inputs and strategically 
investing in the most cost effective projects. The firms have also developed routines for 
budgeting  their  capital.  For  the  most  part,  capital  flows  have  been  erratic,  leading  to 
inconsistent cash flows. All the firms created routines for projecting spending and have put 245 
 
emergency plans in place, such as short-term credit lines to pay for expenses when cash 
flows become problematic.  
 
One inconsistency from the earlier analysis and the response to this question arose from 
MD2. The respondent only marked this as moderately important, when the earlier analysis 
indicated that this as being quite important to the firm. Further information revealed that 
the respondent felt this is very important.   
 
Most of the respondents listed routines relating to learning from earlier financial paths as 
very high (Table 6-31; 5). This is consistent with the earlier findings that one of the most 
important  factors  to  the  development  of  the  firms‟  financial  resources  and  capabilities 
stemmed from the processes that they created to learn from earlier financing decisions. 
These processes were driven by the firms‟ TMTs who learnt how to identify potential 
investors, conserve capital and create strategies to conserve capital. However, these are not 
formal routines that the TMTs think about and put a lot of effort in developing. Rather 
these learning routines occur every day based on the cumulative experience of the past. 
 
For the most part routines related to filing for an initial public offering did not affect the 
firms (Table 6-31; 6). The one exception is DD1, which had to expend considerable effort 
in developing routines for compliance and marketing their stock, which related to their 
IPO. The CEO is the one who has driven this process for DD1. DD2 is also publicly 
traded, but it merged with an already publicly-traded firm, so it avoided having to develop 
many of these routines. Moreover, the firm it merged with has a finance team that deals 
with the on-going maintenance routines of the firm‟s publicly-traded stock. The other firms 
did not file for an IPO because they were not ready to do so, did not have the financial 
capabilities to do this or they simply did not want to commit to creating the processes 
needed for taking the firm public. DD1 would have preferred to have not had to deal with 
these processes, but the high cost of developing their drug forced them down this path. 
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Table 6-31: Financial processes triangulation 
      1= to no extent  7 = to a very great extent 
      1  2  3  4  5  6  7 
1.  Prospecting for capital  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
                   
2.  Dealing with financiers   BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
3.  Budgeting and conserving capital   BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
5.  Learning from earlier financial paths  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
6.  Filing for an initial public offering (IPO)  BA1               
    BA2               
    DD1               
    DD2               
    MD1               
    MD2               
                   
                   
Source: Author 
 
 
6.6 R&D and finance interdependence 
The analysis presents a clear connection of the interdependence of financial and R&D 
resources  and  capabilities  of  innovative  life  science  ventures.  Based  on  this  analysis, 
Figure  6-1  presents  a  model  as  to  how  R&D  and  financial  resources  and  capabilities 
developed in the six innovative life science ventures that this study examined. 
 
Firms  are  started  to  develop  and  commercialise  an  innovative  technology,  which  is 
represented in the figure by the core technology oval. The technology is either purchased 
from another organisation (firm, university or government) or conceptualised prior to the 
start of the new firm. This core technology feeds into the R&D and the financial paths and 247 
 
positions. The technology‟s past paths dictate the development that needs to go into the 
innovation; i.e. how much development does the technology need? Which dictates how 
much financing is called for? For example, an innovation at an earlier stage requires more 
development than an innovation purchased at a later stage. The potential of the technology 
and the  complementary technologies available  are the key  drivers to the technologies‟ 
future  paths,  and  firms  develop  their  innovation  to  pursue  these  paths.  Often  the 
technology comes with scientific capital, such as patents or key scientific personnel, which 
feed into the R&D positions of the firm.  
 
The firm develops R&D processes based on their R&D paths and positions, and then these 
processes create the R&D resources and capabilities of the firm. The feedback loops (i.e. 
the  dotted  lines  in  Figure  6-1  from  R&D  resources  and  capabilities  to  the  paths  and 
positions represent the R&D resources and capabilities feeding back into the firm‟s R&D 
paths  and  positions;  i.e.  the  R&D  resources  and  capabilities  create  new  research 
opportunities and strengthen the R&D positions of the firm.   
 
The core technology is also important to the financial paths of the firm. It dictates the 
capital needed and what source(s) of finance are called for. In all of the cases studied, the 
firms  required  a  large  investment  to  develop  the  core  technology.  Moreover,  the  core 
technology took an extended time to develop, which made the firms sustain long periods 
without revenues. Thus the core technology made specialised financing necessary for the 
firms. None of the firms in the study could source capital from generic places such as 
banks. Thus from the results is clear that financial resources and capabilities for innovative 
start-up life science firms are often specialised resources , not generic resources ; i.e. the 
financial resources  and capabilities cannot be easily obtained and take specialised abilities 
to create (Teece, 1986; Trispas, 1997).  
 
The core technology also feeds into the financial positions because the market potential of 
the core technology is what influences how much capital the firm can raise. All of the 
firms in this study raised the needed capital largely based on the potential profits of the 
innovation. Put differently, the investors and grant committees saw great potential in the 
firms‟ innovations. Initially the firm develops financial processes based on its paths and 
positions.  These  processes  then  create  the  financial  resources  and  capabilities.  The 
feedback  loops  from  financial  resources  and  capabilities  to  the  paths  and  positions 
represent the financial resources feeding back into the firms‟ financial paths and positions; 248 
 
i.e.  the  firms  further  developed  their  capabilities  in  raising  capital,  and  the  additional 
capital increases their financial positions.  
 
The R&D and financial resources and capabilities in turn feed into each other. As the firm 
increases its financial resources and capabilities, it feeds these into the paths and positions 
of  the  R&D  resources  and  capabilities.  The  capital  gives  the  firm  positions  to  further 
develop R&D, and it also gives the firm the capital needed to open up new R&D paths, 
such as developing a new product. Similarly, R&D feeds into the financial resources and 
capabilities of the firm. An increase in R&D gives the firm additional positions from which 
to  raise  capital;  i.e.  the  innovation  is  more  developed  and  shows  even  more  market 
promise. This opens up new financing paths for the firm; i.e. the firm has more options for 
raising future capital because of the R&D resources and capabilities of the firm.  
 
The feedback loops from the R&D and financial resources and capabilities represent the 
R&D and resources and capabilities‟ contributions to progressing the technology. Because 
of the developments in the firms‟ finances and R&D, it is able to get the core technology 
closer and closer to a point of commercialisation, which ultimately perpetuates the firm‟s 
growth. 249 
 
Figure 6-1: Model of technology, R&D and financial interdependence 
 
 
Source: Author250 
 
6.7 Analysis conclusions 
It  is  clear  from  this  analysis  that  R&D  and  financial  resources  and  capabilities  are 
paramount to the growth of innovative life science ventures. R&D and finance build on 
one another and then feed into the development of the firm‟s innovation throughout the 
growth process. The R&D and financial resources and capabilities develop from a unique 
set of paths, positions and processes. Especially important to R&D is the core technology 
that  the  firm  sets  out  to  develop.  This  establishes  the  R&D  needs  and  ultimately  the 
strategic direction of the firm. Unique resources, especially scientific human capital, allow 
the firm to develop processes to seize R&D paths. Financial resources and capabilities also 
develop along the path of the core technology. Developing novel life science innovations is 
costly  and  requires  specialised  financing.  The  firms  use  their  technological  positions, 
scientific  human  capital  and  founders‟  backgrounds  as  the  positions  to  create  the 
capabilities to secure the capital.  
 
Variation  existed  amongst  the  firms  in  terms  of  the  development  of  their  R&D  and 
financial resources and capabilities and the impact these resources and capabilities had on 
growth. For  example, the relative importance  of industry partners, the firm‟s board of 
directors, networking and raising capital differed substantially. For some of these firms, 
these  paths,  positions  and  processes  proved  important,  whilst  for  others  they  did  not. 
Moreover,  the  exact  set  of  paths,  positions  and  processes  varied  amongst  the  firms. 
However,  what  was  consistent  was  that  the  core  technology,  scientific  human  capital, 
experienced founders and alliances were drivers to the development of R&D and financial 
resources and capabilities. The next chapter discusses the importance of these findings in 
relationship to the literature. 
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Chapter 7 – Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter objectives 
 
  To discuss the findings in relation to the research objectives presented in chapter 4. 
 
  To discuss the theoretical contributions this study made. 
 
  To identify implications for practitioners and policy makers. 
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7.1 Introduction 
This thesis examined the resource and capability development of life science ventures. It 
focused on R&D and financial resources and capabilities, what they are and how they are 
determined and deployed by firms‟ towards growth. Previous work has examined the R&D 
and  financial  resources  and  capabilities  of  life  science  firms,  but  only  a  few  studies 
examine these for new life science ventures. The few related R&D studies mostly focus on 
the role of academic and institutional partners‟ research inputs (Calabrese & Silverman, 
2000; Coombs & Deeds, 2000). As such, they fail to take a holistic view of how early 
R&D resources and capabilities are formulated. In a similar vein, only a few studies look at 
the development of financial resources and capabilities of life science ventures. The few 
previous studies on the topic mainly focus on  finance from a ROI standpoint (Lerner, 
1995; Powell et al., 2002). There is a surprising shortage of studies that investigate how 
life science ventures develop capabilities to build or acquire financial resources. Similarly, 
there are only a handful of studies that probe the role of financial resources and capabilities 
on the development of a firm from a management standpoint; i.e. how financial resources 
and capabilities influence the early growth of a firm.  
 
This chapter presents the findings from this study that are related to the knowledge gaps 
discussed  above.  Implications  for  the  literature  are  first  presented  followed  by  the 
implications for practitioners and policy makers. The chapter is structured as follows: 
 
7.2 Development of R&D and financial resources and capabilities 
7.3 Effect of R&D and financial assets and capabilities 
7.4 R&D and financial interdependence 
7.5 Dynamic capabilities  
7.6 VC and grants 
7.7 Implications for practitioners and policy makers 
7.8 Shortcomings 
7.9 Recommendations for future research 
7.10 Summary and final conclusions 
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7.2 Development of R&D and financial resources and capabilities 
The first research objective of this study was to explore and examine how life science 
ventures develop R&D and financial resources and capabilities. This study used an RBV 
influenced  dynamic  capabilities  perspective  to  examine  this  objective.  The  dynamic 
capabilities literature emphasises that paths, positions and processes are important to the 
development of key resources and capabilities (Teece et. al., 1997; Teece, 2007). Work has 
looked  at  important  resources  and  capabilities  (Arora  &  Ceccagnoli,  2006;  Arthurs  & 
Busenitz, 2006; Freear & Wetzel, 1990), but little work examines the paths, positions and 
processes that lead to the development of key resources and capabilities. Trispas (1997) is 
one of the few studies of note to look at the paths, positions and processes that lead to the 
development  of  key  resources.  However,  this  study  focuses  mainly  on  how  changing 
technology influences the paths of developing key resources. It does not provide great 
depth on the positions and processes and how paths, positions and processes interact to 
create the capacities to develop resources.  The present study examined this. Specifically 
the study looked at the paths, positions and processes that lead to the development of R&D 
and financial resources and capabilities. The development of R&D and financial resources 
and capabilities are divided into sections: 7.2.1 and 7.2.2.  
 
7.2.1 R&D Paths, positions and processes 
The results from this study indicate that life science firms develop R&D resources and 
capabilities along a unique set of paths, positions and processes. This section details the 
main findings of the study related to this.  
 
R&D paths 
The  first  question  related  to  R&D  paths  that  this  study  explored  is  „How  does  an 
innovation affect the development of a firm?’ This question also aimed to explore how the 
source and type of innovation affects the development of a firm‟s R&D.  
 
One of the most prevalent themes presented throughout the analysis is that the innovation 
that a firm pursues dictates the firm‟s R&D trajectories. The firms developed their R&D 
resources and capabilities based on the demands of their core innovation. These demands 
emanated from the type of innovation. Although the case firms are all in the life science 
industry,  the  number,  type  and  focus  of  the  firms‟  innovation(s)  dictated  the  R&D 254 
 
resources  and  capabilities  needed  by  each.  For  example,  the  drug  development  firms‟ 
technologies called for R&D knowledge and capabilities revolving around biochemistry 
research  capabilities;  whereas  BA1  and  MD1‟s  core  innovations  called  for  advanced 
engineering capabilities. This is consistent with the new technology-based firm (NBTF) 
literature,  which  suggests  that  firms‟  inception  and  growth  is  often  based  on  a  core 
technology (Lynskey, 2009; Onetti, Zucchella, Jones, & McDougall-Covin, 2010).  It was 
also evident from the findings that firms that have a more focused innovation are more 
successful in developing their innovation. BA1, BA2 and MD2 focused on mainly one 
innovation  in  the  first  five  years,  and  they  were  able  to  successfully  develop  their 
innovations; whereas MD1, DD1 and DD2 pursued a platform technology that took a lot 
longer to develop, which was largely attributable to the resource shortages that the pursuit 
of several innovations caused. It is evident from the study that a more concentrated R&D 
focus is better for life science ventures, and it is the first proposition the study puts forth: 
 
P1)  Firms  that  have  a  narrower  scope  of  R&D  focus  are  more  successful  in 
commercialising  their  innovations  because  they  are  better  able  to  attain  the  core 
resources and capabilities needed to develop their innovations.  
 
This is an important proposition as it could help life science ventures to understand that it 
is better to focus their R&D. The results of this study indicate that a narrower scope of 
focus  allows  firms  to  fully  develop  an  innovation,  whereas  the  pursuit  of  multiple 
innovations stretches resources and puts firms in great a danger of exhausting resources 
before they have advanced their innovations.   
 
The second R&D path-related question that this study looked at is „Do partnerships have a 
major bearing on the development of R&D and financial resources and capabilities?’ This 
question also looked to see how firms know what they have to offer and how firms know 
what potential partners have to offer. 
 
The analysis clearly indicated that partnerships have a major bearing in the development of 
a  firm‟s  R&D.  This  confirms  the  bulk  of  the  existing  literature;  however,  little  work 
examines  this through a dynamic capabilities or CAs lens. Rothaermel  (2001a, 2001b, 
2005) are major exceptions, as these studies specifically examine alliances and CAs. These 
studies provide much insight on the importance of alliances to developing CAs, but these 
studies did not factor in how partnerships influence the overall R&D paths. The present 255 
 
study  extends  Rothaermel‟s  work  by  providing  depth  on  how  partnerships  cause  life 
science firms to rearrange their scientific base to accommodate their partners‟ R&D inputs. 
For example, BA1 entered into a research partnership with the US government, which then 
dictated the early strategic direction of the firm‟s R&D resources.  The firm  refocused 
almost all of its R&D resources to focus on the co-development project with the Army. 
Not all of the firms were this significantly influenced by partners, but all of the firms had 
partners that impacted the strategic makeup of their R&D. 
 
The study‟s results also indicate that firms identify potential partners from their founders‟ 
networks and the scholarly scientific community. All of the firms had at least one major 
partner  who  emanated  because  of  the  founder‟s  background.  The  founders  knew  what 
partners  had  to  offer  because  of  their  unique  scientific  and  management  experiences. 
Similarly, potential partners know what the firms had to offer because of the backgrounds 
of their founders. For example, BA1‟s founder had previously worked with one of the US 
Army‟s chief scientists, and because of this, the chief scientist knew what BA1‟s founder 
was working on and what its potential was. Similarly, DD1‟s founder had worked with 
their VCF in the past, and because of this the VCF knew what the potential of DD1‟s 
technology was; and DD1 knew what the VCF had to offer. This is supportive of the 
literature, which has also indicated that the founders are important in the development of 
partnerships (Witt, 2004).  
 
In a similar fashion, this study found that scholarly journals and conferences are facilitators 
of partnership. Five of the firms used the scholarly community to help them facilitate R&D 
partnerships. For example, DD1 identified independent researchers doing work on areas 
related  to  their  technology  through  scientific  journals.  Likewise,  MD2  found  two 
universities  doing  research  related  to  their  technology  from  scientific  journals.  The 
journals allowed the firms to identify what these organisations were doing and what they 
could  possibly  offer  in  a  partnership.  Staying  active  in  the  scientific  journals  and 
conference also helped five of the firms in this study gain credibility. Their publications 
and conference presentations let other firms know what they had to offer, and the scholarly 
process they underwent certified their credibility. This is supportive of Zucker and Darby 
(1996)  who  suggest  that  biotech  firms  publish  to  help  them  market  their  products. 
However, the present study extends this finding by showing how scholarship helps firms 
develop credibility. The discussion in this paragraph leads to the second proposition: 
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P2)  Life Science ventures that publish in scholarly journals and attend conferences 
are better able to identify complementary technologies and assess the capabilities of 
potential partners.  
 
This is an important proposition, as the literature has not paid much attention to the role of 
scholarly activity in the development of life science firms. Prior research has noted that it 
is corrleated with higher rates of commercialisation (Zucker and Darby, 1996), but it has 
not shown how this can be an important facilitator of partnerships. Thus this proposition 
has the potential to help life science ventures identify and vet potential partners.  
 
In examining the R&D paths of the firm, an important influence that emerged from this 
study  is  the  importance  of  government  approvals.  Directly  or  indirectly,  government 
approval procedures and regulations influenced the R&D paths of the firms in this study. 
FDA approval proved as one of the largest influences. Most of the firms in this study 
developed products that required FDA approval, and in order to obtain it, the firms had to 
meet compliance and testing standards. This forced the firms to design their R&D around 
gaining  these  approvals,  and  it  forced  the  firms  to  devote  substantial  resources  to  it. 
Studies have noted that the FDA is a major hurdle to life science firms (Grabowski, 2002; 
Olson, 1997), but they have not specifically looked at how these approvals affect a firm‟s 
R&D‟s  strategic  paths.  The  present  study  adds  to  these  by  providing  insight  on  how 
government approvals affect the R&D paths of life science ventures.  
 
Interestingly, FDA approval procedures forced three of the firms from this study down an 
internationalisation path.  The firms sought approval for their products first in European 
markets  because  they  felt  they  could  get  their  products  approved  for  market  more 
efficiently there than they could in the US, an interesting finding because the literature on 
life  science  ventures  does  not  provide  great  insight  on  how  government  approval 
procedures  can  force  life  science  ventures  down  an  internationalisation  path.  The 
internationalisation  literature  puts  forth  that  government  approval  can  influence 
internationalisation (Brewer, 1993), but there is little work that explicitly applies this to life 
science ventures. Thus the third proposition of this study puts forth: 
 
P3) Life Science ventures that internationalise are motivated to do so to avoid FDA 
regulatory  bureaucracy,  and  this  is  forcing  firms  to  develop  resources  and 
capabilities for operating in international markets. 257 
 
 
This proposition is notable because applying for foreign government approvals instead of 
US FDA has a major bearing on a firm‟s development. The literature and industry reports 
have  noted  that  the  propensity  to  outsource  functions  such  as  testing  has  increased 
dramatically in recent years (Giovannetti, 2010); however, it has not shown that firms are 
starting to look first at foreign market government approval instead of US FDA approval. 
Evidence from the present study indicates that firms are now in some cases looking to gain 
foreign market approvals first because these are more streamlined, allowing them to get 
their  product  to  market  quicker.  It  is  also  forcing  the  firms  to  develop  resources 
andcompetencies in operating in international markets. 
 
R&D Positions 
This study found that a number of positions are important to the development of a firm‟s 
R&D.  One  particular  position  that  this  study  is  interested  in  is  key  individuals.  More 
specifically, the fourth research question of the study looked at „Are highly trained, skilled 
and experienced individuals driving the development of R&D and financial resources and 
capabilities?’ This question also aimed to examine whether star scientists are vital to the 
development of life science ventures‟ R&D. 
 
All of the firms in this study‟s R&D revolved around the knowledge and capabilities of an 
individual or small group of individuals. Five of the firms noted the particular importance 
of standout scientists. This is supportive of the life science literature, which suggests that 
star scientists are often the impetus of new life science innovations (Rothaermel & Hess, 
2007; Zucker & Darby, 1996, 2001). However, none of the individuals involved with a 
case firm in this study were in the Science and Technology Agents of Revolution (STAR) 
database. Indexing of individuals in this database is based on a complex set of criteria that 
traces the publishing, patenting and commercial activity of a researcher. This database 
originated from Zucker and Darby (1992) where they identified the top 327 biotechnology 
researchers  and  found  that  firms  who  collaborate  with  these  individuals  have  a  much 
higher rate of commercialising innovation. Whilst their findings were profound and have 
been well supported (Zucker & Darby, 2001; Zucker et al., 2002; Zucker et al., 1998), and 
star scientists do account for a statistically significant amount of innovation, overall they 
only  account  for  a  small  percentage  of  life  science  innovation  (Higgins,  Stephan,  & 
Thursby, 2011).  
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The findings from the present study extend the work done by Zucker and Darby (1992) by 
suggesting that standout scientists, not necessarily star scientists, play a key role in the 
development  of  life  science  firms.  The  present  study  identifies  standout  scientists  as 
individuals who have scientific achievements in the top five percent of all scientists, but 
are not in the elite .005% of the scientists in the world as defined by the Zucker and Darby 
(2011) STAR database. Four of the firms in this study had founders or employed scientists 
who were highly noted in the field but were not in the STAR database. For example, 
BA2‟s co-founder was named by The American Chemistry Society in 2010 as one of the 
top fifty researchers in chemistry. Similarly, DD2‟s founder holds seven patents and is 
noted  in  several  publications  as  one  of  the  leading  experts  in  snake  venom.  These 
individuals drove the R&D capabilities of these firms. The last two paragraphs discussion 
leads to proposition four: 
 
P4) Firms that employ one or more standout scientist are better able to develop 
R&D resources because of the standout scientist(s) R&D capabilities and scientific 
contributions. 
 
This proposition is significant, as it has already been noted that star scientists are driving 
innovation. However, star scientists still only account for a small percentage of life science 
innovation. Evidence from the present study suggests that standout scientists are having a 
profound impact on the R&D of life science ventures, and could possibly account for a 
large  portion  of  innovation  in  the  industry.  For  this  reason,  a  more  inclusive  ranking 
system needs to be constructed to capture the impact of standout researchers – not just the 
elite star scientists that represent less than .005% of the scientists in the field (Higgins et 
al., 2011). Such a scale could help firms understand what is driving the development of 
new innovation; it could help firms in identifying standout researchers; and it could also 
help investors in the evaluation of life science firms.  
 
Another interesting finding of this study is the importance of foreign-born and trained 
scientists.  Four  of  the  firms  employed  foreign-born  and  foreign-trained  scientists  who 
played  key  roles  in  the  development  of  their  technology,  and  it  is  evident  that  these 
scientists also made key contributions to the R&D positions of the firm. These scientists 
provided insights based on their overseas training and research that were invaluable to the 
development  of  their  firms‟  technologies.  This  finding  is  consistent  with  the 
internationalisation and NBTF literatures, which suggest that foreign-born employees are 259 
 
often  a  central  asset  to  a  firm‟s  growth  and  internationalisation  (Portes,  Guarnizo,  & 
Haller, 2002; Saxenian, 2002). Whilst this finding is more supportive than novel, it is 
novel in its extension to a dynamic capabilities framework; i.e. foreign-born employees 
can  be  an  important  position  to  the  development  of  a  firm‟s  R&D  resources  and 
capabilities.  
 
R&D Processes 
The fifth research question of this study looked at „What processes are vital to creating 
R&D resources and capabilities?’ 
 
The  dynamic  capabilities  literature  underscores  several  processes  that  lead  to  the 
development of capabilities. Sensing opportunities is a higher-level process identified in 
the literature (Teece, 2007). In an in-depth study on the IBM Corporation, Harreld and 
Tushman (2007) found that sensing opportunities is a dynamic capability that IBM has 
developed,  and  it  has  been  one  of  the  firm‟s  main  sources  of  competitive  advantage. 
Similarly, Trispas and  Gavetti  (2000)  in  an in-depth  study of the Polaroid  corporation 
found that sensing new technological opportunities was an important dynamic capability 
that the firm developed, and this has been one of the firm‟s main competitive advantages. 
In a similar vein, Kaplan, Murray and Henderson (2003) take an in-depth statistical look at 
fifteen pharmaceutical  firms‟ TMTs‟ ability to  recognise scientific opportunities. Their 
findings suggest that sensing is clearly an important routine. The present study‟s results 
support these studies and extend these findings to life science ventures. Specifically, the 
results indicate that the ability to sense and seize scientific opportunities is important to the 
development of R&D resources and capabilities of a life science venture. All of the firms 
identified  a  core  innovation  to  develop,  and  the  ability  to  identify  a  technology  that 
presented both scientific and market potential provided an impetus to the firms‟ growth. 
The  firms  identified  a  technology  and  then  assessed  the  development  it  needed  and 
whether or not the technology could realistically be developed; i.e. did the firm have the 
capabilities and resources to accomplish this. The firms in this study excelled in this area, 
and this was an important driver to their growth.  
 
Learning is perhaps the most cited dynamic capability in the literature. Numerous authors 
emphasise the importance of learning processes (Eisenhardt & Martin, 2000; Romme et al., 
2010; Winter, 2000; Zollo & Winter, 2002). Accordingly, firms learn from their past paths 
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them. The present study’s findings suggest that learning from earlier research paths is 
vital to the development of R&D resources and capabilities. All of the firms learned from 
their  earlier  paths  and  used  this  knowledge  to  further  the  development  of  their 
technologies. In particular, the firms learned how to use their research setbacks to advance 
their technology. For example, MD1 suffered several failed developments, but the firm 
established  processes  for  dissecting  the  reason  for  the  setbacks  and  then  used  this 
information to find ways to overcome them.  
 
This study also finds that in small life science ventures learning processes transpire at the 
network, firm and individual levels. Most of the firms in this study had partners that they 
learned from on joint research projects. Moreover, all of the firms in this study practiced 
inter-organisational  learning;  i.e.  employees  from  within  the  firm  worked  together  to 
acquire new knowledge. Learning prevailed most evidently at the individual level for the 
firms in this study. All of the firms employed researchers who worked independently and 
acquired new scientific knowledge based on their individual work. Previous studies have 
indicated that key individuals are often the source of learning (Cohen, 1991; Rothaermel & 
Hess,  2007).  The  present  study  extends  the  importance  of  individuals  to  the  learning 
process of life science ventures.  
 
The  third  process  this  study  found  vital  to  the  development  of  R&D  resources  and 
capabilities is partnering. This is supportive of earlier research that suggests that firms 
secure important inputs through alliances and partnerships (Das & Teng, 2000; Eisenhardt 
&  Schoonhoven,  1996;  Haeussler  et  al.,  2010).  Furthermore,  networking  is  a  dynamic 
capability that firms can derive competitive advantages from (Blyler & Coff, 2003; Mort & 
Weerawardena, 2006). The present study’s results confirm this and extend it to innovative 
life science ventures. This study‟s findings also support the idea that partnerships can stem 
from  many  different  places  such  as  past  business  dealings,  personal  friendships  and 
scholarly journals (Harris andWheeler, 2005; Hite and Hesterly, 2001; Hsu, 2007). 
 
A fourth important set of processes that surfaced as important to the development of R&D 
resources and capabilities revolved around integrating new knowledge. All of the firms 
took in new knowledge into their operations that they synthesised into their research. Their 
capabilities to use this knowledge underpinned their ability to progress their technology. 
This  finding  supports  absorptive  capacity  as  a  dynamic  capability  that  firms  derive 
competitive  advantages  from  (Deeds  et  al.,  2000;  Zahra  &  George,  2002).  This  is  an 261 
 
important  finding  as  it  provides  needed  empirical  support  to  absorptive  capacity  as  a 
dynamic  capability.  Previous  studies  have  established  this  a  source  of  competitive 
advantage (Cockburn & Henderson, 1998; Lane & Lubatkin, 1998) and have alluded that 
absorptive capacity can be viewed as a dynamic capability, but few studies have directly 
offered support to absorptive capacity in a dynamic capabilities framework; the present 
study does so. 
 
As the discussion above indicates, the results suggest that firms rely on a combination of 
processes to create their R&D resources and capabilities. Processes relating to sensing, 
learning, partnering and integrating proved important to all of the firms.  
 
7.2.2 Financial paths, positions and processes  
For the most part, generic financing has not been available to the firms in this study, which 
is no surprise as start-up life science firms are limited in their funding sources because of 
their risky nature (P. Gompers & Lerner, 2001). In order to develop the needed financial 
resources, the firms leveraged a unique set of paths, positions and processes. 
 
Financial paths 
The first research question looked at „How does an innovation affect the development of 
firms’ resources and capabilities?’ This question also looked at how the source and type of 
innovation affects the financial demands of firms. 
 
Financing is an important path to the growth of life science ventures. Often these firms 
develop  an  innovative  technology  that  is  costly  to  develop  (Colombo &  Grilli,  2009). 
Furthermore,  technology  takes  extensive  time  to  develop,  and  firms  go  years  without 
revenues  whilst  the  technology  is  being  developed  (Zucker  et  al.,  2002).  This  makes 
specialised high-risk capital germane to the development of life science ventures (Baum & 
Silverman,  2004).  All  but  one  of  the  firms  in  this  study  used  a  form  of  specialised 
financing, and the decision to use specialised financing stemmed from the large amount of 
capital that was needed to pursue the development and commercialisation of a novel life 
science innovation. Thus this study supports other research which shows that the novel 
innovation that life science firms pursue is costly to develop (Chakma & Sammut, 2011). 
Evidence from the study also suggests that the type of innovation has a profound effect on 
a firm‟s financial demands.  Furthermore, the study suggests that firms looking to pursue 262 
 
larger scale innovation have more financial difficulties. The three firms (DD1, DD2 and 
MD2) that pursued several innovations had to devote substantial time and resources to 
developing the financial resources needed to fund several different projects. This distracted 
from the scientific activities of the firms. Moreover, it also stretched the financial resources 
of the firms and made all three of the three firms terminate at least one of the innovations 
they were developing. In contrast, MD1, BA1 and BA3 narrowly focused on one type of 
innovation  and  were  able  to  successfully  develop  their  product  largely  because  their 
financial resources were not stretched across several major projects. From this discussion 
proposition five is put forth: 
 
P5)  Life  science  ventures  that  attempt  to  develop  several  innovations 
simultaneously  develop  slowly  and  risk  failure  as  they  create  large  financial 
requirements. 
 
The  third  research  question  looked  at  „How  does  the  pursuit  of  financing  impact  the 
development of life science ventures?’ It was specifically interested in how the financial 
strategies of firms affect their financial trajectories. 
 
The  results  indicate  the  financial  strategies  of  the  firms  have  a  major  bearing  on  the 
financial trajectories of a firm. All of the firms followed a unique financial strategy. Two 
of the firms (BA2 and MD1) made the choice to self-finance their early growth, which 
influenced the investments that could be made; i.e. it limited the funds that the firms had 
available to invest in the development of their technology. On the other hand, this choice 
freed them from having to devote resources to prospecting for capital and dealing with 
investors. In comparison, three of the firms relied heavily on outside investors for capital. 
These investors supplied large sums of capital, but raising this capital and dealing with the 
investors significantly affected the firm‟s operations. Studies have examined the financial 
strategies of new ventures (Freear & Wetzel, 1990; Van Auken, 2001; Willoughby, 2008). 
However, these studies have not provided deep insights on the long term effects of a firm‟s 
early  financial  strategies.  Based  on  the  findings  from  the  present  study  the  following 
proposition is put forth: 
 
P6) Firms that self-finance their growth will have significantly different financial 
trajectories than firms that pursue equity investors, as they will have less capital 
available, but will maintain greater organisational flexibility.   263 
 
 
This  is  a  notable  proposition  because  rigidities  are  created  from  the  early  financial 
strategies,  and  these  limit  the  financial  choices  available  to  firms  in  the  future.  For 
example, DD1 and DD2‟s public stock offering committed them to substantial government 
regulations, which consumed significant time from the firms‟ TMTs. In hindsight, both 
firms would have liked to have reversed their decisions to go public, but it was a decision 
that  they  could  not  change.  Conversely,  BA1  pursued  government  grants  that  did  not 
commit the firm to a stratified financial path. This allowed the firm more flexibility in its 
future financial options. 
 
Financial positions 
The  second  research  question  explored  „Are  highly  trained,  skilled  and  experienced 
individuals driving the development of resources and capabilities?’   
 
The results clearly indicate that founders provide important resources that feed into the 
development  of  the  firm‟s  financial  resources  and  capabilities.  All  of  the  firms  relied 
heavily on their founders‟ background to develop their financial resources and capabilities. 
For  example,  DD2‟s  founders‟  network  provided  access  to  important  financing 
opportunities.  The  firm‟s  founder  had  previously  worked  with  VCs,  and  these  past 
experiences  aided  them  in  securing  financing.  DD1,  MD2  and  BA1‟s  founders  also 
provided an important position that the firms used to „sell‟ the financiers on investing in 
the firm. The most extreme examples of this from this study are DD2 and MD2. Both of 
these firms‟ founders were famous in their respective fields, and because of this name 
recognition,  the  firms  attracted  significant  investor  interest.  Put  differently,  investors 
wanted to invest in these firms because of the founders‟ successful track records. This 
finding  is  supportive  rather  than  unique  as  several  studies  note  the  importance  of  the 
founder‟s background to raising capital (Colombo et al., 2004; Sengupta, 2011; Storey & 
Tether, 1998). The findings also show that founders do not have to have experience in 
running a life science firm to successfully raise capital. BA2 and MD2 founders had no 
business  experience  but  were  still  able  to  develop  the  financial  resources  needed  to 
progress their innovation towards a state of commercialisation.  
 
It is evident from this study that the background and experience level of the founder(s) 
impacts the financial strategies of a firm. The two firms with inexperienced founders, BA2 
and MD2, initiated the venture on a self-financing path mainly because they did not have 264 
 
knowledge or contacts to pursue other financing routes. In comparison, BA1‟s founder was 
highly experienced in using government grants to finance new life science ventures, and 
thus he pursued this route for financing BA1‟s growth; whereas, DD1, DD2 and MD2‟s 
founders were experienced in attracting and working with equity investors and for this 
reason used VCs and private investors to incubate their new ventures. The discussion in 
this section leads to proposition seven: 
 
P7) Inexperienced founders are more likely to  self-finance their venture‟s early 
growth, as opposed to experienced founders who use their background to secure 
financial resources from outside sources.  
 
Another  resource  that  this  study  found  important  to  financial  resources  is  the  firms‟ 
technology. The firms leveraged their technical assets and capabilities to develop their 
financial  resources  and  capabilities.  Almost  all  of  the  firms  displayed  advanced 
technological  knowledge  and  skills  that  helped  attract  specialised  finance.  Previous 
research  on  early  stage  financing  indicates  technological  capabilities  are  important  to 
raising capital (Gompers & Lerner, 2001; Kollmann & Kuckertz, 2009), so this is more 
supportive than novel. However, the findings from the present study add fresh insights to 
this by showing that technological knowledge in some cases helps firms attract alternative 
forms of investment. BA1 and BA2 used their technology to win government grants.  The 
reason the government awarded the firms the grants is because the firms‟ technologies 
showed promise to help solve a problem that the government wanted to address. 
 
Financial processes 
The fifth research question this study explored is „What processes are vital to creating 
R&D and financial resources and capabilities?’ 
 
The R&D of life science firms is costly. This makes raising capital a vital process for new 
technology-based  firms  (Colombo  &  Grilli,  2009).  The  results  from  the  present  study 
indicate that sensing and seizing funding opportunities are important processes. Several of 
the firms in this study relied on routines related to identifying, meeting and negotiating 
with  investors.  These  routines  allowed  these  firms  to  raise  the  capital  they  needed  to 
pursue  the  development  of  their  innovation.  For  DD1,  DD2  and  MD2  these  routines 
consistently proved important, but all of the firms in this study, except MD1, developed 
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a number of sources; VCs, private investors, public stock markets and government grants.  
This study also supports that these processes are driven by one or two individuals from a 
firm. In all but one of the cases in this study the founder or founders drove this process and 
provided the primary inputs into sensing and seizing funding opportunities.  
 
A second suggestion from this study is that processes related to integrating and conserving 
financial resources are vital processes to life science ventures. Almost all of the firms ran 
into troubles forecasting the development costs of their R&D. DD1, for example, started to 
develop a new application for its technology, and it ended up costing much more than the 
firm originally budgeted for. Consequently, the firm went through its initial capital quicker 
than  expected.  Similarly,  MD2  spent  three  times  the  anticipated  amount  on  the 
development  of  their  technology.  At  one  point  or  another  all  of  the  firms  ran  into 
budgeting issues. For this reason it proved important for all of the firms to create routines 
for closely monitoring their spending. Whilst this is not a fresh finding, it is supportive of 
previous work that indicates budgeting is an important process for new ventures (Braden, 
1993; Freear & Wetzel, 1990). 
 
Closely  related,  this  study  finds  that  routines  for  conserving  capital  are  vital  to  the 
financial endowments of the firms. The firms in this study were financially restrained, and 
for this reason all but one of the firms developed advanced systems for cutting costs. Some 
examples of these routines included finding the lowest cost inputs, developing partnerships 
to obtain low cost or free inputs and cutting out operations that were not essential.  It is 
evident from this study that strategic cost cutting is a capability that is vital to the financial 
picture of young life science firms. This finding is in line with previous work that has 
shown how cost cutting is essential to the financial strategies of young ventures (Auken, 
2005; Winborg & Landstrom, 2001). 
 
A third set of processes the present study found important relate to IPOs. DD1 and DD2 
went  public  on  a  US  stock  exchange.  This  was  primarily  motivated  by  a  need  for  a 
substantial sum of capital that was the result of the development of costly innovations.  In 
order to go public, the firms engaged in a number of processes. First, the firms completed 
substantial amounts of legal paperwork with the SEC. The TMTs of these firms spent 
hundreds of hours working with their teams of lawyers to ensure everything was properly 
documented as well as meeting with publicists to promote the stock offering. This included 
meeting with reporters and attending SEC events. The firms also developed systems for 266 
 
reporting their financial and operational issues to the SEC, which was a significant burden 
on the firms as it consumed a substantial amount of the TMTs‟ time. It also forced the 
firms to develop a compliance team to gather the information needed for the SEC.  
 
The findings related to the processes involved with the public stock offering are not new. 
Studies  indicate  that  processes  related  to  public  offerings  consume  vast  amounts  of 
resources  (Dona  &  David,  1997;  Ibbotson,  Sindelar,  &  Ritter,  1988;  Poulsen  & 
Stegemoller, 2008). In particular, firms invest massive amounts of time and resources in 
the filing and marketing of their stock offering. Research also suggests that the capital 
raised is  often not  worth the resources  exerted  (Aggarwal  & Rivoli,  1991;  Poulsen & 
Stegemoller, 2008). However, this research has not gone into great depth on this.  The 
present study‟s findings extend this work by showing that the public offering is a resource 
drain  that  detracts  from  a  firm‟s  operations  because  of  the  tremendous  amount  of  the 
TMTs‟ time that is consumed. From this the eighth proposition of the study is put forth: 
 
P8) IPOs consume valuable time from top management teams, and managers that 
spend less time on IPOs are better able to help their firms develop  operational 
resources.  
 
As the discussion in this section indicates, the results widely support that firms rely on a 
combination of processes to create their financial resources and capabilities.  Processes 
relating to sensing, seizing, integrating and conserving capital proved important to all of 
the firms.  
 
7.3 The effect of R&D and financial assets and capabilities  
The  second  objective  of  this  research  is  to  examine  the  effect  of  R&D  and  financial 
resources and capabilities on the early growth of life science ventures. This study carefully 
investigated how these resources and capabilities formulate, and how these help firms in 
early growth. This section overviews the importance of R&D and financial resources and 
capabilities to early growth.  
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7.3.1 Effect of R&D resources and capabilities 
The sixth research question of this study from an R&D perspective looked at „How are 
R&D resources integral to life science ventures?’ 
 
Results from this study strongly indicate that R&D resources and capabilities are vital to 
the  early  growth  of  innovative  life  science  ventures.  These  resources  and  capabilities 
provided a leverage point from which to attract and develop other resources. The R&D 
resources  consisted  of  the  firms‟  research  facilities,  patents,  employees  and  networks. 
Whilst  the  firms‟  R&D  capabilities  consisted  of  their  abilities  to  sense  and  seize 
opportunities, learn from previous research paths, network, integrate new resources into 
their research, and the capabilities of transforming their R&D resources. In sum, these 
resources and capabilities provided important competitive positions that allowed the young 
resource constrained firms examined in this study to compete in a high velocity industry; 
these can be viewed through the VRIN framework.  
 
First, R&D resources and capabilities are valuable. The results of this study definitively 
indicate that R&D resources and capabilities are of high worth. The R&D resources and 
capabilities of the firms in this study allowed the firms to develop products with high 
market values. This finding is supportive of the R&D literature, which indicates that most 
valuable new products and services are the result of R&D (Cassiman & Veugelers, 2006; 
Cohen & Levinthal, 1989; Sampson, 2007). Second, R&D resources and capabilities are 
rare. The R&D resources and capabilities of the firms in the present study are not readily 
available as they are closely linked to the particular skills and knowledge of individuals. 
Each of the firms possessed resources and competencies which few firms in the world 
possess. This is supportive of the R&D literature, which shows that advanced research 
abilities are rare (Liao, Wang, Chuang, Shih, & Liu, 2010; Pisano, 1990).  
 
Third, the R&D  resources and capabilities of the firms  in  this  study  were imperfectly 
imitable. This is most apparent in the fact that all of the firms held multiple patents, and 
legally patents cannot be perfectly imitated (Markman, Espina, & Phan, 2004). Moreover, 
all of the firms held tacit research knowledge and processes that could not be imitated. 
Fourth, R&D resources and capabilities are non-substitutable. The firms in this study could 
not  substitute  their  R&D  resources  and  capabilities.  The  progression  of  the  firms‟ 
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that the firms could use in place of these to develop the state of the art technologies that 
they were pursuing.  
 
It is apparent from the discussion in this section that R&D resources and capabilities are 
vital to the early development of life science ventures.  
 
Complementary assets 
The seventh and eighth questions of this study pertained to CAs: 7) Can R&D resources 
and capabilities serve as a CA? And 8) Can R&D resources and capabilities serve as 
SCAs? 
 
This study offers support of R&D resources as a category of CAs for life science ventures. 
Teece  (1986)  suggests  that  complementary  technology  is  a  category  of  CAs;  i.e. 
technologies  that  go  along  with  the  core  technology  that  a  firm  is  attempting  to 
commercialise. Similarly, Gans et al. (2002) suggest that the research resources needed to 
get through government approval is a category of CA. Moorman and Slotegraaf (1999) 
discuss product development capabilities and allude to R&D as a potential category of CA. 
Similarly, Lowe and Taylor (1998) allude to R&D as a CA, but do not explicitly call R&D 
a CA. The results from the present study support R&D as a unique category of CA. R&D is 
an auxiliary set of resources and capabilities that allows a firm to progress an innovation 
towards a state of commercialisation.   
 
The present study also found that R&D resources and capabilities can be viewed through a 
SCAs lens. SCAs are specialised auxiliary resources and capabilities that are needed to 
commercialise an innovation (Teece, 1986). An example of an SCA is service capabilities 
of  a  medical  device  firm.  In  many  cases  medical  devices  require  specialised  service 
capabilities to maintain the product, and if a firm is unable to service the device, then the 
device  cannot  be  commercialised.  These  capabilities  are  such  that  they  require 
sophisticated and often tacit knowledge that cannot easily be replicated. Several studies 
have noted R&D as a CA, but few of studies have explored whether R&D is an SCA. The 
present study extends this by examining whether R&D resources and capabilities can serve 
as SCAs. In general, the firms in the present study required auxiliary R&D resources and 
capabilities that were highly specialised. These  were  capabilities that few firms  in  the 
world  possessed,  and  they  were  needed  to  get  the  firms‟  innovations  to  a  point  of 
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The discussion in this section indicates that R&D resources and capabilities can serve as a 
CA and SCA, and that these are important resources to the development of life science 
ventures. Thus proposition nine puts forth: 
 
P9)  Life  science  ventures  with  advanced  R&D  complementary  assets  are  more 
successful in brining their innvotations to market, as the R&D complementary assets 
allow them to progress their innovations to a point of commercialisation.  
 
This proposition is significant as R&D has been alluded to as a CA, but it has not been 
directly offered. Furthermore, R&D has not been viewed through an SCA‟s lens. The CA‟s 
model  emerged  to  explain  the  auxiliary  assets  and  capabilities  needed  in  the 
commercialisation  of  an  innovation  (Taylor  &  Helfat,  2009;  Teece,  1986).  Thus  this 
finding is significant, as it supports this model and extends it by fortifying R&D as a CA 
and it extending R&D as an SCA.  
 
7.3.2 Effect of financial resources and capabilities 
The sixth research question of this study from a financial prospective looked at „How are 
financial resources integral to life science ventures?’ 
 
Results from this study indicate that financial resources and capabilities are vital to life 
science ventures. The firms‟ financial resources consisted mainly of their capital reserves 
and access to financial networks, whilst the firms‟ financial capabilities consisted of their 
abilities to sense and seize funding opportunities, network with financiers, conserve capital 
and work with financiers. These capabilities led to specialised financing in the forms of 
VC investment, IPO, unique investment funds and government grants. This specialised 
financing provides important competitive positions that can be viewed through the VRIN 
framework (Barney, 1991). 
 
First, specialised finance is valuable. This study clearly indicated that specialised financing 
is a precious commodity that is paramount to a life science venture‟s early growth. Second, 
specialised  financing  is  rare.  Financing  for  life  science  ventures  is  hyper-competitive. 
There are three thousand young life-science firms in the U.S, and yet there are only a 
handful of VCs that specialise in life science investments (BIO, 2010). Furthermore, the 270 
 
firms in this study are so specialised that there were only a handful of financiers that would 
consider investing in their technologies.  
 
Third, specialised finance is imperfectly imitable. Whilst, most of the firms in this study 
could  have  received  the  needed  capital  from  other  sources,  the  paths,  positions  and 
processes that the firms leveraged to develop the capabilities to get the financing are in-
imitable. Fourth, specialised financing is non-substitutable. Specialised financing proved 
absolutely critical to the growth of all of the firms. A couple of the firms reduced the 
amount of specialised financing they needed. For example, BA1 limited the capital needed 
because their abilities to outsource important functions to partners for a minimal capital 
outlay. However, BA1, as well as the other firms in this study, could not completely find a 
substitute for the specialised financing their technology demanded.  
 
It is apparent from the discussion in this section that financial resources and capabilities 
are vital to the early development of life science ventures. Financial capabilities create 
competencies  that  allowed  the  firms  to  secure  the  needed  capital  for  the  firms‟ 
development. In general, these competencies were a source of competitive advantage, as 
the case firms out competed scores of other firms for capital. Moreover, in some cases the 
financiers contributed more than just capital, which also fed into the competency base of 
the firms. These contributions are discussed in further detail in section 7.6.  
 
Complementary assets 
The  seventh  and  eighth  questions  of  this  study  pertained  to  CAs,  (7)  ‘Can  financial 
resources and capabilities serve as a CA and (8) can financial resources and capabilities 
serve as a SCA?’ 
 
Early  stage  financing  of  high  technology  firms  is  well-researched  (Colombo  &  Grilli, 
2009; Davila, Foster, & Gupta, 2003). However, no research of note looks at financial 
resources  and  capabilities  through  a  CA‟s  lens.  Most  of  the  research  focuses  on  the 
processes of raising VC (Dimov & Milanov, 2010; Kollmann & Kuckertz, 2009) and the 
management contributions of the VCs (Gompers & Lerner, 2001; Gorman & Sahlman, 
1989). Although the extant research does not explicitly look at finance through a CA‟s 
lens, financing lends itself to being a CA. From a definitional standpoint, it is an auxiliary 
asset needed for the commercialisation of an innovation (Rothaermel, 2007; Teece, 1986; 
Trispas, 1997). Results from the present study support this idea by showing that financial 271 
 
resources and capabilities are auxiliary resources and capabilities that complement other 
important assets. Some scholars may argue that finance is a core function, and therefore it 
is not a CA. But under this logic any category of CA offered in the literature could be 
considered as such. Furthermore, results from the present study suggest that financing for 
life science ventures is much more entailed than just being a source of capital. Certainly 
the capital is needed, but financing is much more encompassing than just being a proxy or 
a  transactional  tool.  The  capital  is  a  generic  asset,  but  capabilities  in  raising  capital, 
working with specialised financiers and conserving capital was displayed by all of the 
firms in this study. 
 
In  certain  cases  these  financial  capabilities  are  an  SCA;  they  are  specialised  auxiliary 
resources and capabilities needed in the commercialisation of an innovation that cannot be 
easily developed or contracted for (Teece, 1986). For example, DD2 and MD2 developed 
an innovation and successfully brought it to market largely because of their specialised 
financial  capabilities.  Another  example  of  specialised  financial  capabilities  are  BA1‟s 
capabilities to conserve capital and to operate on a lean budget. All of the firms displayed 
specialised financial capabilities that proved instrumental to advancing their innovations 
towards a state of commercialisation.  
 
The discussion in this section indicates that financial capabilities can serve as CAs and 
SCAs, which leads to the tenth proposition: 
 
P10) Firms that recognise the complementary and potentially specialised nature of 
finance  and  proactively  manage  these  assets  in  relation  to  their  R&D  are  more 
successful in brining their innovations to a point of commercialisation. 
 
This proposition is significant, as financial capabilities have not been viewed through a 
CA‟s lens. Thus this finding extends the CAs model by offering a new category. The 
purpose of the CAs model is to offer an analytical tool for examining the auxiliary assets 
and capabilities needed in the commercialisation of an innovation (Teece, 1986). Findings 
from this study indicate that by ignoring financial capabilities, the CA model is missing an 
important  set  of  auxiliary  capabilities  that  are  important  to  the  commercialisation  of 
innovation.  
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7.4 R&D and financial interdependence 
This  study  was  particularly  interested  the  bilateral  dependence  of  R&D  and  financial 
resources and capabilities. Questions 6a and 6b addressed this: 6a) How closely linked are 
R&D and financial resources and capabilities and 6b) Do R&D and financial resources 
co-evolve? 
 
The literature notes the interdependence of R&D and finance to the growth of NTBFs 
(Chakma & Sammut, 2011; Colombo & Grilli, 2009). However, it does not emphasize the 
interdependence of these in the development of life science ventures. From this study it 
emerged that there is a bilateral dependence between R&D and finance. This is supportive 
of the growth literature, which suggests that at or near inception developing a product and 
securing financing are the two main focuses of start-up technology firms (Delmar et al., 
2003; Kazanjian & Drazin, 1990).  
 
Results from the present study suggest that the core technology and R&D potential of the 
firm  are  instrumental  in  attracting  specialised  investment  which  comes  primarily  from 
specialised  sources  such  as  VC  or  grants;  which  concurs  with  other  studies  (Baum  & 
Silverman,  2004;  Colombo  &  Grilli,  2009;  Timmons  &  Bygrave,  1986).  The  present 
study‟s findings underscore the fact that specialised investment is not easily raised and that 
unique  capabilities  lead  to  the  acquisition  of  specialised  investment.  The  specialised 
funding is paramount to developing a research infrastructure. Firms use the capital to hire a 
research  staff,  build  research  facilities,  pay  for  testing  and  buy  complementary 
technologies. In turn, these R&D resources and capabilities help develop a product which 
helps attract additional investment.  
 
The results from this study indicate that R&D and financial resources and capabilities are 
interconnected; i.e. financial paths and positions influence R&D paths and positions and 
vice versa. This is not a surprise as previous work has shown that finance is critical to the 
start-up of life science firms (Davila et al., 2003; Hellman & Puri, 2000), and work has 
also shown that R&D is the impetus to new technology-based firm growth (Autio, 1997; 
Gubeli  &  Doloreux,  2005).  However,  these  studies  have  merely  noted  that  financial 
resources and capabilities pay for R&D. The present study’s results indicate that R&D and 
financial resources and capabilities have paths, positions and processes that influence one 273 
 
another  and  are  inextricably  linked.  More  specifically,  the  present  study  shows  that 
financial resources are largely dependent R&D resources and vice versa.  
 
A detailed overview of this was discussed in chapter six, and Figure 7-2 below presents a 
simplified model of this. The model depicts that the core innovation that a firm pursues 
feeds into the R&D (1a) and financial (1b) resources and capabilities of the firm. The core 
innovation dictates how much development the innovation needs and how much capital is 
needed. In turn, the R&D and financial resources and capabilities feed into each other (2). 
The financial resources and capabilities fund the development of R&D, and developments 
in R&D attract additional funding. In turn, progressions in finance and R&D perpetuate the 
innovation  towards  a  state  of  commercialisation  (3a  and  3b),  and  ultimately  the 
progressions in the technology perpetuates the firm‟s growth (4).  
 
 
Figure 7-1: Model of R&D and financial interdependence 
 
Source: Author 
 274 
 
 
As the discussion above indicates, this study found clear evidence that there is a strong bi-
lateral dependence between R&D and finance in life science ventures, and the co-
development of R&D and financial resources are critical to the early growth of life science 
ventures. From this proposition eleven is put forth: 
 
P11) There is a co-specialised relationship between R&D and financial resources 
and these co-evolve throughout the growth process of life science ventures, and 
firms that are adept at co-developing these resources are more successful in 
commercialising their innovations. 
 
7.5 Dynamic capabilities and RBV 
This study took a RBV influenced dynamic capabilities framework to look at the research 
questions,  and  in  doing  so  the  study  made  some  important  contributions  to  dynamic 
capabilities and the RBV. Most notably, it contributes to Helfat‟s (2009a) call for deep 
empirical work on dynamic capabilities. Accordingly, the theory is still in its nascent phase 
of development and needs deep work to extend it. One of the major contributions of the 
present study is showing an output of dynamic capabilities – R&D and financial resources 
and  capabilities.  Results  from  the  study  indicate  that  a  life  science  firm‟s  ability  to 
reconfigure its resources and capabilities leads to the development of R&D and financial 
resources and capabilities. All of the firms in this study faced large resource constraints 
and  competed  against  large  established  competitors,  yet  all  these  firms  successfully 
developed and brought their innovations to a point of commercialisation. The analysis in 
chapter five underscored several dynamic capabilities that allowed the firms to develop the 
key resources needed to compete in such a competitive environment.  
 
All  of  the  firms  leveraged  a  unique  set  of  paths,  positions  and  processes  to  develop 
capabilities that resulted in the development of key resources. To represent this, Figure 7-2 
presents a dynamic capabilities framework of how the case firm BA1 developed its key 
R&D and financial resources.  
 
The firm was presented an opportunity to develop a novel device for analysing biological 
materials, which established the main course of the firm. A second path that profoundly 
affected the firm was the establishment of a key partnership with the U.S Army. This 275 
 
relationship  provided  critical  R&D  and  financial  inputs  that  that  influenced  the 
development of the firm‟s key resources. The third major path that influenced the firm‟s 
strategic course was the decision not to take in equity invesement. This limited the scope 
and speed of the development of the firm‟s key resources, but it also allowed the firm to 
maintain flexibility, which allowed the firm to stay dynamic.  
 
The second box in Figure 7-2 depicts the three most important positions (resources) that 
BA1 leveraged in order to pursue its paths. The most prominent position was the founder. 
He directly contributed to the R&D and financial resources of the firm. From a financial 
standpoint, he invested his  own capital  in  the firm,  and from  an R&D standpoint, his 
scientific knowledge and capabilities allowed the firm to progress their technology. He 
also indirectly contributed resources, in that his background helped attract inputs from 
other  organisations.  For  example,  the  U.S  Army  contributed  substantial  scientific 
knowledge  to  BA1,  and  the  reason  the  Army  worked  with  BA1  is  because  of  the 
longstanding relationship BA1‟s founder had with the Army‟s chief scientist. The second 
position that the firm leveraged was their network position. The firm was well networked 
and used this to obtain key inputs. The third position that the firm relied heavily on was 
their technology. Their unique device was of interest to several prominent organisations, 
and the firm leveraged this to obtain key inputs.  
 
The third box in Figure 7-2 shows that the firm developed and practiced several processes 
(routines) in order to maximise its paths and positions. One of the most important routines 
to BA1 was sensing and seizing opportunities. The central reason the firm successfully 
developed their device stemmed from their abilities to discover scientific opportunities. 
The founder established the firm based on three different sciences that he sensed out. Then 
on  an  ongoing  basis  the  firm  constantly  sensed  and  seized  science  that  helped  in  the 
development of their device. A second process that the firm relied on related to conserving 
resources.  The  financial  and  scientific  capital  available  to  BA1  was  limited.  For  this 
reason,  strategically  using  and  conserving  these  resources  was  critical  to  the  firm‟s 
development. Learning is a third process that proved important to BA1‟s ability to develop 
key resources. For example, the firm constantly learned from its earlier research. It also 
learned  from  its  earlier  financial  decisions  and  interactions  with  partners.  In  turn,  this 
learning greatly aided in the development of the firm‟s key resources. 
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The last box in  Figure  7-2 shows the output of the firm‟s dynamic capabilities. From 
leveraging  its  paths  and  positions  the  firm  created  processes  that  led  to  important 
capabilities.  In  turn,  these  capabilities  led  to  the  development  of  advanced  R&D  and 
financial  resources,  which  proved  critical  to  the  firm‟s  ability  to  compete  in  an  ultra 
competitive  industry.  More  specifically,  the  firm  developed  patents,  tacit  and  unique 
scientific knowledge, financial endowments,  partnerships  and a unique technology that 
allowed the firm to carve out a position in the market.   
 
Although the firms differed in their development, the case of BA1 described above is 
representative of how all of the firms in this study leveraged their dynamic capabilities to 
create the resources on which they competed. One of the biggest criticisms of dynamic 
capabilities is that it does not show what the outputs of dynamic capabilities are (Helfat, 
2009a).  Thus  one  of  the  largest  contributions  of  this  study  is  showing  that  dynamic 
capabilities lead to the development of key resources. Furthermore, this study contributes 
to the dynamic capabilities literature by showing how firms develop and use their dynamic 
capabilities.  This  is  also  a  significant  contribution  as  few  studies  have  holistically 
examined how firms do this (Arend and Bromiley, 2009).   
 
Figure 7-2: BA1's dynamic capabilities outputs 
Source: Author  
 
The findings from this study also weigh in on the on-going debate as to whether resources 
are still relevant to dynamic capabilities. Some scholars believe that there is little use for 
the RBV in dynamic capabilities (Arend & Bromiley, 2009), whilst others see resources as 
what  firms  use  their  dynamic  capabilities  to  reconfigure  (Helfat  &  Peteraf,  2003; 
Makadok, 2001; Teece, 2007). Makadok (2001) goes one step further by suggesting that 277 
 
firms build competitive advantages from both their resource picking abilities and their 
capabilities to reconfigure their resources. Findings from the present study are supportive 
of this notion. All of the case firms displayed competencies in choosing innovations to 
commercialise and picking important complementary resources to further develop their 
innovations. Moreover, resources are clearly an important part of how the firms developed 
and used their dynamic capabilities. Chapter five presents strong evidence on numerous 
resources that proved vital to the development of the firms‟ R&D, but these resources only 
provided value because the firms used their capabilities to maximise the value of these 
resources. For example, specialised R&D facilities provided important resources to BA1 
and DD2, but these facilities only proved valuable to them because they were able to use 
their capabilities to integrate these resources into their R&D.  
 
Emprical support for dynamic capabilities 
In addition to the unique contributions related to dynamic capabilities, the results from this 
study reaffirm several dynamic capabilities that are offered in the literature. For example 
the study supports that learning is an important dynamic capability (Eisenhardt & Martin, 
2000; Winter, 2000; Zollo & Winter, 2002). The within-group analysis in chapter five 
presented ample evidence of the importance of learning to both R&D and finance and is 
substantiated  as  well  by  Tables  6-25  and  6-28  in  chapter  six.  This  study  shows  that 
learning allows firms to use their earlier R&D results to further the progress of their 
research. From a financial standpoint, findings from this study suggest that firms learn 
from  their  previous  financing  paths.  These  findings  are  consistent  with  earlier  studies 
which suggest that learning is a higher level dynamic capability that allows firms adapt to 
rapidly changing environments (Easterby Smith & Prieto, 2008; Verona & Ravasi, 2003; 
Zollo & Winter, 2002).   
 
This study also offers support to sensing and seizing as a dynamic capability. Accordingly, 
all of the firms in this study were heavily reliant on their ability to find and take advantage 
of  research  and  financing  opportunities.  The  firms‟  processes  for  sensing  and  taking 
advantage  of these opportunities  were paramount  to  the firms‟ growth. These findings 
reaffirm work done by Herreld et al. (1997), which shows sensing and seizing are key 
capabilities  in  rapidly  changing  environments.  The  third  dynamic  capability  that  the 
present study’s findings embrace is R&D. Based on case studies of petroleum firms, Helfat 
(1997) suggests that R&D is a dynamic capability that firms use to change their product or 
operations to make to enhance their competitive positions. Findings from the present study 278 
 
unequivocally support this, as all of the case firms used advanced R&D capabilities to 
create new products and/or to advance existing products –ultimately improving the firms‟ 
competitive positions. Table 6-26 and 5-27 from chapter five highlight the unique R&D 
resources and capabilities that allowed the firms to develop a novel life science innovation.  
 
A fourth dynamic capability that this study supports is transformational capabilities. All of 
the firms in this study displayed transformational capabilities. Almost all of the firms had 
situations influenced by outside events or internal breakthroughs that forced the firms to 
transform  their  operations.  For  example,  DD1‟s  drug  did  not  progress  quickly,  which 
forced the firm to transform its R&D to focus on the development of a diagnostic device. 
Several of the firms also encountered events that forced them to reconfigure their financial 
resources. For example, BA2 won a large grant that changed their financial trajectory. This 
grant forced the firm to reorganise its financial resources and priorities. The support of 
transformational capabilities is a notable contribution as the theory of dynamic capabilities 
is based on the central tenet that firms that rearrange their resources and capabilities in 
response to changing conditions perform better (Rindova & Kotha, 2001; Teece et al., 
1997; Winter, 2003). However, little empirical work directly supports this; the results from 
the present study give insights into how and why young life science ventures reconfigure 
their  R&D  and  financial  resources.  These  results  also  support  the  idea  that  strategic 
decisions are triggered by events, and that firms must be able to alter their strategies to 
respond to these events (Canales and Villa, 2005).  
 
7.6 VC and government grants 
This study also produced findings related to VC and government  grants. VC is highly 
influential  on life  science firms  (Baum  & Silverman, 2004).  For this  reason,  and  also 
because of the researcher‟s interest in VC, this study incorporated the influence of VC on 
the development of capabilities and resources in life science ventures. In a similar fashion, 
findings relating to grant-backed firms also emerged as three of the case firms received 
sizable government grants. Although VC and grants are not the central focus of this study, 
some important findings from the study related to these areas surfaced. This section details 
these findings. 
 
For all of the firms in this study that received VC, it provided essential capital, and in most 
of  the  cases  important  management  inputs.  However,  all  of  the  VC  backed  firms, 279 
 
unsolicited, offered an in-depth description of their desire to avoid VC in the future. This is 
mainly because of the founders‟ dilution of equity that happens when VCs invest in a 
company. It is not just the dilution in equity that causes concern, but also the loss of 
control. Once the firms dilute beyond a certain point, they lose control of their overall 
operations. MD2 ran into this problem, and because of it, one of the research projects that 
the founders thought had great potential was discontinued because the VCs wanted to stop 
it, and the VCs had gained enough control to do so. These findings are consistent with 
previous studies, which show that VCs often take large amounts of equity (Hsu, 2004; 
Sahlman, 1990) and that conflicts often arise because of the founders‟ dilution (Berglof, 
1994; Hellmann & Puri, 2002).  
 
Interestingly, BA1, DD1 and MD2‟s CEOs –-without prompting– referred to VC as „a 
necessary evil‟. Similarly, four executives from four different firms (BA1, DD1, MD1 and 
MD2) discussed in detail how the VC model is „broken‟. They specifically pointed to the 
dilution of equity and the amount of resources consumed in attracting VC and dealing with 
the VCs.  
 
Another  interesting  finding  relating  to  VC  that  this  study  gleaned  is  the  impact  the 
recession that started in 2008 had on the funding for life science ventures. The recession 
caused  clear  funding  obstacles  for  the  firms  in  this  study.  Four  of  the  firms  without 
prompting went into detail on how VC for life science ventures „dried up‟. Furthermore, 
the same firms discussed how the recession has fundamentally changed the funding model 
of VCs. They suggested that VCs are no longer interested in financing early stage ventures, 
and VCs would only invest in later stage firms. The impact of this did have a bearing on 
this research as it affected the financial paths of the firms in this study. The research did 
not go into great depth on how the VC model has changed, but the findings are worth 
noting and may be used for future studies examining the impact of the recession on the 
funding of life science ventures.  
 
In order to avoid the drawbacks of the traditional VC funding model, two of the firms 
followed alternative financing paths. BA1 and BA2 financed their early growth through 
personal funds and then received a considerable amount of financing from small business 
innovation research (SBIR) grants. They both received close to a million dollars through 
these grants, which provided the bulk of the financing needed to get the firms to a point of 280 
 
commercialisation.  These  grants  required  no  equity  from  the  firms  and  allowed  the 
founders to keep the decision-making powers in the firm.  
 
Overall the strategy of avoiding VC worked well for BA1 and BA2. This is consistent with 
the previous research, which suggests that grant-funded firms display superior performance 
in comparison to VC backed firms (Gans & Stern, 2003; Lerner, 1996). What the literature 
does  not  show  is  why  SBIR  firms  demonstrate  superior  performance.  Lerner  (1996) 
conjectures this may because of the intense competition for the grants, which results in 
only the very best firms getting them. The results from the present study suggest that grant-
backed  firms  acquire  the  capital  they  need,  but  do  not  have  to  contend  with  the 
inefficiencies created by outside investors.  
 
This section underscores the study‟s finding relating to the recent changes and challenges 
that life science ventures face in financing their development. From this discussion the 
following propositions is set forth: 
 
P12) Grant-backed firms‟ superior performance compared to VC backed firms is a 
result of the grant backed firms not having outside investors creating inefficiencies 
that stifle development.  
 
7.7 Implications for practitioners and policy makers 
The discussions above underscore the findings in relation to the context of life science 
ventures and the key theories that this study draws on. This section goes into more depth 
on the findings from a practical standpoint; more specifically, it provides insights that 
managers of life science ventures can use in their quest to develop R&D and financial 
resources and capabilities. Following Starkey and Madan‟s (2001) argument that academic 
research in management needs to have a connection with the practice of it, the present 
study was designed to have implications for scholars, practitioners and policy makers. This 
study makes several unique contributions to the practical base of knowledge.  
 
First,  the  findings  underscore  the  importance  of  examining  the  paths,  positions  and 
processes available to develop key resources and capabilities. From this strategies can be 
set forth to position a firm. Closely related, this study also supports the valuable, rare, 
imperfectly-imitable and non-substitutable (VRIN) framework as an analytical tool for life 281 
 
science managers to use when evaluating resources. Managers must analyse the resources 
required for their firms and gauge whether or not the resources can serve as a source of 
competitive  advantage.  Analysing  whether  or  not  each  resource  is  valuable,  rare,  and 
imperfectly  imitable  and  non-substitutable  will  determine  it.  Once  key  resources  and 
capabilities  are  identified,  it  is  then  important  for  firms  to  examine  the  options  for 
developing the resources they need: what paths are available to the firm? What positions 
does the firm have to leverage in these paths? What processes is the firm skilled in and 
what processes could they create? For example, MD1 identified several unique options for 
developing their spinal technology and carefully evaluated the possible outcomes of the 
paths available to the firm. From this analysis the firm made the strategic choice to self-
finance and self-develop their device, and these choices has allowed the firm to maintain 
organisational flexibility whilst still developing a state of the art device.  
 
Second, findings from the present study emphasise the importance of partnerships in life 
science ventures. The R&D literature underscores the importance of partnerships in the 
development of novel innovations (Blumenthal et al., 1986; Calabrese & Silverman, 2000; 
Coombs & Deeds, 2000). However, it has largely been neglected from a start-up firm point 
of view and has failed to offer prescriptive insights for practitioners. The present study 
isolates the importance of partners from a life science venture‟s perspective. The results 
indicate that managers must become proficient in sensing partners and developing routines 
to work with their partners. A major catalyst to the development of the firms in this study 
was their ability to find partners that were a good strategic fit; i.e. partners that offered 
needed inputs and were amicable to work with. For example, BA1‟s partnership with the 
US government is the central reason that the firm successfully developed a leading edge 
instrument for identifying diseases. Another prime example of the importance of partners 
is the importance of BA2‟s partnership with a top university. This university provided 
scientific inputs that proved vital to the development of their chiral drug technology. The 
findings from this study also suggest that that scholarly journals and conferences provide a 
means to find and vet potential partners. In addition, this study also indicates that partners 
are often inhibitive to growth. In short, this study reinforces the alliance literature, which 
shows there are both positives and negatives with partnerships (Cassiman & Veugelers, 
2006; Sampson, 2007). Consequently, it is important for managers to carefully sense and 
evaluate potential partners.  
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Third,  firms  should  analyse  at  what  point  in  development  specific  resources  and 
capabilities will become critical.  Several of the firms from this study did not properly 
estimate  the  timing  and  the  amount  of  financing  they  would  need.  This  delayed  their 
entrance into the commercialisation phase and caused a bottleneck in the firms‟ growth. 
For example, MD2 did not properly time its funding rounds, which forced the firm to 
abruptly stop three important projects that they had started because they had not brought in 
enough capital. In general, the study shows that the proper timing of the development or 
acquisition of resources allows firms to avoid many troubles.  
 
Fourth,  this  thesis  underscores  the  importance  of  international  paths.  DD1  and  MD2 
greatly  expedited  the  commercialisation  of  their  products  because  they  first  put  them 
through European approvals. This proved much more efficient and cost effective then FDA 
approval. BA1, BA2 and MD1 also greatly aided their early growth by actively marketing 
their  products  overseas.  The  overseas  revenues  greatly  helped  the  firms  finance  their 
growth.  
 
Fifth,  this  study‟s  findings  suggest  new  ventures  should  explore  all  financing  options 
before committing to a VC path. Although the results of this study are supportive of the 
literature that indicates VC is often needed for life science ventures because of the high 
degree of risk (Baum & Silverman, 2004; Colombo & Grilli, 2009), the results also suggest 
that  alternative  routes  of  financing  are  available.  As  discussed  in  the  literature 
implications, two of the case firms acquired financing from alternative sources; whereas, 
the other four firms did not even consider alternative paths. There might not have been any 
other paths available for the firms that did not pursue alternative financial paths, but the 
results of the study imply that it is not difficult or time consuming to look for them. For 
example, one particular source that many firms often do not consider is government grants. 
 
Policy implications 
On  top  of  the  management  implications,  this  study  also  provides  insights  for  policy 
makers. For starters, it adds to Lerner‟s (1996) findings that SBIR grants are effective in 
developing innovative firms. The present study adds to this by showing not only do these 
grants  offer  the  needed  capital  for  firms  to  develop,  but  these  grants  also  offer  an 
alternative to equity financing. This helps firms by affording them the capital they need, 
but  without  the  drawbacks  of  equity  financing.  BA1  and  BA2  were  greatly  aided  by 
government grants, and for these firms the grants proved highly effective. The grants are 283 
 
the central reason that BA1 commercialised its technology, resulting in the creation of jobs 
and the delivery of a technology that benefited society.  
 
Another policy implication from this study is that governments from around the world 
need  to  better  coordinate  and  standardise  testing  and  development  procedures  for  life 
science innovations. The literature notes this (Giovannetti, 2010; Martínez-Torres & Toral, 
2010), but it does not provide prescriptive advice on how governments can work together 
to  alleviate  this  problem.  Moreover,  Bio  and  several  other  large  life  science  trade 
associations are lobbying for increased standardisation amongst governments across the 
world, but little movement has been made towards this (Bio, 2009). The present study 
suggests that the lack of standardisation is slowing the dissemination of innovation. This is 
hurting the firms that create innovations because these firms are required to expend extra 
resources  in  duplicating  processes  and  procedures  in  order  to  obtain  foreign  market 
approvals. Moreover, this is greatly hurting the proclivity of internationalisation because 
often small life science firms do not have the resources to duplicate the entry procedures 
required in different foreign markets. Most of the case firms in this study focused mainly 
on one market because of the extra resources and time required to obtain approval for 
multiple markets. What is worse is people from all around the world are being barred from 
technologies that could help cure disease. 
 
In short, the negative effect of this on life science firms was evident in most of the case 
firms in this study, as most of them desired to more rapidly enter foreign markets, but 
refrained largely because of the extra regulatory steps needed to enter them. Biotech policy 
makers need to find ways to increase the globalisation of biotech innovations, whilst still 
protecting their citizens from harmful technologies. This is being worked on (BIO, 2009), 
and is a tall order, but one that should receive even further attention.  
 
7.8 Shortcomings 
Management is a complex topic made up of many actors and outside factors. It is nearly 
impossible to properly examine all of these in a single study (Easterby-Smith et al., 2002), 
and for this reason  almost all studies in management are flawed to some extent – the 
present study is no exception. The most glaring shortcoming of this study is that it relied 
on a small subset of life science firms. The life science industry is fundamentally different 
than most other industries – even other technology based industries (Owen-Smith et al., 284 
 
2002b; Powell et al., 2002). Life science innovations take years to develop, and there is 
much more regulation in life science than there is for most other industries, which further 
slows the commercialisation of innovation (Murray and Wolfson, 2010). The fact that this 
study  used  life  science  firms  raises  questions  on  the  generalisability  of  the  findings. 
However,  this  was  factored  into  the  study  design  as  the  questions  and  analysis  were 
carefully crafted to provide both practical and theoretical implications. Furthermore, even 
if future research finds that the present study‟s results are only applicable to life science 
firms, then the findings will still make an impact, as the industry is a major and important 
part of the global economy. Moreover, the author has a practical background working with 
life  science firms and the main motivation  of this  study was  to  help  managers of life 
science firms better understand the key resources and capabilities needed in early growth. 
 
Properly planned and executed qualitative research is valid, needed and important (Yin, 
2008).  However,  qualitative  research  is  always  scrutinized  for  validity,  and  many 
quantitative purists will fault qualitative work without cause (Johnson & Onwuegbuzie, 
2004). Consequently, it is important to reiterate that the approach taken in the present 
study  was  appropriate  and  properly  executed.  First,  the  theoretical  constructs  of  the 
relevant  theories  were  clearly  not  well  developed;  therefore,  these  theories  needed 
qualitative work to extend them (Edmondson & McManus, 2007). Second, the study was 
properly designed and executed to minimise the impact of researcher bias and to establish 
trustworthiness in the findings. The six firms used in this study is an ideal number for case 
research (Eisenhardt, 1989a). Furthermore, a substantial amount of data was collected and 
the study was triangulated through multiple techniques (Yin, 2008). One shortcoming that 
arose from the high volume of data that the study generated is that some of its richness was 
lost in the presentation. Another shortcoming that arose from the data is that there was only 
one researcher who analysed it. Subject experts reviewed several important sections of the 
data, but given the researcher‟s constraints, it was not possible to have another researcher 
analyse all of the data.  
 
Another potential shortcoming of this study stems from the theoretical framework used. 
Even for qualitative work, dynamic capabilities presents many challenges because of its 
lack of theoretical development (Helfat & Peteraf, 2009). Potential problems arose with the 
present study because the study‟s framework is based on a relatively undeveloped theory. 
However,  the  multiple  theoretical  inputs  used  to  design  and  analyse  this  research 
minimised this problem; i.e. the RBV provided a means of theoretical triangulation.  285 
 
 
A third potential problem emanated from the study‟s holistic approach to examining the 
development of R&D and financial resources and capabilities. Developing resources and 
capabilities is a complex phenomenon that evolves over time, and it is difficult to capture 
in a single study. Notwithstanding, scholars contend that it is possible to isolate process-
based phenomenon over time in a single study – if the study is properly executed and 
factors in the element of time (Pettigrew, 1992). The present study followed this advice 
and  longitudinally  examined  the  development  of  R&D  and  financial  resources  and 
capabilities.    286 
 
7.9 Recommendations for future research 
This  study  put  forth  a  number  of  findings  relating  to  the  development  of  R&D  and 
financial resources and capabilities. There are opportunities for future research to both 
qualitatively and quantitatively extend the present study‟s findings in several ways. For 
example, a study is already underway to develop measurable constructs on how to gauge 
the background of a standout scientist.  
 
This  research  found  that  inward  and  outward  international  activity  contributes  to  the 
development of R&D and financial resources and capabilities. Work is underway using the 
present  study‟s  findings  to  create  measurable  constructs  to  quantify  the  importance  of 
international  activity.  The  findings  here  provide  a  good  basis  for  this,  but  there  still 
opportunity to unearth deeper insights on these triggers.  
 
Another major finding from this study is that the traditional VC financing model used by 
many life science firms is inherently flawed. VC is critical because it provides the capital 
needed for high risk ventures to grow (Chakma & Sammut, 2011; Gans & Stern, 2003; 
Timmons & Bygrave, 1986), and VCs in most instances offer non-financial value from 
their management inputs (Hsu, 2004; Unger et al., 2010), but VC financing also has its 
drawbacks (Kortum & Lerner, 2000). The present study unearthed the idea that the VC 
model is broken, which presents an opportunity to go into more depth as to if and why this 
is through qualitative interviews. Similarly,  the findings suggest that there are funding 
models for high technology ventures that are superior to the traditional VC model. There is 
a developed literature on angel investors, but little research has looked at grants as a source 
for funding life science ventures. Lerner (1996) is one of the few noted studies on this 
topic, but this study simply compares performance of grant- backed firms against VC-
backed firms. Findings from the present study suggest there are other reasons as to why 
grant-backed firms perform better, namely that grant-backed firms avoid the drawbacks of 
equity investors. There is ample room for future work to go into more depth on this, and 
also to look for other reasons for this difference.  
   287 
 
7.10 Summary and final conclusions 
The author is a partner in a life science-related venture, and this research was spurred by a 
desire to unearth deeper insights on the development of key  resources and capabilities 
needed in their early growth. Initially the study looked at the effect of internationalisation 
and  VC  on  the  development  of  key  assets  in  life  science  ventures.  The  exploratory 
interviews and initial literature revealed a more relevant question: What influence do R&D 
and financial resources and capabilities have on the early growth of life science ventures? 
A further look into the life science literature revealed several gaps related to this question; 
most  notably,  little  investigates  how  R&D  and  financial  resources  and  capabilities  are 
formulated and how these resources and capabilities affect the early growth of life science 
ventures.  This  motivated  the  author  to  holistically  examine  the  R&D  and  financial 
resources and capabilities needed in the early growth of life science firms. 
 
This study unearthed several unique insights on the development of R&D and financial 
resources and capabilities. This study was especially interested in life science firms, which 
are firms that are in turbulent environments and are driven by innovation (Azzone & Dalla 
Pozza, 2003; Bergeron & Chan, 2004). Despite the fact these firms are in such dynamic 
environments, few studies have examined them through a dynamic capabilities lens. Life 
science firms are technology-based, highly dynamic and important to the global economy. 
For these reasons and because the researcher was interested in the industry, life science 
firms served as the focus. 
 
The  research  influences  and  the  fact  that  this  study  drew  on  a  relatively  undeveloped 
theory made a qualitative research approach appropriate (Edmondson & McManus, 2007). 
Case studies have gained credibility in the field of management (Eisenhardt, 1989a; Yin, 
1981, 2008). For this reason and the flexibility that case studies offer, this study implored a 
case method. Six case firms were carefully selected, and the data for the firms came from 
multiple rounds of interviews with multiple key informants and a considerable amount of 
secondary data. The research started with a broad interest on resources and capabilities and 
honed down the resources and capabilities that emerged as important. The multiple rounds 
of interviews allowed more specific questions to be designed from the earlier round of 
interviews, which allowed the study to further hone down on the key themes. The analysis 
began  with  a  multiple  step  process  of  abstracting  themes.  From  this  the  categories  of 
themes emerged that provided the structure for the analysis. The firms were categorised 288 
 
into three groups and a within-case, cross-group and cross-case analysis was performed. 
Following  Maitlis  and  Lawerence  (2007),  a  systematic  trail  of  evidence  supported  the 
findings.  Although  the  methods  are  not  highly  unique,  what  is  unique  is  the  massive 
amounts of data that this study collected and analysed. The study yielded over 500 pages 
of transcripts and over 3000 pages of secondary data. What is also unique is the depth of 
analysis for the relatively large number of case firms and massive amount of data that the 
study drew on. Another interesting aspect of the research is the unique questionnaire that 
the study used to triangulate and validate the findings.  
 
This thesis examined the resource and capability development of life science ventures. It 
was particularly interested in R&D and financial resources and capabilities; what they are, 
how they are determined and deployed by firms towards competitive advantage. Table 7-1 
presents  the  unique  contributions  of  this  study.  These  are  contributions  that  offer 
something materially different from what is already offered in the literature, and advance 
the  body  of  knowledge  on  the  research  topics.  Clearly  the  study  produced  significant 
insights on the research topics.  
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Table 7-1: Study's propositions 
P1)  Firms  that  have  a  narrower  scope  of  R&D  focus  are  more  successful  in 
commercialising their innovations because they are better able to attain the core resources 
and capabilities needed to develop their innovations.  
 
P2)  Life Science ventures that publish in scholarly journals and attend conferences are 
better able to identify complementary technologies and assess the capabilities of potential 
partners.  
 
P3)  Life  Science  ventures  that internationalise  are  motivated  to  do  so  to  avoid  FDA 
regulatory bureaucracy, and this is forcing firms to develop resources and capabilities for 
operating in international markets. 
 
P4)  Firms  that  employ  one  or  more  standout  scientist  are  better  able  to  develop  R&D 
resources because of the standout scientist(s) R&D capabilities and scientific contributions. 
 
P5)  Life  science  ventures  that  attempt  to  develop  several  innovations  simultaneously 
develop slowly and risk failure as they create large financial requirements. 
 
P6)  Firms  that  self-finance  their  growth  will  have  significantly  different  financial 
trajectories than firms that pursue equity investors, as they will have less capital available, 
but will maintain greater organisational flexibility.   
 
P7) Inexperienced founders are more likely to self-finance their venture‟s early growth, as 
opposed to experienced founders who use their background to secure financial resources 
from outside sources.  
 
P8) IPOs consume valuable time from top management teams, and managers that spend less 
time on IPOs are better able to help their firms develop operational resources.  
 
P9) Life science ventures with advanced R&D complementary assets are more successful in 
bringing their innovations  to  market,  as  the R&D  complementary  assets  allow them to 
progress their innovations to a point of commercialisation. 
 
P10) Firms that recognise the complementary and potentially specialised nature of finance 
and  proactively  manage  these  assets  in  relation  to  their  R&D  are  more  successful  in 
bringing their innovations to a point of commercialisation. 
 
P11) There is a co-specialised relationship between R&D and financial resources and these 
co-evolve throughout the growth process of life science ventures, and firms that are adept at 
co-developing these resources are more successful in commercialising their innovations. 
 
P12) Grant-backed firms‟ superior performance compared to VC backed firms is a result of 
the  grant  backed  firms  not  having  outside  investors  creating  inefficiencies  that  stifle 
development.  
 
Source: Author 
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In conclusion, this study makes a number of incremental but important contributions to the 
practice  and  scholarship  of  management.  First,  it  unearths  key  paths,  positions  and 
processes that lead to the development of R&D and financial resources and capabilities. 
Second, it offers insights on the influence of R&D and financial resources and capabilities 
in  the  early  growth  of  life  science  ventures.  Third,  it  offers  empirical  support  to  the 
dynamic capabilities framework (i.e. the paths, positions and processes framework). This 
framework can serve as it did in this study to further the examination of the development 
of  key  resources,  but  it  can  also  be  adapted  for  more  general  uses  for  strategic 
management. Put differently, results from this study contribute to the resurgence of the 
dynamic capabilities framework and offer a base for other studies to use in the examination 
of dynamic capabilities. Fourth, this study at least partially answers Helfat‟s (2009) call for 
deep  empirical  research to  examine what  the outputs  of dynamic capabilities are. The 
present study examined what Teece (2007) sees as one of the most important outputs of 
dynamic capabilities, the development of key assets. Specifically this study looked at the 
paths, positions and processes leading to the development of R&D and financial resources 
and  capabilities.  Fifth,  this  study  gives  rise  to  the  idea  that  the  VC  funding  model  is 
flawed.  
 
This  thesis  provides  a  platform  for  a  research  career.  Two  papers  have  already  been 
published from this thesis: the first presents the results from exploratory interviews on the 
influences  on the development of  resources  and capabilities, and the second is  on the 
important resources that serve as the antecedents to dynamic capabilities. Another paper 
that stems from the present study reviews and reconceptualises dynamic capabilities based 
on the extant literature and the findings from the present study. Several top scholars have 
reviewed the paper, and it is under revision for one of the top journals in management. In 
addition, several other papers will soon be written based on this thesis. For example, one 
paper will present the empirical findings on the paths, positions and processes that lead to 
the development of R&D and financial resources and capabilities. These are the papers 
slated in the near-term. There are opportunities for many more papers to emanate from this 
thesis in the long-term.  
 
The life science industry is an important part of the global economy. Innovations from the 
industry have been the main force that has increased the average life expectancy of a 
person living  in  the U.S from  sixty-six in  1950 to  seventy-eight in  2008 (Bio,  2009). 
Moreover, innovations in the industry produce over $80 billion in revenue per year. Small 291 
 
firms are germane to this innovation, as it is estimated that forty per cent of innovation 
emanates from firms that employ fewer than 250 (Van Beuzekom and Arundel, 2009). 
Despite the importance of small firms, little is known on how small resource constrained 
firms develop the R&D and financial resources and capabilities to develop financially and 
scientifically capitally intensive innovations. This study makes considerable contributions 
to filling this gap. 
 
In short, this is a rigorous, well planned and executed study that provides great depth on 
the  R&D  and  financial  resources  and  capabilities  germane  to  the  early  growth  of  life 
sciences ventures. It makes several unique contributions to the scholarship and practice of 
management. 292 
 
Appendix A: Data Reduction Tables 
Table A1: Level 1 data summary 
PRIORI THEMES  
Founder‟s experience  (Toole & Czarnitzki, 2009) 
Founder‟s education  (Toole & Czarnitzki, 2009) 
Industry alliances (Audretsch, 2001; Rothaermel, 2001) 
University alliances (Anselin, Varga, & Acs, 1997; Gubeli & Doloreux, 2005) 
Government alliances (Giesecke, 2000) 
VC monitoring activities (P. A. Gompers, 1995) 
VC inputs (P. Gompers & Lerner, 2001) 
International inputs (Athreye & Godley, 2009; Welch & Luostarinen, 1993) 
International markets (Andersson & Wictor, 2003) 
R&D capabilities (Tripsas & Gavetti, 2000) 
Complementary technologies (A. Arora & Gambardella, 1990; Teece, 2007) 
Sensing and seizing technological opportunities (Teece, 2007) 
Distribution assets and capabilities (Trispas, 1997) 
Service assets and capabilities (Teece, 1986)  
Intellectual property (A. M. Arora & Ceccagnoli, 2006; Trajtenberg, 1990) 
R&D facilities (Pisano, 1990)  
Production assets (Schmenner, 2009) 
INDUCTIVE THEMES  
Unique technology  
Industry developments  
FDA  approval  
Pursuit of patents influences development 
Failed R&D projects 
Raising capital is necessary 
Raising capital consumes time and resources 
Core technology is vital to raising capital 
Integrating resources is vital 
Raising VC wastes time and energy 
TMTs waste time with VC 
The VC model is broken 
Source: Author 
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Table A2: Level 2 data repackaging 
R&D     Founder‟s experience 
  Founder‟s education 
  Industry alliances 
  University alliances 
  Government alliances 
  International inputs 
  International markets 
  R&D capabilities 
  Complementary technologies 
  Sensing and seizing technological 
opportunities 
  Intellectual property resources 
  R&D facilities 
 
Financial    Founder‟s experience 
  Founder‟s education 
  Industry alliances 
  Government alliances 
  VC inputs 
  FDA  approval 
  Raising capital is necessary 
  Raising capital consumes time and 
resources 
  Core technology is vital to raising 
capital 
  Integrating resources is vital 
VC model is flawed    VCs do not want to invest in early stage 
firms 
  TMTs waste time with VC 
  Raising VC wastes time and energy 
Source: Author 
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Table A3: Level 3 data structure and framework 
Metathemes  Emergent Themes 
R&D paths     Unique technology  
  Partnership opportunities 
  Gaining FDA approval 
  Complementary technologies 
  Scientific developments 
 
 
R&D positions    Core technology 
  Patents 
  Scientists 
  Star scientists 
  Founders 
  Networks 
  Research facilities 
 
R&D processes    Seizing scientific opportunities 
  Learning from earlier research 
  Navigating government approval 
  Developing scientific partnerships 
  Transforming R&D 
Financial paths    Core technology made specialised 
financing necessary 
  Obtaining capital is resource 
consuming 
  VC 
  IPO 
  Revenue generation 
Financial positions    The core technology 
  Scientific staff  
  Founders 
  TMTs 
  Government resources 
Financial processes    Sensing financing opportunities 
  Integrating financial resources 
  Budgeting financial resources 
  IPO related processes 
  Dealing with investors 
Source: Author 
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Appendix B: Interview Schedule I 
 
 
 
Preliminary Research on 
Resources, Dynamic Capabilities 
and the Role of Venture Capital in 
Life Science Firms 
 
Professor Marian V Jones 
Jon Carrick 
 
 
 
 
 
 
 
 
 
   
Instructions to Interviewers 
Fill in one booklet per firm (or per interviewee). 
The interview should follow the format of open questions, answered 
in the respondent‟s own words; followed by closed, checklist 
questions. 
1.  Write the answers to the open questions as told by the 
respondent, use as much space as necessary. 
2.  Follow each section of open questions immediately with the 
corresponding closed questions in order to verify the 
respondent‟s story. 
3.  Ask the closed questions precisely and enter the answers in 
the spaces provided 
4.  Once the form is completed, ask the respondent to elaborate 
on any issues that have emerged during the interview that 
they think are of particular importance to the future 
development of their firm 
Time: 
Date: 
Interviewer 1: 
Interviewer 2: 
Company Name: 
Address: 
 
 
Telephone:     e-mail 296 
 
Section A. Open Questions: The Firm’s current position 
Q. Please tell us about this firm. In your own words please describe your firm, the 
business it does, the nature of its products, its role within the industry and its 
competitiveness in domestic and any foreign markets. 
Prompts (for guidance)  Please allow the respondent to answer in their own way, and 
record their responses in their own words 
  Business, products 
and manufacturing 
or production 
processes 
 
  Firms‟ role in its 
industry (identify the 
industry). 
 
  Suppliers, buyers, 
new entrants, 
substitute products, 
concentration. Your 
position on the 
industry value chain 
 
  Customers / 
domestic market, 
who, where? 
 
  Competitive 
position, market 
share, unique niche, 
etc. source of 
competitive 
advantage in 
domestic market 
 
  Describe your firms 
overseas markets, 
where are they, how 
many are they, what 
do you sell there, 
what is your source 
of competitive 
advantage there? 
 
 
Continue on reverse if necessary 297 
 
 Section A. Closed Questions: The Firm’s current position  
(Please ask questions and record answers precisely in this section.) 
 
A1. Business and Products 
 
1.1  Would you classify your firm primarily as: 1. a manufacturing firm ______ 2. a firm 
producing services ______ 3. an R&D laboratory_________ or 4. other, please 
describe_______________________? (tick one) 
 
1.2  What percentage of your firm‟s annual income comes from: 1. Sale of hardware 
products________ %, 2. Sale of software products__________ %, 3. Sale of 
services_________ %, 4. Research grants_________ %, 5. Other _____________% 
(check total = 100%) 
 
1.3  What proportion of your firm‟s annual income comes from: 1. Business activities/ 
sources in the UK ________%, 2. Business activities / sources overseas 
___________ % ? (check total = 100%) 
 
1.4  What is your major product? 
____________________________________________________________________
______ ? 
 
1.5   Is your major product sold to: 1. consumer markets _________ , 2. organisational 
markets ________ 3. both _________ ? 
 
1.6  Would you describe your product as: (tick all that apply) 
 
  Having a narrow range of applications within one or a few industries / 
markets______________  
  Having a wide range of industry applications across a number of industries / 
markets_________________ 
  Specific to a target group of customers with particular needs_______________ 
  A niche product with local applicability (UK 
only)_________________________ 
  A niche product with global applicability (foreign markets) 
__________________ 
  General to a wide range of industries / markets in UK and abroad 
______________ 
 
1.7 Would you describe your major product as: (tick one only) 
  Innovative, leading edge technology ___________________________ 
  An incremental innovation of relatively new technology_______________ 
  Other, please describe 
________________________________________________________________
________________________________________________________________
________________________________________________________________
____________________________________ 
 
1.7  Do you have a portfolio of products? 1. Yes __________, 2. No __________? (tick 
one) 
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1.8 Could any of your products be described as a Cash Cow? 1. Yes ____ 2. No ____ 3. 
Might be in the future _______ ? 
 
A2. Industry Structure 
 
2.1 Approximately how many direct competitors do you have in the US _________ ? 
 
2.2 Are your main competitors large firms ____________, or small firms 
_____________? 
 
2.3 If you have few competitors, can you identify them by name? 
______________________________________________? 
 
2.4 If you have few competitors, are these firms US owned _________________, foreign 
owned ___________, both ______ ? 
 
2.5 How unique is your product or service ______________________________ ? 
 
2.6 How important is your product e.g. could customers use something else in its place 
_____________? What _____________________________ ? 
 
A3. Competitive Advantage 
3.1 Please describe the source of your firm‟s competitive advantage in the US? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___ 
 
 
3.2 Please describe the source of your firm‟s competitive advantage in its overseas 
markets if any? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________ 
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Section B. Open Questions: The Firm’s Foundation Process 
 
Q. In your own words, please describe how your firm was founded, who was involved, 
how it was supported, why it was founded and the aspirations, aims and objectives of the 
founding members. 
Prompts (for guidance)  Please allow the respondent to answer in their own 
way, and record their responses in their own words 
  Was there a particular reason for 
its foundation eg to exploit a new 
technology or innovation, or 
other? 
 
  Is there any pre-foundation 
history that influenced the 
establishment of this firm eg spin-
out or spin-off, MBO etc.? 
Reasons? Opportunities or 
threats? 
 
  Who were the founders, describe, 
them, what role did they play in 
founding, what role do they play 
now? 
 
  What international connections 
did the firm, or its founders have 
at foundation? What 
role/contribution have these made 
to the growth of the firm (in 
general internationally). 
 
  How was the firm resourced at 
foundation (financial, physical 
resources, human resources)? 
Where did the resources come 
from, how did the firm go about 
getting them? 
 
  Where there any important 
university connections? 
 
  Were there any important industry 
partnerships?  
 
  Did the firm use Venture Capital 
in the foundation process? What 
were the main motivations for 
using VC?  
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 Section B. Closed Questions: The Firm’s Foundation Process 
(Please ask questions and record answers precisely in this section.) 
 
1.  In what year was the firm founded? ________________ 
2.  a) Was the firm founded specifically to develop a scientific/technological 
innovation? 
  Yes______________(go to 2.1) 
  b) Since founding, has your firm developed a scientific / technological innovation? 
  Yes______________(go to 2.1) 
  (If no to both 2a and 2b, go to 3) 
2.1 Please describe that innovation 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________ 
2.2  What was the source of the firm‟s first scientific/ technological innovation?  
Yes/No   Source Country 
  In-house development   ____________________ 
  University  ____________________ 
  Other firm  ____________________ 
  Previous employer  ____________________ 
  Acquisition of patent rights from third party  ____________________ 
  Other_________________________________________________________ 
2.3  Does the firm have intellectual property rights for that innovation here and/or 
abroad? (Note all countries and sequence in which IPRs were sought.) 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
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2.4  Does the firm have FDA approval for the US Market?   
2.5  Yes _________   Date __________ 
2.6  No _______       Pending__________ 
 
3.  Why was the firm founded? 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
4.  How was the firm financed? (tick all that apply) 
  Research Grant  ____________________________________________ 
  Enterprise / start-up funding from Government ______________________ 
  Bank loan  ___________________________________________ 
  Founder‟s personal sources _____________________________________ 
  Other  __________________________________________________ 
5.  Was the firm founded as an independent new firm with no corporate history? 
Yes________(go to 7), No _____ (go to 6) 
6.  Was the firm founded as: (tick one only) 
a.  A spin-off from another firm ___________________________________ 
b.  A spin-off from a university  __________________________________ 
c.  Merger/takeover  ____________________________________________ 
d.  Management worker buy-out___________________________________ 
e.  Other  _________________________________________________ 
7.  How many founders were there? _________________________. 
8.  What personal, social or business contacts and networks with individuals or 
organisations overseas, did the founding team have at start-up? 
________________________________________________________________
________________________________________________________________
________________________________________________________________ 
9.  To what extent have those links and networks contributed to the development 
and growth of the firm? 
________________________________________________________________
________________________________________________________________
________________________________________________________________
__________________________________ 
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10.  The table below relates to the human and social capital of the firm at founding. 
Please record relevant details on each of the founders. 
 
  Founder 
1 
Founder 
2 
Founder 
3 
Founder 
4 
Founder 
5 
Age           
Gender           
Nationality           
Current role/position?           
Previous entrepreneur? 
Yes/No 
         
Family history of 
entrepreneurship Yes/No 
         
Highest Level of 
education, e.g 
School Cert, College 
degree/diploma (CD), 
University 1st Degree 
(UD), 
Advanced degree(AD), 
Doctoral degree (Dr), 
Professional bodies, 
         
Overseas education? 
Where ? Country (ies) 
 
         
Overseas working 
experience 
Where? Country (ies) 
 
SME/MNE?  
Role Position? 
 
         
Working experience in a 
Domestic 
internationalising firm? 
         
Foreign language ability? 
Languages? 
Spoken/written/fluent? 
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Section C. Open Questions: Critical Events and Milestones 
(Timeline) 
Q. Please tell us about events in the history of the firm that you see as major milestones, 
or critical incidents in the development of the firm, or things that happened, internally or 
externally, that triggered change in the firm’s development process? 
Enter the foundation date of the firm at the left of the time-line. 
1.  Record the nature of each event 
2.  Write the date on the approximate place on the time-line 
3.  Write the story surrounding the event (continue over for space) 
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Section C. Open Questions: Prompts Relating to Events on the Firm’s 
Timeline 
Q. Please allow the respondent to discuss each event as fully as possible. The prompts 
relate to each relevant event 
 
Prompts (for guidance)  Please allow the respondent to answer in their own way, 
and record their responses in their own words 
  When did the firm get venture 
capital investment? 
  What triggered this event? 
 
  Were business networks and 
alliances important in any of these 
milestones? What role did VC 
play in aligning these networks?  
 
  What were the implications for 
the future growth and 
development of the firm? 
 
  What were the implications for 
the functional areas of the firm: 
R&D, manufacture, marketing, 
distribution, new product 
development, commercialisation, 
funding, etc. 
 
  What implications did the event 
have for internationalisation or 
international aspects of the firm‟s 
business? 
 
  What new processes or strategies 
were triggered? 
 
  What aspects of the firm‟s 
business were dropped? 
 
  What were the immediate effects 
on profitability, financing, sales, 
revenues, etc. 
 
  In retrospect, what were the long-
term effects? 
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Section D. Open Questions: The Internationalisation Process 
(Timeline) 
Q. Please tell us about the firm’s internationalisation process from its first international 
links and contacts, to its first international contracts and investments, to its current 
situation as regards involvement in international business. 
Enter the foundation date of the firm at the left of the time-line. 
1.Record the nature of each internationalisation event recounted, as far as 
possible as the respondent describes it, with countries. 
2.  Write the date on the approximate place on the time-line 
3.  Write the story surrounding the internationalisation event (continue over 
for space) 
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Section D.1. Open Questions: Prompts Relating to Events on the Firm’s 
Internationalisation Timeline  
Q. Please allow the respondent to discuss each event as fully as possible. The prompts 
relate to each relevant event
 
Prompts (for guidance)  Please allow the respondent to answer in their own 
way, and record their responses in their own words 
  What role did the VC play in the 
internationalization of the firm? 
 
  How did your firm‟s involvement in 
international business evolve? 
 
  What was the nature of the cross-border 
arrangements you had? Export, import 
licensing in or out of technology, source 
of technological knowledge, raw 
materials etc. 
 
  What was the purpose of them? Increase 
knowledge, expand sales, exploit 
opportunities, avoid unfavourable 
conditions in home country? 
 
  Were there any investments involved 
(FDI), investment in technology etc.? 
 
  What were the implications of your 
international involvement for the 
functional areas of the firm: R&D, 
manufacture, marketing, distribution, new 
product development, commercialisation, 
funding etc. 
 
  How important is your international 
activity to firm growth and development 
in general? 
 
  What did the firm learn from its overseas 
involvement in relation to overseas 
markets, new product development, 
marketing techniques and processes, 
technological techniques and processes, 
R&D, technology transfer and the 
protection of intellectual property 
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Section E. Open Questions: Boldness, Creativity and innovativeness of 
International Ventures 
Q. Please tell us about anything in your firm’s international activities that you would 
consider to be bold / innovative / venturesome / creative? (If the respondent feels that 
nothing they do is particularly bold / innovative / venturesome or creative, ask them to 
explain why and what makes them say so). 
 
Prompts (for guidance)  Please allow the respondent to answer in their own 
way, and record their responses in their own words 
  What particular international activities in 
which your firm is involved could be 
described in those terms? 
  Why would you describe them in that 
way? 
 
  Did the VCs have an influence an 
influence on these events? Did they 
encourage innovation? 
 
  Have the VC(s) helped increase your 
capabilities? 
 
  Have the VC(s) helped you become more 
dynamic and able to expand change your 
capabilities quickly to respond to the 
market? 
 
  How did these activities evolve, develop 
or come about? 
 
  What was it within the firm that led to 
these developments? 
 
  What stimuli/ events in the external 
environment? 
 
  Were there specific opportunities or 
threats that were responded to? (new 
markets, new production methods etc.). 
  To what extent did you actually search to 
find this stimulus? 
 
  Did anyone provide you information or a 
hint, or advice on that stimulus, and if yes, 
how did you use it? 
  How would your competitors see you in 
terms of: 
1.  Your optimism to achieve difficult 
/specific goals? 
2.  Your creativity in discovering 
attractive stimuli that others don‟t 
see?  
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Section F. Open Questions: R&D and Product Portfolio Management 
Q. Please describe the role of R&D in your firm, how it is organised, its relation to your 
portfolio of products, and to the development of new products for local and overseas 
markets.  
Prompts (for guidance)  Please allow the respondent to answer in their own 
way, and record their responses in their own words 
  How have the VC(s) affected 
the R&D of the firm? 
  Has the VC involvement 
adversely affected the R&D 
process? 
 
  Do you have an in-house 
R&D department and if so, 
how much importance is given 
to it in terms of numbers of 
employees, annual investment 
as a percentage of turnovers 
etc. 
 
  When was the R&D 
department established? 
 
  What role does it play? 
Research for internal 
purposes, research for other 
firms under contract? 
Research for strategic 
partners? 
 
  What international 
connections, contracts, and 
involvement does your firm 
have in relation to R&D? 
 
  What are the purposes of the 
international connections, and 
how does the firm benefit? 
 
  What R&D-based 
international connections has 
the firm had that have resulted 
in commercial business 
ventures? 
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Section F. Closed Questions (Please ask questions and record answers 
precisely in this section.) 
 
F.1 Strategy and Planning 
1.1  Would you describe your firm‟s development as: (tick one only) 
1.  Organic (evolutionary process in response to events and triggers) ______________  
2.  Strategic (develops according to our pre-determined plans)___________ 
3.  A combination of 1. and 2. __________  
 
1.2  Does your firm have a formal, written strategic plan? Yes / No. 
 
1.3   If yes, does that plan make explicit reference aims and objectives relating to your 
firm‟s involvement or future involvement in international business activity? Yes / No. 
 
1.4  If yes, does that plan contain explicit targets for Research and Development? Yes / No 
. For 1 year, 2 years, 3 years, 4 years, 5years, over 5 years?  
 
1.5  If yes, does that plan make explicit reference to(Yes/No) 
 
1.  Product portfolio planning ____________; 
2.  New product development____________;  
3.  Adaptation of products for foreign markets _________;  
4.  Entry into new foreign markets_________ 
5.  Withdrawal from any current international business activities 
_________; 
6.  Cessation of R&D _________. 
 
F.2 Firm Performance and Projections 
 
2.1 How would you rate the performance of this firm in its first five years, on a scale of 1-
10, with 1 being unsuccessful, 10 being successful? 
 
Unsuccessful   1  2  3  4  5  6  7  8  9  10   Successful 
 
2.2  Was the firm profitable in the each of the first five years? 
 
Year 1 Y/N  Year 2 Y/N   Year 3 Y/N   Year 4 Y/N   Year 5 Y/N 
 
2.3  What percentage of the firm‟s revenue was derived from overseas in each of the first 
five years? 
 
Year 1 _____% Year 2 _____%  Year 3 _____%  Year 4 _____%  Year 5 _____% 
 
2.4  What is your firm‟s current percentage of profits is derived from foreign operations? 
________% of total profits? 
 
2.5  What is your firm‟s current percentage of sales is derived from foreign operations? 
________% of total sales? 
 
2.6  Would you mind telling us the approximate total sales of your firm in the last financial 
year £_________________? 
 
2.7 Would you mind telling us the profitability of your firm in the last financial year as a 
percentage of total sales______ % 
 
2.8 How many staff (FTEs), including working directors, does your firm currently 
employ_________? 310 
 
Appendix C: Interview Schedule II 
 
 
 
Research on R&D and financial 
assets and capabilities. 
 
Jon Carrick 
 
 
 
 
 
 
 
 
 
   
Instructions to Interviewers 
Fill in one booklet per firm (or per interviewee). 
The interview should follow the format of open questions, answered in the 
respondent‟s own words; followed by closed, checklist questions. 
5.  Write the answers to the open questions as told by the respondent, use 
as much space as necessary. Follow each section of open questions 
immediately with the corresponding closed questions in order to verify 
the respondent‟s story. 
6.  Ask the closed questions precisely and enter the answers in the spaces 
provided 
7.  Once the form is completed, ask the respondent to elaborate on any 
issues that have emerged during the interview that they think are of 
particular importance to the future development of their firm 
Time: 
Date: 
Interviewer 1: 
Interviewer 2: 
Company Name: 
Address: 
 
 
Telephone:     e-mail 311 
 
Section A. Open Questions: R&D and financial assets and 
capabilities 
Q. In your own words please describe your firm’s important R&D and financial assets and 
capabilities and how these were developed. 
  
Prompts (for guidance)  Please allow the respondent to answer in their own way, and 
record their responses in their own words 
  Key paths 
-Core technology 
-Scientific 
opportunities 
-Partnerships 
 
  Key positions 
-Core technology 
-Scientific staff 
-Founder 
 
  Key processes 
-Learning 
-Sensing 
-Integrating 
 
  R&D  
-VC Influence 
-Founders 
connections 
 
 
  Financing 
-VC Influence 
-Founders 
connections 
 
 
 
 
 
Continue on reverse if necessary 
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Section B. Open Questions: Critical Events and Milestones 
(Timeline) 
Q. Please tell us about events in the history of the firm that you see as major alliance 
milestones important to the firm’s development process?  
Enter the foundation date of the firm at the left of the time-line. 
4.  Record the nature of each event 
5.  Write the date on the approximate place on the time-line 
6.  Write the story surrounding the event (continue over for space) 
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 Section B. Open Questions: Effect of R&D and financial assets and 
capabilities on early growth (Timeline) 
Q. In your own words please describe the effect of R&D assets on the early growth of the 
firm. Define early growth: from the time the firm started until the time that it started to 
generate a significant amount of revenue. 
  
Prompts (for guidance)  Please allow the respondent to answer in their own way, and 
record their responses in their own words 
  Key paths 
-Core technology 
-Scientific 
opportunities 
-Partnerships 
 
  Key positions 
-Core technology 
-Scientific staff 
-Founder 
 
  Key processes 
-Learning 
-Sensing 
-Integrating 
 
  R&D Alliances 
-VC Influence 
-Founders 
connections 
 
 
  Financing alliances 
-VC Influence 
-Founders 
connections 
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Section C. Open Questions: The Value of Alliances 
Q. In your own words, please describe how your firm’s important alliances have affected 
your firm’s early growth.(Define early growth for respondent)  
 
Prompts (for guidance)  Please allow the respondent to answer in their own way, 
and record their responses in their own words 
 
  Did any of the alliances 
help the firm obtain 
financing? 
 
  Did any of the alliances 
lead to development in 
R&D? 
 
  Did the alliances formed 
through the facilitation of 
the VCs result in more 
valuable alliances?  
 
  Did the alliances formed 
from within the VCs 
portfolio have more value 
than the other alliances?  
 
  How did the alliances help 
in the early growth of the 
firm? What involvement 
did the VC have in these? 
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Section C. Closed Questions: Major Partners 
 
  Alliance 
Partner 1 
Alliance 
Partner 2 
Alliance 
Partner 3 
Alliance 
Partner 4 
Alliance 
Partner 5 
Firm Type/same 
industry 
         
Alliance Facilitated 
by 
         
Relationship duration           
Purpose of alliance           
Specialised Assets 
created from 
alliance 
 
         
Alliance was critical 
to firms early 
growth 
         
Alliance was critical 
to firms 
internationalisation 
         
Is partner 
international 
         
Did alliance help in 
the firms 
internationalisation 
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Section C. Closed Questions: The Firm’s Alliances 
(Please ask questions and record answers precisely in this section) 
 
C.1 Alliances and Types of Alliances 
 
1.8  How many strong alliances does your firm have_________? 
 
1.9  What was the primary way that these alliances were formed? 1. CEO contacts______ 
2. VC facilitating alliances with other firms within their portfolios_____ 3. VCs 
facilitating alliances with firms outside of their portfolios____ 4. Industry networking 
events____  
5. Other, please describe____________________. 
 
1.10How many products did R&D alliances help your firm develop or jointly 
develop_____________? 
 
1.11How many of the R&D alliances were facilitated by your VC_____________? How 
many of these were from firms within the VCs portfolio_______? 
 
1.12 How important were the VCs in facilitating alliances ? 
Unimportant 1  2  3  4  5  6  7  8  9  10 Very Important 
 
 
C.2 Alliance Formation 
2.1 Please describe how your major alliances were formed? 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_______________________________________________________________________ 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
______________________________________________ 
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Section D. Open Questions: The VC Business Model 
Q. Please tell us your opinion of the VCs business model? (Make sure to explain what is 
meant by the VC business model.) 
 
Prompts (for guidance)  Please allow the respondent to answer in their own way, 
and record their responses in their own words 
  What was the most detrimental part of 
the VCs business model?  
 
 
 
  In what ways was the VCs business 
model good for your firm? 
 
 
 
  Have the VC(s) helped you become 
more dynamic and able to expand 
change your capabilities quickly to 
respond to the market? 
 
 
 
  Did the firm‟s executives waste a lot of 
time meeting with the VCs and writing 
reports for them? 
 
 
  Is the VC business model broken? 
   
 
  If you were to do it all over again would 
you pursue VC for the firm? 
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Section D. Closed Questions (Please ask questions and record answers 
precisely in this section) 
 
E.1 Strategy and Planning 
1.6  Was it the intent of the firm from its inception to attract VC investment? Yes / No. 
 
1.7   Did the strategic direction of the firm change once VC came on board? Yes / No. 
 
1.8  Did the VC encourage the internationalisation of the firm? Yes/No. 
 
1.9  Did the VCs encourage you to incorporate alliances into your strategy? Yes/No.  
 
1.10Overall was the VC investment positive on your firm‟s early growth?  
 1.5a Why or Why not? 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_____________________ 
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Appendix D: Triangulation Survey 
 
Questionnaire 
 
R&D and financial resource development of small life science firms 
Jon Carrick / University of Glasgow 
 
 
Dear 
Name: Given Name: 
Position: 
Company: 
Responsible for the firms since: 
 
 
In my research I am analysing the variables that impact the development of small life science 
firms. Your valuable feedback is very important to me, and I would greatly appreciate if you 
would complete this questionnaire and return it to me as soon as possible. 
 
 
 
 
 
The questionnaire will need approximately 45 minutes. 
I assure that all information will be kept strictly confidential and will only be used for 
the purpose of this project. Thank you very much for your support. 
Contact address: 
 
 
Jon Carrick 
5720 Old Ocean BLVD 5W 
Ocean Ridge, FL 33435 
+1-561-214-3657 
Email: carrickjon 320 
 
Closed question on R&D and Financial Assets 
and Capabilities 
 
1. R&D assets and capabilities  
 
Focus: R&D paths (past decisions and future opportunities) that influenced the 
development of your firm‟s R&D assets and capabilities. Put differently, these pursuits 
influenced the strategic direction of the firm‟s R&D. To what extent did the following 
opportunities have on the development of your firms R&D? 
 
                                                                        1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Your firm‟s core innovation(s)               
2.  Venture capital investment               
3.  Industry partnerships               
4.  University partnerships               
5.  Government partnerships               
6.  Scientific breakthroughs by your firm               
7.  Scientific breakthroughs in the industry               
8.  FDA, EU or other approvals               
9.  Patenting               
10.  Other:               
11.  Other:                
 
Focus: Resources influencing the development of your R&D assets and capabilities. 
To what extent did the following resources have on the development of your firms R&D? 
                                                                                1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Your firm‟s core technology               
2.  Your firm‟s knowledge and capabilities               
3.  Your firm‟sscientific staff               
4.  Star scientists*               
5.  Founders               
6.  Executive staff and board of directors               
7.  University inputs                
8.  Industry partners‟ inputs               
9.  Government inputs               
10.  Patents               
11.  Specialized R&D facility***                
12.  Other:               
13.  Other:               
 
*Star scientists are individuals who are highly accomplished. These individuals hold a 
great number of patents, have scientific papers that are frequently cited, have been central 
to the development of notable products in the field or a combination thereof.  
 
*** Specialized R&D facilities are those that could not readily be leased or built 321 
 
Focus: Processes influencing the development of your firm‟s R&D assets and capabilities. 
To what extent did the following processes have on the development of your firms R&D? 
                                                                              1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Finding (sensing) the core technology               
2.  Finding (sensing) complementary technologies               
3.  Networking               
4.  Learning from previous research paths               
5.  Tracking and sharing information               
6.  Other:               
7.  Other:               
 
Focus: Effect of R&D on the firm‟s early growth; early growth is defined as the time from 
when the firm was incepted until the time it developed and commercialised its main 
product (s). 
 
How important were your firm‟s R&D assets and capabilities to the following: 
                                                               1= no importance  7= highly important 
    1  2  3  4  5  6  7 
1.  Developing the core technology               
2.  Refining the core technology               
3.  Developing a platform technology               
4.  Allowing firm to progress technology               
5.  Developing new applications                
6.  Aiding in the attraction of key employees               
7.  Aiding in the attraction of research partners                
8.  Aiding in the attraction of investment capital               
9.  Gaining FDA, EU, or other approvals               
10.  Helping in the firm‟s growth               
11.   Other:                
12.  Other:               
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2. Financial assets and capabilities  
 
Focus: Financial paths (past decisions and future opportunities) that influenced the 
development of your firm‟s financial assets and capabilities. Put differently, these pursuits 
influenced the strategic direction of the firm‟s financial assets and capabilities. To what 
extent did the following have on the development of your firm‟s financial assets and 
capabilities? 
                                                                                1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Costly to develop innovation(s)               
2.  Raising capital               
3.  Dealing with investors               
4.  Initial public stock offering (IPO)               
5.   FDA, EU or other approvals               
5.  Other:               
6.  Other:               
 
Focus: Resources influencing the development of your financial assets and capabilities. 
To what extent did the following resources have on the development of your firm‟s 
financial assets and capabilities: 
                                                                                1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Founder(s)‟ experience               
2.  Founder(s)‟ networks within financial community               
3.  Executive staff‟s and board members‟ experience               
4.  Executive staff‟s and board members‟ networks               
5.  Networks within financial community               
6.  Venture capital investor(s)‟ networks               
7.  Venture capital investor(s)‟ management 
contributions 
             
8.  Core technology‟s value in attracting capital               
9.  Company‟s staff               
10.  Other:               
11.  Other:               
 
Focus: Processes influencing the development of your firm‟s financial assets and 
capabilities. 
To what extent did the following processes have on the development of your firm‟s 
financial assets and capabilities? 
                                                                                1= to no extent  7 = to a very great extent 
    1  2  3  4  5  6  7 
1.  Prospecting for capital               
2.  Negotiating for capital               
3.  Dealing with financiers                
4.  Budgeting capital for operations               
5.  Learning from earlier financial paths               
6.  Filing for an initial public offering (IPO)               
7.  Other:               
8.  Other:               323 
 
Focus: Effect of financial resources on the firm‟s early growth; early growth is defined as 
the time from when the firm was incepted until the time it developed and commercialised 
its main product (s). 
 
How important were financial assets and capabilities to the following? 
                                                                                1= no importance  7= highly important 
    1  2  3  4  5  6  7 
1.  Developing the core technology               
2.  Developing key R&D assets and capabilities               
3.  Allowing firm to progress its technology               
4.  Aiding in the attraction of key employees               
5.  Gaining FDA, EU or other approvals               
6.  Helping in the firm‟s growth               
7.  Other:               
8.   Other:               
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